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SUMMARY
Ligation of the B cell antigen receptor (BCR) on B lymphocytes has 
divergent effects including anergy, apoptosis, proliferation or differentiation 
depending on the developmental state of the cell. Immature B cells are sensitive 
to the process of negative selection enabling the removal of self-reactive B 
lymphocytes. Consequently, ligation of the BCR on immature B cells induces 
growth arrest and apoptosis. However, co-ligation of CD40 can rescue 
immature B cells and enable them to survive, mature and proliferate. The 
murine 8 cell lymphoma cell line WEN 1-231 is widely used as a model of clonal 
deletion of immature B lymphocytes. This investigation has explored the 
signalling mechanisms used by the BCR and CD40 to differentially regulate the 
survival and proliferation of WEHl-231 immature B cells. In particular, the role of 
extracellular signal regulated kinase-mitogen-activated protein kinase (Erk- 
MAPK) in controlling these processes was examined.
The activity of Erk-MAPK in WEHl-231 cells was investigated by Western 
blotting. WEHl-231 cells were shown to undergo a transient activation (<2 hr) of 
Erk that was associated with the induction of the BCR-driven mitochondrial 
death pathway. However, a second, more sustained (12-48 hr) Erk signal was 
also identified and this appears to be critical for the proliferation of WEHl-231 
cells. This sustained Erk signal was suppressed by ligation of the BCR and this 
seems to be mediated by the induction of MAPK phosphatases rather than a 
downregulation of upstream activators of Erk. However, co-ligation of CD40 
restored sustained and cyclic activation of Erk to WEHl-231 cells and thus 
enabled them to undergo cell cycle progression and proliferation, as shown by 
measuring the uptake of fH ] thymidine. A dual role for Erk-MAPK in BCR-driven 
apoptosis and CD40-mediated rescue of WEHl-231 cells was thus identified.
The mechanisms used to regulate the activity of Erk-MAPK in WEHl-231 
cells were further examined using WEHl-231 cells that were transfected with 
constitutively active forms of Ras. These studies showed that Ras is an 
important upstream activator of Erk in WEHl-231 cells and it can induce Erk1/2 
activation via Raf-1 and/or phosphatidylinositol-3-kinase (PI-3-K) pathways. The 
induction of sustained and cyclic Erk signals and hence proliferation of WEHl- 
231 cells therefore requires active Ras and stimulation of its downstream
effectors. In addition to stimulating sustained Erk signals, the Ras-dependent
ii
activation of PI-3-K was shown to induce the pro-survival Bel-2-family member, 
Bc I-Xl and the induction of B c I-x l  by CD40 appears to be critical for suppressing 
BCR-driven apoptosis.
A key event in the stimulation of BCR-driven apoptosis in WEHl-231 cells 
is the induction of early (^2 hr) Erk signals since this appears to contribute to 
the activation of cytosolic phospholipase A2 (CPLA2). Previous studies have 
shown that following the activation of CPLA2 , arachidonic acid is produced at the 
mitochondria, leading to a disruption of mitochondrial function and the 
stimulation of cathepsin B. However, CD40 signalling has widely been reported 
to rescue WEHl-231 cells from BCR-driven apoptosis. In this study, evidence is 
presented to show that the induction of Bc I-Xl by CD40 is critical for mediating 
this rescue. Indeed, analysis of the sub-diploid DMA content of WEHl-231 cells 
showed that the expression of B c I-x l  in these cells impaired BCR-driven 
apoptosis. Furthermore, the mechanism of Bcl-xu-dependent survival was 
implicated by its ability to prevent mitochondrial PLA2 activity, disruption of 
mitochondrial function, cathepsin B activation and hence post-mitochondrial 
execution of the cell. Moreover, expression of Bc I-xl  protected WEHl-231 cells 
from arachidonic acid-induced apoptosis suggesting it acts downstream of 
CPLA2 to impair BCR-driven apoptosis, presumably by protecting the integrity of 
the mitochondrial membranes. Nonetheless, Bc I-xl was also shown to prevent 
arachidonic acid-mediated activation of CPLA2 independently of its regulation of 
mitochondrial membrane potential and this is likely to further suppress the BCR- 
driven mitochondrial death pathway. The induction of Bc I-x l  by CD40 is thus 
critical for enabling the survival of BCR-stimulated WEHl-231 cells.
However, expression of B c I-Xl did not prevent BCR-driven growth arrest 
and Western blotting for Erk-MAPK indicated that this was due to the fact that 
Bc I-Xl was insufficient to restore sustained and cyclic activation of Erk. By 
contrast, metabolites of arachidonic acid were implicated as mediators of CD40- 
dependent rescue from BCR-driven growth arrest. In particular, ligation of CD40 
was shown to induce cyclooxygenase 2 enabling arachidonic acid to be 
metabolised to prostaglandin E2 . The metabolism of arachidonic acid impaired 
BCR-driven apoptosis not only by reducing the levels of arachidonic acid but 
also because eicosanoids appear to have a role in promoting sustained Erk 
signals and hence proliferation of WEHl-231 cells.
i i i
Additional regulators of Erk-MAPK have also been identified in these 
investigations. In particular, the protein kinase C (PKC) isoforms PKCa, PKCÔ, 
PKCe and PKC^ appear to be capable of promoting the induction of sustained 
Erk signals and hence impair BCR-driven growth arrest of WEHl-231 cells. 
Nonetheless, PKC may also promote proliferation of WEHl-231 cells 
independently of inducing Erk since expression of kinase-dead mutants of 
PKCa and PKCô were unable to enhance Erk signalling despite promoting 
proliferation of WEHl-231 cells. Specific PKC isoforms therefore appear to 
promote proliferation of WEHl-231 cells and this is likely to be mediated by 
several mechanisms.
PKCa and PKCô were also implicated as having a role in regulating the 
induction of B c I-Xl in WEHl-231 cells. Indeed, Western blotting for B c I-xl  
indicated that expression of these isoforms of PKC increased B c I-x l  levels and 
impaired BCR-driven apoptosis, as indicated by analysing the sub-diploid DNA 
content of the cells. Similarly, sphingosine-1-phosphate was identified as an 
important mediator of CD40-dependent induction of B c I-x l  since inhibition of 
sphingosine kinase reduced the levels of B c I -x l  in WEHl-231 cells. 
Nonetheless, ligation of CD40 enhanced the survival of Bcl-XL-overexpressing 
WEHl-231 cells that were cultured in the presence of sphingosine kinase 
inhibitors suggesting CD40 may also induce B c I-xl  via sphingosine kinase- 
independent mechanisms or CD40 may promote survival of WEHl-231 cells via 
Bcl-XL-independent mechanisms. Consistent with this, expression of PKC^ was 
found to increase the survival of WEHl-231 cells without inducing B c 1-x l  
suggesting PKC^ may act downstream of Bc I-xl  or in parallel to Bc I-x l .
This investigation has thus demonstrated that the differential regulation of 
Erk-MAPK signals and Bc I-xl  by the BCR and CD40 is critical for determining 
the survival and proliferation of WEHl-231 immature B cells. Much of this 
investigation has focused on the temporal regulation of Erk1/2 and Bc I-xl  in 
WEHl-231 cells and the mechanisms used by the BCR and CD40 to control 
these signalling molecules. Indeed, a complex network of signalling pathways 
has been shown to regulate the activity of Erk-MAPK and the expression of Bci- 
x l and this is likely to ensure the survival and proliferation of immature B cells is 
carefully regulated.
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CHAPTER 1 - General Introduction
1.1 The immune system
The immune system protects the host from a diverse range of pathogens 
including bacteria, viruses and parasites. Protection is enabled by a series of 
non-specific and specific mechanisms of defence. The non-specific (innate) 
immune response forms the initial line of defence against invading pathogens. It 
is rapidly activated and can effectively eliminate infections. Two families of 
phagocytic cells, the monocytes/macrophages and the granulocytes, are 
responsible for mediating innate immunity. Phagocytes express receptors for a 
variety of molecules commonly found on the surface of pathogens and 
activation of these receptors leads to the internalisation of the pathogen where it 
is exposed to a variety of killing mechanisms including proteolytic enzymes, 
reactive oxygen species, pH changes, nitric oxide and cationic proteins. In 
addition to their role in killing pathogens, phagocytes also amplify the immune 
response by releasing pro-inflammatory cytokines and assisting the activation of 
a specific immune response.
The specific (adaptive) immune response is initiated more slowly than the 
non-specific response but it is specifically adapted to target the invading 
pathogen. Mediators of the adaptive immune response, lymphocytes, 
specifically recognise individual pathogens. There are two types of 
lymphocytes: B cells and T cells. B lymphocytes are the key cellular mediators 
of the humoral immune response and produce antigen-specific antibodies. 
Antibodies are particularly important for fighting extracellular pathogens 
including bacteria and parasites. T lymphocytes have multiple roles in the 
specific immune response. Helper (CD4^) T cells co-ordinate the immune 
response by regulating B cell development and proliferation and by interacting 
with phagocytes to aid the destruction of internalised pathogens. Cytotoxic 
(CD8^) T cells are particularly important for fighting intracellular pathogens since 
they can directly destroy infected host cells. The co-ordinated action of cells of 
the adaptive immune response therefore provides the body with comprehensive 
protection against both extracellular and intracellular pathogens. Furthermore, 
the adaptive immune response can remember previous infections and the
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quality of the specific immune response improves with each successive 
encounter with the same pathogen.
1.2 B cell development
B lymphocytes are the key cellular mediators of the humoral immune 
response and produce antigen-specific antibodies. The development of B cells 
has two basic criteria: firstly, a large repertoire of B cells must be generated so 
that the pool of B lymphocytes within the body can recognise a wide variety of 
antigens, enabling effective protection from pathogens; secondly, non­
productive and self-reactive B cells must be eliminated to ensure a successful 
humoral immune response can be generated without attacking the body itself 
(1). In order to fulfil these criteria B cell development is a continuous (2) and yet 
wasteful process.
The B cell antigen receptor (BCR) (reviewed in (3)) is critical for B cell 
development and function. It contains surface immunoglobulin non-covalently 
bound to the accessory molecules Iga and Igp (figure 1.1). Surface 
immunoglobulin (sig) is composed of two identical heavy chains and two 
identical light chains that come together to form antigen-recognition sites. The 
cytoplasmic domain of sig is not large enough to directly activate signal 
transduction pathways but signals can be activated via Iga and Igp (4, 5). The 
binding of antigen to sig induces the tyrosine phosphorylation of Iga and Igp at 
specific regions called immunoreceptor tyrosine-based activation motifs 
(ITAMs). The resultant phospho-tyrosine residues provide anchoring sites for 
the activation of intracellular signalling cascades that can regulate the survival, 
activity and function of the B lymphocyte.
1.2.1 Generation of a diverse range of OCRs
Each B cell expresses a single type of BCR and this will differ to the BCR
expressed on other newly generated B cells. Different BCRs are created by
somatic rearrangement of heavy and light chain immunoglobulin genes, Each
chain has a constant and a variable segment with the variable segment being
involved in antigen-recognition. The variable region of the heavy chain is
generated by two random recombination events; firstly the Dh and the Jh chains
are joined then the Vh chain is joined to the DhJh segment (figure 1.2A). There
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are about 300 variable (Vh) genes, 30 diversity (Dh) genes and 6 joining (Jh) 
genes therefore there is the potential to make more than 50,000 possible heavy 
chains via somatic recombination. Further diversity is generated by TdT 
(terminal deoxynucleotide transferase), an enzyme that can randomly add 
nucleotides into the heavy chain genes without following a template. The 
variable region of the light chain is also generated by somatic recombination but 
it lacks a D segment and is created via a single recombination event (figure 
1.2B). Two possible genes, kappa or lambda encode the light chain of the BCR. 
Both genes encode multiple V and J segments allowing the potential for several 
hundred different variable light chain regions.
Surface immunoglobulin of the BCR is generated by the coming together 
of rearranged heavy and light chains therefore somatic rearrangement of the 
variable segments of these chains enables a huge repertoire of BCRs to be 
generated. However, the recombination process is not always successful and 
non-productive rearrangements, for example out-of-frame joining of the genes 
encoding the immunoglobulin variable segments, are common. B cell 
development contains a series of checkpoints to eliminate developing B cells 
with unsuccessful heavy and light chain gene rearrangements. Another 
potential problem associated with the generation of a huge repertoire of B cells 
is the risk of creating self-reactive BCRs therefore checkpoints also exist to 
eliminate these cells.
1.2.2 Antigen-independent B cell development
In mammals, B lymphocytes develop in the liver of the fetus and in the 
bone marrow after birth. Newly formed B cells leave the bone marrow and 
further mature in the periphery and lymph nodes. B cells therefore develop 
through a series of well-defined stages starting with B-Iineage commitment in 
the bone marrow and finishing with fully immunocompetent B lymphocytes in 
the periphery. The initial stages of B cell development occur independently of 
antigen (Ag) whilst later stages are shaped by exposure to antigen (figure 1.3). 
Studies using knockout mice have provided valuable information to help 
characterise the different stages of B cell development. Each of the different 
stages can be distinguished by their surface phenotype (figure 1.4) and the 
expression of B-lineage genes, specific transcription factors, the mu (p) heavy
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Chain and the kappa (k) light chain (6-9).
The pluripotent hematopoietic stem cell (HSC) is the progenitor of all ceils 
of the immune system including lymphocytes. HSCs give rise to common 
lymphoid progenitor cells (CLP), which in turn can either form T or B 
lymphocytes. Early stages of B-lineage commitment require the expression of at 
least three transcription factors, E2A, EBP (early B cell factor) and Pax5 (10, 
11). For example, heterozygous mice undergo B cell
developmental arrest at the early pro-B cell stage and pax5'^' mice undergo a 
similar developmental arrest (12-14). E2A and EBF regulate the expression of 
proteins that are required in the recombination process including TdT and the 
recombinase enzymes RAG1 and RAG2 . Rearrangement of the 
immunoglobulin p heavy chain gene begins at the intermediate pro-B cell stage 
with D h-J h joining, followed by V h- D hJ h joining in late pro-B cells. Following 
rearrangement of the p heavy chain, it is expressed on the surface of the 
developing B cell in conjunction with the surrogate light chain (X5, VpreB) and 
Iga/lgp to form the pre-BCR complex. Expression of the p heavy chain causes 
RAG 1/2 to be downregulated to prevent further rearrangement of the heavy 
chain gene. This is necessary for allelic exclusion of the heavy chain locus that 
is it ensures only one type of heavy chain is expressed in any one particular 
developing B lymphocyte.
Like the BCR complex of immature and mature B lymphocytes, the 
immunoglobulin of the pre-BCR complex couples to the accessory signal 
transduction molecules Iga and Igp. Iga and Igp are first expressed on the 
surface of late pro-B cells in association with the integral membrane protein and 
molecular chaperone calnexin (figure 1.4) (7, 15) and they are necessary for 
pre-BCR signal transduction. Unlike the BCR complex of immature and mature 
B cells no antigen has been identified for the pre-BCR. It has been proposed 
that ligand-independent basal signals generated through the ITAMs of Iga and 
Igp are sufficient for promoting pro-B cell to pre-B cell development with the 
functional pre-BCR serving to anchor Iga/p to the plasma membrane (16). 
Furthermore, it has recently been suggested that the induction of signals by the 
pre-BCR involves the ligand-independent aggregation of components of the 
pre-BCR (17). Alternatively, it has been suggested that a bone marrow stromal 
factor such as galectin-1 may bind to and activate the pre-BCR leading to the
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phosphorylation of ITAMs in Iga/p (18).
The successful rearrangement of the immunoglobulin p heavy chain and 
the expression of this chain as a functional pre-BCR complex is necessary for 
the development of pre-B cells since the pre-BCR complex initiates signals, 
including the Erk (extracellular signal regulated kinase)~MAPK (mitogen- 
activated protein kinase) cascade, that are essential for the survival and 
proliferation of the developing B cell (19). It is likely that the pre-BCR complex 
uses similar intracellular signalling molecules to the mature BCR complex. For 
example, the protein tyrosine kinase Btk (Bruton’s tyrosine kinase) is essential 
for pre-BCR signalling and a deficiency in Btk impairs B cell development at the 
pre-B cell stage, as indicated by the diseases X-linked agammaglobulinaemia in 
humans or the less severe X-linked immunodeficiency in mice (15, 20). 
Furthermore, mice deficient in the tyrosine kinase Syk have impaired pre-BCR 
signalling leading to a disruption in B cell development at the pro-B to pre-B cell 
transition (21, 22). IL-7 is also a survival factor for late pro-B cells and large pre- 
B cells since IL-7, like the pre-BCR, can activate Erk in these cells (19, 23). 
Signals activated downstream of the pre-BCR thus promote survival and 
proliferation of the pre-B cells. Cells that have been unsuccessful in rearranging 
their immunoglobulin heavy chain and cannot express a functional pre-BCR do 
not undergo proliferation and cannot progress to the next stage of development.
The pre-BCR complex is only expressed transiently on the surface of large 
pre-B cells and following a limited number of cell division cycles the pre-BCR is 
lost from the surface of the cells. The resultant small pre-B cells are non­
proliferative and they express the recombinase machinery (RAG1 and RAG2 ) 
allowing the rearrangement of the light chain genes. This initially occurs at the 
kappa gene locus but should this be unsuccessful the lambda gene will be 
rearranged. Successful rearrangement of the light chain allows it to be 
expressed with the p heavy chain to form the BCR.
1.2.3 Antigen-dependent B cell development
The mature BCR is first expressed on the surface of immature B cells. 
Immature B cells are generated in the bone marrow from small pre-B cells but 
they migrate to the periphery as transitional B cells where they can survive for
2-4 days. Cells that express the BCR undergo antigen-dependent development.
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;Immature and transitional B cells are largely exposed to self-antigen therefore 
these cells undergo negative selection in order to prevent the survival of auto­
reactive B lymphocytes. In negative selection, ligation of the BCR complex has 
three possible out comes: anergy, receptor editing or apoptosis (9, 24). Soluble 
antigens or low affinity interactions with the BCR generally stimulate anergy or 
receptor editing. Anergic cells are non-responsive and short-lived. Receptor 
editing involves the activation of the recombinase machinery and editing of the 
light chain by using a different J gene or the heavy chain by using a new V gene 
(25). Receptor editing is sometimes able to rescue self-reactive B cells. High 
affinity interactions with the BCR induce programmed cell death (apoptosis) 
leading to the clonal deletion of self-reactive B lymphocytes. The strength and 
nature of the interaction between self-antigen and BCR of immature and 
transitional B cells therefore directs the fate of the ceil.
Additional factors also influence negative selection including the 
microenvironment of the immature B cell and contact with other cells. Immature 
B cells from bone marrow or periphery (spleen) of mice undergo apoptosis 
within 16 hr of treatment of these cells with anti-BCR antibodies in vitro (26), 
However, within the microenvironment of the bone marrow, ligation of the BCR 
on immature B cells does not stimulate apoptosis but causes RAG2 to be 
upregulated, allowing receptor editing. Cell-to-cell contact is important for the 
activation of receptor editing. The microenvironment of the bone marrow thus 
delays apoptosis of self-reactive immature B cells, allowing them time to edit the 
BCR (27). Once the immature B cells leave the bone marrow they travel to the 
spleen through the vascular system. The microenvironment of the spleen does 
not favour receptor editing therefore ligation of the BCR on these transitional 
immature B cells induces the default pathway of apoptosis (27). However, co­
stimulation by T cells can rescue these B cells from apoptosis. The fate of 
immature B cells therefore depends upon ligation of the BCR and additional co­
stimuli that can be provided by the microenvironment of the cell.
The surface phenotype of immature and transitional B lymphocytes is also 
thought to have some role in determining the sensitivity of these cells to 
antigen-induced apoptosis (7, 28-30). Immature B cells express surface IgM but 
do not express surface IgD. The sIgM allows antigen detection and antigen 
binding tends to favour the induction of receptor editing over apoptosis.
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Immature B cells are largely located within the bone marrow but they form 
transitional 1 1  cells and these can be found in the bone marrow, blood and 
spleen (30-32). In the spleen, T1 transitional cells are located in the outer 
periarteriolar sheet, close to the primary follicle (8 ). T1 B cells are very sensitive 
to BCR-driven apoptosis and a 20 min exposure to anti-lg (anti-immunoglobulin) 
is adequate to stimulate death signals. T 1 cells die within 16 hr of BCR- 
stimulation unless they receive T cell-derived rescue signals such as CD40 
stimulation or IL-4 (29, 33-35). T1 transitional cells express higher levels of 
sIgM and do not express sIgD. The high levels of sIgM are thought to increase 
the sensitivity of these cells to antigen-induced apoptosis and ligation of slgM 
on T1 cells does not readily activate recombinase so is unlikely to induce 
receptor editing.
T1 cells that do not undergo apoptosis develop into T2  transitional B cells 
(IgM' ’^^ '^ lgD*^ '^ *^ ), which are less sensitive to antigen-induced apoptosis. T2 cells 
are located inside the follicle of the spleen. During the transition between T1 
and T2 cells, the ligand BAFF (B cell activating factor) binds to its receptor 
(BAFF-R) and drives the formation of T2 transitional cells (36). A deficiency in 
either BAFF or BAFF-R blocks B cell development at the T1 stage (37). Ligation 
of the BAFF-R enhances B cell survival by activating the MARK cascade and 
N F -k B leading to an upregulation of pro-survival Bcl-2 family members (Bcl-2 
and BcI-xl) and a decrease in the expression of the pro-apoptotic protein Bak 
(38, 39). The interaction of BAFF and the BAFF-R cannot overcome B cell 
negative selection therefore it does not promote the survival of autoreactive B 
lymphocytes (40). BAFF is expressed on the surface of cells of the myeloid 
lineage including monocytes and dendritic cells, it may be expressed on the 
surface of some T cells and it can exist in a soluble form. The formation and 
survival of T2 transitional B cells is thus enhanced by the presence of myeloid 
cells and T lymphocytes that express BAFF (37).
T2 transitional B cells can develop into naïve mature B lymphocytes 
(lgM'°'^lgD^‘^ '^ ). Mature B lymphocytes express the BAFF-R and activation of this 
receptor promotes survival of these cells (36, 37). However, the formation of 
naïve mature B cells also requires signalling through the BCR (8 ). Naïve mature 
B cells have low levels of sIgM but have high sIgD expression. Some signals 
activated downstream of the BCR in mature B cells appear to be different to
those activated in immature/transitional B cells (41, 42). In particular ligation of 
the BCR on mature B cells does not induce growth arrest and apoptosis but can 
stimulate proliferation and activation of the cell (7, 33, 35, 43). Activation of 
mature B cells with a relatively high affinity antigen at the BCR and with 
appropriate co-stimulation initiates a humoral immune response (44, 46). 
Activated mature B cells undergo proliferation and can differentiate into either 
plasma cells or memory B cells (46). Plasma cells are antibody-secreting cells 
that mediate the primary immune response. Memory B cells are required for the 
induction of a secondary immune response.
1.2.4 Formation of memory B cells
Memory B cells are formed during primary immune responses to T cell- 
dependent antigens. The generation of memory B cells takes place in 
specialised regions known as germinal centres (figure 1.5). Following 
stimulation of a B cell by a T cell-dependent antigen, B cell blasts undergo 
exponential growth in areas rich in follicular dendritic cells (FDCs). FDCs are 
able to stimulate helper T cells and they retain unprocessed antigen on their 
surface that can be used later in the selection of high affinity memory B cells 
(47). The expanded population of B cell blasts migrates into the centre of the 
follicle, forming the dark zone of the germinal centre. In the dark zone B cell 
blasts continue to proliferate but no longer express sIgM and are now called 
centroblasts. Centroblasts undergo somatic hypermutation of the V regions of 
the BCR. This is a random process that will generate B cells with BCRs with 
either increased or decreased affinity for the activating antigen (25). Following 
hypermutation the centroblasts stop proliferating, migrate to the light zone of the 
germinal centre and express the new BCR on the cell surface. The cells, now 
called centrocytes, are particularly sensitive to apoptosis. FDCs within the light 
zone present antigen to the newly formed centrocytes. The availability of 
antigen is limited therefore only centrocytes expressing high affinity BCRs can 
bind to antigen. Survival of centrocytes also requires a second signal that can 
be provided by ligation of CD40, suggesting a role for helper T cells in the 
selection of centrocytes (48). Positively selected centrocytes form a pool of 
memory B cells that can act as precursors for plasma cells with Improved 
antibody affinity (47-49).
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1.3 Cell Cycle
The cell cycle ensures DNA is replicated and the cellular mass is doubled 
prior to cell division. There are four basic stages to the cell cycle (figure 1.6 A). 
Initially cells undergo a period of growth (G1 phase) before replicating their DNA 
(S phase). DNA replication is followed by a second growth phase (G2) that 
generally passes more quickly than the G 1 phase since the cell has more 
ribosomes by the G2  phase allowing faster protein synthesis. The final stage of 
the cell cycle is mitosis (M phase) in which the cell divides to form two daughter 
cells.
The cell cycle is a very tightly regulated process with two major 
checkpoints (figure 1.6B). Firstly at the G1-S boundary where cells commit to 
DNA synthesis and secondly at the G2-IVI transition where cells commit to 
mitotic cell division. Progression through these checkpoints is dependent upon 
the activity of cyclin-dependent kinases (Cdks) and their regulators, the cyclins 
(figure 1.6B). Progression through the early stages of the G1 phase of the cell 
cycle requires the activation of Cdk4 and Cdk6 . These are cyclin D kinases and 
are activated by cyclin D1, D2 or D3. Cdk2 and its activator cyclin E are 
required during the late stages of G1 and for progression into S phase. The 
Cdk-cyclin complexes of G 1 phase promote cell cycle progression by 
phosphorylating the retinoblastoma (Rb) pocket domain protein (50). 
Hypophosphorylated Rb binds to transcription factor III B and to upstream 
binding factor so preventing transcription mediated by RNA polymerase III. RNA 
polymerase III is required for the generation of transfer RNA and the small 
ribosomal subunit and hence protein synthesis and cell growth. Phosphorylation 
of Rb allows RNA polymerase Ill-mediated transcription and hence cellular 
growth. Hypophosphorylated Rb also binds to the transcription factor E2F and 
prevents it from forming dimers with DP transcription factors. Dimérisation with 
a DP family member is essential for E2F to activate transcription therefore Rb 
prevents E2F-dependent transcription. Phosphorylation of Rb by Cdks causes 
Rb to dissociate from E2F, allowing transcription to proceed. Activation of E2F 
is necessary for the G1-S phase transition since it regulates the expression of 
genes required for DNA synthesis and cell cycle progression including DNA 
polymerase alpha, thymidine synthetase, cyclin D3, cyclin E and cyclin A (33, 
50-54).
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DNA is replicated during S phase of the cell cycle and this phase Is 
sustained by cyclins A and E and Cdk2 . On completion of DNA synthesis the 
cells enter the second period of growth, the G2 phase. During G2  the Cdk2- 
cyclin B complex accumulates (55) and Cdc25, a protein phosphatase that is 
only expressed once DNA replication is complete, can activate this complex. 
Phosphorylation of various target proteins by the active Cdk2-cyclin B complex 
allows cells to enter mitosis. Cdk2-cyclin B can also phosphorylate and inhibit 
itself thus forming a negative feedback loop.
The ability of Cdk-cyclin complexes to allow cell cycle progression is 
regulated by two structurally distinct families of Cdk inhibitors (figure 1.6B). 
Firstly the WAF1 family (p21, p27 and p57) of proteins and secondly the INK4 
(inhibitor of Cdk4) family (p15, p16, p18 and p19). The inhibitors p15 and p16 
are specific for cyclin D kinases therefore they are particularly important 
regulators of Rb and hence can suppress progression through G1 phase and 
entry into S phase of the cell cycle. The inhibitor p27 suppresses Cdk2-cyclin A 
(56). Several Cdk-cyclin complexes can be inhibited by p21 including Gdk4- 
cyclin D1 , Cdk2-cyclin E, Cdk2-cyclin A and Gdc2 -cyclin A (51) Thus, the 
activation of p21 can inhibit DNA synthesis and induce cell cycle arrest at both 
G1 and G2  phases (57). Expression of the gene encoding p2 1  can be 
stimulated by p53, the “guardian of the genome" (58, 59). The levels of p53 
within a cell are increased during cellular stress or damage and the activity of 
p53 can be enhanced by p19'^ '^ ,^ which stimulates the degradation of MDM2 , 
an inhibitor of p53 (60, 61). By stopping DNA synthesis and cell cycle 
progression, p53 is able to prevent the replication of faulty DNA or a damaged 
cell (51). Following the activation of p53 and cell cycle arrest, proteins involved 
in DNA-repair are induced and minor damage to DNA is repaired. The 
expression of MDM2 is regulated by p53, creating a negative feedback loop that 
enables cell cycle progression to proceed once DNA damage has been 
repaired.
In addition to its role in regulating the cell cycle, p53 is also a mediator of 
apoptosis. Indeed, thymocytes and immature B cells that lack p53 are resistant 
to apoptosis induced by specific stimuli (51, 58). One mechanism by which p53 
induces apoptosis is by increasing the expression of the pro-apoptotic protein 
Bax (59, 62-64). The ability of p53 to induce apoptosis is regulated by multiple
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factors. For example, treatment of rat embryo fibroblasts with the adenovirus 
E1A protein induces p53-dependent apoptosis but the adenovirus normally 
expresses E1B proteins that impair p53-dependent transcription and p53- 
mediated apoptosis (51).
1.4 Apoptosis
At least two distinct types of cell death have been characterised: necrosis 
and apoptosis. Necrosis is induced following acute injury of the cell and the 
distinctive features are cytoplasmic swelling and membrane rupturing without 
significant alteration of the nucleus. Necrotic cells release their contents into the 
surrounding area and this may trigger an inflammatory response, in contrast, 
apoptosis, the process of programmed cell death, does not affect neighbouring 
cells and is unlikely to induce inflammation. Apoptosis is an active process 
whilst necrosis is passive. The characteristic features of apoptosis are swelling 
and disruption of intracellular organelles, cytoskeletal collapse, membrane 
blebbing, chromatin condensation, DNA fragmentation and cellular 
disassembly. Apoptosis is essential for the development and maintenance of 
healthy organisms. For example, in mammals apoptosis is used for limb 
modelling and neurological development. Furthermore, in the immune system 
apoptosis is required to eliminate self-reactive cells and to terminate an immune 
response (65, 6 6 ).
1.4.1 Bcl-2 family proteins - regulators of apoptosis
Members of the Bcl- 2  family are important regulators of apoptosis in
eukaryotic cells. The Bcl-2 family can be split into three groups based on their
expression of Bcl-2 homology (BH) domains (figure 1.7) (67). Two groups of
Bcl-2 family proteins promote apoptosis and the third group favours survival.
The pro-survival group of Bcl-2 family proteins e.g. Bcl-2 and Bc 1-Xl have all
four BH domains (BH1-4). The pro-apoptotic groups of Bcl-2 family proteins
have either 3 BH domains (BH1-3) e.g. Bax and Bak, or the BH3 domain alone
e.g. Bid and Bik. The BH1, BH2 and BH3 domains of a Bcl- 2  family protein can
come together to form a hydrophobic pocket. The BH3 domain of another Bcl-2
family protein can bind to this pocket to form a dimer. Using this mechanism
homo- or hetero-dimers are formed and the nature of these dimers determines
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the fate of the cell.
Bcl-2 family proteins are largely regulated at the transcriptional level and 
the fate of a cell depends upon the balance of expression of pro-survival and 
pro-apoptotic members of the Bcl-2 family (67). Post-translational modification 
can further regulate the dimérisation and hence function of Bcl- 2  family 
members. For example, in the interleukin-3 (IL-3)-dependent FL5.12 cell line, 
lL-3 induces the serine phosphorylation of the pro-apoptotic protein Bad 
causing it to dissociate from B c I-x l  and to bind to 1 4 -3 -3  proteins. This 
sequesters Bad and prevents it from promoting apoptosis thus enabling B c I-xl  
to mediate its pro-survival functions (6 8 , 69). Additional mechanisms of 
regulation have also been observed for Bcl-2 proteins that only contain a BH3 
domain. In particular, some of these proteins are constitutively expressed but 
can be sequestered and inactivated by binding to the cytoskeieton (70). Bid is 
also regulated by proteolysis; activation of caspase 8  results in the cleavage of 
the inactive 22 kD Bid to form an active 15 kD tBid (truncated Bid) that is 
targeted to the mitochondria by N-myristoylation where it can promote apoptosis 
(71, 72).
Pro-survival members of the Bcl-2 family normally bind to the membranes 
of organelles, especially the mitochondria, and maintain the integrity of the 
membrane to prevent the contents of the organelle leaking into the cytoplasm 
(73). In apoptosis, pro-apoptotic Bcl-2 family proteins are upregulated and they 
can form dimers with pro-survival Bcl-2 family members to suppress their 
guardian function. Alternatively, pro-apoptotic Bcl- 2  proteins can dimerise with 
other pro-apoptotic Bcl-2 family proteins to promote apoptosis. In particular, 
dimers of pro-apoptotic Bcl-2 family proteins induce apoptosis by forming pores 
in the outer mitochondrial membrane resulting in a loss of mitochondrial 
integrity. Loss of mitochondrial function has three particularly significant effects. 
Firstly, ATP can no longer be produced therefore the regular functions of the 
cell cannot be sustained. Secondly, the loss of mitochondrial integrity increases 
the production of reactive oxygen species and these are toxic to the cell. 
Thirdly, and perhaps most importantly, the formation of pores in the outer 
mitochondrial membrane causes the contents of the mitochondria to be 
released into the cytoplasm, providing co-factors for the activation of caspases, 
an important group of proteins that can mediate apoptosis.
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1.4.2 Caspase-dependent apoptosis
Key mediators of apoptosis are the caspases, a family of evolutionary 
conserved cysteine proteases. Caspases were first studied in C. elegans (figure 
1.8A) where the caspase CED3 mediates all somatic cell death. CED3 is 
activated by a single protein, CED4 and the activity of CED4 is regulated by the 
proteins CED9 and EGL-1. CED9 physically blocks the association of CED4 
and CED3 so is a negative regulator of these proteins whilst EGL-1 inhibits 
CED9, allowing the activation of CED4 and CED3 (74, 75).
Mammalian cells express homologues of the C. elegans apoptotic 
machinery and can undergo apoptosis using a similar mechanism. However, 
apoptosis in mammalian cells is more complex than in C. elegans since they 
express multiple regulators, initiators and effectors of apoptosis (figure 1.8A). 
Indeed, more than fourteen mammalian caspases have been identified and they 
have been divided into three groups based on their substrate specificity. 
Substrates of caspases are cleaved at the C-terminal side of an aspartic acid 
residue. The four amino acids to the N-terminal side of the Asp residue 
determine the substrate specificity of a particular caspase (67). The three 
categories of mammalian caspases, DEXDases, WEHDases and 
(IVL)EXDases, require different tetrapeptide sequences. The WEHDases can 
function as inflammatory mediators whilst members of the other two classes of 
caspases regulate apoptosis either as initiator or effector caspases.
All caspases are expressed as zymogens with an N-terminal pro-domain, 
a central p20 domain and a C-terminal plO domain (67). Activation of caspases 
requires two proteolysis reactions firstly to remove the pro-domain and secondly 
to cleave between the p2 0  and p1 0  subunits allowing two of each of these 
subunits to come together to form a catalytically active tetramer (figure 1.8B). 
Caspases can either be activated by autocleavage or by proteolysis catalysed 
by an upstream caspase. In general, initiator caspases are activated by 
autocleavage and effector caspases are stimulated downstream of initiator 
caspases.
Initiator and effector caspases of mammals can be physically
distinguished by the length the their pro-domain (67). Initiator caspases
(caspases 2, 8 , 9 and 10) have long pro-domains whereas effector caspases
(caspases 3, 6  and 7) have short pro-domains. The pro-domains not only
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function to inhibit the caspase when it is not required but they also provide 
docking sites that help to stimulate the caspase under apoptotic conditions. For 
example, the long pro-domains of initiator caspases include protein-protein 
interaction domains, allowing them to bind to upstream regulators. Caspases 2 
and 9 have caspase activation and recruitment domains (CARD) whereas 
caspases 8  and 10 have death effector domains (DED). CARD domains 
generally associate with other CARD domains. The CED4 homologue Apaf-1 is 
a particularly important CARD domain-containing protein that activates pro- 
caspase 9 (figure 1.9). In healthy cells, Apaf-1 is associated with the 
mitochondria using pro-survival Bcl-2 family proteins. However, Apaf-1 is 
displaced from the mitochondria during apoptosis due to the increased levels of 
pro-apoptotic Bcl-2 family proteins. Furthermore, the pro-apoptotic Bcl- 2  family 
proteins disrupt the integrity of the mitochondria resulting in the contents of the 
mitochondria being released into the cytoplasm and the cytoplasmic levels of 
cytochrome c, ATP and Ca^^ become elevated. Cytochrome c binds to the 
WD40 repeats in the C-terminal region of Apaf-1, opening the conformation and 
allowing ATP to bind to the nucleotide binding domain of Apaf-1. Adjacent to the 
nucleotide-binding domain of Apaf-1 is an N-terminal CARD domain that can 
then bind to the CARD domain of pro-caspase 9. This complex of cytochrome c, 
ATP, Apaf-1 and pro-caspase 9 is known as the Apaf-1 apoptosome and it is 
likely to form multimeric complexes with other Apaf-1 apoptosomes. These 
complexes function as holoenzymes since caspase 9 is most active when it is 
associated with Apaf-1 (67, 75-77). Caspase 9 induces apoptosis of the cell via 
the activation of effector caspases including caspase 3 (67).
Caspase 3 and other effector caspases can also be activated via DED 
domain-containing caspases. These are stimulated in a slightly different way to 
CARD domain-containing caspases. DED domains can physically interact with 
other DED domains or death domains. Death domains can be found in 
association with many pro-apoptotic receptors including CD95 (Fas). Ligation of 
Fas induces oligomerisation of the receptor and any associated proteins 
including FADD (Fas-associated death domain) which can bind to the DEDs of 
pro-caspases 8  and 10 (figure 1.10). This creates a high local concentration of 
protease enabling the low intrinsic activity of the pro-caspase to mediate 
autocleavage and activation of caspases 8  and 1 0 . These initiator caspases can
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then cleave and activate pro-caspase 3 to induce apoptosis of the cell (67, 74, 
78). Furthermore, caspase 8  can cleave and activate Bid, which can dimerise 
with Bax to cause damage to the mitochondria resulting in the activation of 
CARD domain-containing caspases and additional effector caspases (figure 
1.10) (71, 72).
Effector caspases mediate apoptosis of the cell via the proteolysis of 
multiple target proteins (67, 79). For example, caspase-activated DNase is 
stimulated by caspase-mediated proteolysis and it can then cleave the DNA 
between nucieosomes to cause DNA laddering (80). Effector caspases also 
cleave nuclear lamins resulting in the shrinkage of the nucleus and cytoskeletal 
proteins like fodrin and gelsolin to induce a loss of the shape of the cell (67), 
Furthermore, in Jurkat T cells that are undergoing Fas-induced apoptosis, 
PAK2 , a member of the p21-activated kinase family, is constitutively activated 
by effector caspase-mediated proteolysis. PAK2 alters the morphology of the 
cell by phosphorylating myosin and has also been implicated in stimulating JNK 
(c-Jun N-terminal kinase) MAPK to further promote the death response of the 
cell (81, 82).
Caspase-mediated apoptosis is a carefully regulated process. In non- 
apoptotic cells pro-survival Bcl- 2  family members protect the mitochondria and 
other intracellular organelles to ensure there is no release of caspase-activating 
co-factors into the cytoplasm. Furthermore, lAPs (inhibitor of apoptosis proteins) 
are present in the cytoplasm to suppress the activation of caspases. For 
example, XIAP can bind to and inhibit the protease activity of caspase 9, 
preventing its stimulation and subsequent activation of caspase 3. Fas- 
dependent activation of caspase 8  is also suppressed in healthy cells by the 
FADD-inhibitor FLIP (FLICE-like inhibitory protein) (83). During an apoptotic 
response pro-apoptotic Bcl-2 family members are upregulated and activated 
leading to a loss of mitochondrial integrity. As previously described, disruption 
of the mitochondria is necessary for the formation of the Apaf-1 apoptosome 
and the activation of caspases. Disruption of the mitochondria also releases the 
pro-apoptotic protein Smac (also known as DIABLO) into the cytoplasm (84). 
Smac promotes apoptosis by associating with the Apaf-1 apoptosome and 
inhibiting lAPs resulting in an increased activation of caspases (67, 78, 84). The 
induction of caspases is therefore a tightly regulated process that ensures
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caspases are suppressed in healthy cells but are potently induced in apoptotic 
cells enabling rapid and efficient execution of the cell.
1.4.3 Apoptosis-independent functions of caspases
Caspases are undoubtedly important mediators of apoptosis. However, 
they also perform non-apoptotic functions; for example, caspase 8  can interact 
with the I-kB kinase signalosome resulting in an increased kinase activity and 
the potential to enhance NF-kB activity (79). Caspases have also been 
implicated in regulating the activities of JNK and p38 MAPKs (81, 85, 8 6 ). 
Furthermore, FADD and caspases have been implicated in promoting 
proliferation of T and B lymphocytes (reviewed in (79)). For example, 
thymocytes and peripheral T cells that are deficient in FADD not only have 
impaired death receptor-mediated apoptosis but they also have defective T cell 
antigen receptor (TCR)-driven proliferation (87). These cells have abnormal 
regulation of cell cycle proteins including increased expression of the cell cycle 
inhibitor p21 and constitutive activation of Cdks 2 and 6 , and this causes the 
cells to undergo growth arrest at the G1 to S phase transition. These 
observations suggest FADD promotes proliferation of antigen-stimulated T cells. 
Furthermore, caspase 8 -deficient humans have defects in their activation of B 
lymphocytes, T lymphocytes and natural killer cells (8 8 ).
There have also been several reports suggesting caspases are activated 
downstream of the TCR without inducing apoptosis. Indeed, caspases have 
been shown to cleave multiple proteins involved in regulation of the cell cycle. 
For example, in endothelial cells the cell cycle inhibitors p21 and p27, which 
normally suppress cyclin-Cdk2  complexes to prevent G 1 to S phase transition, 
can be cleaved by caspase 3 to prevent the inhibitors binding to cyclin-Cdk2  
complexes and hence the activity of Cdk2  is increased (89). Furthermore, 
caspase-mediated cleavage of p27 has been observed in non-apoptotic 
proliferating lymphoid cells suggesting caspases may promote proliferation of 
lymphocytes (90).
The differential regulation of apoptosis and proliferation of cells by 
caspases may depend on the intracellular location of the activated caspases. 
Furthermore, post-transiational modifications of substrates are likely to 
determine their susceptibility to cleavage by caspases (79).
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1.4.4 Caspase-independent apoptosis
Caspases are unlikely to be essential for all forms of apoptosis (74, 91). 
Initial reports of caspase-independent apoptosis came from the observation that 
in specific systems caspase inhibitors are unable to prevent all the symptoms of 
apoptosis. For example, in Jurkat T cells apoptosis is characterised by a loss of 
cell viability, cell shrinkage, potassium efflux, altered mitochondrial membrane 
potential and DNA fragmentation. Cell shrinkage and the change in 
mitochondrial membrane potential are observed prior to the other symptoms of 
apoptosis. Treatment of the Jurkat cells with inhibitors of caspases (DEVD to 
inhibit caspase 3 or lETD to Inhibit caspase 8 ) prevented the damage to DNA 
but were unable to protect the cells from the other symptoms of apoptosis. 
Furthermore, treatment of the cells with calcium ionophores prevented cell 
shrinkage, potassium efflux and the change in mitochondrial membrane 
potential but they did not prevent DNA damage. These observations suggest 
that cell shrinkage, potassium efflux and changes in the mitochondrial 
membrane potential in Jurkat cells can occur separately to DNA degradation 
and via pathways that are largely independent of caspases (65). A similar 
situation was observed in Rat-1 fibroblast cells treated with zVAD.fmk (N- 
benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone) or BD.fmk (pan-caspase 
inhibitors). Inhibition of caspases protected these cells from DNA damage that 
would normally occur under apoptotic conditions but other characteristics of 
apoptosis such as cell shrinkage and membrane blebbing proceeded in the 
presence of caspase inhibitors (92). These observations imply caspases are 
critical mediators of nucleosomal laddering and DNA damage in apoptosis but 
other symptoms of apoptosis including cell shrinkage, membrane blebbing and 
loss of mitochondrial function can be performed by caspase-independent 
pathways.
Bcl- 2  family members are potential mediators of caspase-independent
apoptosis (74). For example, in Jurkat T cells and cerebellar granule cells,
overexpression of Bax can induce apoptosis that is not prevented by zVAD.fmk
despite this inhibitor being able to suppress caspase 3 and protect the cells
from nuclear fragmentation (93, 94). Indeed, studies in knockout mice have
indicated Bax, Bak and Bim are important mediators of negative selection to
remove autoreactive thymocytes (95). Under apoptotic conditions Bax rapidly
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translocates to the mitochondria and inserts into the outer mitochondria! 
membrane causing a disruption in mitochondrial function and inducing cell 
death (76, 77). Several pro-survival factors protect the cell from Bax indicating 
the importance of this Bcl-2 family protein in apoptosis. For example, 
overexpression of Bc I-xl  during rod photoreceptor apoptosis prevents Bax from 
translocating to the mitochondria and inhibits subsequent apoptosis (96). The 
small peptide humanin also protects cells from apoptosis by binding to Bax, 
preventing Bax from undergoing the conformational change that is required for it 
to translocate to the mitochondria (97). These observations strongly suggest 
Bax can mediate apoptosis independently of caspases and a critical stage of 
this process is the translocation of Bax to the mitochondria and subsequent 
disruption of mitochondrial function. Other pro-apoptotic proteins including Bak, 
Bik and Bim are known to be essential for apoptosis of specific cell types (95, 
98-100) therefore Bax may not be the only Bcl- 2  family protein that can mediate 
apoptosis in the presence of caspase inhibitors.
In the classical apoptotic pathway, disruption of the mitochondria leads to 
the activation of caspases and these mediate the execution of the cell (figure 
1.9 and 1 .1 0 ). However, proteases other than caspases have also been 
implicated in mediating apoptosis (74, 91). For example, disruption of the 
mitochondria causes the cytoplasmic levels of calcium to be elevated and Ca^  ^
can activate the calpain group of proteases. Calpains have been implicated as 
mediators of irradiation or dexamethasone-driven apoptosis in thymocytes (74). 
Calpains may also help regulate clonal deletion in immature B cells since 
ligation of the BCR in these cells can stimulate calpains whilst co-stimulation of 
CD40 causes calpastatin to be upregulated resulting in the inhibition of calpains 
(1 0 1 ). Calpains can cleave the cytoskeletal protein fodrin therefore they can 
mediate disruption of the cytoskeieton leading to a loss of cell shape and 
membrane blebbing. The cathepsins are another group of proteases that have 
been implicated in caspase-independent apoptosis of lymphocytes (102). For 
example, sphingosine-induced apoptosis of Jurkat T cells requires cathepsin D 
and possibly cathepsins B and L and the activation of these cathepsins seems 
to precede the disruption of the mitochondria! membrane (103). Indeed, in 
human T cells, mitochondrial-dependent apoptosis can be induced by cathepsin 
D since this mediates the activation of Bax resulting in the formation of pores in
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the outer mitochondrial membrane (104). The lysosomal protease cathepsin D 
can be induced in the apoptotic response of HeLa cells following exposure to 
interferon (IFN) gamma or Fas and in U937 cells treated with TNF (tumor 
necrosis factor) a (105). Furthermore, in TNF-induced apoptosis of WEHI-S 
fibrosarcoma cells cathepsin B is the main executioner protease (106).
It is important to note that several caspase inhibitors are also capable of 
inhibiting cathepsins and calpains. For example, the general caspase inhibitor 
zVAD.fmk, which is widely used to inhibit caspases and caspase-dependent 
apoptosis, can also inhibit additional cellular proteases including cathepsins B 
and H and calpains (74, 91, 106, 107). Caspase inhibitors must thus be used at 
relatively low concentrations when investigating the mechanism of apoptosis 
and the use of caspase-inhibitors is not necessarily adequate proof that 
caspases are essential for apoptosis.
1.5 The B cell antigen receptor complex
The BCR complex (reviewed in (3)) is a multiprotein structure that is held 
together by disulphide bonds (figure 1.1). It includes sig, which is required for 
antigen-recognition. There are five classes of immunoglobulin, IgM, IgD, IgG, 
IgE and IgA. All five can be expressed on the surface of B cells depending on 
the maturation state of the cell with IgM being the major form found on the 
surface of immature B lymphocytes (108). The majority of the sig structure is 
extracellular with only a small section of it being found in the cytoplasm. The 
precise length of the cytoplasmic region may depend on the class of 
immunoglobulin (3) but it is generally agreed that the cytoplasmic tail of sig is 
too short to possess any intrinsic catalytic activity, implying accessory 
molecules are required for signal transduction.
In 1988 two accessory molecules were discovered and cloned (4, 5). 
Encoded by the mb-1 and B29 genes respectively, iga (CD79a) and Igp 
(CD79P) exist as disulphide-linked heterodimeric complexes with extracellular 
and intracellular domains (3, 109, 1 1 0 ). Iga/lgp are essential for the transport 
and surface expression of the BCR (111) and are necessary for activating 
signals downstream of the BCR. Iga and Igp do not have intrinsic catalytic 
activity but they do contain conserved ITAMs. These motifs have the consensus 
sequence -YXXL/I-Xe s-YXXL/I- where X is any amino acid. Ligation of the BCR
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complex by antigen or anti-lg antibodies causes receptor aggregation and 
subsequent phosphorylation of tyrosine residues in the ITAMs of Iga/lgp, This 
occurs mainly at the membrane-proximal tyrosine and creates phospho-tyrosine 
motifs that can recruit other signalling molecules using their SH2 (Src homology 
2) domains. Nonetheless, both tyrosine residues of ITAMs can be 
phosphoryiated and this provides a specific binding site for the two SH2 - 
domains of the tyrosine kinase Syk (110). Phosphorylation of ITAMs of Iga/lgp 
is essential for the propagation of signals downstream of sig. Mutagenesis of 
the cytoplasmic domain of Iga or Igp has shown that these molecules are not 
functionally redundant with Iga being particularly important for pre-B cell 
development and Igp being specifically required for progression beyond the 
immature B cell stage (112-114).
1.6 BCR signalling in mature B lymphocytes
Ligation of the BCR on B lymphocytes leads to three possible outcomes, 
activation, anergy or apoptosis, depending on the developmental state of the 
cell. The signalling pathways activated downstream of the BCR have largely 
been studied in mature B lymphocytes although similar signalling networks 
appear to be stimulated by the BCR of immature B cells.
1.6.1.1 Activation of non-receptor tyrosine kinases
Following ligation of the BCR complex, three different families of non­
receptor tyrosine kinases are activated: the Src-family (Lyn, Fyn and Bik), Syk 
and the Tec-family (Btk). Experiments performed using knockout mice have 
revealed that each of these families has important roles in BCR signalling and in 
B cell development (115). Mice deficient in Lyn have an increased number of 
immature B cells but have fewer peripheral B cells indicating Lyn is required for 
the immature to mature B cell transition. The early events of BCR signalling are 
delayed in splenic B cells of Lyn' '^ mice indicating Lyn has a role in initiating 
BCR signalling but functional redundancy means BCR signalling can proceed, 
albeit at a slower rate, in the absence of Lyn (116). Syk is also an important 
component of the BCR complex and of other signalling complexes. Syk is 
especially required for pre-BCR signalling since irradiated mice reconstituted
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with Syk-deficient fetal liver display a B cell developmental block at the pro-B to 
pre-B cell transition. Syk is also required for the production or maintenance of 
mature B cells (21, 22). The Tec-family tyrosine kinase Btk is another essential 
component of pre-BCR signalling since a deficiency in Btk impairs B cell 
development at the pre-B celt stage, as indicated by the diseases X-iinked 
agammaglobulinaemia (humans) and X-linked immunodeficiency (mice). Mice 
lacking Tec and Btk have impaired peripheral B cell activation indicating these 
kinases are also required for BCR signalling (15, 2 0 ).
The activation of Src-family, Syk and Tec-family tyrosine kinases 
downstream of the BCR complex is thus necessary for normal B cell 
development and function. However, the precise mechanisms underlying the 
initial activation of these kinases following aggregation of the BCR complex are 
poorly understood. Kinetic analysis experiments suggest Src family kinases are 
activated before Syk and Btk (117). The activity of Src-family kinases is 
dependent on the phosphorylation state of two key residues: Tyr"^ ®^ and Tyr^^ .^ 
Tyr"^ ®^ is located in the catalytic domain of the enzymes and phosphorylation of 
this residue, often catalysed by autophosphorylation, can increase the activity of 
the kinase. However, in unstimulated cells Src-family kinases are autoinhibited 
by the phosphorylation of Tyr^^^ (Tyr®°® of Lyn). Tyr^^^ is located in the C- 
terminus of the kinase and when phosphoryiated this residue can interact with 
the N-terminal SH2 domain of the kinase to prevent substrate binding. In BCR 
signalling, Csk (C-terminal Src kinase) is particularly important for mediating the 
phosphorylation of the C-terminal tyrosine residue of Src-family kinases 
resulting in a suppression of their kinase activity (117-119). Activation of Src- 
family kinases requires the dephosphorylation of the inhibitory tyrosine residue 
or the competitive binding of a phospho-tyrosine-containing protein to the SH2 
domain of the kinase (120). In BCR signalling, CD45, a transmembrane tyrosine 
phosphatase, appears to be responsible for mediating the dephosphorylation of 
the C-terminal inhibitory tyrosine residue of Src-family kinases. Indeed, CD45- 
deficient B cells display hyperphosphorylation of Lyn at Tyr®°® and a resultant 
decrease in the recruitment and activation of Lyn following BCR ligation. This 
impairs the activation of additional signals downstream of the BCR complex (3, 
117, 121). CD45 is thus required for efficient activation of Lyn following ligation 
of the BCR complex.
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Once activated, Lyn can phosphorylate the tyrosine residues of ITAMs of 
Iga/lgp. In particular, Lyn phosphorylates the proximal tyrosine residues of 
ITAMs (122) to create phospho-tyrosine residues that can bind to SH2 domain- 
containing proteins including additional molecules of Lyn and other Src-family 
kinases. The binding of Lyn and other Src-family kinases to the ITAMs via their 
SH2 domains leads to their activation by inducing a conformational change that 
allows substrates to bind to the catalytic domain of the kinase (123). 
Furthermore, it has been reported that Lyn and Fyn Src-family kinases can 
associate with both phosphoryiated and non-phosphorylated cytoplasmic 
domains of Iga/lgp. However, the region of the Src-family kinase involved in the 
interaction depends on the phosphorylation-state of Iga/lgp: the N-terminal 1 0  
residues of Src-family kinases interact with non-phosphorylated Iga/lgp whilst 
the SH2  domain of the kinases binds to phosphoryiated ITAMs. The activation 
of Src-family kinases therefore may require the phospho-tyrosines of iga/lgp to 
induce a change in orientation of the associated kinase that can alter its activity 
(124).
In addition to increasing the activity of Src-family kinases, the induction of 
Lyn at the BCR complex leads to the stimulation of Syk. Syk has two SH2  
domains therefore it requires two phospho-tyrosine residues in the ITAMs in 
order to bind to Iga/lgp. It has been proposed that the initial recruitment of Syk 
to the BCR complex is mediated by the binding of the SH2 domains of Syk to 
phospho-tyrosine residues of other tyrosine kinases including Lyn (125). Syk is 
an allosteric enzyme that is potently stimulated by binding to the phospho- 
tyrosines of ITAMs in Iga/lgp (122). Syk can then catalyse the phosphorylation 
of both tyrosine residues of ITAMs leading to further recruitment and activation 
of Syk and other tyrosine kinases. For example, the Tec-family kinase Btk is 
recruited to tyrosine phosphoryiated ITAMs of Iga/lgp following ligation of the 
BCR complex. At the BCR complex, Btk is stimulated by phosphorylation of the 
activation loop at Tyr^ ®^  by Src-family kinases or Syk, followed by 
autophosphorylation at Tyr^^  ^ (1 1 0 , 126).
Ligation of the BCR complex therefore leads to the recruitment and 
activation of multiple tyrosine kinases. The kinases can phosphorylate tyrosine 
residues of ITAMs leading to further activation of non-receptor tyrosine kinases. 
Furthermore, the phospho-tyrosine residues of Iga/lgp and of the tyrosine
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kinases themselves provide docking sites for additional SH2-domain~containing 
proteins and the recruitment of these molecules is critical for stimulating 
downstream signalling pathways. Ultimately the activation of these signalling 
pathways regulates the activity, proliferation and survival of the B lymphocyte.
1.6.1.2 CD22
Appropriate B cell function requires careful regulation of signals stimulated 
downstream of the BCR complex. In particular, the activity of non-receptor 
tyrosine kinases must be regulated since their activation represents one of the 
earliest events of BCR signal transduction. CD22 is a co-receptor of B 
lymphocytes that can both positively and negatively regulate BCR signalling by 
targeting the early signals activated downstream of the BCR complex. CD22 
binds to ligands with a-2,6-sialic acid residues (127, 128) and is rapidly 
phosphoryiated at tyrosine residues following ligand binding or BCR-activation 
(129). Lyn can catalyse the phosphorylation of CD22 although maximal 
phosphorylation also requires Syk (130, 131).
Lyn and Syk phosphorylate the cytoplasmic domain of CD2 2  at three 
specialised regions known as ITIMs (immunoreceptor tyrosine-based inhibitory 
motifs). These are characterised by the amino acid sequence -V/IXYXXL- 
where X is any amino acid. Phosphorylation of ITIMs on CD22 creates docking 
sites for SH2 domain-containing proteins including the protein tyrosine 
phosphatase SHP-1 (SH2 domain-containing phospho-tyrosine phosphatase-1).
In unstimulated cells, SHP-1 is autoinhibited by the binding of the SH2 
domains of SHP-1 to its phospho-tyrosine phosphatase domain (132, 133). 
Stimulation of CD22 and subsequent phosphorylation of ITIMs causes SHP- 1  to 
be recruited via its SH2 domain, which induces a conformational change in 
SHP-1 that activates its phosphatase activity (128, 129). SHP-1 is a negative 
regulator of BCR signalling (132) and this was demonstrated using mice with 
deficiencies in this enzyme. For example, SHP-1 deficiencies are largely 
responsible for the symptoms observed in mice homozygous for the motheaten 
(me/me) or the allelic viable motheaten {me^/me^) mutations (134). Motheaten 
mice do not express SHP-1 and motheaten viable mice express catatytically 
inactive SHP-1. B cells from these mice have a reduced threshold for B cell 
activation and this contributes to the development of severe autoimmunity and
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inflammation in these mice (134). SHP-1 therefore is a very important negative 
regulator of BCR signalling.
CD22' '^ mice have a similar phenotype to motheaten mice but with less 
severe symptoms since SHP-1 is also required downstream of 
immunomodulatory receptors other than CD22 (132, 135). Nonetheless, CD22- 
mediated activation of SHP-1 is important for appropriate B cell activation and 
function since SHP-1 can dephosphorylate and inhibit Iga/lgp and BCR- 
associated tyrosine kinases including Lyn and Syk and their downstream 
targets including the adaptor protein BLNK (B cell linker protein) and 
phospholipase Cy (PLCy). This leads to a suppression of further BCR-regulated 
signals including MAPK activation and calcium signalling. CD22-associated 
SHP-1 also suppresses BCR signalling by inhibiting the co-receptor CD19, 
which amplifies BCR-activated signals. The activation of SHP- 1  by CD22 
therefore inhibits B cell activation (131, 134, 136-138).
SHP-1 is believed to act in concert with CD45. Mice deficient in SHP- 1  
have enhanced BCR signalling and CD45-deficient mice have impaired BCR- 
driven tyrosine phosphorylation. The B cells of mice deficient in both CD45 and 
SHP-1 have appropriate induction of protein kinase activity, MAPK activation 
and BCR-driven proliferation. This suggests that CD45 and SHP-1 are 
important regulators of BCR signalling and they have opposing effects on the 
regulation of specific signalling molecules and pathways downstream of the 
BCR (139).
However, CD22 can recruit signalling molecules in addition to SHP- 1  
including Lyn, Syk, PLCy, PI-3-K (phosphatidylinositol-3-kinase) and Grb-2 . The 
significance of these interactions is controversial but it has been suggested that 
their association with CD22 may lower the threshold for BCR-stimulation (127, 
132, 136). Different phospho-tyrosine residues in the cytoplasmic tail of CD22 
are used to bind to SHP-1 and Grb-2 (130) therefore the ability of CD22 to 
suppress or enhance BCR signalling may be regulated by the differential 
phosphorylation of specific tyrosine residues in the cytoplasmic tail.
1.6.2 Recruitment of adaptor proteins
Following activation of non-receptor tyrosine kinases, additional signalling 
molecules are recruited to the BCR complex. Ultimately, this results in the
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stimulation of four key signalling pathways: Erk-MAPK, PLCy, PI-3-K and the 
Rho-family of GTPases (figure 1 .1 1 ). Activation of these pathways requires 
adaptor proteins to couple the BCR to the upstream components of these 
signalling cascades. The BCR does not activate isolated signalling cascades 
but instead it stimulates a complex network of signals that have many points of 
"cross-talk” between the pathways. Activation of signals downstream of the 
BCR regulates the activity and the fate of the cell leading ultimately to 
proliferation, differentiation or apoptosis (figure 1 .1 1 ).
Adaptor proteins are molecules that mediate protein-to-protein and 
protein-to-lipid interactions via modular interaction domains. Adaptor proteins 
often have multiple interaction domains enabling them to bring several 
signalling molecules into close proximity. Different modular interaction domains 
have distinct properties. For example, SH2 domains are regions of 
approximately 1 0 0  amino acids that form three-dimensional structures that can 
bind to phospho-tyrosine residues. The amino acids that surround the phospho- 
tyrosine confer specificity for distinct SH2 domains (120, 140, 141); for instance, 
the SH2 domain of the adaptor protein Grb- 2  recognises the motif pYXNX (142, 
143).
Many SH2  domain-containing proteins also have SH3 (Src homology 3) 
domains. These are regions of approximately 50 amino acids that form a 
structure that can bind to proline-rich regions to mediate protein-to-protein 
interactions (120). Adaptor proteins can also mediate protein-to-lipid 
interactions; for example, PH (pleckstrin homology) domains can bind to 3- 
phosphorylated phosphatidylinositol lipids including phosphatidylinositol-3, 4, 5- 
trisphosphate ( P I P 3 ) .  This interaction is important for enabling membrane 
anchorage of specific proteins. Modular interaction domains thus direct the 
formation of complexes of multiple signalling molecules and they can determine 
the intracellular location of these complexes.
Several adaptor proteins have been identified as mediators of BCR 
signalling and each of these adaptors can be characterised by their modular 
interaction domains (figure 1.12) (110, 126, 144-151). The SH2  domains enable 
specific adaptor proteins to be recruited to phosphoryiated ITAMs of lga/lg(5. 
One such adaptor protein, BLNK (also known as SLP-65), forms an essential 
component of the BCR signalling network and is required during B cell
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development. Deficiencies in BLNK cause B lymphocyte development to arrest 
at the pro-B cell to pre-B cell transition (152-154). In peripheral B lymphocytes, 
BLNK is phosphoryiated downstream of the BCR by Syk (146), creating multiple 
phospho-tyrosine residues that can recruit additional signalling molecules via 
their SH2 domains (figure 1.13). Amongst the BLNK-associated proteins is the 
tyrosine kinase Btk and one of its substrates, PLCy. PLCy is activated by 
phosphorylation catalysed by Syk and Btk therefore BLNK acts as a scaffold for 
PLCy-activation (146, 155-157). Furthermore, the substrate of PLCy is a 
component of the plasma membrane therefore BLNK also brings PLCy into 
close proximity to its substrate. Phospho-tyrosine residues on BLNK can recruit 
additional signalling molecules including Vav, a guanine nucleotide exchange 
factor of Rho-family G-proteins. The simultaneous activation of PLCy and Rho- 
family G-proteins is required for the stimulation of JNK and p38 MAPK (146) 
therefore BLNK serves as a scaffold for the activation of multiple signalling 
pathways.
The adaptor protein Nek can also bind to phospho-tyrosine residues on 
BLNK using its SH2 domain (110, 149). Nek can interact with p21-activated 
ser/thr kinases (PAKs) and the Wiscott-Aldrich syndrome protein (WASP), both 
of which are involved in regulating the cytoskeletal structure of cells. PAK can 
also regulate MAPKs in several different cellular systems including Jurkat T 
cells, where PAK is required for Fas-mediated activation of JNK (81, 82, 158- 
162).
BLNK can also couple the BCR to Erk-MAPK via the recruitment of the 
adaptor protein Grb-2 . Grb-2 has two SH3 domains separated by a single SH2 
domain. It binds to BLNK via the SH2  domain and can then associate with the 
guanine nucleotide exchange factor SOS (Son of Sevenless) using its SH3 
domains. The recruitment of SOS to the membrane complex enables SOS to 
activate the monomeric G protein Ras, which can then lead to the stimulation of 
several signalling molecules including Erk-MAPK.
LAB (linker for activation of B cells) is a recently identified adaptor protein 
of BCR signalling that can interact with similar molecules to BLNK (figure 1.13). 
Ligation of the BCR induces the tyrosine-phosphorylation of LAB leading to the 
recruitment and activation of Grb-2/SOS and hence Ras/Erk. LAB can also bind 
to PLCy to enhance calcium signalling (150, 151). Deficiencies in BLNK can
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impair B cell development and BCR signalling indicating BLNK and LAB are not 
functionally redundant (152-154). The BCR thus uses several adaptor proteins 
to stimulate specific signalling cascades presumably to allow careful regulation 
of these signalling pathways.
In addition to LAB and BLNK, the BCR can stimulate the Grb-2/SOS 
pathway via the adaptor protein She (figure 1.13) (163). The recruitment and 
phosphorylation of She at the BCR complex requires both Src-family and Syk 
tyrosine kinases since Src-family kinases contribute to the activation of Syk and 
Syk can directly associate with and phosphorylate She (123, 163). She can also 
associate with the adaptor protein Gab- 1  (Grb-2-associated binder-1), which is 
phosphoryiated at tyrosine residues following ligation of the BCR. The phospho- 
tyrosine residues of Gab-1 can interact with multiple proteins including She, PI- 
3-K, SHP-2 and possibly Crk-L (figure 1.13) (147, 164). Both She and SHP- 2  
can bind to Grb-2 thus linking Gab- 1  to the activation of Erk-MAPK (110, 117, 
132, 165). The association of Gab-1 and SHP-2 /Grb- 2  has also been observed 
downstream of the receptors for epidermal growth factor (EGF) and platelet- 
derived growth factor (PDGF) and this interaction was specifically associated 
with the sustained activation of Erk1/2 (166). This suggests that the signalling 
networks generated by specific adaptor proteins can influence the kinetics of 
activation of particular signalling cascades. Furthermore, the co-localisation of 
SHP- 2  and P1-3-K at Gab- 1  can co-ordinate the activation of Erk by these two 
signalling molecules (167).
The association of Gab-1 and P1-3-K leads to the activation of PI-3-K 
therefore regulation of this interaction can determine the activity of PI-3-K. For 
example, in immortalised mlMCD-3 epithelial cells treated with hepatocyte 
growth factor, Erk phosphorylates threonine residues on Gab-1 to enhance the 
interaction of PI-3-K and Gab-1 and to increase PI-3-K activity. However, 
treatment of these cells with EGF leads to the Erk-mediated recruitment of 
SHP-2 and subsequent dephosphorylation of tyrosine residues on Gab-1 
resulting in a decreased association of Gab-1 and PI-3-K (168). Regulation of 
the association of Gab-1 and P1-3-K can thus determine the activity of PI-3-K. In 
Ramos B cells, Gab-1 and its associated signalling molecules can be found in 
the membrane-enriched particulate fraction therefore another function of Gab-1 
is to recruit signalling molecules to cellular membranes (164). P1-3-K catalyses
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the phosphorylation of phosphatidylinositol lipids therefore the Gab-1-mediated 
recruitment of PI-3-K to cellular membranes brings PI-3-K into close proximity 
with its substrates.
The BCR can also recruit and stimulate P1-3-K via the adaptor protein Cb! 
(figure 1.13). Ligation of the BCR induces Syk-mediated tyrosine 
phosphorylation of Cbl. The p85 subunit of P1-3-K binds to phospho-tyrosine 
residues of Cbl, inducing a conformational change in P1-3-K that greatly 
enhances its kinase activity often leading to relatively slow but sustained 
activation of PI-3-K (169). The phospho-tyrosines of Cbl can also bind to Crk-L 
and Crk-ll bringing these molecules to the plasma membrane. Crk can function 
as an adaptor protein since it has two SH3 domains in addition to its SH2  
domain. For example, in human embryonic kidney 293T cells Pyk2 can 
stimulate JNK MAPK via Crk (170). Crk is also an upstream regulator of Erk- 
MAPK since the SH3 domains of Crk can bind to SOS, leading to the activation 
of Ras and Erk, and to C3G a guanine nucleotide exchange factor for Rapi 
(171, 172). In B cells C3G is constitutively associated with Crk (171). C3G 
activates Rapi by exchanging GDP for GTP and Rapi can regulate Erk-MAPK 
both positively and negatively since Rapi inhibits the kinase Raf-1 leading to a 
suppression of Erk but activates B-Raf to stimulate Erk. The outcome of Rapi 
activation therefore depends on the relative amounts of Raf-1 and B-Raf in the 
cell (173).
In addition to regulating PI-3-K and Crk, Cbl has also been found to play a 
significant role in suppressing BCR signals. A loss of Cbl-b in mature B cells 
prolongs BCR-signalling resulting in sustained activation of PLCy, Erk and JNK 
(174). Cbl has a RING finger domain, a proline-rich region and a N-terminal 
tyrosine kinase-binding region that includes a SH2  domain, a four-helix bundle 
and calcium-binding EF-hand motif (figure 1.12) (148). The tyrosine kinase- 
binding region enables Cbl to bind to non-receptor tyrosine kinases and the 
RING finger domain allows Cbl to interact with ubiquitin conjugating enzymes. 
Downstream of the BCR, Cbl associates with Syk using the tyrosine kinase- 
binding domain and this leads to the ubiquitylation and subsequent degradation 
of Syk (174, 175). In B cells, Cbl is thus a negative regulator of signalling 
mediated by Syk and given the importance of Syk in initiating signals at the 
BCR complex it is possible that Cbl helps to set the threshold for BCR signalling
28
(174). Similarly in T cells, Cbl can drive the ubiquitylation and degradation of 
Fyn and Lck tyrosine kinases (176). Cbl also functions to exclude Lck from lipid 
rafts to further inhibit TCR signalling (177).
Adaptor proteins therefore have several functions. Firstly, they couple the 
BCR to multiple downstream signalling molecules via their different modular 
interaction domains. Secondly, they co-localise specific signalling molecules to 
enable their efficient regulation. Thirdly, adaptor proteins localise signalling 
molecules at a particular intracellular location and this can bring the signalling 
molecule into close proximity with its substrate. Finally, adaptor proteins can act 
as a platform for mediating the inhibition of specific signalling molecules.
1.6.3 Signalling pathways activated by the BCR complex
Ligation of BCR results in the stimulation of non-receptor tyrosine kinases 
and the phosphorylation of specific substrates including the adaptor proteins. 
Adaptors proteins enable the efficient regulation of four main signalling 
pathways: PI-3-K (figure 1.14), PLCy (figure 1.15), Rho-family of G-proteins 
(figure 1.16) and Erk-MAPK (figure 1.17).
1.6.3.1 PI-3-K
PI-3-K enzymes are lipid and protein kinases. They have been divided into 
four classes ( Ia ,  Ib , II and 111) based on their structural characteristics and 
substrate-specificity (reviewed in (178)). Class U enzymes are heterodimers of 
a regulatory subunit (p85a, p55a, p50a, p85p or p55y) and a catalytic subunit 
(pi 10a, p or Ô). The regulatory subunits have two SH2  domains and the region 
separating these domains is constitutively associated with the catalytic subunit. 
Class Ia regulatory subunits also have an SH3 domain, at least one proline-rich 
domain and a Bcr Homology domain that can bind to Rac-1/Cdc42. Only one 
member of the class Ib PI-3-K enzymes is known. It is a heterodimer of p i01 
regulatory subunit and pIlOy catalytic subunit. The plOI regulatory subunit 
lacks many of the structural domains of class U P1-3-K regulatoiy subunits and 
the p110y subunit cannot bind to regulatory subunits of class U PI-3-K 
enzymes. Class Ia and le enzymes therefore have the same substrate- 
specificity but are regulated by different mechanisms. There are three known
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members of the class II PI-3-K family and they are ubiquitously expressed. The 
C-termini of these enzymes have two distinctive domains: a phox homology 
domain to bind 3-phosphorylated phosphatidylinositol lipids, probably to enable 
membrane-anchorage and a C2 domain of unknown function. Class II PI-3-K 
enzymes are activated downstream of receptors for integrins, chemoklnes and 
some growth factors. Only one mammalian class III PI-3-K enzyme is known 
and it is constitutively active in vivo. It appears to regulate the trafficking of 
proteins through lysosomes (178).
It is difficult to study the function of specific PI-3-K enzymes in any system 
since no isoform-specific inhibitors are commercially available. Knockout mice 
therefore have been used to elucidate the function of specific P1-3-K enzymes 
(reviewed in (178)). However, knockout mice of class II and class III PI-3-K 
enzymes have not been generated and hence the function of these PI-3-K 
enzymes is poorly understood. Nonetheless, knockout mice of class U and Ib 
PI-3-K enzymes have been generated. Mice lacking either p i 10a or pIlOp die 
in utero but p llO ô ’ '^ or pHOy'^" mice develop normally suggesting embryonic 
development has specific requirements for pi 10a and p1 1 0 p. The regulatory 
subunits p85a, p55a and p50a are all generated from the same gene but mice 
lacking p85a are viable whilst mice lacking all three gene products die after 
birth suggesting an essential rote for p55a or p50a in the development of the 
mouse. Mice lacking p85p are viable and develop a functional immune system 
indicating this regulatory subunit is not required to mediate an immune 
response.
The function of class II and III PI-3-K enzymes in the immune system is 
poorly understood. However, class I a and I b enzymes are required in cells of 
the immune system including B cells. B lymphocyte development is impaired at 
the pro-B cell to pre-B cell transition in mice that lack either pi 106 or p85a (178,
179). Furthermore, pllOÔ'^' mice have a reduced number of marginal zone B 
cells and the mice have impaired antibody production in response to T cell- 
dependent and T cell-independent antigens (179). In addition, the splenic B 
cells of mice deficient in pllOô or p85a undergo a poor proliferative response 
following stimulation at the BCR or CD40 indicating the activation of P1-3-K is 
required for BCR-driven proliferation (179-181).
The stimulation of PI-3-K downstream of the BCR is dependent on both
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Ras and protein tyrosine kinases (110). Both class Ia and Ib Pi-3-K enzymes 
can interact with Ras in a GTP-dependent manner enabling Ras to activate 
these enzymes (182). In quiescent cells the C-terminal region of p85 prevents 
Ras-GTP from activating class Ia p110 enzymes. Activation of protein tyrosine 
kinases leads to the production of tyrosine-phosphorylated peptides that bind to 
the p85 subunit, inducing a conformational change that allows Ras-GTP to 
activate p 1 1 0 . The active p110 can be inhibited by the recruitment of SHP- 1  to 
the plasma membrane via the p85 subunit (183). The activation of class le PI-3- 
K also requires Ras-GTP to bind to the catalytic subunit of the enzyme. The 
regulation of this process is not fully understood but the Ras-dependent 
stimulation of p llO y appears to involve the induction of a conformational 
change since relocation of pIlOy to the plasma membrane is insufficient to 
activate the enzyme (182).
The SH3 domain of the tyrosine kinase Lyn can bind to the proline-rich 
domain of p85 PI-3-K but Lyn-deficient mice do not have impaired stimulation of 
PI-3-K downstream of the BCR indicating Lyn is not essential for the activation 
of PI-3-K (156). Syk tyrosine kinase has also been implicated in coupling the 
BCR to p85 PI-3-K activation and BCR-mediated tyrosine phosphorylation of 
the catalytic subunit of PI-3-K is abolished in Syk-deficient DT40 cells (156). 
Indeed, Syk can phosphorylate the multidomain signalling protein Cbl to create 
a phospho-tyrosine residue that is recognised by the SH2  domains of the p85 
subunit. Dominant negative Syk prevents the tyrosine phosphorylation of Cbl 
and blocks the association of Cbl and P1-3-K. The binding of the p85 subunit of 
PI-3-K to the phospho-tyrosine residue of Cbl Induces a conformational change 
in P1-3-K that greatly enhances its kinase activity often leading to relatively slow 
but sustained activation of PI-3-K. Syk and Cbl are located at the plasma 
membrane therefore the newly activated Pi-3-K is in close proximity to its lipid 
substrate (169). The role of Ras in the activation of PI-3-K via Cbl has yet to be 
established suggesting the BCR may stimulate PI-3-K via more than one 
mechanism.
PI-3-K phosphorylates phosphatidylinositol lipids at the 3' position of the 
inositol ring generating PI-3, 4, 5-Ps (PIP3) from PI-4, 5-Pz (PIP2) and Pl-3, 4-P2 
from PI-4-P. Phosphatidylinositol lipids with 3' phosphorylation are recognised 
by proteins with PH domains. The action of P1-3-K therefore enables specific
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proteins and complexes of proteins to be recruited to the cellular membranes 
(figure 1.14).
The activation of PI-3-K is necessary for the stimulation of multiple 
proteins including protein kinase B (PKB/Akt). Akt and its activating kinase 
PDK-1 (phosphoinositide-dependent kinase-1 ) are recruited to PIP3 at the 
plasma membrane via their PH domains. PDK-1 phosphorylates Akt at Thr °^® 
and this contributes to the activation of Akt but Akt must also be phosphoryiated 
on Ser'^^  ^ for efficient stimulation of the kinase. The enzyme responsible for 
phosphorylating Ser"^ ^^  is an unknown kinase termed PDK-2. PIP3 is essential 
for Akt stimulation but phosphorylation of Ser'^^  ^ also requires PI-3, 4 -P2 
suggesting PDK-2 may be recruited to the plasma membrane via PI-3, 4-Pz 
(184). Protein phosphatase 2A (PP2A) can inhibit Akt by catalysing the 
dephosphorylation of Thr^ ^® and Ser"^ ^^  indicating the importance of these 
residues in regulating the activity of this kinase (185). Furthermore, heat shock 
protein 90 can prolong Akt activation by preventing its dephosphorylation by 
PP2A (186). However, Tyr'^ '^^  of Akt has also been proposed to be a regulatory 
amino acid since a 55% reduction in Akt activity can be observed when this 
residue is mutated to Phe to prevent its phosphorylation (187). The activation of 
Akt may thus be dependent on multiple protein kinases.
Akt is a serine/threonine protein kinase that promotes cell survival (186). 
Akt protects cells from apoptosis by phosphorylating and inhibiting capase-9, 
Bad and the family of forkhead-related transcription factors (188). Akt also helps 
to retain Bax in the cytoplasm to prevent it from causing damage to the 
mitochondria (189) and Akt phosphorylates MDM2 to increase its translocation 
to the nucleus where it can inhibit p53 (186). In CD4^ T lymphocytes, CD28- 
mediated activation of Akt can also prevent Fas-induced apoptosis (190) 
suggesting Akt can suppress caspases 8  and 3. However, in lL-3-dependent 
32D cells withdrawal of cytokine causes Fas-activated caspases to cleave Akt 
resulting in its degradation (191). The balance of Akt and caspase activity can 
thus determine the survival of a cell.
Akt is an important mediator of B and T lymphocyte survival. This is 
illustrated by the observation that many B and T ceil malignancies have high 
levels of the TCL1 (T cell leukemia 1) gene product, which can activate Akt by 
enhancing its concentration and phosphorylation at the plasma membrane
32
(192). Furthermore, B cells of mice that are deficient in the p1 10ô subunit of Pl-
3-K are prone to apoptosis, possibly reflecting their inability to activate Akt (179,
180). In splenic B cells, the activation of PI-3-K/Akt downstream of the BCR can 
promote cell survival by stimulating NF-kB, which can increase the transcription 
of pro-survival factors including c-Myc (193). Akt can activate NF-k B by 
catalysing the phosphorylation of I-kB and this can lead to further stimulation of 
Akt since NF-k B is able to increase the expression of Akt (188, 194). BCR- 
mediated activation of Akt also enhances the activity of NF-AT (nuclear factor 
for activated T cells) by inhibiting glycogen synthase kinase 3. NF-AT activates 
AP-1-like transcription factors to regulate gene expression and this may 
contribute to the survival of the B cell (195). The mammalian target of 
rapamycin and p70®® kinase have also been implicated as mediators of PI-3-K- 
dependent proliferation of B cells downstream of the BCR (196). Akt, PDK-1 
and PKC (protein kinase C) ^ can all contribute to the phosphorylation and 
activation of p70®  ^kinase (197).
PDK-1 and Akt are not the only PH-domain containing proteins involved in 
B cell signalling. For example, the recruitment of PKC^ to the plasma 
membrane via P I P 3  enhances the activation of this atypical PKC enzyme by 
Ras (198). B lymphocytes from PKC^^’ mice undergo spontaneous apoptosis 
and have impaired activation and antibody production suggesting PKC^ has an 
important role in promoting B cell survival and activation (199), The production 
of P I P 3  downstream of the BCR can also induce Vav leading to changes in the 
cytoskeleton and the activation of MAPK enzymes (178).
Furthermore, the B cells of mice that are deficient in the pi 106 subunit of 
PI-3-K have impaired BCR-driven activation of Btk, PLCy and calcium 
mobilisation suggesting PI-3-K can regulate each of these signalling molecules. 
Mice lacking pi lOô have impaired proliferation suggesting these molecules can 
promote proliferation of B cells downstream of the BCR (179, 180). Btk has a 
PH domain therefore the production of PIP3 can bring Btk to the plasma 
membrane and the BCR signalling complex. This increases the activity of Btk 
and brings it into close proximity to its substrates including PLCy which can also 
be recruited via its PH domains (20, 169). The stimulation of PLCy results in 
increased calcium signalling and the activation of downstream molecules 
including PKC (178).
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1.6.3.2 PLCy
There are three families of phospholipase C enzymes (figure 1.15A). The 
PLCy family has two members, PLCy1 and PLCy2. Both PLCy enzymes have a 
similar structure that includes two PH domains separated by two SH2 domains 
and a SH3 domain (figure 1.15A). These domains have important functions in 
the regulation of PLCy activity. B lymphocytes predominantly express PLCy2 
and it is stimulated downstream of the BCR (117). The activation of PLCy2 
downstream of the BCR is impaired in cells that are deficient in the adaptor 
protein BLNK, or the tyrosine kinases Syk and Btk indicating all three molecules 
are required for efficient stimulation of PLCy (126, 146, 155, 199). Following 
ligation of the BCR the tyrosine kinase Syk is stimulated and Syk 
phosphorylates BLNK at multiple tyrosine residues (126). Both Btk and PLCy 
are recruited to the BCR complex by binding to the tyrosine phosphoryiated 
BLNK using their SH2 domains (figure 1.15B). The translocation of Btk to the 
BCR complex is assisted by the presence of 3-phosphorylated 
phosphatidylinositol lipids since these enable Btk to associate with the plasma 
membrane via its PH domain. PLCy also has a PH domain and this may assist 
the translocation of PLCy to the BCR complex or it may help to maintain its 
localisation at the BCR complex (126). Activation of PLCy at the plasma 
membrane requires phosphorylation of Tyr^^  ^and Tyr^ ®® of PLCy. Btk has a far 
greater ability than Syk to phosphorylate these residues indicating the principal 
role of Syk in the activation of PLCy is to phosphorylate BLNK and enable the 
PLCy-BLNK-Btk complex to be formed (157). The close proximity of Btk and 
PLCy in this complex enables Btk to phosphorylate and activate PLCy (155).
B lymphocytes that lack BLNK have impaired but not abolished PLCy2 
activation suggesting the BCR can also stimulate PLCy via a BLNK- 
independent pathway. The adaptor protein LAB is a likely candidate for 
mediating the BLNK-independent pathway since LAB is phosphoryiated 
downstream of the BCR and this enables it to bind to PLCy (126, 150).
In addition to assisting the activation of PLCy, the recruitment of PLCy to 
the plasma membrane via LAB/BLNK brings the enzyme into close proximity 
with its substrate Pl-4, 5 -P2 . PLCy cleaves the lipid PIP2 to generate 
diacylglycerol (DAG) and inositol-1, 4, 5-trisphosphate ( I P 3 )  (figure 1.15B). I P 3  is
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a cytosolic second messenger that can bind to IP3 receptors on the 
endoplasmic reticulum and Induce the release of calcium from intracellular 
stores (200, 201). The elevation of cytosolic calcium levels activates 
downstream signalling molecules including calcineurin (a Ca^^-sensitive protein 
phosphatase), conventional PKC isoforms and JNK MAPKs (117, 202, 203).
DAG is a lipid soluble second messenger therefore it is membranous. 
DAG can activate phorbol ester-sensitive isoforms of PKC and hence it 
stimulates conventional PKC isoforms (a, pi, pll and y) and novel PKC isoforms 
(Ô, e, 0 , j], v) (204-208). The functions of PKC enzymes in cells of the immune 
system are incompletely understood but the activation of PKC can enhance the 
activity of MAPKs especially Erk1 / 2  (202). For example, in IL-3-stimulated 
murine hematopoietic cells phorbol ester-sensitive isoforms of PKC can directly 
phosphorylate and activate Raf-1 (209).
There are many different types of PKC enzymes and they are likely to 
have specific functions within particular cell types. For example, PKCp" '^ mice 
have impaired humoral immune responses and their B cells respond poorly to 
BCR-stimulation (210) indicating PKCp provides an important activating signal 
in B lymphocytes. The phenotype of PKCp  ^ mice is similar to that of Btk- or 
PLCy-deficient cells suggesting PKC(3 functions in the same signalling pathway 
as the PLCy-BLNK-Btk complex (reviewed by (199)). The PLCy-BLNK-Btk 
complex is required for BCR-dependent activation of the transcription factor NF- 
k B and this in turn regulates the expression of the genes encoding the pro­
survival proteins Bc1-Xl and Bcl-2 (199, 211). BCR-stimulated B celts from 
PKCp'^" mice have impaired activation of the Bc1-xl and Bcl- 2  but cyciin D2 
levels are unaffected suggesting PKCp is more involved in regulating survival 
than proliferation. The function of T lymphocytes is not impaired in PKCp' '^ mice 
suggesting this enzyme is specifically required in B cells. However, PKC0  is 
required for TCR-mediated activation of NF -k B and no defects in B cell N F -k B 
activation have been observed in PKC0 "^ ' mice. Furthermore, the pre-BCR can 
stimulate N F -k B via PKCX indicating the function of particular PKC isoforms will 
depend on the type of cell and developmental stage of that cell (2 1 2 ).
Moreover, PKCÔ is required in addition to PKCp for appropriate function of
mature B cells. However, B cells of PKCÔ mice have enhanced B cell
proliferation, elevated antibody production and are prone to autoimmunity
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suggesting PKCô is normally a negative regulator B cell activation (199). The 
different PKC isoforms can thus differentially regulate B cell activation and 
survival.
1.6.3.3 Rho-family of GTPases
The Rho-family of GTPases is activated downstream of the BCR via the 
guanine nucleotide exchange factor Vav. Vav has one SH2 domain and two 
SH3 domains and is recruited to the BCR complex via BLNK. At the BCR 
complex Vav is tyrosine phosphoryiated and activated, probably by Syk, 
enabling it to stimulate the Rho-family of G-proteins including R ad, RhoA and 
Cdc42 (144). R ad is a mediator of actin polymerisation and can alter the 
cytoskeleton of the cell. Rearrangement of the actin cytoskeleton is required for 
capping of the antigen receptor and for optimal calcium signalling in 
lymphocytes (1 1 0 , 213). Rac1/Cdc42 also contributes to the stimulation of 
PLCy2 and PI-3-K downstream of the antigen receptors of B cells (figure 1.16) 
and T cells and these can enhance calcium mobilisation and activate additional 
signalling molecules including Akt (146, 178, 213-216). Furthermore, the 
activation of Vav/Rho downstream of the BCR can stimulate 
phosphatidylinositol-4-phosphate-5-kinase (figure 1.16). This lipid kinase is 
responsible for maintaining the levels of Pl-4, S-Pg in cellular membranes and 
thus ensures there is a constant supply of substrate for PLCy (1 1 0 ).
In B and T lymphocytes Rac1/Cdc42 can also contribute to the activation 
of MAPK proteins, especially those of the JNK and p38 families (144, 146). For 
example, in DT40 B cells Rac1/Cdc42 activates JNK-MAPK via the stimulation 
of the serine/threonine protein kinases MEKK-1 or PAK1 and the dual-specificity 
kinases MKK4 or MKK7 (figure 1.16) (3, 217). Furthermore, in HeLa cells Rac- 
1/Cdc42 can activate Erk-MAPK via the stimulation of PAK1/3, which 
phosphorylates and activates Raf-1 (162). In addition to JNK and p38 MAPK, 
the BCR may thus couple to Erk-MAPK via Rac.
1.6.3.4 Erk-MAP kinase cascade
The classical mechanism of activating Erk-MAPK (figure 1.17) is via the
adaptor protein Grb-2 . The SH3 domains of Grb-2 bind to the guanine
nucleotide exchange factor SOS. SOS activates the monomeric G-protein Ras
36
by exchanging GDP for GTP. Ras-GTP can then bind and activate the 
serine/threonine protein kinase Raf-1, leading to the stimulation of the dual­
specificity protein kinases MEK1 and MEK2. MEK1/2 activates Erk-MAPK by 
phosphorylating the threonine-glutamate-tyrosine (T-E-Y) motif of the activation 
loop and Erk172 can phosphorylate a wide range of substrates including 
cytoplasmic molecules such as phospholipase Ag (218) and nuclear substrates 
including the transcription factors Elk-1 and c-Myc (219). The particular 
substrates of Erk-MAPK will depend on the duration of Erk-activation, the 
intensity of the Erk signal and the presence of additional signalling complexes. 
For example, in fibroblasts a transient Erk signal is Insufficient to stimulate the 
transcription factor c-Fos but a prolonged Erk signal can mediate the 
phosphorylation and stabilisation of c-Fos to promote AP-1-mediated 
transcription (220). The activation of Erk-MAPK in B cells is associated with a 
variety of cellular responses including proliferation and apoptosis.
The BCR complex can couple to Grb-2 via additional adaptor proteins 
including She (123, 163), BLNK (110, 153) and LAB (150). Furthermore, the 
BCR-associated adaptor Gab-1 can bind to She and SHP-2 and these can both 
bind to Grb-2/SOS (1 1 0 , 117, 132, 165). The association of Gab-1 and SHP- 
2/Grb-2 has also been observed downstream of the receptors for EGF and 
PDGF and this interaction was specifically associated with sustained activation 
of Erk1 / 2  (166). The ability of the BCR to couple to Grb-2 /SOS via multiple 
adaptor proteins may therefore regulate the kinetics of Erk-MAPK activation.
The BCR can further couple to the MAPK cascade via the multidomain 
protein Cbl (figure 1.17) since ligation of the BCR causes Syk to phosphorylate 
Cbl. The resultant phospho-tyrosine residues can bind to P1-3-K leading to its 
activation (169) and to Crk, bringing it to the plasma membrane (171), Crk can 
bind to SOS, leading to the activation of Ras and Erk and to C3G leading to the 
activation of Rapi (171, 172). Rapi has the same effector domain as Ras 
therefore it competes with Ras for substrate binding. Rapi is both a negative 
and a positive regulator of Erk-MAPK since Rapi inhibits Raf-1 but activates B- 
Raf. The outcome of Rapi activation therefore depends on the relative amounts 
of Raf-1 and B-Raf in the cell. This is illustrated by the differential regulation of 
Erk in PCI2  cells. Differentiation of PCI2  cells following exposure to nerve 
growth factor requires sustained activation of Erk and this is mediated by
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Crk/C3G/Rap-1 and B-Raf. A transient Erk signal stimulates proliferation of 
PC12 cells and this is mediated by Ras/Raf-1-dependent activation of Erk (173). 
Furthermore, in DT40 B cells ligation of the BCR can stimulate Erk-MAPK via 
Raf-1 or B-Raf but the distinct pathways of activation result in different 
intensities and durations of Erk activation. Consequently, either pathway can 
induce immediate early genes but only B-Raf-stimulated Erk can activate NF-AT 
(221). The differential regulation of Erk-MAPK by Raf-1 and B-Raf can thus 
determine the duration of Erk-stimufation and the substrates that become 
phosphoryiated by Erk.
Rapi stimulation has been observed downstream of the BCR in primary 
splenic B cells and in various B cell lines but the precise mechanism of Rapl- 
activation is incompletely understood. In Ramos B cells stimulation of the BCR 
has been shown to induce the tyrosine phosphorylation of Cbl leading to the 
recruitment of Crk and the activation of C3G and Rapi (171). However, it has 
also been proposed that the BCR may activate Rapi via a Crk-independent 
pathway that requires activation of PLCy and the production of DAG. The 
mechanism of DAG-dependent stimulation of Rap- 1  is incompletely understood 
but it may be mediated by DAG-activated isoforms of PKC (172).
1.6.3.5 Additional signalling pathways activated by the BCR
In mature B lymphocytes, ligation of the BCR can activate phospholipase 
D (PLD), a lipid hydrolysing enzyme. Two types of phosphatidylcholine-PLD 
have been cloned, PLD1 and PLD2. PLD1 is largely located in the Golgi and 
endoplasmic reticulum whereas PLD2 is predominantly found at the plasma 
membrane. PLD enzymes are stimulated by conventional isoforms of PKC, the 
Arf-family of monomeric G-proteins and Rho-family G-proteins. Furthermore, PI- 
4, 5 -p2 is a cofactor that is required for their activation. Both PLD enzymes can 
hydrolyse phospholipids to generate phosphatidic acid (PA). PA can function as 
a second messenger that activates phosphatidylinositol-4-phosphate-5-kinase, 
PKCti and PKC^. Moreover, PA can be hydrolysed to DAG, to generate a 
sustained DAG signal that can activate conventional and novel PKC isoforms. 
However, PA can also be converted to lysophosphatidic acid and when 
secreted, lysophosphatidic acid can induce mitogenesis via a G-protein-coupled 
receptor (2 2 2 ).
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Mature B lymphocytes undergo at least two different types of PLD 
signalling. Indeed, ligation of the BCR stimulates a non-phosphatidylcholine- 
hydrolysing PLD enzyme leading to the production of DAG and the stimulation 
of mitogenesis. However, extracellular ATP can inhibit anti-lg-induced 
proliferation of mature B cells via the stimulation of p2-purinoreceptors. Ligation 
of Pa-purinoreceptors induces a phosphatidylcholine-hydrolysing PLD, resulting 
in the production of PA and the induction of growth arrest. Furthermore, 
ceramide and sphingosine can also stimulate phosphatidylcholine-PLD leading 
to a suppression of B cell proliferation. The differential regulation of distinct 
types of PLD therefore can either induce growth arrest or promote B cell 
proliferation (222, 223). Interestingly, the BCR on immature B lymphocytes is 
not coupled to the early induction of either of these PLD pathways. The 
induction of growth arrest and apoptosis downstream of the BCR in immature B 
cells therefore is not mediated by early signalling via phosphatidylcholine-PLD 
or inhibition of non-phosphatidylcholine-PLD (223).
1.6.4 Integration of signalling pathways
Ligation of the BCR induces the activation of four main pathways: P1-3-K, 
PLCy, Rho GTPases and Erk-MAPK cascade. However, these signalling 
cascades are not activated in isolation and cross-talk between the pathways is 
common (224). This is an important mechanism of regulating these signals and 
controlling the activation of specific downstream targets.
For example, the Erk-MAPK cascade and the PI-3-K pathway frequently 
interact since Ras can activate both Erk-MAPK and PI-3-K (225-227). 
Furthermore, PI-3-K can negatively regulate the Erk-MAPK cascade via the 
activation of Akt since Akt can inhibit Raf-1 by phosphorylating Ser^ ^® and inhibit 
B-Raf by phosphorylating an N-terminal regulatory domain (228-230). 
Moreover, Erk can also regulate the activity of PI-3-K in both a positive and a 
negative manner by determining the phosphorylation state of the adaptor 
protein Gab-1 and hence affecting the ability of PI-3-K to associate with Gab- 1  
(168). Consequently, the relative activity of Erk and P1-3-K can determine the 
activity and fate of a cell (226, 231). For example, in vascular smooth muscle 
cells PDGF induces a strong and prolonged activation of PI-3-K/Akt leading to 
the inhibition of Raf-1/Erk and to the induction of mitogenesis. In contrast,
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thrombin stimulates a transient and weak Pl-3-K/Akt signal in these ceils 
enabling strong and prolonged activation of Erk and this causes the cells to 
undergo differentiation (232).
Erk and PI-3-K can also co-operate to regulate the activity of specific 
downstream targets. For example, in the Burkitt’s lymphoma cell line ST486 the 
simultaneous activation of Erk-MAPK and P1-3-K leads to the stimulation of 
p90®® ribosomal kinase. The activation of p90®® ribosomal kinase enhances the 
survival of the cells by phosphorylating and inhibiting Bad (233). Furthermore, in 
N1H-3T3 cells the simultaneous activation of Erk-MAPK and PI-3-K is necessary 
for the induction of DNA synthesis since Erk can stimulate the transcription 
factors Fra1 and Fra2 whilst PI-3-K induces cyciin D1 and both of these factors 
are required for DNA synthesis (234).
Moreover, in B lymphocytes BCR-dependent activation of cyciin D2 and 
subsequent cell cycle progression requires the induction of BLNK, P1-3-K and 
Btk (33). Indeed, the stimulation of cyciin D2 is impaired in BLNK-deficient mice 
(199) and B cells from mice lacking the p8 6 fx subunit of PI-3-K or Btk (181). 
However, the precise mechanism by which BLNK, PI-3-K and Btk mediate the 
induction of cyciin D2 to promote B cell proliferation is incompletely understood.
The survival of B lymphocytes is also regulated by multiple signalling 
cascades. For example, the activation of the transcription factor N F -k B can 
promote mature B cell survival since N F -k B can induce the transcription of pro­
survival factors including c-Myc, Bc1-Xl and Bcl-2 (193, 199, 211). Moreover, the 
induction of N F -k B is impaired in B lymphocytes from various types of knockout 
mice including mice deficient in the p85a subunit of PI-3-K, Btk, BLNK, PLCy or 
PKCp (181, 199). This suggests that BCR-dependent activation of N F -k B in 
mature B cells requires the activation of PI-3-K and PLCy. Indeed, Akt can 
phosphorylate and inhibit I-k B suggesting a potential mechanism of P1-3-K- 
dependent induction of N F -k B (194). Furthermore, B cells of PKCp' "^ mice have 
defective activation of I-k B kinase leading to impaired inhibition of I-k B (199) 
suggesting PKCp induces NF-KB by activating I-k B kinase. However, the 
observations from the knockout mice suggest that the efficient induction of NF- 
k B downstream of the BCR complex requires the co-ordinated stimulation of Pl- 
3-K and PLCy-regulated pathways.
Similarly, P1-3-K and PLCy signals can both regulate the transcription
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factor NF-AT. For example, the production of IP 3  by PLCy induces calcium 
mobilisation and this can stimulate the calcium-sensitive phosphatase 
calcineurin. Calcineurin can then dephosphorylate NF-AT causing it to 
translocate to the nucleus where it can induce gene expression via AP-1-like 
transcription factors. However, NF-AT is inhibited by glycogen synthase kinase 
3 since phosphorylation of NF-AT Induces a conformational change that reveals 
a nuclear export signal. Ligation of the BCR can promote NF-AT activity via the 
induction of PI-3-K and Akt since Akt can inhibit glycogen synthase kinase 3 
(195). Furthermore, the Erk-MAPK cascade also contributes to the activation of 
NF-AT in B lymphocytes. For example, in DT40 B cells BCR-driven activation of 
NF-AT requires a strong and prolonged Erk signal that requires B-Raf activity 
(221).
1.7 Co-Receptors
Signals activated by ligation of the BCR complex can regulate the activity 
and the fate of B lymphocytes. However, B cells express additional surface 
receptors, known as co-receptors, that can activate or inhibit the signalling 
pathways regulated by the BCR. Co-receptors can determine the activation 
threshold of the BCR, the phenotype of the activated cell and the duration of 
BCR stimulation. Several significant co-receptors have been studied in B cells 
including CD19, FcyRIIB and CD40 (127).
1.7.1 GDIS
CD 19 is a co-receptor that can enhance BCR-signalling. It is expressed 
throughout B cell development until plasma cell differentiation. On the surface of 
B cells, CD19 is found in association with CD21 and CD81. CD21 is a type 2 
complement receptor that recognises C3d-labelled antigen. The simultaneous 
activation of the BCR and CD21 by C3d-labelled antigen can significantly lower 
the threshold for B cell activation (3, 127, 235).
Following ligation of CD21 and/or the BCR, the cytoplasmic tail of CD19
becomes phosphoryiated at tyrosine residues. However, Lyn-deficient B cells
do not have impaired CD19 phosphorylation indicating Lyn is not essential for
the function of CD19 (236). The phosphorylation of Tyr"^ ®^  and Tyr®^  ^ of CD19
can directly recruit the p85 subunit of PI-3-K using the SH2 domains of P1-3-K
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(237). This leads to the activation of PI-3-K and 3-phosphorylated 
phosphatidylinositol lipids are generated, providing anchoring points for PH 
domain-containing proteins (figure 1.18). This pathway occurs independently of 
Cbl (43, 126, 156, 169). The activation of PI-3-K by CD 19 is necessary for 
efficient stimulation of Akt downstream of the BCR (238). However, CD19 also 
amplifies and prolongs the activation of Btk although it is not essential for BCR- 
mediated stimulation of Btk (239). The combined induction of PI-3-K and Btk by 
CD19 enhances the activity of PLCy and its downstream signals including 
calcium mobilisation (165, 235).
B cells that are deficient in CD19 are hyporesponsive to antigenic- 
stimulation and consequently generate poor immune responses. However, 
inactivation of the lipid phosphatase PTEN (phosphatase and tensin 
homologue) can compensate for the CD19-deficiency. PTEN reduces the 
cellular levels of 3-phosphorylated phosphatidylinositol lipids by removing the 3' 
phosphate group from the lipids. PTEN therefore catalyses the conversion of PI- 
3, 4, 5 -P3 to Pl-4, 5 -P2 and hence opposes the action of PI-3-K. The ability of 
PTEN Inactivation to compensate for CD 19-deficiency suggests the main 
signalling molecule activated by CD 19 is PI-3-K (240).
However CD 19 has also been found to bind to Vav via phospho-Tyr^®^ 
(figure 1.18). Vav may contribute to the activation of PLCy and calcium 
signalling. Furthermore, Vav is known to activate JNK MAPK downstream of the 
BCR (figure 1.16) therefore CD19-mediated activation of Vav may amplify BCR- 
dependent activation of JNK. Tyr^ ®^  of CD 19 has also been suggested to 
contribute to the activation of Erk-MAPK in a Vav-independent manner 
suggesting Tyr^ ®^  of GDI 9 can interact with several molecules to amplify BCR 
signalling (235, 236).
1.7.2 FcyRIIB
In the early stages of an immune response, ligation of the BCR leads to B 
cell activation including increased gene transcription, protein synthesis and 
antibody production. In the later stages of the immune response, FcyRIIB, the 
low affinity receptor for the Fc portion of IgG, is recruited to BCR-containing lipid 
rafts enabling immune complexes to co-ligate the BCR and FcyRIIB. Co-ligation 
of FcyRIIB suppresses BCR-mediated signalling including calcium mobilisation,
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Akt activation and stimulation of MAPK. FcyRIIB thus inhibits BCR-driven 
proliferation ensuring the activation of 8 lymphocytes is a carefully regulated 
process (241, 242).
The co-aggregation of the BCR and FcyRIIB induces the tyrosine 
phosphorylation of a single ITIM located in the cytoplasmic tail of FcyRIIB (114, 
127). Lyn is required for phosphorylation of FcyRIIB and B cells from Lyn- 
deficient mice display enhanced BCR-mediated induction of MAPK and 
proliferation reflecting the importance of Lyn in the negative regulation of BCR 
signalling (116). The main protein to be recruited to the phosphoryiated ITIM of 
FcyRIIB is the phosphatase SHIP (SH2 domain-containing inositol 5- 
phosphatase) (figure 1.19). SHIP removes the S' phosphate residue from Pl-3, 
4, 5 -P3 (PIP3) and inositol-1, 3, 4, 5-tetraphosphate (IP4). IP4 is an activator of 
an endothelial membrane Ca^^ channel therefore the degradation of IP4 by 
SHIP reduces the intracellular calcium flux (127, 241). The degradation of PIP3 
by SHIP impairs the ability of the BCR to recruit and activate PH domain- 
containing proteins. SHIP can thus decrease the calcium flux further by 
impairing the activation of PLCy (131). Furthermore, the degradation of PIP3 by 
SHIP can inhibit Akt and Btk thus promoting apoptosis (131, 241). indeed, the 
activity of Akt is enhanced in bone marrow-derived mast cells from SHIP'''' mice 
(184). However, Akt can also be stimulated by Pl-3, 4-P2, the product of SHtP- 
mediated dephosphorylation of PIP3 , therefore SHIP could potentially activate 
Akt under conditions in which Pl-3, 4 -P2 is allowed to accumulate (127). 
Nonetheless, FcyRIIB signalling is generally reported to be inhibitory of Akt 
(131, 241). Indeed, ligation of FcyRIIB in mature B cells can induce PTEN 
resulting In a depletion of 3’-phosphorylated phosphatidylinositol lipids and an 
antagonism of PI-3-K and Akt signalling (243).
The Erk-MAPK cascade can also be inhibited by FcyRIIB (figure 1.19) 
since SHIP and Grb-2 directly compete for the binding of phospho-tyrosine 
residues on She. Consequently, SHIP impairs the formation of Grb-2/SOS 
complexes, resulting in a suppression of the MAPK cascade (241). 
Furthermore, FcyRIIB and SHIP can suppress the MAPK cascade via the 
recruitment and activation of p62 Dok (62 kD protein downstream of tyrosine 
kinase), also known as Doki (figure 1.19). The N-terminal region of Doki has a 
PH domain to allow phospholipid/membrane-binding. Doki also has a phospho-
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tyrosine-binding domain and a C-terminal pro/tyr-rich region that regulates the 
repertoire of proteins that can associate with Dok1 (figure 1.12). Co-aggregation 
of FcyRIIB and the BCR increases the tyrosine phosphorylation of SHIP 
enabling Dok1 to bind to SHIP using its phospho-tyrosine-binding domain. At 
the plasma membrane, Dok-1 becomes tyrosine phosphoryiated allowing it to 
interact with and activate RasGAP (Ras GTPase activating protein). RasGAP 
enhances the intrinsic GTPase activity of Ras leading to the inhibition of Ras 
and its downstream effectors including Erk (114, 131, 244). FcyRIIB can also 
suppress BCR-mediated activation of Erk via the induction of the MAPK 
phosphatase Pac-1 leading to dephosphorylation and inhibition of Erk (243).
Ligation of FcyRIIB can thus impair P1-3-K signalling, PLCy activation and 
the induction of MAPK. SHIP is the main mediator of FeyRlIB-driven 
downregulation of BCR signalling but under some circumstances FcyRIIB can 
also bind to SHP-1 and SHP-2 in vitro. The physiological relevance of SHP-1 
and SHP-2 in FcyRIIB signalling is uncertain as it does not appear to be 
essential for FcyRIIB function (131, 245). SHP-1 is activated by binding to 
phospho-tyrosine residues of ITIMs and it generally functions to inhibit the 
signals activated by the BCR and CD19 (134). SHP-1 can bind to and inhibit the 
tyrosine kinases Lyn and Syk resulting in the suppression of early signals 
activated by the BCR complex and CD19. SHP-1 also associates with BLNK to 
block signals activated downstream of this adaptor protein. SHP-1 can thus 
negatively regulate PLCy and Ca^ "^  signalling, MAPK activation and PI-3-K 
stimulation (134, 136, 137, 165). SHP-2 is structurally related to SHP-1 but 
SHP-2 is generally considered to be a positive regulator of cell signalling. For 
example, SHP-2 can bind to Grb-2 leading to the activation of Erk-MAPK (132, 
165, 166).
1.7.3 CD40
1.7.3.1 Functions of CD40 in mature B lymphocytes
CD40 is a 45 kD transmembrane glycoprotein that is a member of the TNF 
receptor family. It is expressed on several cell types including B cells, 
macrophages and dendritic cells. CD40 can be activated by CD40 ligand 
(CD40-L), which is expressed on activated CD4^ T helper cells and via this
44
interaction T cells can assist the stimulation of B cells (246). The expression of 
CD40-L on T cells is a carefully regulated process that is initiated by activation 
of the T cell (247).
Knockout studies have shown that CD40 and CD40-L are required for 
germinal centre formation and the activation of B cells by T cell-dependent 
antigens (246, 248). Furthermore, hyper-lgM syndrome is an X-linked 
immunodeficiency caused by a genetic alteration of CD40-L resulting in a 
reduced ability to generate T cell-dependent antibody responses and patients 
lack circulating IgG, IgA and IgE and are unable to form memory B cells (246). 
CD40 therefore has important functions in the activation of B cells by T cell- 
dependent antigens and in the maturation of the immune response including 
germinal centre formation and immunoglobulin isotype switching from IgM to 
high affinity antibodies.
Ligation of CD40 alone on splenic mature B cells is mitogenic but co­
ligation of CD40 and the BCR reduces the threshold for B cell activation 
resulting in enhanced B cell proliferation and inhibition of apoptosis (249, 250). 
CD40 therefore acts as a co-receptor to enhance BCR-mediated activation of 
the cell. Furthermore, ligation of the BCR alone is insufficient to trigger isotype 
switching in B lymphocytes (251). However, stimulation of CD40 can induce the 
expression of genes involved in immunoglobulin class switching from IgM to 
IgG, IgA and IgE (249, 252). Isotype switching is also directed by cytokines 
since these can determine the nature of the immunoglobulin class switch (246, 
253).
CD40 also plays a significant role in directing the maturation of naïve 
mature B lymphocytes. In particular, it is required for the formation of germinal 
centres, the affinity maturation of B lymphocytes and the development of 
memory B cells (254). Activation of naïve B cells by T cell-dependent antigens 
in T cell-enriched regions of lymphoid follicles can lead to the formation of B 
centroblasts in the germinal centre. The germinal centre is required for affinity 
maturation of B lymphocytes. Ligation of CD40 in the germinal centres 
stimulates the B cells to express particular germinal centre markers including 
Fas. The upregulation of Fas renders the maturing B cells sensitive to 
apoptosis. However, cells that express antibodies with a high affinity for antigen 
will also undergo activation of the BCR and this triggers the upregulation of pro­
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survival genes and enables these ceils to survive (255, 256), CD40 therefore 
assists the selection of B cells that produce high affinity antibodies in the 
germinal centre,
CD40 also directs the differentiation of B cells to plasma cells and memory 
B cells. The terminal differentiation of B cells to plasma cells requires a 
disruption in the CD40/CD40-L association. Consequently, prolonged activation 
of CD40 promotes the formation of memory B cells whilst a shorter exposure to 
CD40 favours differentiation to plasma cells. This may be one mechanism of 
ensuring antibody is not released in the germinal centres (48, 246, 257, 258).
1.7.3.2 CD40-dependent signalling in mature B lymphocytes
CD40 exists as a monomer but the binding of CD40-L causes CD40 to 
polymerise and this is necessary for the activation of intracellular signals. CD40 
itself lacks kinase activity and any known consensus sequence for binding 
kinases but the cytoplasmic region of CD40 does have two binding sites for 
TRAP (TNF-receptor-associated factor) proteins. TRAFs have several functional 
domains including a zinc finger domain and a RING finger domain, which may 
mediate DNA-binding and a TRAP domain to enable protein-protein 
interactions. TRAFs 1, 2, 3, 5 and 6 and an as yet unidentified 23 kD 
transmembrane protein have been found in association with CD40 and they 
assist the transduction of signals downstream of CD40 (246, 248, 259, 260). 
TRAP 3 knockout mice do not have impaired B cell activation signals 
suggesting TRAFS is not essential. In contrast, the RING finger domain of 
TRAP 2 is required for CD40-mediated activation of NF-kB. However, TRAP 5 
can also activate NF-kB downstream of CD40 (246).
Ligation of CD40 on primary murine B cells leads to the activation of 
protein tyrosine kinases including Lyn and Syk and multiple downstream 
signalling cascades including JNK and p38 MAPK, PLCy and P1-3-K (figure 
1.20) (246, 254). The activation of these pathways is important for regulating 
the activity of specific transcription factors and hence the expression of 
particular genes. For example, CD40 induces the expression, activation and 
nuclear translocation of NF-k B. In particular, CD40 mediates the induction of 
RelB with minimal activation of c-Rel. This pathway cannot be stimulated by 
anti-IgM or LPS suggesting it is specifically regulated by CD40 (261, 262).
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CD40-mediated activation of NF-kB can increase the transcription of y1 gene to 
promote isotype switching to lgG1 (253). The induction of RelB is thus required 
for isotype switching of B lymphocytes.
CD40-mediated induction of NF-k B can also promote proliferation of 
mature B cells. Furthermore, it can Induce proliferation in splenic B cells from X- 
linked immunodeficient mice despite these cells being unable to undergo BCR- 
driven proliferation (263). CD40 therefore enhances the proliferation of splenic 
B cells via the activation of NF-k B and independently of Btk. BCR mediated 
proliferation of splenic B cells involves the induction of the NF-KB component c- 
Rel and subsequent transcription of the c-myc gene (33, 193). RelB may also 
induce the transcription of this gene to promote proliferation of B cells. 
Moreover, CD40 can also increase the survival of mature splenic B cells. The 
Inhibitor of apoptosis c-lAP can be found in association with CD40-coupled 
TRAFs suggesting a potential mechanism for the inhibition of apoptosis in 
mature B cells (260).
1.8 Lipid rafts
Lipid rafts are evolutionarily conserved membranous structures that are 
rich in cholesterol, sphingolipids and glycolipids. They have a relatively ordered 
structure compared to the surrounding glycerophospholipid bilayer. Proteins can 
bind to the extracellular and intracellular surface of lipid rafts and some 
transmembrane proteins can enter rafts. In particular, the abundance of 
cholesterol and glycosphingolipids in rafts attracts the acyl chains of 
glycosylphosphatidytinositol-anchored or acylated proteins including Src-family 
kinases, monomeric and heterotrimeric G-proteins, CD4, CD8 and LAT. 
However, the protein content of rafts is variable and this can assist signalling 
processes. Lipid rafts therefore form a compartment that can differentially 
segregate and hence regulate signalling molecules (264-267).
In unstimulated mature T cells lipid rafts help to suppress signals 
downstream of the TCR by excluding the receptor from the rafts. The rafts are 
rich in several components of TCR signalling including Src-family kinases, PIP2 , 
Grb-2 and Ras thus preparing the cell to respond rapidly to TCR stimulation. 
Activation of the TCR causes it to translocate into lipid rafts along with several 
other signalling molecules including PLCy. Lipid rafts of active T cells thus
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accumulate specific signalling molecules and help to propagate signals 
downstream of the TCR (266-269).
Signalling through the BCR is also initiated from within lipid rafts. In 
unstimulated mature B cells the BCR complex is excluded from lipid rafts but 
the rafts are rich in signalling molecules including Src-family kinases. Ligation of 
the BCR enables the BCR and additional signalling molecules to enter lipid rafts 
thus assisting BCR signalling (270). The translocation of the BCR into lipid rafts 
is usually a transient process but it can be prolonged by the activation of co­
receptors including CD19/CD21 (267). CD40 is always excluded from lipid rafts 
of mature B cells but ligation of CD40 enhances the movement of the BCR and 
other signalling molecules to rafts. (270, 271). Furthermore, ligation of CD40 
can promote the formation of lipid rafts by increasing the production of ceramide 
via the activation of acid sphingomyelinases (271, 272). This could assist the 
formation of signal transduction complexes at the plasma membrane.
Following the accumulation of signalling molecules in rafts, a clustering of 
rafts can be observed, presumably to bring signalling molecules of several 
different rafts into a single larger compartment (267, 273, 274), This can 
enhance BCR signalling by bringing components of the signalling complex into 
close proximity but it may also assist the termination of BCR signalling by 
bringing negative regulatory co-receptors into the same compartment as the 
BCR. For example, FcyRIIB is constitutively associated with rafts but it does not 
suppress BCR signalling under activating conditions. Inhibition of BCR 
signalling by FcyRIIB requires either an increased recruitment of FcyRIIB into 
lipid rafts or a fusion of lipid rafts containing the BCR with those that include 
FcyRIIB (242). Lipid rafts thus assist the formation of a BCR signalling complex, 
propagate the BCR signals and help to regulate the signalling process.
An additional function of lipid rafts in mature B cell signalling is to assist 
the internalisation of the BCR/antigen complex. This is necessary for processing 
and presentation of antigen on MHC class II complexes thus enhancing the 
activation of T cells (275, 276). Lipid raft-independent mechanisms of BCR/Ag 
internalisation are also known and it has been suggested that the different 
mechanisms of internalisation may affect the intracellular trafficking of the 
complex (276).
Lipids rafts can further regulate the composition of the plasma membrane
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by assisting the translocation of the lipid phosphatidylserine from the 
intracellular leaflet of the plasma membrane to the exoplasmic side. This 
process is triggered by an influx of Ca^^ through plasma membrane calcium 
channels and this is promoted by the activation of Erk-MAPK. The redistribution 
of phosphatidylserine is often observed under apoptotic conditions and it is 
thought to assist the recognition of the cell by phagocytes thus enhancing its 
destruction and removal (277).
Lipid rafts can also contribute to the development of an anergic state In 
lymphocytes. In anergic B cells the BCR can still bind to antigen but this does 
not lead to the recruitment and activation of tyrosine kinases and other 
downstream signalling molecules (278). An important difference in BCR 
signalling of naive and tolerant B cells is ligation of the BCR on tolerant B cells 
does not induce the translocation of the BCR into lipid rafts. The BCR is thus 
physically excluded from the signalling molecules retained in lipid rafts and this 
may impair the activation of specific pathways that are important for B cell 
stimulation and proliferation (279).
A similar situation is observed in immature B and T cells. Ligation of the 
antigen receptor on these cells can cause receptor aggregation but it does not 
induce the translocation of the BCR/TCR into rafts. Exclusion of antigen 
receptors from lipid rafts in immature lymphocytes will segregate the activated 
receptors away from the signalling molecules located in the rafts. Consequently, 
the signalling pathways activated downstream of the antigen receptors of 
immature lymphocytes will be restricted compared to those of mature cells. For 
example, exclusion of the antigen receptors from lipid rafts in immature B cells 
might prevent them activating the proliferative signals observed in BCR- 
stimulated mature B cells. This is thought to be an important determinant of the 
different outcomes of ligation of the antigen receptors on immature and mature 
lymphocytes (267, 270, 280-282).
1.9 BCR signalling in immature B cells
Ligation of the BCR on immature and mature B lymphocytes has very 
different consequences. Whilst stimulation of the BCR on mature B cells leads 
to proliferation, activation and differentiation, ligation of the BCR on immature B 
cells induces growth arrest and apoptosis. This is necessary for negative
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selection to remove autoreactive B lymphocytes.
1.9.1 WEHI-231 B cell lymphoma
The murine B cell lymphoma WEHI-231 is widely used as a model for 
immature B cell clonal deletion (283). The surface phenotype of WEHI-231 B 
cells, IgM"^  IgD"^ '^ MHC class 11*°'^  FcR‘°'^  Fas'®'", is very similar to that of primary 
immature/transitional B cells (table 1.1). Furthermore, ligation of the BCR on 
WEHI-231 cells induces growth arrest and apoptosis (284, 285) whilst co­
ligation of CD40 can rescue the cells from these BCR-driven effects (286, 287). 
The signalling mechanisms underlying BCR-driven apoptosis and CD40- 
mediated rescue are incompletely understood.
1.9.2 Signalling pathways activated by the BCR complex of immature B 
cells
Ligation of the BCR on immature and mature B cells leads to the induction 
of very similar signalling elements including P1-3-K, PLCy, Rho GTPases and 
the Erk-MAPK cascade and the downstream signalling molecules of these 
complexes (see section 1.6.3). However, ligation of the BCR on immature B 
cells leads to growth arrest and apoptosis whereas BCR-stimulation on mature 
B cells induces proliferation, activation and differentiation indicating there are 
important differences in the signals activated downstream of these BCRs. 
Indeed, there are likely to be many points of divergence including differences in 
the kinetics of activation of particular pathways and the intracellular location of 
the signalling molecules. Furthermore, some significant differences in the 
components of BCR signalling of mature and immature B cells have been 
observed.
For example, immature B cells and thymocytes express cytosolic
phospholipase A2 (CPLA2) and it is activated under conditions that lead to clonal
deletion. In contrast, mature B and T cells do not express cPLAz and expression
cannot be induced following culture with a variety of different cytokines (218,
222, 288). Ligation of the BCR on immature B cells activates CPLA2 via the Erk-
MAPK cascade and calcium signals (222, 289). Cytosolic PLA2 is the major
form of intracellular PLA2 and this 85 kD protein specifically hydrolyses lipids
with a polyunsaturated fatty acid at the sn-2 position including
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phosphatidylcholine. Activation of CPLA2 in immature B ceils leads to the 
production of arachidonic acid (218, 222) and arachidonic acid can potently 
induce apoptosis of the cells (102). The coupling of Erk-MAPK and calcium 
signalling to the stimulation of cPLAg and arachidonic acid production in 
immature B cells is thus an important pro-apoptotic signalling pathway. The 
absence of BCR-driven CPLA2 activity in mature B lymphocytes suggests that 
they are unable to initiate this pathway.
In addition to these differences in pro-apoptotic signals, mature and 
immature B lymphocytes also have divergent proliferative and pro-survival 
signals. For example, at least two different types of PLD signalling have been 
found in mature B cells (section 1.6.3.5) that cannot be detected in immature B 
cells. One of these pathways is activated downstream of the BCR and it 
involves a non-phosphatidylcholine-hydrolysing PLD that can increase the 
intracellular levels of DAG to promote proliferation. The absence of this pathway 
in immature B cells is likely to contribute to the lack of proliferation observed 
following stimulation of the BCR in these cells. The second PLD pathway 
involves a phosphatidylcholine-hydrolysing PLD that is activated downstream of 
Pa-purinoreceptors and promotes growth arrest of the mature B lymphocytes. 
The absence of this early signalling pathway in immature B cells indicates BCR- 
driven growth arrest does not require early coupling to phosphatidylcholine- 
hydrolysing PLD (222, 223).
As well as having impaired PLD signalling, immature B cells have reduced 
PKC activity. In mature B cells BCR-ligation leads to PIP2 hydrolysis, calcium 
mobilisation and stimulation of PKC (see section 1.6.3.2). In immature B cells 
BCR-ligation can mobilise calcium but PIP2 hydrolysis and subsequent PKC 
activation are significantly reduced. PKC is an activator of PLD therefore the 
suppression of PKC signalling in immature B cells may contribute to the lack of 
PLD signalling in these cells. PLD is also a potential regulator of PKC since 
PLD can generate phosphatidic acid, a second messenger that stimulates 
PKCri and PKCÇ. Mature B lymphocytes from PKC^"^“ mice undergo 
spontaneous apoptosis and have impaired activation, including reduced ability 
to produce antibody. This suggests that PKCC promotes survival and activation 
of mature B cells therefore a suppression of this signal in immature B cells is 
likely to prevent them from inducing antibody production and increases their
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sensitivity to apoptosis (199).
In addition to stimulating PKCi^ and PKCL PA can be converted to DAG, 
enabling the activation of phorbol ester-sensitive PKC isoforms. One such 
phorbol ester-sensitive PKC enzyme is PKCp. This PKC isoform seems to 
participate in the activation of mature B celts since PKC§^ mice have reduced 
humoral immune responses and their B lymphocytes have impaired activation 
downstream of the BCR (210). More specifically, mature B lymphocytes from 
PKCp^ mice are less able to induce B c I-xl  and Bcl-2 and hence are prone to 
apoptosis (199, 290). The expression of pro-survival Bcl-2 family members is 
also an important survival signal in immature B cells since induction of these 
proteins can protect them from BCR-driven apoptosis (290-293). The impaired 
activation of PKC in BCR-stimulated immature B cells therefore could increase 
their sensitivity to apoptosis by reducing the levels of pro-survival Bcl-2 family 
proteins. Indeed, treatment of primary splenic immature B cells or WEHI-231 B 
cells with phorbol ester can prevent BCR-driven apoptosis strongly suggesting 
the diminished activation of conventional and novel PKC isoforms in immature B 
cells contributes to their cell death (294, 295).
Furthermore, in mature B cells BCR-dependent PKC activity can induce 
NF-kB and this increases the survival of the cells since NF-kB can regulate the 
transcription of pro-survival factors including c-Myc, B c 1-x l  and Bcl-2 (193, 199, 
211). Ligation of the BCR on immature B cells cannot sustain NF-kB activation, 
perhaps due to their defective stimulation of PKC. The reduction in NF-kB 
activity in BCR-stimulated immature B cells is likely to contribute to their death 
since NF-kB signalling is enhanced by conditions that favour cell survival, 
including CD40 co-stimulation (261, 296, 297).
1.9.3 CD40 signalling in immature B cells
Ligation of the BCR on immature B cells induces growth arrest and 
apoptosis and this is necessary for the clonal deletion of self-reactive B cells. 
This process can be regulated by the presence of T lymphocytes since ligation 
of CD40 protects immature B cells from BCR-driven growth arrest and 
apoptosis (286, 287). Consequently, enforced and prolonged expression of 
CD40-L can result in the production of autoantibodies (298, 299).
The structure of CD40 on immature B cells is essentially the same as on
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mature B lymphocytes (see section 1.7.3.2) and the propagation of signals 
downstream of CD40 requires the recruitment of TRAFs, Following the 
multimerisation of TRAFs, several signalling cascades are activated including 
the MARK, PI-3-K and PLCy pathways. These cascades can then regulate 
additional signalling molecules to influence the survival and proliferation of the 
immature B cells (figure 1.21).
As in mature B cells, ligation of CD40 stimulates the activation of NF-kB 
but in immature B cells c-Rel complexes are particularly induced by CD40 
(297). CD40 mediates the activation of NF-kB in immature B cells by inducing 
the sustained degradation of l-xBa. NF-kB can then regulate the expression of 
specific target proteins including protooncogene p/m-1 The induction of Pim-1 
correlates with increased survival and proliferation of B lymphocytes (300). 
Furthermore, CD40-mediated activation of NF-kB is likely to induce the 
expression of c-myc since the activation of NF-kB downstream of the BCR and 
CD40 correlates with the changes in expression of the c-myc gene in WEHI-231 
immature B cells. Indeed, ligation of the BCR induces a transient activation of 
NF-KB and c-myc gene expression whilst co-ligation of CD40 stimulates a 
sustained NF-kB signal and prolonged expression of c-myc (301). The induction 
of c-Myc is important for CD40-mediated rescue from BCR-driven loss of 
immature B cell viability (302).
CD40 can also regulate the survival of immature B cells by controlling the 
expression of Bcl-2-family proteins. For example, ligation of CD40 or 
overexpression of Bcl-2 can protect WEHI-231 cells from apoptosis induced by 
concanamycin A, an inhibitor of vacuolar ATPases (303). Furthermore, ligation 
of CD40 on WEHI-231 cells induces the expression of the pro-survival protein 
A1 and expression of A1 can partially protect immature B cells from BCR-driven 
apoptosis but not growth arrest (302, 304).
Moreover, in WEHI-231 immature B cells ligation of CD40 can greatly 
enhance the expression of the bcl-xt gene without increasing the expression of 
bcl-2 or bax (293). Ligation of CD40 also increases the protein levels of B c I-xl  
whilst stimulation of WEHI-231 cells with anti-IgM or anti-lgD does not induce 
Bc I-xl  (2 9 2 ) . The use of antisense oligonucleotides for bci-xt can partially block 
CD40-driven rescue from BCR-mediated apoptosis suggesting the upregulation 
of B c I -xl is required for rescue from apoptosis (293). Furthermore,
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overexpression of B c I-x l , but not Bcl-2, in WEHI-231 cells can protect them 
from BCR-driven apoptosis in the absence of CD40 stimulation (292). B c 1-xl  
transfectants also display increased resistance to ceramide-driven apoptosis 
(305). Bc I-x l  is therefore an important mediator of CD40-dependent rescue from 
BCR-driven apoptosis. However, the signalling pathways used by CD40 to 
upregulate B c I-x l  are incompletely understood. Nonetheless, CD40-stlmu!ation 
is also known to activate p38 and JNK MAPKs but inhibition of these MAPKs 
does not impair the ability of CD40 to protect immature B cells from BCR-driven 
apoptosis suggesting they are not necessary for CD40-mediated survival (306- 
310).
B c I-Xl appears to be specifically involved in preventing apoptosis of 
immature B cells since overexpression of B c I-Xl , unlike ligation of CD40, does 
not rescue WEHI-231 cells from BCR-driven growth arrest. CD40 thus regulates 
the survival and proliferation of immature B cells via distinct signalling pathways
(311). Indeed, mutagenesis of CD40 has shown that distinct regions of CD40 
are required to induce B c 1-xl  and proteins involved in cell cycle progression
(312). However, the mechanism of CD40-dependent rescue from BCR-driven 
growth arrest is poorly understood. WEHI-231 cells that overexpress Bc I-xl can 
be made resistant to BCR-dependent growth arrest by inducing the 
overexpression of either E2F1 or the viral oncoprotein E1A. The activity of E2F 
is negatively regulated by hypophosphorylated retinoblastoma (Rb) protein but 
ligation of CD40 induces the phosphorylation of Rb, releasing E2F and allowing 
the transcription of genes required for DNA synthesis and cell cycle progression 
(52). CD40 can also upregulate the activity of the cyclin D kinases Cdk4 and 
Cdk6 (312) and Rb is a known substrate of these kinases therefore CD40 may 
induce E2F to allow entry into S phase by enabling cyclin D kinases to 
phosphorylate and inhibit Rb (50).
1.10 Regulation of apoptosis and proliferation in immature B lymphocytes
1.10.1 Regulation of apoptosis in immature B cells
1.10.1.1 Bcl-2 family proteins in immature B lymphocytes
The Bcl-2 family of proteins can regulate the survival of many different cell
types including immature B lymphocytes (67). The viability of a cell is critically
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dependent on the relative abundance of pro-survival and pro-apoptotic proteins 
of the Bcl-2 family. Conditions that elevate pro-survival proteins will favour 
survival by retaining the integrity of the membranes of intracellular organelles 
including the mitochondria. However, signals that induce pro-apoptotic proteins 
result in a loss of mitochondrial integrity and the activation of apoptotic 
mediators including the executioner proteases (70, 76, 78, 313).
Initial studies on immature B lymphocytes recognised that certain 
apoptotic stimuli can decrease the cellular levels of pro-survival Bcl-2 family 
proteins. For example, prolonged ligation of the BCR can decrease the cellular 
levels of Bcl-2 in WEHI-231 cells (292) and vaccinia virus can induce apoptosis 
of these cells by down regulating the intracellular levels of Bcl-2 (314). This 
suggests that decreasing the levels of pro-survival Bcl-2 family proteins in these 
cells assists the induction of apoptosis. However, several strains of WEHI-231 
cells that are resistant to BCR-driven apoptosis appear to have normal levels of 
Bcl-2 indicating protection from apoptosis requires the upregulation of 
alternative pro-survival Bcl-2 family members (315, 316).
Indeed, immature B cells can be protected from specific apoptotic stimuli 
by the induction of other pro-survival Bcl-2 family proteins. For example, 
treatment of WEHI-231 cells with immunosuppressants (rapamycin, cyclosporin 
A or FK-506), an inhibitor of protein synthesis (emetine) or an inhibitor of the 
Ca^^-ATPase of the endoplasmic reticulum (thapsigargin) can induce apoptosis 
that is prevented by overexpression of the pro-survival protein B c I-x l . These 
agents also induce growth arrest of the WEHI-231 B cells but this cannot be 
rescued by overexpression of B c I-xl  suggesting survival and proliferation are 
differentially regulated in immature B cells (291, 292).
Furthermore, BCR-stimulated growth arrest and apoptosis of immature B 
cells can be prevented by co-ligation of CD40. CD40 induces an upregulation of 
B c I-xl  without increasing the expression of Bcl-2 or Bax (290, 292, 293) and 
overexpression of Bc I-x l  in  WEHI-231 cells protects the cells from BCR-driven 
apoptosis (292, 311). The upregulation of Bc 1-xl  can thus protect immature B 
cells from BCR-driven apoptosis. Moreover, mutagenesis of CD40 suggested 
that the same region (amino acids 246-269) of CD40 is required to stimulate 
Bc I-x l  and to protect WEHI-231 cells from BCR-driven apoptosis (312).
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However, additional anti-apoptotic Bcl-2 family members, especially A1 
and Mcl-1, may also contribute to the survival of immature B cells (302), For 
example, stimulation of WEHI-231 cells at CD40 can upregulate the expression 
of the a1 gene and overexpression of A1 can partially protect the cells from 
BCR-driven apoptosis (304). However, A1 seems to protect the immature B 
cells by inhibiting caspase 9 and subsequent activation of caspase 7 enabling 
A1 to protect the cells from BCR-induced DNA laddering (317).
1.10.1.2 Caspase-dependent apoptosis in immature B cells
The signalling networks used to mediate BCR-driven apoptosis are 
complex and are likely to involve caspase-dependent and caspase-independent 
mechanisms (102, 317-319). Initial reports of caspase-dependent apoptosis 
involved the use of caspase inhibitors such as the general caspase inhibitor 
zVAD.fmk, which was reported to suppress BCR-driven apoptosis (63). 
Furthermore, Doi et al. observed that inhibition of caspases in BCR-stimulated 
WEHI-231 cells prevents some of the characteristics of apoptosis without giving 
protection against others, in particular, zVAD.fmk prevented BCR-driven 
cleavage of poly(ADP-ribose) polymerase (PARP), nuclear fragmentation, 
hypodiploidy and DNA fragmentation. However, it only partially suppressed 
BCR-driven changes in cellular oxidation-reduction potential and movement of 
phosphatidylserine to the outer leaflet of the plasma membrane. Furthermore, 
zVAD.fmk was unable to prevent BCR-driven disruption of the plasma 
membrane and loss of the mitochondrial membrane potential (318). These 
observations suggest that caspase-dependent signals are involved in mediating 
damage to the nucleus and DNA of BCR-stimulated WEHI-231 cells but 
additional characteristics of apoptosis, Including disruption of the mitochondrial 
membrane potential, can occur independently of caspases. Nonetheless, 
overexpression of B c I-x l protects the WEHI-231 cells from all the symptoms of 
apoptosis suggesting it is able to prevent caspase-dependent and caspase- 
independent apoptosis (318).
The initiation and execution of caspase-dependent cell death downstream 
of the BCR in immature B cells is incompletely understood. However, ligation of 
the BCR is known to activate a neutral sphingomyelinase leading to the 
production of ceramide and ceramide can activate caspases and induce the
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cleavage of PARP (102, 320). Caspase-dependent apoptosis therefore may be 
initiated by the production of ceramide downstream of the BCR. Overexpression 
of B c I-x l does not prevent the production of ceramide but it can protect the cells 
from ceramide-induced cell death (305).
A mechanism of caspase-dependent apoptosis has been proposed for 
human immature and mature B cell lines (319). It has been suggested that 
BCR-driven caspase-dependent apoptosis involves the stimulation of caspases 
2 and 3 downstream of calcineurin. Caspase 9 activity was also observed and 
this may serve to amplify the caspase signals but caspases 1 and 8 were not 
found to be active (319). This is a novel caspase-dependent pathway that may 
be exclusive to human cell lines since inhibition of caspases 2 and 3 in murine 
WEHI-231 B cells does not prevent BCR-driven apoptosis (53, 319).
However, BCR-driven caspase 9 activity has been detected in WEHI-231 
cells and it leads to the induction of caspase 7 (317). Furthermore, co­
stimulation of the cells at CD40 can suppress caspase 7 activity by upregulating 
the pro-survival Bcl-2 family protein A1. Overexpression of A1 in these cells can 
also partially suppress BCR-driven apoptosis suggesting caspase 7 may be a 
mediator of this apoptotic process and the inhibition of this signal by CD40 may 
promote cell survival (302, 317). However, BCR-driven apoptosis is not 
suppressed by the specific inhibition of caspase 7 (53), suggesting BCR-driven 
apoptosis can use alternative caspase-dependent mechanisms of apoptosis 
and/or caspase-independent apoptotic pathways.
1.10.1.3 Caspase-independent apoptosis in immature B cells
A caspase-independent mechanism of BCR-driven apoptosis has been 
elucidated in immature WEHI-231 B cells (figure 1.22) (102). Ligation of the 
BCR on immature B cells activates cPLAg via the Erk-MAPK cascade and 
calcium signals. Calcium causes cPLAz to translocate from the cytosol to 
membranes of the nucleus, endoplasmic reticulum and mitochondria thus 
bringing cPLAg into close proximity to its lipid substrates (289). MAPK activates 
CPLA2 by phosphorylation of Ser®°® (222). Treatment of immature B cells with 
IL-4 reduces BCR-mediated activation of CPLA2 and lL-4 also protects the cells 
from BCR-driven apoptosis suggesting CPLA2 is a component of the pro- 
apoptotic pathway activated by the BCR (288). Indeed, activation of CPLA2 in
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immature B cells leads to the production of the pro-apoptotic molecule 
arachidonic acid (218, 222).
The mechanism of arachidonic acid and BCR-mediated apoptosis has 
been investigated in WEHI-231 cells (figure 1.22) (102). Ligation of the BCR or 
treatment of WEHI-231 cells with exogenous arachidonic acid induces a loss of 
mitochondrial membrane potential and subsequent depletion of cellular ATP 
levels. However, stabilisation of the mitochondrial membrane potential using the 
mitochondrial inhibitors antimycin or oligomycin can maintain a normal 
mitochondrial membrane potential and protect the WEHI-231 cells from BCR- 
driven apoptosis. Furthermore, the mitochondrial membrane potential is 
stabilised and cellular levels of ATP are retained by co-ligation of CD40 and it is 
widely recognised that CD40 can protect immature B cells from BCR-driven 
apoptosis. The loss of mitochondrial membrane potential is therefore a critical 
stage in the induction of apoptosis by the BCR and arachidonic acid.
However the loss of mitochondrial integrity does not induce the release of 
the caspase co-factor, cytochrome c and caspase 3 activity is not stimulated by 
ligation of the BCR. Furthermore, treatment of BCR-stimulated WEHI-231 cells 
with caspase inhibitors does not protect these cells from BCR-driven apoptosis. 
This suggests that the classical caspase-dependent pathway of apoptosis is not 
activated by ligation of the BCR on immature B cells (102). Indeed, caspase- 
independent cell death has also been observed in several other systems 
including glucocorticoid-induced and CD45-mediated death of thymocytes, 
death of hematopoietic cell lines following withdrawal of growth factors, Bax- 
mediated cell death and germinal centre B cell apoptosis (see section 1.4.4) 
(93, 104, 313, 321-324). Furthermore, many non-caspase proteases including 
the cathepsins and the calpains, can cleave some of the classical caspase 
substrates suggesting these alternative proteases can mimic the effects of 
caspases to mediate cell death (324). Indeed, ligation of the BCR in WEHI-231 
cells does induce cathepsins and inhibition of cathepsin B protects the cells 
from BCR-driven apoptosis. This suggests that BCR-driven apoptosis of WEHI- 
231 cells is executed by cathepsins and the activation of these proteases is 
mediated by the disruption of mitochondrial integrity (102). The activation of 
CPLA2 and subsequent production of arachidonic acid is the initiating step of 
this apoptotic pathway.
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1.10.1.4 NF-kB
N F -k B is an important survival factor that is activated downstream of the 
BCR in mature B lymphocytes (193, 199, 211). However, ligation of the BCR on 
immature B cells is unable to sustain N F-k B activation and agents that inhibit 
NF-KB induce apoptosis of WEHI-231 cells (296). Furthermore, co-stimulation 
of CD40 induces N F-k B via the sustained degradation of I-k B u  and 
overexpression of the pro-survival factor BcI-xl can protect WEHI-231 cells from 
apoptosis induced by agents that inhibit NF-k B. These observation suggest NF- 
KB is an important determinant of cell survival in WEHI-231 B cells (261, 297, 
301, 312, 325).
However, the signalling pathways regulated by NF-kB in WEHI-231 cells 
are incompletely understood. NF-kB is a transcription factor and it can stimulate 
the transcription of genes that contain a NF-xB-regulatory region including c- 
myc (297), Indeed, NF-kB induces the transcription of c-myc in mature B 
lymphocytes (34, 211, 262) and in WEHI-231 immature B cells it is thought to 
be at least partially responsible for the induction of c-myc expression (301). 
Nonetheless, the transcription factor CTCF has also been implicated as a 
regulator of c-myc gene expression in WEHI-231 cells. However, CTCF 
appears to suppress c-myc gene expression downstream of the BCR to 
promote apoptosis of the cells. CTCF may also promote growth arrest of 
immature B cells by increasing the expression of regulators of the cell cycle 
including p21, p27, p53 and pi 9. (325).
1.10.2 Regulation of proliferation in immature B cells
Ligation of the BCR on immature B cells induces growth arrest and 
apoptosis that can be rescued by co-ligation of CD40. Survival and proliferation 
are likely to be mediated by distinct signalling pathways since they can be 
regulated independently of each other. For example, B c I-x l is a key mediator of 
CD40-dependent rescue from BCR-driven apoptosis but cannot prevent BCR- 
induced growth arrest (312).
In mature B cells, ligation of the BCR stimulates proliferation by Inducing 
Cdk4 and cyclin D2 to allow progression through the early stages of G1 phase 
of the cell cycle and by enhancing the expression of cyclin E and Cdk2 to
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enable the G1 to S phase transition. In contrast, ligation of the BCR on 
immature B cells enhances the levels of Cdk4 and cyclin D2 but does not 
increase the expression of cyclin E and Cdk2. Consequently, ligation of the 
BCR on immature B cells induces growth arrest at G1 phase. However, BCR- 
induced growth arrest can be overcome by co-culture of immature B cells with 
IL-4 since IL-4 enhances the expression of Cdk2 and cyclin E (33).
A potential mediator of these effects is c-Myc since the expression of c- 
myc is elevated in immature and mature B cells under conditions that allow 
proliferation but it is not expressed during growth arrest (302). Furthermore, the 
expression of c-myc can be reduced in WEHI-231 cells by BCR-dependent 
induction of CTCF and under these conditions there is an increase in the 
expression of cell cycle regulators including p21, p27, p53 and pi 9 (325). The 
induction of these proteins promotes growth arrest and apoptosis. In addition, 
BCR-ligation induces Rb to inhibit E2F and decrease the levels of cyclin A thus 
preventing entry into S phase. In contrast, ligation of CD40 on WEHI-231 cells 
inhibits Rb and rescues the cells from growth arrest (53, 56, 58). Proliferation of 
WEHI-231 cells is thus dependent on the differential regulation of Rb and E2F 
by the BCR and CD40.
1.11 Aims and objectives
Immature B cells are sensitive to the process of negative selection 
therefore ligation of the BCR on these cells induces growth arrest and 
apoptosis. However, co-ligation of CD40 can rescue the immature B cells and 
enable them to survive and proliferate. The aim of this investigation was to 
explore the signalling mechanisms used by the BCR and CD40 to differentially 
regulate survival and proliferation of immature B cells. In particular, the role of 
Erk-MAPK in controlling these processes was examined using the WEHI-231 
immature B cell line.
The specific aims and objectives of this investigation were:
1. to investigate the dual role for Erk-MAP kinase in BCR-driven apoptosis 
and CD40-mediated rescue of WEHI-231 immature B cells and to explore the 
mechanisms regulating Erk activity in this system
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2. to explore the role of arachidonic acid in mediating the induction of 
apoptosis downstream of Erk and to investigate the role of metabolites of 
arachidonic acid in regulating survival and proliferation of WEHI-231 cells
3. to further explore the mechanism of CD40-dependent rescue of WEHI- 
231 cells by determining the role of B c I-x l in rescuing the cells from BCR-driven 
growth arrest and apoptosis
4. to investigate other potential mediators of CD40-dependent rescue by 
analysing the role of sphingosine kinase in regulating survival and proliferation 
of WEHI-231 cells and by examining the mechanism of sphingosine-1- 
phosphate (SPP) signalling in this system
5. to investigate the observation that immature B cells have impaired 
induction of PKC signalling compared to mature B cells by exploring the role of 
PKC in regulating the survival and proliferation of WEHI-231 ceils and by 
examining the signalling mechanisms used by PKC to regulate these 
processes.
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Figure 1.1. The B cell antigen receptor. The BCR complex consists of surface 
immunoglobulin non-covalently bound to accessory signalling molecules Iga 
and Igp. Surface immunoglobulin contains two identical heavy chains and two 
identical light chains that come together to form the antigen binding site. The 
binding of antigen to sig results in the phosphorylation of Iga and Igp at tyrosine 
residues located within ITAMs. The resultant phospho-tyrosine residues are 
required to initiate intracellular signalling cascades that ultimately determine the 
survival, proliferation and activity of the B lymphocyte.
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Figure 1.2. Somatic recombination of immunoglobulin heavy and light chains. 
(A) The variable region of the heavy chain is generated by two random 
recombination events; firstly the Dh and the Jh chains are joined then the Vh 
chain is joined to the DhJh segment. (B) The variable region of the light chain is 
generated by a single random recombination event in which the V l chain is 
joined to the Jl segment. Each somatic recombination event is catalysed by 
recombinase (RAG1 and RAG2).
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Figure 1.3. Stages of B cell development. The initial stages of B cell 
development occur in the bone marrow and are antigen-independent. 
Pluripotent hematopoietic stem cells (HSC) give rise to common lymphoid 
progenitors (CLP) and these can form pro-B cells. There are three types of pro- 
B cells, early, intermediate and late. Immunoglobulin heavy chain gene 
rearrangement takes place at the pro-B cell stage, followed by positive selection 
of cells with a functional heavy chain expressed in the pre-B cell receptor. 
Expression of the pre-BCR enables late pro-B cells to form large pre-B cells. 
After a series of cell divisions large pre-B cells give rise to non-dividing small 
pre-B cells. Rearrangement of the immunoglobulin light chain takes place in 
small pre-B cells. Successful gene rearrangement leads to the expression of the 
BCR complex on immature B cells. Further B cell development is antigen- 
dependent. Ligation of the BCR on immature B cells leads to receptor editing or 
apoptosis thus eliminating self-reactive B cells. B cells that survive this process 
of negative selection are mature B cells and are located in the periphery where 
they can be used to generate a humoral immune response following ligation of 
the BCR by foreign antigen. Mature B cells can differentiate into antibody- 
secreting plasma cells or memory B cells.
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Figure 1.4. Characterisation of the different stages of B cell development. 
Knockout models of particular proteins induce developmental arrest at a specific 
stage of B cell development indicating an essential role for that protein in 
progression beyond that stage. B cell development can be characterised by the 
changes in surface phenotype of the cells. CD45, also known as B220, is a 
protein phosphatase that promotes BCR signalling. CD19 and CD21 enhance 
BCR signals. CD23, also known as FceRII is a surface receptor for the constant 
region of antibodies. CD40 is an important co-stimulus of BCR signalling in 
immature and mature B cells. Iga and Igp are essential components of the pre- 
BCR and BCR complex. They are first expressed in conjunction with calnexin at 
the surface of the late pro-B cell. Expression of a functional pre-BCR is 
essential for the development of pre-B cells. IgM and IgD are mature BCRs. IgM 
is the main BCR of immature B cells whilst IgD is predominantly found in mature 
B lymphocytes.
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Figure 1.5. Mature B cell development in the germinal centre. Naïve mature B 
cells migrate into the follicular mantle (1) during a T cell-dependent immune 
response. B cells undergo extensive proliferation as centroblasts (2), cease to 
express surface IgM and form the dark zone. Centroblasts undergo somatic 
hypermutation in the dark zone then they migrate to the light zone as surface 
IgM-expressing centrocytes (3). Centrocytes are highly susceptible to 
apoptosis, enabling the elimination of cells expressing low affinity BCRs. 
Survival of the centrocytes requires ligation of the BCR by antigen and the 
provision of appropriate co-stimuli. Surviving B cells form a pool of memory B 
cells (4) or high-affinity antibody-producing plasma cells (5).
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Figure 1.6. The cell cycle. (A) The cell cycle contains several stages. Quiescent 
cells (GO) enter the cell cycle at G1 phase where cells undergo growth. On 
completion of G1 phase, cells undergo DNA synthesis (S phase), followed by 
another growth phase (G2) and then they undergo mitosis (M phase). (B) The 
cell cycle is carefully regulated with distinctive checkpoints at the end of each 
growth phase. Progression through the cell cycle is regulated by cycIin-Cdk 
complexes and by regulators of these complexes including Rb, p15, p16, p21, 
p27, p53 and p i 9.
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Figure 1.7. The Bcl-2 family can be split into three groups. Pro-survival Bcl-2 
family proteins Including Bcl-2 and BcI-xl have four BH (Bcl-2 homology) 
domains (BH1-4) and a C-terminal membrane attachment domain. Pro- 
apoptotic Bcl-2 family proteins such as Bax and Bak have three BH domains 
(BH1-3) and a C-terminal membrane attachment domain. A different group of 
pro-apoptotic Bcl-2 family proteins including Bid and Bik has only one BH 
domain (BH3) and may or may not have a membrane attachment region (67). 
BH1-3 can form alpha-helical structures that enable dimérisation between 
different Bcl-2 family proteins. BH3 only proteins can also bind to the alpha- 
helical cleft to form dimers with other groups of Bel proteins. BH1-2 is required 
for the formation of a membrane-spanning pore.
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Figure 1.8. Caspase-dependent apoptosîs and the activation of caspases. (A) 
Caspase-dependent apoptosis in C. elegans and mammals. Apoptosis in C. 
elegans is mediated by the caspase CED3. CED3 is activated by autocleavage 
following binding to CED4. The activity of CED4 is negatively regulated by 
CED9 and is stimulated by EGL-1. Caspase-mediated apoptosis in mammals is 
more complex than in C. elegans. Mammals have several effector caspases 
(caspases 3, 6 and 7) and their activity is regulated by multiple initiator 
caspases (caspases 2, 8, 9 and 10). The activation of caspases is regulated by 
mitochondrial co-factors including Apaf-1 and by death receptor-associated co- 
factors like FADD. These co-factors are regulated by members of the Bcl-2 
family and by ligands of receptors containing associated DED domains. (B) 
Activation of caspases by proteolysis. Caspases are expressed as inactive 
zymogens that include a pro-domain, a p20 subunit and a plO subunit. 
Activation of caspases requires proteolysis to remove the pro-domain and to 
separate the p20 and plO subunits. Two p20 subunits combine with two plO 
subunits to form a catalytically active tetramer.
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Figure 1.9. Formation of the Apaf-1 apoptosome and activation of caspase 9. 
Under non-apoptotic conditions pro-survival members of the Bcl-2 family such 
as Bcl-2 protect the mitochondria. An apoptotic stimulus induces an 
upregulation of pro-apoptotic Bcl-2 family proteins including Bax. Bax and Bcl-2 
form dimers on the surface of the mitochondria leading to the formation of a 
pore on the outer mitochondrial membrane. Mitochondria burst, releasing their 
contents including ATP, calcium and cytochrome c into the cytoplasm. 
Cytochrome c binds to Apaf-1 causing it to oligomerise. In the presence of ATP, 
cytochrome c and Apaf-1 form an Apaf-1 apoptosome, leading to the activation 
of pro-caspase 9 and subsequent stimulation of effector caspases (caspases 3, 
6 and7). Effector caspases mediate apoptosis by cleaving multiple target 
proteins to induce DMA laddering, chromatin condensation, nuclear shrinkage, 
cytoskeletal collapse and membrane blebbing.
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Figure 1.10. Caspase-mediated apoptosis in mammalian cells. Fas ligand 
induces the oligomerisation of Fas and the associated FADD proteins. Pro- 
caspase 8 associates with FADD via its DED domain resulting in an increased 
local concentration of the pro-caspase and it is activated by autocleavage. 
Caspase 8 can cleave and activate effector caspases resulting in the induction 
of apoptosis. Caspase 8 also cleaves and activates Bid and the resultant tBid 
promotes mitochondrial disruption by dimerising with pro-apoptotic Bcl-2 family 
proteins including Bax. Further disruption of the mitochondria is also promoted 
by Bcl-2/Bax dimers, which also form pores in the outer mitochondrial 
membrane. The contents of the mitochondria are released into the cytoplasm 
including Smac, an inhibitor of lAPs, thus preventing the inhibition of caspases. 
The mitochondria also release components of the Apaf-1 apoptosome resulting 
in the activation of pro-caspase 9 and the enhanced stimulation of effector 
caspases. Effector caspases mediate apoptosis by cleaving multiple target 
proteins to induce DNA laddering, chromatin condensation, nuclear shrinkage, 
cytoskeletal collapse and membrane blebbing.
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Figure 1.11. Signals activated downstream of the BCR complex. Ligation of the 
BCR induces the activation of four main pathways: PI-3-K, PLCy, Vav/Rho and 
Erk-MAPK, Stimulation of these pathways regulates the expression of genes 
and can regulate the differentiation, apoptosis and proliferation of the cells.
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Figure 1.12. Adaptor proteins in BCR signalling. The BCR complex requires 
several adaptor proteins to regulate downstream signalling pathways. The 
different adaptor proteins are characterised by the presence of distinct modular 
interaction domains.
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Figure 1.13. Interaction of adaptor proteins with downstream signalling 
molecules. The adaptor proteins associated with the BCR complex couple the 
BCR to specific signalling pathways by mediating protein-to-protein and protein- 
to-lipid interactions via their modular interaction domains. Interactions between 
proteins are represented by a line with an arrow head at both ends whilst the 
inhibition of Syk by Cbl is represented by a line with a blunt end.
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Figure 1.14. The activation of PI-3-K signals downstream of the BCR. PI-3-K 
can catalyse the phosphorylation of phosphatidylinositol lipids at the 3’ position 
leading to the production of PI-3, 4, 5 -P3 and Pl-3, 4 -P2 . PH domain-containing 
proteins can interact with 3-phosphorylated phosphatidylinositol lipids. PH 
domain-containing proteins used downstream of the BCR complex include 
PDK1, PDK2, PKC, Btk and Vav. Akt is activated by PDK1/2 resulting in the 
inhibition of pro-apoptotic proteins and the activation of pro-survival signalling 
molecules. Protein-to-protein or protein-to-lipid interactions are represented by 
a line with an arrow head at both ends, the activation of signalling molecules is 
represented by a line with a single arrow head and the inhibition of signalling 
molecules is indicated by a line with a blunt end.
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Figure 1.15. The structure of PLC and PLCy signalling downstream of the BCR. 
(A) The structure of the PLC family. The three members of the PLC family can 
be distinguished by their different structures. In addition to the domains of PLCp 
and PLCÔ, PLCy has two extra PH domains, two SH2 domains and an SH3 
domain. (B) The activation of PLCy signals downstream of the BCR complex. 
The activation of PLCy requires the phosphorylation of BLNK by Syk and the 
formation of a PLCy/BLNK/Btk complex. Both Btk and PLCy can bind to PIP3 via 
their PH domains to help to localise them at the BCR complex. Once activated, 
PLCy catalyses the cleavage of PIP2 to form DAG and IP3 . IP3 induces the 
mobilisation of intracellular calcium stores contributing to the activation of PKC. 
DAG can also stimulate PKC enzymes. PKC in turn can regulate the activity of 
MAPK. Protein-to-protein or protein-to-lipid interactions are represented by a 
line with an arrow head at both ends and the activation of signalling molecules 
is represented by a line with a single arrow head.
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Figure 1.16. The activation of Vav/Rho signals downstream of the BCR 
complex. Vav/Rho can be recruited to the BCR complex via BLNK. Rho-family 
proteins can stimulate phosphatidylinositol-4-phosphate-5-kinase (PI-4-P-5- 
kinase) and PI-3-K leading to the production of PIP2 and PIP3 , respectively. 
Rho-family proteins can also activate PLCy and JNK/p38 MAPK. Protein-to- 
protein or protein-to-lipid interactions are represented by a line with an arrow 
head at both ends and the activation of signalling molecules is represented by a 
line with a single arrow head.
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Figure 1.17. The activation of Erk-MAPK downstream of the BCR complex. 
Various adaptors can couple the BCR complex to Grb-2/SOS. SOS is an 
activator of Ras, which in turn leads to the stimulation of Raf-1, MEK and 
Erk1/2. The adaptor protein Cbl can also couple the BCR to Erk via the 
recruitment of Crk/C3G. C3G is an activator of Rap-1, which can inhibit Raf-1 to 
suppress Erk1/2 activity or it can activate B-Raf to stimulate Erk-MAPK. Protein- 
to-protein interactions are represented by a line with an arrow head at both 
ends, the activation of signalling molecules is represented by a line with a single 
arrow head and the inhibition of signalling molecules is indicated by a line with a 
blunt end.
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Figure 1.18. Amplification of BCR-signalling by the co-receptor CD19. GDI 9 
exists as a complex with GD81 and CD21. C3d-associated antigen 
simultaneously binds to CD21 and the BCR. Ligation of CD21 leads to the 
phosphorylation of tyrosine residues in the cytoplasmic region of GDI9. The 
phospho-tyrosine residues of GDI9 can then recruit and activate PI-3-K and 
Vav leading to the induction of downstream signalling molecules including Akt 
and Btk. CD19 amplifies BCR signalling and lowers the threshold for B cell 
activation.
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Figure 1.19. Inhibition of BCR signalling by FcyRIIB. FcyRIIB is a low affinity 
receptor for the Fc component of IgG therefore it can recognise antibody-bound 
antigen. Ligation of FcyRIIB causes Lyn to phosphorylate the single ITIM of the 
cytoplasmic region of FcyRIIB. The phospho-ITlM can recruit and activate the 
phosphatase SHIP. SHIP removes the 5’ phosphate from PIP3 leading to 
impaired recruitment and activation of PH domain-containing proteins. 
Furthermore, SHIP suppresses the BCR-mediated activation of MARK by 
disrupting the association of She and Grb-2 and by recruiting and activating 
RasGAP via Dok-1. FcyRIIB can also impair the activation of Erk via the 
induction of Pac-1. Moreover, FcyRIIB induces the phosphatase PTEN to 
further impair PI-3-K signalling. FcyRIIB therefore suppresses the PI-3-K 
pathway and the Erk-MAPK cascade.
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Figure 1.20. CD40 signalling in mature B lymphocytes. Ligation of CD40 
induces the multimerisation of CD40-associated TRAFs including TRAFs 2, 3, 5 
and 6. This leads to the activation of several intracellular signalling molecules 
including non-receptor tyrosine kinases, MARK proteins, PI-3-K, PLCy and NF- 
k B . These signalling molecules can regulate transcription factors, gene 
expression and the activity of signalling molecules to control various cellular 
functions including susceptibility to apoptosis.
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Table 1.1. Comparison of WEHI-231 cell line, primary immature B cells and 
primary transitional B cells. WEHI-231 cells are widely used as a model for 
clonal deletion of immature/transitional B cells. Indeed, WEHI-231 cells have 
very similar surface expression and behavioural characteristics to immature and 
transitional B cells.
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Comparison of WEHI-231 cell line, primary immature B cells and primary 
transitional B cells.
WEHI-231 cells Immature B 
cells
Transitional B 
cells
igM + + +
igD +/- - +/“
CD40 + + +
CD23 +/- - +/-
Fas +/- - +
MHO II +/- +/- +/“
Receptor editing - + -
Proliferation + -
BCR-driven
apoptosis
+ + +
CD40-dependent
rescue
+ + +
Figure 1.21. CD40 signalling in immature B lymphocytes. Ligation of CD40 
induces the multimerisation of CD40-associated TRAFs. This leads to the 
activation of several intracellular signalling molecules including non-receptor 
tyrosine kinases, MARK proteins, PI-3-K and PLCy. These signalling molecules 
can then promote B cell survival by upregulating the pro-survival members of 
the Bcl-2-family and by activating NF-kB. CD40-mediated signals also promote 
proliferation of immature B cells by stimulating cyclin D kinases Cdk4 and Cdk6, 
leading to the phosphorylation and inactivation of retinoblastoma. This allows 
the activation of E2F and the induction of proliferation.
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Figure 1.22. Induction of BCR-driven apoptosis in immature WEHI-231 cells. 
Ligation of the BCR on immature B cells leads to the activation of Erk-MAPK 
and calcium mobilisation. Calcium recruits CPLA2 to the plasma membrane, 
where it can be activated by phosphorylation, catalysed by Erk1/2. Cytosolic 
PLA2 hydrolyses membrane lipids to form arachidonic acid. Arachtdonic acid 
induces apoptosis by disrupting the mitochondrial membrane potential, leading 
to a depletion of cellular ATP and the activation of cathepsin B. Cathepsin B is 
an executioner protease that mediates death of the immature B lymphocyte. 
Immature B cells can be protected from BCR-driven apoptosis by co-ligation of 
CD40. Stimulation of CD40 enables the cells to retain a normal mitochondrial 
membrane potential and consequently cellular ATP levels are not depleted and 
the cell does not undergo apoptosis.
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CHAPTER 2 - Materials and Methods
2.1 Antibodies
2.1.1 Primary antibodies
Protein^ Supplier Host Clone or 
ID
Dilution Usage^
Akt New England 
Biolabs
Rabbit 9272 1:1000 WB
Phospho-Akt
(pS""")
New England 
Biolabs
Rabbit 9271 1:1000 WB
Phospho-Akt
(PT""")
New England 
Biolabs
Rabbit 9275 1:1000 WB
Bcl-Xus^ Santa Cruz 
Biotechnology
Rabbit S-18 1:500 of 
200 pg/ml 
stock
WB
CD40^ - Rat FGK45 - Stimulation
Erk1/2-MAPK^ New England 
Biolabs
Rabbit 9102 1:1000 WB
IP
Phospho- 
Erk1/2 MAPK 
(pf°2/pY2°4)3
New England 
Biolabs
Rabbit 9101 1:1000 WB
Phospho- 
Erk1/2 MAPK
( p f  )
Promega Rabbit V8081 1:4000 WB
Phospho- 
Erk1/2 MAPK
(p y 2 0 4 )3
Santa Cruz 
Biotechnology
Rabbit E-4 1:600 of 
200 pg/ml 
stock
WB
Ig mu chain^ Rat B7.6 - Stimulation
MEK1/2^ New England 
Biolabs
Rabbit 9122 1:1000 WB
IP
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Protein Supplier Host Cione or 
ID
Dilution Usage
Phospho-
MEK1/2
New England 
Biolabs
Rabbit 9121 1:1000 WB
PAC-1 ^ Santa Cruz 
Biotechnology
Goat C-20 1:500 of 
200 pg/ml 
stock
WB
S H P -f Santa Cruz 
Biotechnology
Rabbit C-19 1:500 of 
200 pg/ml 
stock
WB
SHP-2^ Santa Cruz 
Biotechnology
Rabbit C-18 1:500 of 
200 pg/ml 
stock
WB
 ^Antibodies were originally raised against the murine form of the protein unless 
otherwise indicated.
^Abbreviations: WB, Western blotting: IP, immunoprécipitation 
 ^ Antibodies were raised against the human form of the protein but are 
crossreactive with the mouse protein.
 ^Antibodies were raised against the rat form of the protein but are crossreactive 
with the mouse protein.
® Antibodies were from hybridoma cell lines, see antibody purification, section 
2.5.
2.1.2 Secondary antibodies
Protein Conjugate Supplier Host Clone or ID Dilution
Goat IgG MRP Jackson
ImmunoResearch
Donkey 705-035-147 1:10000 
of 0.8 
mg/ml 
stock
Rabbit IgG HRP New England 
Biolabs
Goat 7074 1:2000
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2.2 All other reagents and chemicals
Reagent Supplier
Agarose Roche Diagnostics Inc.
Antipain Sigma-Aldrich Laboratories
Akt control cell extracts New England Biolabs
Bovine serum albumin Sigma-Aldrich Laboratories
Bromophenol blue ICN Biomedicals Inc.
Chemiblocker Chemicon International
Chymostatin Sigma-Aldrich Laboratories
Disodium hydrogen orthophosphate (Na2 HP0 4 ) BDH Laboratory Supplies
EDTA Fisher Scientific
Effect!ne transfection reagent Qiagen
Ethyl-3,4-dihydroxybenzylidenecyanoacetate (LOI) Alexis Biochemicals
Fetal calf serum Gibco-BRL
G418 antibiotic Promega
Glycerol BDH Laboratory Supplies
Glycine Fisher Scientific
Hydrogen peroxide Sigma-Aldrich Laboratories
Kodak X-ray film Wolf Laboratories Ltd.
Indomethacin ICN Biomedicals
Leupeptin Sigma-Aldrich Laboratories
L-glutamine Gibco-BRL
Luminol (3-aminophthalhydrazide) Sigma-Aldrich Laboratories
MEK assay kit TCS Biologicals
MEM non-essential amino acids Gibco-BRL
2-Mercaptoethanol (for tissue culture) Gibco-BRL
2-Mercaptoethanol (for all other uses) BDH Laboratory Supplies
Methanol BDH Laboratory Supplies
MicroBCA protein assay Pierce
N-[2-(Cyclohexyloxy)-4- Calbiochem
nitrophenyl]methanesulfonamide (NS-398)
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Reagent Supplier
N, N-Dimethyt-D-erythro-sphingosine (DMS) Alexis Biochemicals
Nitrocellulose Amersham International
NP40 Fisons Scientific Inc.
NuPAGE buffers and reagents Invitrogen
p-Coumaric acid (4-hydroxycinnamic acid) Sigma-Aldrich Laboratories
Penicillin Gibco-BRL
Pepstatin A Sigma-Aldrich Laboratories
PGE2 competitive binding immunoassay kit Cayman Chemical
Phenylmethylsulfonylfluoride Sigma-Aldrich Laboratories
p42 MAP kinase recombinant control proteins New England Biolabs
Polybrene Sigma-Aldrich Laboratories
Potassium chloride (KCl) BDH Laboratory Supplies
Potassium dihydrogen orthophosphate (KH2 PO4) Fisher Scientific
Propidium iodide (PI) Calbiochem
Protein G-sepharose beads Sigma-Aldrich Laboratories
RNase A Sigma-Aldrich Laboratories
RPMI-1640 medium Gibco-BRL
Sodium azide Sigma-Aldrich Laboratories
Sodium chloride (NaCI) Sigma-Aldrich Laboratories
Sodium dodecyl sulphate (SDS) BDH Laboratory Supplies
Sodium deoxycholate Sigma-Aldrich Laboratories
Sodium Dihydrogen orthophosphate (NaH2 PÛ4) BDH Laboratory Supplies
Sodium orthovanadate Sigma-Aldrich Laboratories
Sodium pyruvate Gibco-BRL
Sodium (tri) citrate Sigma-Aldrich Laboratories
Streptomycin Gibco-BRL
[6-^H] thymidine (5 Ci/mmol) Amersham International
Tris Sigma-Aldrich Laboratories
Triton-X-100 Sigma-Aldrich Laboratories
Tween-20 Sigma-Aldrich Laboratories
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2.3 Company and distributor addresses
Alexis Biochemicals, Nottingham, UK
Amersham International, Buckinghamshire, UK
BDH (WVR) Laboratory Supplies, Lutterworth, Leics, UK
BioRad, Hemel Hempstead, Hertfordshire, UK
Calbiochem, Cambridge, MA, USA
Cayman Chemical, Ann Arbor, Ml, USA
Chemicon International, Temecula, CA, USA
Fisher Scientific, Loughborough, Leics, UK
Fisons Scientific Inc., Loughborough, Leics, UK
ICN Biomedicals, Aurora, Ohio, USA
Gibco-BRL, Paisley, Scotland, UK
Jackson Immunoresearch Laboratories, Inc., West Grove, PA, USA
Invitrogen, Paisley, UK
New England Biolabs, Hitchin, Herts, UK
Pierce, Rockford, IL, USA
Promega, Madison, Wl, USA
Qiagen, Valencia, CA, USA
Roche Diagnostics Inc., Indianapolis, IN, USA
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA
Sigma-Aldrich Laboratories, Poole, Dorset, UK
TCS Biologicals, Botolph Claydon, Buckinghamshire, UK
Wailac, Turku, Finland
Wolf Laboratories Ltd, Pocklington, York, UK
2.4 Cells
2.4.1 WEHI-231 immature B cells
The murine B cell lymphoma, WEHI-231 was cultured in RPMI-1640 
medium supplemented with 5% (v/v) fetal calf serum, L-glutamine (2 mM), 
penicillin (100 U/ml), streptomycin (100 pg/ml) and 2-mercaptoethanol (50 pM) 
(RPMI complete medium) at 37°C in 5% (v/v) CO2 atmosphere at 95% humidity. 
All cell culture reagents were of the highest quality available.
89
2.4.2 Generation o f B c I-x l WEHI-231 cells
WEHI-231.7 JM cells were transfected by electroporation with the pSFFV- 
Neo plasmid containing either the human bd-xt gene (B c I-Xl WEHI-231) or no 
insert as control (Neo WEHI-231) (291). Stable transfectants were selected for 
the acquisition of neomycin resistance by growth in the presence of the 
antibiotic G418 (1 mg/ml) and were a gift from Dr. C. B. Thompson (University 
of Pennsylvania). Overexpression of B c I-x l was confirmed by Western blotting 
using an anti-Bcl-xus antibody.
2.4.3 Retroviral transfection of WEHI-231 cells
Retroviral constructs were generated by subcloning the gene of interest 
into the retroviral vector pMXI-egfp, 5’ to the internal ribosomal entry site and 
green fluorescence protein (GFP) was encoded 3’ to this site. Amphotropic 
phoenix cells were used as packaging cells for the retroviral transfection 
system. Pheonix cells were transfected using the effectine transfection reagent 
as per manufacturers instructions (Qiagen) with pMXI-egfp vectors containing 
no construct (empty vector control, pMXI-egfp), SHIP-CI construct, SHIP-SH2 
construct or Dok-PH/PTB construct (see table 2.1 A for details of constructs). 
Two days after transfection, the supernatants were collected, filtered (0.22 pm) 
and polybrene was added to a final concentration of 4 pg/ml. WEHI-231 B cells 
(5x10® cells/ml) were centrifuged in 12-well plates to promote adherence. Viral 
supernatants were added to adherent cells followed by centrifugation at 1,000 g 
for 2 hr at 32®C. Cells were then incubated at 32°C overnight before transferring 
them into 25 cm^ flasks for expansion. Following expansion, cells were sorted 
for GFP-expression (Mo-Flo, Cytomation, Fort Collins, CO). Successful 
transfectants were a gift from Dr. S. B. Gauld (National Jewish Medical and 
Research Center, Denver, CO).
2.4.4 Transfection of WEHI-231 cells by electroporation
WEHI-231 cells (5x10® cells) undergoing logarithmic growth were washed 
and resuspended (2 x 10  ^ cells/ml) in electroporation media (RPMI-1640 with 
20% FCS). Linearised DNA (5 pg), recovered from an agarose gel, was chilled 
on ice for 5 min in an electroporation cuvette. WEHI-231 cells (5 x 10®) were
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added to the cuvette, gently mixed and chilled for 1 0  min on ice. Cells were 
electroporated at 960 pFarads at 220 Volts and were then chilled on ice for a 
further 10 min. Cells were then removed from the cuvette and were grown in 
RPMI complete medium for 48 hr at 37°C in 5% (v/v) COg atmosphere at 95% 
humidity before selecting for successful transfectants using the antibiotic G418 
(500 pg/ml). Electroporation of WEHI-231 B cells was used to generate several 
mutant WEHI-231 cells (table 2.1B) including an empty vector control, 
pcDNA3.1. Transfection of WEHI-231 cells by electroporation was performed in 
collaboration with Derek Blair, in this laboratory.
2.5 Purification of antibodies from hybridoma cell lines
2.5.1 Purification of anti-CD40 antibody
Anti-CD40 was purified from the FGK 45 hybridoma. FGK 45 cells were 
cultured in RPMI complete medium and the antibody-rich tissue culture 
supernatant was collected. Immunoglobulin was precipitated from the 
supernatant by mixing equal volumes of saturated ammonium sulphate solution 
and tissue culture supernatant (FGK 45) overnight at 4®C. The precipitated 
immunoglobulin was isolated by centrifugation and dialysed exhaustively in 
phosphate buffered saline (PBS) solution (160 mM NaCI, 3.2 mM KCl, 9.7 mM 
N8 2 HP0 4 , 1 . 8  mM KH2 PO4 pH 7.2). A column of 1 ml protein G-sepharose 
beads (immunoglobulin capacity > 2 0  mg/ml) was washed with binding buffer 
(0.2 M NaH2 P0 4 .2 H2 0 , 0.2 M Na2 HP0 4 .2 H2 0 , pH 7.0) and the dialysed 
immunoglobulin solution was run through the column at 4^C. The column was 
washed with binding buffer and the immunoglobulin was eluted in 1 ml fractions 
using elution buffer (0.1 M glycine, pH 2.7). The protein concentration of each 1 
ml fraction was determined using spectrophotometry to measure the 
absorbance at 280 nm (an optical density of 1.4 was approximately equivalent 
to 1 mg/ml of protein). The most protein-rich fractions were pooled and dialysed 
exhaustively in PBS. The resultant anti-CD40 was filter sterilised and stored at - 
2 0 °C.
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2.5.2 Purification of anti-lg (anti-mouse p-chain) antibody
Anti-lg was purified from the B7.6 hybridoma. B7.6 cells were cultured In 
RPMI complete medium and the antibody-rich tissue culture supernatant was 
collected. Anti-lg was purified using a protein G-sepharose column. The column 
of 1 ml protein G-sepharose beads (immunoglobulin capacity >20 mg/ml) was 
washed with binding buffer (0.2 M NaH2 P0 4 .2 H2 0 , 0.2 M Na2 HP0 4 .2 H2 0 , pH 
7.0) then tissue culture supernatant (B7.6) was run through the column at 4°C. 
The column was washed with binding buffer then the immunoglobulin was 
eluted in 1 ml fractions using elution buffer (0.1 M glycine, pH 2.7). The protein 
concentration of each 1 ml fraction was determined using spectrophotometry to 
measure the absorbance at 280 nm (an optical density of 1.4 was 
approximately equivalent to 1 mg/ml of protein). The most protein-rich fractions 
were pooled and dialysed exhaustively in PBS. The resultant anti-lg was filter 
sterilised and stored at -20°C.
2.6 Measurement of DNA synthesis
Proliferation of WEHI-231 cells was assessed by measurement of DNA 
synthesis. WEHI-231 cells (1 x lO'  ^ cells/well) were cultured in triplicate in 96- 
well round-bottomed microtitre plates in RPMI complete medium supplemented 
with 1% (v/v) MEM non-essential amino acids and sodium pyruvate (1 mM), in 
the presence of appropriate stimuli in a total volume of 200 pi. Cells were 
cultured at 37°G in a 5% (v/v) CO2 atmosphere with 95% humidity for up to 72 
hr. [6-®H] thymidine (0.5 pCi/well) was added 4 hr prior to harvesting onto glass 
fibre filter mats using a betaplate 96-well automated cell harvester (Amersham 
International). Incorporated [®H] thymidine was determined by liquid scintillation 
counting (Beta-plate counter, Wailac) and is represented as mean cpm 
incorporated ± standard deviation, n=3 or mean cpm of several experiments ± 
standard error of the mean (sem).
2.7 Stimulation of ceils and preparation of whole cell lysates
WEHI-231 cells (1 x 10  ^ cells) were stimulated as required in RPMI 
complete medium at 37°C in 5% (v/v) CO2 atmosphere at 95% humidity. 
Reactions were terminated by centrifugation at 500 g for 7 min at 4°C followed
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by resuspension of cells in ice cold lysis buffer (150 mM sodium chloride, 50 
mM Tris pH 7.5, 2  % (v/v) NP4 0 , 0.25 % (w/v) sodium deoxycholate and 1 mM 
EDTA pH 8  with freshly added 10 mM sodium orthovanadate, 0.5 mM 
phenylmethylsulfonylfluoride, 1 0  pg/ml chymostatin, 1 0  pg/ml leupeptin, 1 0  
pg/ml antipain and 1 0  pg/ml pepstatin A). Lysates were solubilised for 30 min 
on ice followed by centrifugation at 13,000 g for 1 0  min at 4^C. The resultant 
supernatants (whole cell lysates) were transferred to fresh tubes and were 
stored at -20®C.
2.8 Immunoprécipitation
Whole cell lysates (100 pg total protein) were precleared with 5 pi protein 
G-sepharose beads in lysis buffer (50% slurry) for 1 hr at 4°C with constant 
rotation. Lysates were centrifuged at 13,000 g for 10 min at 4°C and the 
supernatants were transferred to a fresh tube. The proteins of interest were 
immunoprecipitated from the precleared lysates by the addition of an 
appropriate antibody (1-2 pg) for 5 hr at 4°C with constant rotation. The 
protein/antibody immunocomplex was captured using 1 0  pi protein G- 
sepharose beads in lysis buffer (50% slurry) overnight at 4°C with constant 
rotation. Immunocomplexes were isolated by centrifugation at 13,000 g for 10 
min at 4°C and washed 3 times in lysis buffer. Immunocomplexes were 
resuspended in 30 pi 2 x sample loading buffer (100 mM Tris pH 6.8, 20% (v/v) 
glycerol, 0 .2 % (w/v) SDS and 4% (v/v) bromophenol blue with 5% 2 - 
mercaptoethanol), boiled for 10 min at 100°C, pulse centrifuged and used in gel 
electrophoresis or stored at -20°C.
2.9 Gel electrophoresis and transfer
Equal protein loadings of whole cell lysates (determined by MicroBCA
protein assay (Pierce)) or immunoprecipitates were resolved by gel
electrophoresis. One of two gel systems was used. In the first system, lysates
or immunoprecipitates were denatured in 2 x sample loading buffer (100 mM
Tris pH 6 .8 , 2 0 % (v/v) glycerol, 0.2% (w/v) SDS and 4% (v/v) bromophenol blue
with 5% 2-mercaptoethanol) by heating for 1 0  min at 100°C. Following pulse
centrifugation, the samples were resolved using 10% Tris-HCI pre-cast gels
(BioRad) with electrophoresis buffer (25 mM Tris, 192 mM glycine and 0 .1 %
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(w/v) SDS) in a BioRad gel electrophoresis kit. The resolved proteins were 
transferred onto nitrocellulose (Amersham) using transfer buffer (42 mM Tris, 39 
mM glycine, 0.38% (w/v) SDS and 20% (v/v) methanol).
The second system of gel electrophoresis used the XCell SureLock Mini- 
Cell kit with NuPAGE No vex high-performance pre-cast Bis-Tris gels and 
NuPAGE buffers and reagents (all supplied by Invitrogen) as directed by the 
manufacturers instructions. In brief, equal protein loadings of lysates were 
diluted in lysis buffer to a constant final volume and the appropriate volume of 4 
X NuPAGE LDS sample buffer and 10 x NuPAGE reducing agent were added 
prior to heating samples to 70°C for 10 min. Samples were resolved using 
NuPAGE Bis-Tris gels (10%) with NuPAGE MOPS running buffer 
(supplemented with NuPAGE antioxidant) and transferred onto nitrocellulose 
(Amersham) using NuPAGE transfer buffer with 20% (v/v) methanol.
2.10 Western blot analysis
Following transfer, nitrocellulose membranes were washed once in Tris 
buffered saline (TBS) (0.5 M NaCI and 20 mM Tris pH7.5) with 0.1% (v/v) 
Tween-20 (TBS/Tween) and blocked for 1 hr in TBS/Tween with either 5% non­
fat milk or 5% bovine serum albumin (BSA). Alternatively, blots that were to be 
probed with an antibody generated in a goat were blocked for 1 hr in a 1 in 4 
dilution of a non-animal blocking reagent, Chemiblocker (Chemicon 
International). Membranes were then incubated with the appropriate primary 
detection antibody overnight at 4°C. All antibodies were diluted in TBS/Tween 
with either 5% non-fat milk, 5% BSA or 1 in 4 dilution of ChemiBlocker. 
Following incubation with primary antibody nitrocellulose membranes were 
washed (6x5  minutes) with TBS/Tween and incubated in the appropriate horse 
radish peroxidase (HRP)-conjugated secondary antibody for 1 hr at room 
temperature. Nitrocellulose membranes were then washed (10x10  minutes) 
with TBS/Tween and protein bands were visualised using the ECL detection 
system. Nitrocellulose membranes were incubated in a mixture of equal 
volumes of ECL solution A (2.5 mM luminol, 0.4 mM p-coumaric acid and 100 
mM Tris pH8.5) and ECL solution B (0.002% hydrogen peroxide and 100 mM 
Tris pH8.5) for 1 min before exposing membranes to Kodak X-Ray film.
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Nitrocellulose membranes were sometimes stripped and re-probed with a 
new primary antibody. Membranes were stripped at room temperature for 1-3 hr 
(depending on the strength of the previous Western blot signal) in stripping 
buffer (100 mM 2-mercaptoethanol, 2% SDS and 62.5 mM Tris pH6.7). 
Nitrocellulose membranes were washed thoroughly in TBS/Tween before re­
starting the Western blotting protocol.
2.11 Dot blot analysis
Equal volumes of immunoprecipitates were heated for 10 min at 100°C 
followed by transfer onto nitrocellulose using a slot blotter (BioRad). 
Nitrocellulose membranes were washed once in TBS/Tween before being used 
in the Western blotting protocol (described in section 2.10).
2.12 Flow cytometry
2.12.1 Flow cytometry analysis of DNA content and cell cycle analysis
WEHI-231 cells (5 x 10® cells/well) were cultured in RPMI complete 
medium supplemented with 1% (v/v) MEM non-essential amino acids and 
sodium pyruvate (1 mM), in the presence of appropriate stimuli. Cells were 
cultured at 37°C in a 5% (v/v) CO2 atmosphere with 95% humidity for up to 48 
hr. WEHI-231 cells (5x10® cells) were harvested and washed twice in ice-cold 
FACS buffer (PBS with 1% BSA and 0.1% sodium azide). Cells were 
resuspended in 100 pi propidium iodide (PI) stain (0.1% (w/v) sodium (tri) 
citrate, 0.1% (v/v) triton-X-100, 50 pg/ml propidium iodide and 200 pg/ml RNase 
A) for 45 min at room temperature. Cells were passed through nitex and 
analysed for PI fluorescence on a FACScalibur™ (Becton Dickinson) using 
CELLQuest™ software (Becton Dickinson).
Cell cycle analysis was used to determine the percentage of cells in the 
different phases of the cell cycle: sub-diploid (apoptotic), G0/G1, S phase or 
G2/M (figure 1.6). PI fluorescence was measured using both FL3 (linear scale) 
and FL2 (logarithmic scale) channels. When using FL3, the voltage was 
adjusted until the large G0/G1 peak was at 200-300 units. This voltage was kept 
constant whilst the data from any one experiment was acquired. Data was 
analysed by setting gates (figure 2.1A(i)). The G0/G1 peak represents 2N DNA
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(50 units), the centre of this peak was identified and a gate was set to span 25 
units either side of the centre point. The 2N DNA peak was doubled 
(representing 4N DNA) and markers were set 50 units either side of this point to 
form the G2/M gate. The S phase gate represents the cells between G0/G1 and 
G2/M phases. Cells located before the G0/G1 peak are the sub-diploid 
(apoptotic) cells. The sub-diploid peak starts at 5 units in order to eliminate non­
specific fluorescence, as indicated in figure 2.1A(ii) in which cells were stained 
with a stain solution that lacked PI but were analysed in exactly the same way 
as Pl-stained cells.
When using FL2, the voltage was adjusted until the large G0/G1 peak was 
at 10  ^ units. This voltage was kept constant whilst the data from any one 
experiment was acquired. Data was analysed by setting gates (figure 2.1 B(i)). 
The G0/G1 peak represents 2N DNA (30 units), the centre of this peak was 
identified and a gate was set to span 15 units either side of the centre point. 
The 2N DNA peak was doubled (representing 4N DNA) and markers were set 
30 units either side of this point to form the G2/M gate. The S phase gate 
represents the cells between G0/G1 and G2/M phases. Cells located before the 
G0/G1 peak are the sub-diploid (apoptotic) cells. The sub-diploid peak starts at 
1 unit in order to eliminate non-specific fluorescence, as indicated in figure 
2.1B(ii) in which cells were stained with a stain solution that lacked PI but were 
analysed in exactly the same way as Pl-stained cells.
2.12.2 Flow cytometry analysis of green fluorescence
Unstimulated retroviral I y transfected cells (empty vector (pMXI-egfp), 
SHIP-CI, SHIP-SH2 and Dok-PH/PTB mutant WEHI-231 cells) were tested for 
successful transfection using FACS to detect the expression of the green 
fluorescent protein (GFP) marker. Cells (1x10®) were washed twice in ice-cold 
FACS buffer, solubilised in FACS buffer with 7 pg/ml PI and passed through 
nitex. Green fluorescence was detected on a FACScalibur™ (Becton Dickinson) 
using CELLQuest™ software (Becton Dickinson).
Non-transfected WEHI-231 cells were used as a negative control since 
these cells do not contain the gene encoding GFP. GFP positive cells were 
rigorously gated by exclusion of the peak of cells observed in the negative 
control (figure 2.2). In the culture of empty vector control, pMXI-egfp, cells, 99%
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were GFP positive but inclusion of a construct into the vector reduced the 
success rate of transfection. However, even with these rigorous gates, 71% of 
cells in the SHIP-CI culture were GFP positive and 83% of cells in the SHIP- 
SH2 culture expressed GFP. The Dok-PH/PTB WEHI-231 was the least 
homogeneous culture with 50% of the cells being GFP positive.
2.13 Measurement of intracellular prostaglandin Eg
Prostaglandin Eg (PGEg) concentration in WEHI-231 whole cell lysates 
was determined using a PGEg competitive binding immunoassay kit (Cayman 
Chemical) based on spectrophotometric detection (A405), as described in the kit 
protocol. Briefly, whole cell lysates were prepared as described in section 2.7 
except indomethacin (10 pg/ml), an inhibitor of cyclooxygenase, was added to 
the lysis buffer. Whole cell lysate (50 pg) was incubated with 50 pi PGEg- 
Acetylcholinesterase conjugate plus 50 pi PGEg monoclonal antibody solution in 
a 96-well goat anti-mouse IgG coated plate for 2 hr at room temperature. The 
plate was washed three times before adding Ellman’s reagent for 1 hr at room 
temperature. Ellman’s reagent contains the substrate for acetylcholinesterase 
and forms a yellow-coloured product that absorbs strongly at 405-420 nm. The 
absorbance at 405 nm was measured using a microplate reader with 
wavelength correction set at 570 nm.
2.14 In vitro Erk-MAPK kinase (MEK) assay
Whole cell lysates were prepared from WEHI-231 B cells (1 x 10^)
stimulated with medium or anti-lg (10 pg/ml) for up to 48 hr. MEK1/2-containing
immune complexes were prepared from lysates (100 pg) using an anti-MEK1/2
antibody and protein G-sepharose beads. The MEK1/2 immunoprecipitates
were assayed for MEK activity using the MEK Assay Kit (TCS Biologicals), and
0.5 U human activated MEK1 was used as the positive control sample. Briefly,
the immune complex samples, or human activated MEK1, were incubated with
assay buffer (20 mM MOPS pH7.2, 25 mM p-glycerol phosphate, 5 mM EGTA,
1 mM sodium orthovanadate and 1 mM DTT), Mg^^-ATP mixture (75 mM
magnesium chloride and 500 pM ATP in assay buffer) and 1 pg of inactive
GST-p42 MAPK at 30°C for 30 min. Samples were then analysed by gel
electrophoresis using pre-cast 10% Tris-HCI gels (BioRad). Western blotting
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was performed using anti-phospho-p44/p42 MAPK (Thr^ ^^ /Tyr^ ®"^ ) (New England 
Biolabs) to detect phosphorylated GST-p42 MAPK (62 kD). The amount of 
GST~p42 MAPK is proportional to the activity of MEK1/2 in the sample. Blots 
were stripped and reprobed with anti-MEK1/2 (New England Biolabs) to check 
the loading of the gel.
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Table 2.1. Constructs used in transfection of WEHI-231 cells. (A) Constructs 
used in retroviral transfection of WEHI-231 cells. Constructs were Inserted into 
the pMXI-egfp vector and retroviral transfection was used to generate SHIP-CI, 
SHIP-SH2 and Dok-PH/PTB mutant WEHI-231 cells. Successful transfectants 
were selected based on their expression of GFP. (B) Constructs used in 
transfection by electroporation of WEHI-231 cells. Constructs were inserted into 
the pcDNA3.1 vector and electroporation was used to generate multiple PKC, 
Ras and MEKK3 mutant WEHI-231 cells. Successful transfectants were 
selected based on their resistance to G418 antibiotic.
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(A) Constructs used in retroviral transfection of WEHI-231 cells
Activity Mutation/ Coding 
Sequence
SHIP-CI phosphatase inactive
SHIP-SH2 prevents SHIP-plTlM 
association
residues 1-114
Dok-PH/PTB lacks pro/tyr-rich region residues 1-258
(B) Constructs used in transfection by electroporation of WEHI-231 cells
Activity Mutation/ Coding 
Sequence
PKCaKR kinase inactive residues 2-672 (K^®R)
PKCaCAT constitutively active residues 326-674
PKCÔKR kinase inactive residues 2-674 (K^'^R)
PKCôCAT constitutively active residues 334-674
PKCeKR kinase inactive residues 2-732 (K‘*^ ‘'R)
PKCeCAT constitutively active residues 395-737
PKCAKR kinase inactive residues 2-592 (K^^^M)
PKCACAT constitutively active residues 239-592
RasV'^ constitutively active, 
interacts with all Ras effectors
W  “
RasV^^S' '^’ constitutively active, 
only interacts with Raf-1
RasV^^C*" constitutively active, 
only interacts with PI-3-K
AMEKK3 constitutively active residues 340-626
Figure 2.1. FACS analysis of Pi-stained cells. WEHI-231 cells (5x10® cells/ml) 
were cultured for 24 hr. Cells were prepared for FACS analysis by staining with 
either 50 pg/ml PI (i) or Pi-free (ii) stain solution. FACS analysis with FL3 (A) or 
FL2 (B) fluorescence was used to analyse the populations of cells. Histograms 
show gates relating to apoptotic cells (sub-diploid DNA), cells in G0/G1 (2N 
DNA), S phase cells and cells in G2/M (4N DNA).
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Figure 2.2. FACS analysis of retrovirally transfected WEHI-231 cells for 
expression of GPP. The expression of GPP in cultures of unstimulated 
retrovirally transfected WEHI-231 cells (1 x 10® cells/ml) was measured by 
PACS analysis. The pMXI-egfp vector contains the gene encoding GPP 
therefore successful transfectants express GPP whilst non-transfected cells are 
GPP-negative since they do not contain the gene encoding GPP. GPP-positive 
cells were gated by exclusion of the peak of cells observed in the non- 
transfected WEHI-231 culture.
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CHAPTER 3 " Dual role for Erk-MAP kinase in BCR-driven apoptosis and 
CD40-mediated rescue of WEHI-231 immature B ceils 
3.1 BCR signalling in B lymphocytes
Ligation of the BCR on B lymphocytes leads to three possible outcomes, 
activation, anergy or apoptosis, depending on the developmental state of the 
cell. The signalling pathways activated downstream of the BCR have largely 
been studied in mature B lymphocytes but similar signalling pathways have 
been observed in BCR-stimulated immature B cells. However, the divergent 
outcomes of BCR-ligation in mature B cells (activation) and immature B cells 
(growth arrest and apoptosis) suggests that there are important differences in 
the signals transduced from these receptors.
3.2 MAP kinases in lymphocyte signalling
It is well documented that MAPKs from the Erk, JNK and p38 families are 
activated downstream of the BCR and TCR (27, 219, 306, 326). Furthermore, 
ligation of CD40 on mature and immature B cells can stimulate MAPKs from all 
three families (219, 306, 307, 309). However, the response of a B cell to the 
differential regulation of MAPK by the BCR and CD40 depends on the 
developmental stage of the cell. In mature B cells the activation of Erk can 
stimulate proliferation (327). In contrast, BCR-dependent activation of Erk in 
immature B cells has been associated with the induction of apoptosis whilst 
CD40 has been shown to preferentially couple to JNK and p38 MAPK 
suggesting these kinases are more involved in mediating B cell survival (306- 
309). Nonetheless, recent reports have suggested that in immature B cells the 
BCR and CD40 can both induce Erk-MAPK and the kinetics of Erk1/2 activation 
are critical for determining the fate of the cell (219, 328). The differential 
regulation of Erk-MAPK by the BCR and CD40 plays a significant role in 
regulating the survival and proliferation of immature B cells (328).
3.3 MAP kinase family
The MAPK family is a large family of highly conserved serine/threonine 
protein kinases. There are at least three types of MAPK proteins, the Erk-
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MAPKs, the JNK MAPKs, also known as stress-activated protein kinases, and 
the p38 MAPKs. Erk-MAPK can usually be activated by mitogenic stimuli 
including growth factors whilst JNK and p38 MAPKs are generally considered to 
be stimulated in response to cellular stress.
MAPKs are activated via a signalling network that is conserved from yeast 
to mammals (figure 3.1) (329-331). At each stage of the signalling network there 
is amplification. Stimulation of MAPK proteins requires the upstream activation 
of a MKK (MAPK kinase) and a MKKK (MAPK kinase kinase). MKKK are 
serine/threonine protein kinases that phosphorylate and activate MKKs. MKKs 
are dual-specificity protein kinases therefore they can phosphorylate 
serine/threonine and tyrosine residues. MKKs phosphorylate the threonine and 
tyrosine residues of a conserved T-X-Y motif of the activation loop of the MAPK. 
The X residue is different in each family of MAPKs: Erk has a T-E-Y motif, JNK 
has a T-P-Y motif and p38 has a T-G-Y motif. Phosphorylation of the T-X-Y 
motif activates the MAPKs allowing phosphorylation of a specific repertoire of 
cytoplasmic and nuclear proteins including various transcription factors. The 
substrate specificity of MAPKs is influenced by the X residue of the T-X-Y motif 
and by the amino acids surrounding this motif since this region can affect the 
availability or conformation of the substrate binding groove (326, 332-334).
MAPKs can regulate the activity and the fate of a cell therefore the MAPK 
cascade is carefully regulated, in yeast and mammals scaffolding proteins have 
been identified that couple MAPKs to their upstream regulators (329, 330, 335, 
336). Moreover, each MAPK enzyme can be activated by a number of different 
upstream MKKs and MKKKs, allowing a broad range of stimuli to trigger the 
activation of MAPK (337). However, each MAPK, MKK and MKKK enzyme has 
unique properties regarding its regulation, substrate specificity and the kinetics 
of activation. Furthermore, the activity of specific proteins within the MAPK 
cascade can be regulated by many other signalling molecules including PI-3-K, 
PKC and protein kinase A (PKA). Finally, negative feedback mechanisms exist 
to ensure MAPK enzymes are not activated constitutively (338, 339). For 
example, MAPK can induce protein phosphatases that dephosphorylate and 
inhibit MAPK (340).
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3.4 Erk-MAP kinase
3.4.1 The Erk-MAP kinase family
The Erk-family of MAPKs contains several members, the best studied 
being Erk1 and Erk2. Erk1 (p44) was initially purified and investigated as the 
regulator of microtubule-associated protein 2 kinase and ribosomal S6 kinase 
downstream of the insulin receptor (341). Soon after, Erk2 (p42) was cloned 
indicating several Erk proteins existed (342). Erk3 (62 kD) is ubiquitously 
expressed and constitutively localised to the nucleus. A serine residue in Erk3 
replaces the threonine residue of the T-X-Y motif of Erk1/2. Despite its 
structural similarities to Erk2, Erk3 has a unique set of substrates (342, 343). 
Erk5 (also known as Big MAPK since it has 815 amino acids and is 
approximately 110 kD in size) is stimulated by MEK5 in the cytoplasm by 
phosphorylation of a T-E-Y activation motif. Activated Erk5 translocates to the 
nucleus to regulate transcription mediated by the MEF2 (myocyte enhancer 
factor 2) proteins. Erk5 may also target cytoskeletal elements within the 
cytoplasm of the cell. Erk5 and Erk1/2 have been reported to work together to 
mediate the activation of NF-kB and p90®® ribosomal kinase (344-346). Erk6 
(45 kD) is required for differentiation of myoblasts to myotubules. Mutation of 
Tyr^ ®® of the T-X-Y motif impairs ErkG function suggesting it may be regulated 
by tyrosine phosphorylation (347). Erk7 (61 kD) is an autoactivated MAPK 
enzyme that has high basal activity and this is not increased by factors that 
normally activate Erk. The phosphorylation of the T-E-Y motif of Erk7 increases 
its activity but MEK-inhibitors do not prevent the activation of Erk7 and it is 
thought that Erk7 may autophosphorylate the T-E-Y motif (348). Erk8 
(approximately 60 kD), like Erk7, is not inhibited by inhibitors of MEK1, 2 or 5 
but Erk8 has low basal activity. Erk8 has two SH3 domains allowing it to bind to 
Src-family tyrosine kinases and this may be required for Its activation (349).
3.4.2 Activation of Erk1/2
As stated above, Erk 1 and 2 are regulated by phosphorylation of a T-E-Y
motif (350). The phosphorylation of the threonine and tyrosine residues can
occur independently of each other and does not have to be in any particular
order for Erk to be stimulated but both residues must be phosphorylated for full
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activation of Erk (351). MEK1 and 2 are threonine/tyrosine kinases that catalyse 
the phosphorylation of the threonine and tyrosine residues of Erk1/2 and can 
fully activate Erk (352-354). MEK1/2 can be activated by phosphorylation of 
Ser^ ^^ ^^ ^® and Ser^^\ catalysed by Raf-1. RKIP (Raf kinase inhibitor protein) can 
bind to Raf-1 to prevent its association with MEK thus inhibiting Erk (355, 356). 
Raf-1 is the major activator of MEK1/2 but MEK1/2 can also be stimulated by 
other protein kinases including Raf-B, c-Mos and MEKK1 (217, 357, 368).
Raf-1 is activated downstream of the monomeric G-protein Ras. Raf-1 
binds to Ras-GTP via a Ras-binding domain but the full activation of Raf-1 also 
requires an adjacent cysteine-rich domain, which can enhance the interaction of 
Raf-1 and Ras. The mechanism of Raf-1 activation is complex and has several 
requirements including membrane translocation of Raf-1, phosphorylation of 
stimulatory residues and dephosphorylation of inhibitory residues (figure 3.2) 
(reviewed in (359)). Under unstimulated conditions, Raf-1 is suppressed by the 
binding of its amino terminal domain to its kinase region (360). Inactive Raf-1 is 
also phosphorylated at Ser^ ®® and Ser®^  ^ allowing Raf-1 to bind to 14-3-3 
proteins and this stabilises the inactive conformation of Raf-1. The activation of 
Raf-1 requires Raf-1 to translocate from the cytosol to membranes. Raf-1 can 
bind to phosphatidic acid and to Ras, both have been implicated in directing the 
membrane-translocation of Raf-1 (361, 362). The binding of Raf-1 to Ras 
displaces 14-3-3 proteins allowing PP2A to dephosphorylate Ser^ ®®, and 
possibly Ser®^  ^ (363). The dephosphorylation of Ser^ ®® enhances the 
association of Raf-1 to Ras and to MEK and is required for Raf-1 activation 
(362, 364). Phosphorylation of Ser®®® and Tyr®"^  ^ is also essential for activation 
of Raf-1 (365). Phosphorylation of Ser®®® enhances the binding of Raf-1 to MEK 
whilst phosphorylation of Tyr®'^  ^ has been suggested to enhance the 
phosphorylation of Ser®®® and may remove the negative regulatory domain from 
the kinase domain of Raf-1 (366). Phosphorylation of Tyr®'^  ^ also participates in 
the targeting of Raf-1 into lipid rafts where it can then bind to Ras (367). Raf-1 
and Ras bind with high affinity. Phosphorylation of Ser'^ ® by PKA reduces the 
affinity of Raf-1 for Ras resulting in an inhibition of Raf-1 (359, 368). Raf-1 can 
also be inhibited by phosphorylation of Ser^ ®® catalysed by Akt (364).
The Ras family of GTPase proteins is encoded by three ubiquitously 
expressed genes generating H-Ras, K-Ras (4A and 4B) and N-Ras. All four
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Ras proteins are structurally similar and include a C-terminal CAAX motif where 
C is cysteine, A is an aliphatic amino acid and X is serine or methionine. The 
CAAX motif is post-translationally modified to increase the hydrophobicity of the 
C-terminus allowing membrane attachment of Ras (369). The activity of Ras 
depends on its association with guanine nucleotides and this is regulated by 
guanine nucleotide exchange factors and GTPase-activating proteins (370, 
371). Ras can be activated by the ubiquitously expressed guanine nucleotide 
exchange factor SOS, which is activated downstream of receptor tyrosine 
kinases, tyrosine kinase-coupled receptors and heterotrimeric G-protein- 
coupled receptors (370). SOS can be recruited to membrane-bound receptor 
complexes using adaptor proteins such as Grb-2.
3.6 Ras IS involved in multiple signalling pathways
Ras-GTP has several effectors (370). The best-characterised effector is 
Raf-1 but it can also stimulate the related molecules B-Raf and A-Raf. Ras-GTP 
activates Raf-1 via a complex mechanism involving translocation of Raf to 
membranes, phosphorylation and dephosphorylation (figure 3.2) (359-361, 364- 
367). The activation of Raf by Ras leads to the stimulation of Erk 1/2. Ras-GTP 
can also activate PI-3-K and the simultaneous activation of Erk and PI-3-K by 
Ras-GTP has been implicated in promoting BCR-driven activation of p90^® 
ribosomal kinase and subsequent inhibition of the pro-apoptotic protein Bad 
(233). However, the precise mechanism of Ras-dependent activation of PI-3-K 
is not fully understood and may involve Ras-dependent translocation of PI-3-K 
to the plasma membrane although the activation of PI-3-K is also dependent on 
tyrosine kinases. PI-3-K is a protein and a lipid kinase, it generates 3- 
phosphorylated phosphatidylinositol lipids and this contributes to the activation 
of Akt. A third effector of Ras-GTP is a family of guanine nucleotide exchange 
factors for Ral including RalGDS, Rgll and Rif. The activation of Ral guanine 
nucleotide exchange factors results in the stimulation of the monomeric G- 
protein Ral and this may contribute to the oncogenic transformation of cells 
(370).
Mutant forms of Ras have been generated to restrict the repertoire of 
effectors that are activated downstream of Ras. Thus, RasV^^ is a constitutively 
active form of Ras that can activate Raf, PI-3-K and RalGDS. In contrast,
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RasV^ ^S®® can activate Raf-1 but has low affinity for PI-3-K and RalGDS and 
RasV^ ^C"*® can stimulate PI-3-K but has low affinity for Raf-1 and RalGDS. 
These mutants can be used to better understand the signals activated 
downstream of Ras to induce particular cellular functions (226, 227, 370).
3.6 Regulation of the Erk-MAP kinase cascade
The regulation of Erk-MAPK is a highly complex process that involves 
controlling the activity of the different components of the MAPK cascade. This 
can be mediated by other intracellular signalling molecules; for example, Raf-1 
can be activated by Ras and PAK but is inhibited by Akt and PKA thus coupling 
Raf-1 to Ras, Rac, PI-3-K and cyclic nucleotide signalling pathways (372). 
However, Erk can also be regulated by positive and negative feedback loops. 
For example, MEK can phosphorylate and activate Raf-1 forming a positive 
feedback loop (340, 373). In contrast, Erk-MAPK can phosphorylate SOS 
leading to a dissociation of SOS and Grb-2 thus preventing further activation of 
Erk (374).
Furthermore, once activated, Erk1/2 can move into the nucleus and 
regulate the activity of several transcription factors including Elk-1, c-Jun, c-Fos 
and c-Myc. This results in the regulation of gene expression and the hence 
cellular functions. However, in addition to regulating the expression of genes 
required for the cell to respond to the stimulus that activated Erk, Erk1/2 can 
also enhance the expression of negative regulators of MAPK including MAPK 
phosphatases (340, 372). The Erk-MAPK cascade Is thus regulated by several 
mechanisms including intrinsic negative feedback loops.
3.7 MAP kinase phosphatases
MAPKs contain distinct regions for binding to their upstream activating 
kinases, to their downstream substrates and to protein phosphatases (375, 
376). MAPKs are activated by phosphorylation of their T-X-Y motif and full 
activity requires phosphorylation of both the threonine and the tyrosine 
residues. MAPKs can be inhibited by dephosphorylation of their T-X-Y motif and 
this can be catalysed by three different types of protein phosphatases: dual­
specificity phosphatases, threonine phosphatases and tyrosine phosphatases
(figure 3.3) (333, 377-379). For example, the MAPK phosphatases for Erk2
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include, the dual-specificity phosphatase MKP3, the threonine phosphatase 
PP2A and the tyrosine phosphatase HePTP (380).
3.7.1 Dual-specificity protein phosphatases
Dual-specificity protein phosphatases form a family of proteins that can 
dephosphorylate both the threonine and tyrosine residues of the T-X-Y motif 
(378). The activity of dual-specificity phosphatases is largely regulated at the 
transcriptional level and the expression of specific protein phosphatases allows 
the selective inhibition of particular MAPK proteins since each phosphatase has 
a precise substrate-specificity (381). For example, PAC-1 dephosphorylates Erk 
and p38 whilst MKP-1 acts on all three families of MAPKs. In contrast, MKP-2 
preferentially dephosphorylates Erk and JNK and MKP-M dephosphorylates 
JNK (382, 383). Indeed, each member of the dual-specificity phosphatase 
family has a unique set of properties including tissue distribution, subcellular 
localisation, regulation and substrate-specificity (378, 381). For example, PAC-1 
is a dual-specificity phosphatase specifically located in the nucleus of 
hematopoietic cells. PAC-1 preferentially dephosphorylates Erk-MAPK and it 
acts on the tyrosine residue of the T-E-Y motif prior to dephosphorylating the 
threonine residue (384). The expression of PAC-1 in B and T cells is increased 
by various mitogenic stimuli since the transcription of the pac~1 gene can be 
activated by transcription factors that are regulated by Erk (385). For example, 
ligation of the TCR in Jurkat T cells activates Erk, leading to the increased 
expression of PAC-1 and termination of the Erk signal (384).
The duration of an Erk signal can thus be regulated by controlling the 
expression of dual-specificity phosphatases and consequently, the expression 
of these proteins is dependent on multiple factors. For example, treatment of 
Rat-1 cells with EGF can lead to a biphasic activation of Erk. The activation of 
Erk can be inhibited by MKP-1 and the expression of MKP-1 is dependent on 
both Erk, to allow negative feedback, and on calcium signals, to enable 
sustained Erk signals to be generated (386). Dual-specificity phosphatases 
often have a short half-life to prevent excessive inhibition of MAPK (378). 
However, the degradation of dual-specificity phosphatases can also be 
regulated by MAPKs thus creating the potential for prolonged activation of Erk 
(387).
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3.7.2 Serine/threonine protein phosphatases
There are several accounts of serine/threonine protein phosphatases 
regulating the activity of Erk, JNK and p38 by targeting upstream activators of 
these MAPKs (388-392). For example, PP2A can dephosphorylate and inhibit 
Raf-1 and MEK downstream of the PDGF receptor in NIH-3T3 cells leading to a 
suppression of Erk (393). However, Erk is also known to be a direct substrate of 
serine/threonine phosphatases and their action can suppress the activity of Erk 
(381). For example, in PC12 cells inactivation of an early transient Erk signal is 
mediated by the dephosphorylation of the threonine residue of T-E-Y by PP2A 
(394). Serine/threonine protein phosphatases are generally constitutively 
expressed and located in the cytoplasm of the cell therefore they are well suited 
to suppressing basal Erk activity in resting cells or to rapidly inhibiting newly 
activated cytoplasmic Erk (381).
3.7.3 Tyrosine protein phosphatases
Tyrosine phosphatases are also predominantly located in the cytoplasm of 
cells and may function to suppress cytoplasmic Erk. For example, the tyrosine 
phosphatase HePTP is expressed in hematopoietic cells and is activated 
downstream of the TCR resulting in an inhibition of Erk1/2 and p38 without 
affecting the activity of upstream activators of MAPK (333, 381). Another 
tyrosine phosphatase, PTP-SL, can inhibit Erk5 and prevent ErkS from 
translocating into the nucleus of cells (396). Similarly, in Cos-7 and HEK-293 
cells, the tyrosine phosphatases PTP-SL and STEP can bind to Erk2 to 
inactivate Erk2 by dephosphorylation of the T-E-Y motif and by preventing its 
nuclear translocation (396). Tyrosine phosphatases therefore inhibit MAPKs by 
dephosphorylation of the T-X-Y motif and by preventing nuclear translocation.
3.8 SHP-1 and SHP-2
The SH2 domain-containing protein tyrosine phosphatases SHP-1 and 
SHP-2 are cytosolic tyrosine phosphatases with 60% sequence identity and 
similar structural features. Both SHP proteins have two N-terminal SH2 
domains, a tyrosine phosphatase (catalytic) domain and a C-terminal regulatory 
region, which contains tyrosine residues that can be phosphorylated. The C-
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terminal region of SHP-2 also has a proline-rich domain that is absent in SHP-1 
(132). In the cytosol SHP-1 and SHP-2 are inactivated by autoinhibition via the 
binding of an N-terminal SH2 domain to a phospho-tyrosine residue of the C- 
terminal regulatory region of SHP. This blocks the catalytic domain and retains 
the enzyme in an inactive conformation (figure 3.4). The other N-terminal SH2 
domain has greater flexibility and may be involved in the activation of SHP. SHP 
is activated by the binding of its SH2 domains to tyrosine phosphorylated ITIM 
motifs (figure 3.4) (133).
SHP-2 is ubiquitously expressed but SHP-1 is largely found in 
hematopoietic and epithelial cells. The function of SHP-1 has been investigated 
using SHP-1-deficient mice. Motheaten mice do not express SHP-1 and 
motheaten viable mice express catalytically inactive SHP-1. Both of these 
mutations cause premature death of the mice. SHP-1-deficient mice display 
multiple immunological defects including elevated numbers and inappropriate 
activation of myeloid cells, impaired differentiation of natural killer cells and 
hyper-responsiveness of peripheral B and T cells. SHP-1 deficiency therefore 
causes severe autoimmunity and inflammation. Furthermore, SHP-1-deficient B 
cells have a reduced threshold for B cell activation resulting in enhanced 
numbers of peripheral mature B cells, indicating SHP-1 is an important negative 
regulator of BCR signalling (132, 165).
In unstimulated B cells SHP-1 is constitutively, but weakly associated with 
the BCR complex and it helps to keep the BCR complex inactive by 
dephosphorylating the ITAMs of lga/lg|3. Consistent with this, un stimulated B 
cells that are deficient in SHP-1 have impaired inhibition of the BCR complex 
resulting in a reduced threshold for activation. Ligation of the BCR normally 
causes SHP-1 to dissociate from the BCR complex, allowing ITAMs to be 
phosphorylated and the B cell to be activated. However, the activation of 
tyrosine kinases downstream of the BCR can lead to tyrosine phosphorylation 
of ITIMs of the co-receptors CD22, PIR-B, CD72 and FcyRIIB and SHP-1 can 
bind to these pITIMs leading to its stimulation. SHP-1 forms a negative 
feedback loop since its activation leads to an inhibition of signals stimulated by 
the BCR and CD19. For example, SHP-1 binds to and inhibits the tyrosine 
kinases Lyn and Syk thus inhibiting upstream signals of the BCR complex and 
CD19. SHP-1 also associates with BLNK to block signals downstream of this
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adaptor. The binding of SHP-1 to these signalling molecules results in a 
downregulation of PLCy and Ca^^ signalling, MAPK stimulation and P1-3-K 
activation. SHP-1 performs a similar role in the maintenance of resting T cells 
and in the inhibition of T cell activation following ligation of the TCR (134, 165).
SHP-2 is structurally very similar to SHP-1 and is retained in an inactive 
state in unstimulated cells by autoinhibition. Despite these similarities, SHP-1 
and SHP-2 are functionally distinct, as indicated by the phenotype of motheaten 
mice since these mice lack SHP-1 but still express SHP-2. SHP-2 has been 
implicated as both a negative and a positive regulator of signalling initiated by 
the BCR and several tyrosine kinase-associated receptors. For example, SHP-2 
can dephosphorylate and inhibit STAT1 downstream of the IFNy receptor in 
293T cells, resulting in a suppression of STAT1-mediated transcription (397). 
However, SHP-2 has also been implicated as a positive regulator of cell 
signalling pathways downstream of multiple receptors, (n particular, the Erk- 
MAPK pathway can be stimulated by SHP-2 (167). For example, ligation of the 
BCR induces the tyrosine-phosphorylation of the adaptor protein Gab-1 and this 
creates a binding site for various proteins including SHP-2. SHP-2 binds to 
Gab-1 via its SH2 domain resulting in the activation of SHP-2. SHP-2 can then 
associate with Grb-2 leading to the recruitment of SOS and the stimulation of 
Erk-MAPK (110, 117, 132, 165). Furthermore, the association of Gab-1 and 
SHP-2/Grb-2 has been observed downstream of the receptors for EGF and 
PDGF and this interaction is required for the sustained activation of Erk1/2 
(166). SHP-2, via its association with Grb2, can therefore be a positive regulator 
of Erk signalling.
3.9 SHIP
SHIP is a highly conserved cytosolic phosphatase that can be activated 
downstream of FcyRIIB in mature B lymphocytes where it functions as a 
negative regulator of BCR signalling (see section 1.7.2) (131, 184). SHIP can 
remove the 5' phosphate from PI-3, 4, 5 -P3 (PIP3) resulting in the depletion of 
lipids that serve as anchors for PH domain-containing proteins. SHIP therefore 
antagonises the function of PI-3-K and can suppress the activation of Akt (127, 
131, 184, 241).
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SHIP is also a regulator of the Erk-MAPK pathway. SHIP binds to She 
using the same phospho-tyrosine residues as are required for the formation of 
the Grb2-Shc complexes so preventing the activation of SOS and the classical 
MAPK cascade (241). However, more recent reports have also suggested that 
tyrosine phosphorylation of She downstream of the BCR in mature B cells is 
SHlP-dependent and the formation of SHIP-Shc-Grb-2 complexes are 
necessary for mitogenic BCR signalling (398). Furthermore, tyrosine 
phosphorylated SHIP can bind to the adaptor protein p62 Dok (Doki) via the 
phospho-tyrosine-binding domain of Dok1. This brings Dok1 into close proximity 
with tyrosine kinases and the C-terminal region of Dok1 becomes 
phosphorylated. Phosphorylation of p62 Dok increases its association with 
RasGAP (Ras GTPase activating protein) and Doki can regulate the activity of 
RasGAP. RasGAP enhances the intrinsic GTPase activity of Ras leading to the 
inhibition of Ras and the downstream effectors of Ras including Erk 1/2 and Pl- 
3-K (244).
3.10 Dok
The Dok family of proteins contains multiple modular interaction domains 
(figure 1.12) suggesting they can function as adaptor proteins. Dok proteins 
have an N-terminal PH domain to enable attachment to phospholipids and 
membranes and they have a central phospho-tyrosine-binding domain to allow 
binding to proteins with phospho-tyrosine residues. Furthermore, the C-terminal 
region of Dok proteins is rich in proline residues to allow binding to SH3 
domains and in tyrosine residues that are potential sites of phosphorylation. The 
C-terminal region is the most variable section of Dok allowing distinct members 
of this family to bind to a different repertoire of proteins (399).
The first Dok protein to be identified was Doki (p62 Dok). Doki is a direct 
target of Bcr-AbI; the chimeric protein found in almost all patients with chronic 
myeloid leukemia. In hematopoietic progenitor cells isolated from patients with 
chronic myeloid leukemia, Doki is phosphorylated by Bcr-AbI at five tyrosine 
residues. Two of these phospho-tyrosine residues bind to RasGAP resulting in 
an inhibition of RasGAP and the prolonged activation of Ras and Erk. This is 
likely to contribute to the inappropriate cell division of these cells. The identity of 
the proteins that are recruited to the remaining three phospho-tyrosine residues
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of Dok1 has not been established although several additional Dok1-interacting 
proteins have been identified. It is likely that some of these proteins will 
influence the activity of RasGAP at Dok1 since Dok1 is both a positive and a 
negative regulator of RasGAP (400, 401). For example, in B cells, co-ligation of 
the BCR and FcyRIIB leads to the phosphorylation of SHIP and Doki 
downstream of FcyRIIB. This increases the association of Doki with RasGAP 
and in this system Dok1 activates RasGAP leading to an inhibition of Ras and 
Erk (244). Similarly, in mast cells, the phosphorylation of Doki is enhanced 
following activation of FceRI leading to an activation of RasGAP and an 
inhibition of Ras/Erk (402).
Several Doki-associated proteins have been identified in addition to 
RasGAP. For example, in T cells Dok1 is tyrosine-phosphorylated by Lck and 
Fyn downstream of the CD2 receptor leading to the recruitment and activation 
of Crk-L (399, 403). Crk can function as an adaptor protein that binds to SOS 
and C3G (171, 172) leading to either the activation or inhibition of Erk-MAPK 
(see section 1.6.3.4). Crk is also an activator of JNK MAPK (170). CD2- 
mediated activation of Dok1 can suppress the activity of Erk1/2 but Doki can 
also inhibit PLCy signalling and Ca^"’ mobilisation (399). This suggests that 
additional proteins are still to be identified that can be recruited to the Doki 
complex to regulate these signalling cascades.
Doki is phosphorylated downstream of the insulin receptor leading to the 
recruitment and activation of RasGAP (404) and the adaptor protein Nek (110). 
Nek can then recruit additional signalling molecules to the Doki complex. For 
example, Nek can bind to PAK and WASP (110, 149). In hematopoietic cells, 
stem cell factor induces the phosphorylation of Dok1 by Btk and this leads to 
the recruitment of the adaptor proteins Grb2 and Grb7, the pS5 subunit of PI-3- 
K and Src-family kinases (405). Doki can also bind to Csk, the kinase that 
controls the basal activity of Src-family kinases by phosphoryiating the C- 
terminal inhibitory tyrosine residue leading to inhibition of Src-family kinases 
(151). The regulation of signalling pathways by Doki is therefore a very 
complex process involving many different signalling molecules that ultimately 
affect the activity of MAPK, PLCy and P1-3-K.
The Dok-family of proteins has at least two additional members, p56 Dok 
(Dok2) and Dok3. Dok2 functions alongside Doki in mast cells to couple the
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FceRI receptor to Cas/Crk-L/Nck leading to the rearrangement of the 
cytoskeleton (402). Dok2 is also expressed in T cells and It functions to couple 
CD2 receptor to RasGAP and Nek (399). Dok1 and Dok2 therefore can regulate 
similar pathways. Dok3, also known as DokL, appears to be highly expressed in 
hematopoietic cells including B cells. It has been proposed that ligation of the 
BCR induces tyrosine phosphorylation of Dok3 by Src-family kinases. Dok3 
cannot bind to RasGAP or Nek since it lacks the required YXXL motif (where X 
is any amino acid). However, Dok3 appears to directly bind to two negative 
regulators of BCR-signalling, SHIP and Csk, and this may result in a 
suppression of BCR-dependent activation of NF-AT and cytokine release (406, 
407).
3.11 Aims and objectives
Recent reports have suggested that in immature B cells the BCR and 
CD40 can differentially regulate the activity of Erk-MAPK (219, 328). The 
kinetics of Erk1/2 activation appear to be critical for determining the survival and 
proliferation of immature B cells (328).
The aims of this investigation were:
1. to examine the effects of ligation of the BCR and CD40 on the survival 
and proliferation of WEHI-231 cells
2. to investigate the role of Erk-MAPK in the induction of apoptosis of 
BCR-stimulated WEHI-231 cells
3. to examine the role of Erk in regulating proliferation of WEHI-231 cells
4. to investigate the mechanisms used by the BCR to regulate Erk activity 
in WEHI-231 cells
5. to explore the role of Ras and PI-3-K in regulating the activity of Erk and 
other signalling pathways in WEHI-231 cells.
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3.12 Results and Discussion
3.12.1 Ligation of the BCR on WEHI-231 cells induces growth arrest
Ligation of the BCR on immature B cells leads to the induction of growth 
arrest and apoptosis. This is necessary for the elimination of newly developed B 
lymphocytes that are self-reactive and hence have the potential to cause 
autoimmune diseases (9, 27, 29). However, immature B cells can be rescued 
from growth arrest and apoptosis by receiving T cell-derived signals including 
co-ligation of CD40 (27, 34).
The murine WEHI-231 cell line is a B cell lymphoma that is widely used as 
an in vitro model of negative selection in immature IgM '^ '^ l^gD’^ '^ B cells (see 
section 1.9.1) (30, 283-285). The BCR of WEHI-231 cells can be stimulated 
experimentally using anti-IgM antibodies (anti-lg) whilst CD40 can be activated 
using anti-CD4Q antibodies. Proliferation of WEHI-231 cells was measured by 
detecting the incorporation of [®H] thymidine since this indicates the level of 
DNA synthesis.
Ligation of the BCR by treating WEHI-231 cells with anti-lg induced growth 
arrest in a dose-dependent manner (figure 3.5A). Concentrations of anti-lg 
greater than 0.01 pg/ml stimulated cell cycle arrest with a 60% decrease in DNA 
synthesis being observed between 0.01 and 0.1 pg/ml anti-lg. Optimal growth 
arrest was obtained at 1-10 pg/ml anti-lg. In addition, co-stimulation of immature 
B cells at CD40 is known to rescue the cells from BCR-driven growth arrest and 
apoptosis. Indeed, co-ligation of the BCR and CD40 completely rescued WEHI- 
231 cells from BCR-driven growth arrest (figure 3.5B) whilst treatment of WEHI- 
231 cells with anti-CD40 antibodies (10 pg/ml) alone had little effect on their 
proliferation.
3.12.2 Ligation of the BCR on WEHI-231 cells induces apoptosis
In addition to inducing growth arrest, ligation of the BCR on immature B 
cells can also stimulate apoptosis. The level of apoptosis in a population of 
WEHI-231 cells was determined by measuring the number of cells with sub- 
diploid DNA using the DNA-binding dye propidium iodide (PI) and FACS 
analysis. Asynchronous populations of cells were used in these experiments 
therefore populations of untreated WEHI-231 cells contained cells at each of the
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four stages of the cell cycle (figure 3.6A and E). After 24 hr in culture, 
approximately 6% of these untreated cells were sub-diploid (apoptotic) (figure 
3.6A) and after 48 hr 10% had sub-diploid DNA (figure 3.6E).
Treatment of WEHI-231 cells with anti-lg (10 pg/ml) for 24 hr increased the 
percentage of sub-diploid cells from 6% to 8% (figure 3.6B) indicating a small 
amount of apoptosis had been induced. However, after 48 hr, anti-lg increased 
the percentage of sub-diploid cells from 10% to 20% and hence doubled the 
number of cells with sub-diploid DNA (figure 3.6F). Ligation of the BCR 
therefore induces apoptosis of WEHI-231 cells. Furthermore, the induction of 
apoptosis by anti-lg in WEHI-231 cells has previously been indicated by 
disruption of mitochondrial membrane potential, annexin V staining and DNA 
laddering (102, 285).
Analysis of the cell cycle of WEHI-231 cells also showed that anti-lg 
induced growth arrest of WEHI-231 cells after 24 hr and 48 hr (figures 3.6B and 
F). This was indicated by anti-lg increasing the number of cells in G0/G1 whilst 
decreasing the number of cells in S phase and G2/M. Anti-lg therefore induces 
growth arrest at the G0/G1 phase of the cell cycle. These observations confirm 
the thymidine data, which showed that ligation of the BCR, induces growth 
arrest of WEHI-231 cells. Furthermore, previous studies by Carman et a!, have 
shown that ligation of the BCR on immature B cells induces cell cycle arrest at 
the G1 to S phase transition since BCR-stimulation prevents the cells from 
inducing cyclin E and Cdk2 despite being able to increase the expression of 
cyclin D2 and Cdk4 (33). Moreover, after 24 hr there was a greater induction of 
growth arrest than apoptosis indicating the onset of anti-lg-induced apoptosis 
takes longer than the induction of growth arrest in WEHI-231 cells.
Co-culture of the WEHI-231 cells with anti-lg plus anti~CD40 for 24 hr or 
48 hr replenished the populations of cells in S phase and G2/M. This is 
consistent with the thymidine data which showed anti-CD40 can protect WEHI- 
231 cells from anti-lg-induced inhibition of DNA synthesis. Co-culture with anti- 
lg plus anti-CD40 for 24 hr or 48 hr also rescued the cells from anti-lg-induced 
apoptosis (figures 3.6C and G). Furthermore, rescue from apoptosis has 
previously been indicated by abrogation of loss of mitochondrial membrane 
potential, annexin V staining and DNA laddering (102). Anti-CD40-treatment 
alone had little effect on the death rate and the cell cycle progression of WEHI-
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231 cells (figures 3.6D and H). Ligation of the BCR on WEHI-231 cells therefore 
induces growth arrest at G0/G1 phase of the cell cycle and apoptosis but co­
ligation of CD40 enables the cells to survive and proliferate.
3.12.3 BCR-dependent induction of an early Erk-MAPK signal is 
associated with commitment to apoptosis of WEHI-231 cells
It is well documented that the BCR can couple to Erk-MAPK and in mature 
B lymphocytes the activation of Erk1/2 is associated with the stimulation of 
proliferation (327). In contrast, BCR-dependent activation of Erk in immature B 
cells has been associated with the induction of apoptosis whilst CD40 has been 
shown to preferentially couple to JNK and p38 MAPKs suggesting these 
proteins are more involved in mediating immature B cell survival (306-309).
Erki/2-MAPK is regulated by controlling the phosphorylation state of the 
Thr-Glu-Tyr motif within Its activation loop (352-354). The activity of Erk1/2 can 
thus be measured by Western blotting with an antibody that specifically 
recognises active (dual-phosphorylated) Erk 1/2. Western blotting for total Erk 
(non-phosphorylated plus phosphorylated Erk) can be used to check gel loading 
since Erk is regulated post-translationally therefore total Erk levels are generally 
constant within a cell. The differential regulation of Erk-MAPK by the BCR and 
CD40 in immature B cells was thus investigated by Western blotting of WEHI- 
231 whole cell lysates for dual-phosphorylated, active Erk.
Work initially performed in collaboration with Stephen Gauld (328) 
indicated that treatment of WEHI-231 cells with increasing concentrations of 
anti-lg for 30 min induced the activation of Erk2 with minimal induction of Erki 
(appendix 1A). The induction of Erk2 was observed between 5 and 25 pg/ml 
anti-lg. Furthermore, analysis of the kinetics of activation indicated Erk2 was 
stimulated within 1 min of treatment with anti-lg and maximal Erk activity was 
detected at 30 min (appendix 1B). In contrast, ligation of CD40 on WEHI-231 
cells did not induce the activation of Erk over the 1 hr time course (appendix 
1C). This is consistent with previous observations that suggest CD40 is less 
capable than the BCR at inducing early Erk signals (219, 306, 309). Co-culture 
of WEHI-231 cells with anti-lg plus anti-CD40 did increase the activity of Erk but 
to a lesser extent than treatment with anti-lg alone (appendix ID). These 
observations show that the BCR and CD40 differentially regulate Erk1/2 in
117
WEHI-231 cells suggesting Erk1/2 is likely to be important for mediating the 
response of immature B cells to ligation of the BCR and CD40. In contrast, 
treatment of WEHI-231 cells with anti-lg, anti-CD40 or a combination of anti-lg 
plus anti-CD40 for 30 min in serum-supplemented conditions did not 
significantly increase the activity of p38 or JNK MAPKs above basal levels 
(328).
3.12.4 Inhibition of early Erk signals abrogates BCR-mediated apoptosis 
of WEHI-231 cells
The above observations therefore suggest that the BCR of WEHI-231 cells 
couples preferentially to early Erk signals implicating Erk as a potential mediator 
of BCR-driven growth arrest and apoptosis. Furthermore, the suppression of 
early Erk signals by CD40 may help to protect WEHI-231 cells from the effects 
of BCR ligation. In order to further investigate the importance of early Erk 
signals, pharmacological inhibitors of MEK (PD98059 and U0126) were 
employed to suppress Erk signals in anti-lg-treated WEHI-231 cells (328).
Apoptosis of WEHI-231 cells treated with MEK inhibitors was investigated 
using Pl-staining followed by FACS analysis. Pretreatment (2 hr) of WEHI-231 
cells with U0126 (similar results were obtained using PD98059) induced a 
dose-dependent decrease in BCR-driven apoptosis with maximal effect being 
obtained at 1-5 pM U0126 (appendix IE  and results not shown). Indeed, 1 pM 
D 0126 protected WEHI-231 cells from BCR-driven apoptosis without altering 
the extent of apoptosis in unstimulated cells. In contrast, treatment of WEHI-231 
cells with a p38 inhibitor (SB203580) did not prevent BCR-driven apoptosis, 
which is consistent with the observation that ligation of the BCR did not 
significantly stimulate p38 MAPK (328). Furthermore, it has previously been 
reported that p38 MAPK is activated downstream of the BCR and TCR but 
inhibition of this does not impair antigen receptor-induced apoptosis in either of 
these cell types (308).
Inhibition of early Erk signals thus suppresses BCR-driven apoptosis. This 
is consistent with the observation that ligation of the BCR on immature B cells 
can induce apoptosis via the induction of CPLA2 , a MAPK-sensitive enzyme 
(102). Cytosolic PLAg is activated by Erk 1/2 and Ca^^ downstream of the BCR 
in WEHI-231 cells and this leads to the production of arachidonic acid.
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Arachidonic acid can disrupt the mitochondrial membrane potential leading to 
the activation of proteases and execution of the cell. Indeed, it has been 
observed that inhibition of early Erk 1/2 activity in BCR-stimulated WEHI-231 
cells can prevent anti-lg-induced activation of cPLAa, as indicated by measuring 
arachidonic acid production (328).
The BCR of WEHI-231 immature B cells thus couples to the early (:S1 hr) 
activation of Erk-MAPK and suppression of this signal can protect the cells from 
BCR-driven activation of CPLA2 and subsequent apoptosis. BCR-driven 
apoptosis therefore requires the early stimulation of Erk and co-stimulation of 
CD40 can partially prevent BCR-mediated apoptosis by decreasing the early 
Erk signal. These observations are consistent with those made in T 
lymphocytes in which Erk signals have been shown to be required for negative 
selection of double positive thymocytes and also for activation-induced cell 
death of mature T ceils (408-410).
3.12.5 Proliferating WEHI-231 cells undergo sustained and cyclic 
activation of Erk-MAP kinase
The above results implicate Erk-MAPK in the induction of apoptosis of 
anti-lg-treated WEHI-231 cells. However, inhibition of this early Erk signal in 
WEHI-231 cells enhanced, rather than inhibited, BCR-driven growth arrest 
(appendix IE). These observations specifically associate the early Erk signal 
with regulation of apoptosis and do not exclude the possibility that a more 
sustained proliferative Erk signal also exists in immature B cells. Indeed, there 
are numerous reports that associate Erk1/2 activity with the induction of 
proliferation (50, 331, 337, 411, 412). For example, BCR-driven proliferation of 
mature B lymphocytes requires the activation of Erk-MAPK (327). Moreover, the 
duration of Erk activation can affect the proliferation of particular cell types (173, 
412, 413). For example, the induction of sustained Erk 1/2 activity can enable 
entry into S phase of the cell cycle and promote proliferation of fibroblasts 
whereas a transient activation of Erk is insufficient to sustain proliferation of 
these cells (220). Furthermore, treatment of CD4^ lymphoblast cell lines with 
IFNa2b inhibits proliferation via the suppression of 24-48 hr Erk signals (414).
The regulation of sustained Erk-MAPK signalling in WEHI-231 cells was 
thus investigated. In studies initiated by Stephen Gauld, Western blotting of
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WEHI-231 whole cell lysates for dual-phosphorylated Erk1/2 showed 
proliferating (untreated or CD40-stimulated) WEHI-231 cells exhibit strong 
activation of Erk-MAPK between 8 hr and 48 hr (appendix 2A and D). The 
majority of active Erk in WEHI-231 cells was Erk2 (p42). This sustained 
activation of Erk does not merely reflect a constitutive activation of MAPK but 
instead reflects the prolonged and cyclic activation of Erk with peaks between 8- 
16 hr and 32-48 hr (appendix 2D and results not shown). Proliferating WEHI- 
231 cells therefore undergo sustained cyclic activation of Erk1/2.
3.12.6 Apoptotic signalling via the BCR suppresses sustained cyclic 
activation of Erk that can be re-established by CD40-mediated rescue
Treatment of WEHI-231 cells with anti-lg altered the pattern of activation 
of Erk1/2-MAPK over a 48 hr time period (appendix 2B). Firstly, ligation of the 
BCR enhanced early (<2 hr) Erk1/2 signals whilst co-ligation of the BCR and 
CD40 (appendix 2C), or stimulation with CD40 alone (appendix 2D), reduced 
these early Erk signals. This is consistent with the data presented in appendix 1 
in which the BCR was shown to enhance early Erk signals leading to the 
induction of apoptosis in WEHI-231 cells.
In addition to enhancing early Erk1/2 signals, ligation of the BCR on 
WEHI-231 cells also inhibited sustained (>2 hr) cyclic activation of Erk-MAPK 
(appendix 2B). This suggests that sustained Erk signals may have a role in 
promoting survival or proliferation of WEHI-231 cells. Furthermore, treatment of 
WEHI-231 cells with a combination of anti-lg plus anti-CD40 restored the 
sustained Erk signals (appendix 2C). These results show that WEHI-231 cells 
exhibit sustained cyclic activation of Erk1/2 under proliferative conditions and 
these Erk signals are suppressed in cells that are undergoing growth arrest and 
apoptosis.
3.12.7 Inhibition of sustained cyclic activation of Erk-MAPK can block 
basal proliferation and CD40-mediated rescue
Work performed in collaboration with Stephen Gauld and Derek Blair has
demonstrated that the sustained cyclic activation of Erk is associated with
proliferation of WEHI-231 cells (328). MEK inhibitors (U0126 and PD98059)
were used to suppress Erk signals in WEHI-231 cells. However, a single
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application of these inhibitors was only effective at suppressing Erk for ^6 hr. 
Consequently, the application of MEK inhibitors (U0126 or PD98059) was 
repeated every 4 hr to inhibit sustained Erk signals in WEHI-231 cells. 
Repeated exposure of WEHI-231 cells to these inhibitors not only enhanced 
BCR-driven growth arrest but also blocked DNA synthesis of unstimulated, anti- 
CD40-treated or anti-lg plus anti-CD40-stimu!ated WEHI-231 cells (appendix 
3A). To ensure that these results reflected the inhibition of sustained Erk 
signals, the effects of a single dose of PD98059 or U0126 were investigated 
(appendix 3C-D). These results agreed with previous observations that 
inhibition of early Erk signals had minimal effect on the proliferation of WEHI- 
231 cells. These observations thus strongly imply that proliferation of WEHI-231 
cells requires sustained cyclic activation of Erk-MAPK and inhibition of these 
signals using anti-lg or pharmacological MEK inhibitors can induce growth 
arrest. Furthermore, ligation of CD40 was unable to restore proliferation to cells 
treated with MEK inhibitors indicating the induction of sustained cyclic Erk 
signals is critical for CD40-mediated restoration of proliferation.
To determine whether the observed inhibition of DNA synthesis following 
suppression of prolonged Erk signals reflected the induction of apoptosis, the 
sub-diploid DNA content was determined In cells exposed to PD98059 and 
U0126 (appendix 3B). These observations revealed that sustained inhibition of 
MEK and hence proliferation in unstimulated WEHI-231 cells induced apoptosis. 
This was not due to inhibitor toxicity since ligation of CD40 (in the presence and 
absence of anti-lg) prevented this Induction of apoptosis. This also indicates 
CD40 can initiate signals that enable WEHI-231 cells to survive in the presence 
of MEK inhibitors despite being unable to restore proliferation to these cells.
Work performed in collaboration with Derek Blair further implicated 
sustained and cyclic activation of Erk as being necessary for proliferation of 
WEHI-231 cells (328). Laser scanning cytometry was used to measure the 
levels of phospho-Erk in WEHI-231 cells at different stages of the cell cycle (G1, 
S phase and G2/M). These investigations showed that cycling WEHI-231 cells 
have high levels of phospho-Erk whilst <50% of newly divided cells displayed 
phospho-Erk staining (appendix 4A-B). Sustained Erk signals can be inhibited 
by the addition of anti-lg or cell cycle blockers (olomoucine or aphidicolin) and 
treatment of WEHI-231 cells with these agents greatly reduced the amount of
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phospho-Erk in growth arrested cells (appendix 4B and data not shown). 
However, within 48 hr of release from olomoucine-induced growth arrest, 
phospho-Erk levels in G1 cells were restored. Furthermore, the levels of 
phospho-Erk were restored by rescuing the cells from growth arrest via the 
addition of anti-CD40 (appendix 4B).
Collectively these results strongly suggest that WEHI-231 cells require 
sustained and cyclic activation of Erk-MAPK in order to proliferate and growth 
arrest can be induced by suppression of these Erk signals. In particular, these 
results show that inhibition of sustained Erk signals by ligation of the BCR is a 
critical stage for the induction of growth arrest whilst CD40-dependent rescue 
from growth arrest, but not apoptosis, requires prolonged Erk signals to be 
restored.
Erk can promote cell cycle progression in eukaryotic cells via the induction 
of cyclin D1/Cdk2 and cyclin E/Cdk2, leading to the phosphorylation and 
inhibition of Rb (50, 416). This allows cells to progress through the G1 to S 
phase transition. However, ligation of the BCR on immature B cells induces 
arrest of the cell cycle at the G1 to S phase transition. Furthermore, BCR- 
stimulation prevents the cells from inducing cyclin E/Cdk2 despite being able to 
increase the expression of cyclin D2/Cdk4 and hence impairs the 
phosphorylation of Rb (33, 53). Taken together, these observations suggest that 
sustained Erk signals may promote proliferation of WEHI-231 cells via the 
induction of cyclin E/Cdk2 leading to the phosphorylation and inhibition of Rb. 
However, BCR-ligation on WEHI-231 cells also stimulates other cell cycle 
inhibitors including p21, p27 and p53 therefore these proteins may also be 
targeted by Erk-MAPK to allow cell cycle progression (56, 58, 325, 416).
3.12.8 BCR-mediated inhibition of sustained Erk-MAPK signalling does 
not involve a dissociation of MEK from Erk or a suppression of MEK 
activity
Proliferating WEHI-231 cells therefore undergo sustained and cyclic 
activation of Erk-MAPK. Ligation of the BCR inhibits prolonged Erk signals and 
this is important for the induction of growth arrest whilst restoration of these 
signals can be mediated by co-ligation of CD40. To investigate the signalling
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mechanism of BCR-dependent suppression of cycling Erk-MAPK activation, the 
effect of anti-lg on the activity of MEK In WEHI-231 cells was determined.
MEK is a direct activator of Erk1/2 therefore the association of MEK and 
Erk was analysed by preparing immune complexes of Erk1/2 from whole cell 
lysates of WEHI-231 cells followed by Western blotting for MEK1/2 (figure 3.7A- 
D). In unstimulated cells, the interaction of MEK and Erk was observed 
throughout the 48 hr time period (figure 3.7A). However, the amount of MEK 
bound to Erk varied in a cyclic manner with the greatest MEK-Erk association 
being evident at 1 hr, 4-8 hr and 24-48 hr. The cyclic association of MEK and 
Erk was also evident in anti-CD40-treated cells (figure 3.7C). These 
observations are consistent with those of appendix 2 in which proliferating 
WEHI-231 cells were observed to undergo cyclic activation of Erk. The pattern 
of MEK-Erk association thus parallels that of Erk activation in proliferating 
WEHI-231 cells.
In contrast, treatment of WEHI-231 cells with anti-lg did not induce a 
dissociation of MEK and Erk (figure 3.78) despite these conditions being able to 
inhibit cycling Erk activity. Of particular interest, the levels of MEK1/2 were high 
in Erk1/2 immune complexes prepared between 24 hr and 48 hr suggesting that 
the BCR can inhibit the cyclic activation of Erk without dissociating Erk from its 
upstream activator MEK.
However, a significant dissociation of MEK and Erk was observed in early 
(<8 hr) samples of cells treated with anti-lg plus anti-CD40 (figure 3.7D). This 
implies that the ability of CD40 to rescue from BCR-dependent apoptosis may 
involve a down regulation of early Erk signals via a suppression of upstream 
activators of Erk-MAPK. However, the association of MEK and Erk was restored 
in 12-48 hr lysates prepared from these cells thus enabling the induction of 
sustained Erk signals. WEHI-231 cells therefore display high levels of 
association between MEK and Erk in 12-48 hr samples and this is not 
prevented by ligation of the BCR in the presence or absence of CD40 
stimulation.
The inability of the BCR to dissociate MEK and Erk at times of low Erk 
activity suggests that inhibition of sustained cyclic activation of Erk by the BCR 
might not be mediated via the suppression of upstream activators of Erk, 
However, the results of figure 3.7A-D do not indicate the activity of MEK in
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WEHI-231 cells. MEK Is a component of the MARK cascade therefore it is 
activated by phosphorylation of Ser^ ^^ ^^ ^® and Ser^^\ catalysed by Raf-1 (372). 
The activity of MEK in WEHI-231 can thus be estimated by Western blotting 
using antibodies that are sensitive to the phosphorylation state of MEK. High 
levels of phospho-MEK were detected in 12-48 hr whole cel! lysates of 
unstimulated WEHI-231 cells or cells treated with anti-lg, anti-CD40 or a 
combination of anti-lg plus anti-CD40 (figure 3.7E-H). These observations 
strongly suggest that MEK is highly active in both proliferating and growth 
arrested WEHI-231 cells and critically this can be observed at times when the 
activity of Erk1/2 is suppressed.
The mechanism by which the BCR suppresses cycling Erk activation in 
the induction of growth arrest was further investigated using an in vitro MEK 
kinase assay to determine the activity of MEK in anti-lg-treated WEHI-231 cells. 
The MEK kinase assay determines the activity of MEK in MEK1/2 immune 
complexes prepared from WEHI-231 whole cell lysates. The activity of MEK in 
these complexes is indicated by its ability to phosphorylate an Erk-GST 
substrate in vitro. The activity of MEK in this assay is therefore directly 
proportional to the levels of dual phosphorylated Erk-GST. Levels of phospho- 
Erk-GST were determined by Western blotting using an antibody that 
specifically recognises dual-phosphorylated Erk.
Interestingly, despite the ability of the BCR to suppress the activity of 
cycling Erk, levels of phosphorylated Erk-GST were comparable in untreated 
and anti-lg-treated WEHI-231 cells between 12 hr and 48 hr (figure 3.8A-B). 
Furthermore, the levels of phospho-MEKI/2 in the MEK immune complexes 
were also similar between 12 hr and 48 hr. In contrast, the levels of phospho- 
MEK appear to be depleted by anti-lg in ^8 hr samples despite there being no 
apparent loss of MEK activity at these times. This observation was surprising 
and suggests that the levels of phospho-MEK do not always correlate with MEK 
activity. Nonetheless, the results of figure 3,8 do agree with those of figure 3.7, 
which suggested that MEK1/2 was highly active between 12 hr and 48 hr 
despite the activity of Erk1/2 being inhibited by BCR ligation at these times. This 
data therefore indicates that the BCR does not uncouple Erk1/2 from upstream 
regulators of Erk but rather appears to induce negative feedback mechanisms 
that can inhibit Erk despite the ongoing activity of upstream activators.
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3.12.9 Sustained cyclic activation of Erk-MAPK is inhibited by BCR- 
dependent activation of protein phosphatases
The presence of sustained MEK1/2 signals in anti-lg-treated WEHI-231 
cells suggests BCR-dependent suppression of cyclic activation of Erk is 
mediated by the direct inhibition of Erk 1/2. The activity of Erk-MAPK can be 
inhibited by the action of three types of protein phosphatase: dual-specificity 
phosphatases, tyrosine phosphatases and serine/threonine phosphatases (see 
section 3.7) (380, 381). Indeed, work performed in collaboration with Stephen 
Gauld (328) has shown that treatment of WEHI-231 cells with anti-lg increases 
the expression of PAC-1, a dual-specificity MAPK phosphatase (appendix 5A). 
Furthermore, ligation of the BCR increased the amount of PAC-1 detected in 
Erk immune complexes (appendix 5B). Co-ligation of CD40 did not appear to 
decrease the expression of PAC-1 but it did reduce the amount of PAC-1 
detected in Erk immune complexes (results not shown and appendix 5B). These 
results implicate PAC-1 as a mediator of BCR and CD40 signalling and suggest 
that the BCR may, at least in part, suppress cyclic activation of Erk by 
upregulating PAC-1 and increasing its association with Erk. CD40 appears to 
prevent the association of PAC-1 and Erk thus suggesting one mechanism of 
CD40-dependent restoration of prolonged Erk signals in WEHI-231 cells. These 
results are consistent with previous observations in mature B lymphocytes in 
which the immunomodulatory products secreted by filarial nematodes can elicit 
B cell unresponsiveness by suppressing BCR-mediated Erk-MAPK activity via 
the induction of PAC-1 (417). Furthermore, PAC-1 can negatively regulate Erk- 
MAPK in T lymphocytes and the expression of PAC-1 is rapidly increased 
following ligation of the TCR on Jurkat cells (382, 384, 385).
The mechanism used by the BCR to induce PAC-1 in immature B cells is 
incompletely understood. However, Erk-MAPK has been associated with 
inducing the transcription of the pac~1 gene in T cells and is a likely candidate 
for mediating pac-1 expression in B ceils (385). Most genes are regulated by 
multiple factors therefore additional mechanisms of inducing PAC-1 are likely to 
exist. One possible mediator is p53 since p53 is capable of stimulating the 
expression of pac-1 in other systems and ligation of the BCR on WEHI-231 cells 
is known to induce p53 (64, 325). Furthermore, CD40 can suppress p53 in
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BCR-stimulated WEHI-231 cells (325), and this could contribute to the 
restoration of sustained cyclic activation of Erk in proliferating cells.
However, it is important to recognise that there are many different protein 
phosphatases that are capable of regulating the activity of Erk-MAPK and in any 
particular system multiple phosphatases will control the activity of Erk. For 
example, it has been proposed that the cytosolic protein phosphatases HePTP, 
PP2A and PP2C can regulate the initial activation of Erk-MAPK in the cytosol of 
activated T cells. However, these phosphatases do not appear to enter the 
nucleus therefore nuclear MAPK must be suppressed by nuclear phosphatases 
including members of the dual-specificity phosphatase family (381, 418).
To further investigate the role of protein phosphatases in the regulation of 
Erk MAPK in WEHI-231 cells, the differential phosphorylation of the T-E-Y motif 
in the activation loop of Erk1/2 was explored by Western blotting using 
antibodies that are sensitive to the phosphorylation state of this motif (figure 
3.9). The sensitivity of these antibodies was tested using recombinant Erk2 
proteins supplied by New England Biolabs. Two recombinant Erk2 proteins 
were used: non-phosphorylated (T-E-Y) Erk2 and fully (dual)-phosphorylated 
(pT-E-pY) Erk2. Western blotting of these recombinant proteins indicated that 
the phospho-Erk1/2 ( p f  ° /^pY °^' )^ (pTpY-Erk) antibody exclusively bound to 
phosphorylated Erk since it was unable to recognise non-phosphorylated Erk2. 
The phospho-Erk1/2 (pY^ °"^ ) (pY-Erk) antibody did not detect either of the 
recombinant Erk2 proteins indicating this antibody was unable to bind to non- 
phosphorylated or dual-phosphorylated Erk2. This is consistent with this 
antibody being specific for Erk that is only phosphorylated at the tyrosine 
residue of the T-E-Y motif. In contrast, the phospho-Erk1/2 (pT^ ®^ ) (pT-Erk) was 
able to recognise dual-phosphorylated Erk2 indicating this antibody did not 
exclusively bind to the single-phosphorylated pT-Erk. However, this antibody did 
not recognise non-phosphorylated Erk2 therefore it was specific for 
phosphorylated Erk. Finally the total Erk1/2 (Erk) antibody recognised both 
recombinant forms of Erk indicating this antibody was able to bind to Erk 
regardless of the phosphorylation state of the activation loop.
Whole cell lysates prepared from untreated and anti-lg-stimulated WEHI- 
231 cells were analysed by Western blotting using the phosphorylation-sensitive 
Erk1/2 antibodies. Western blotting for dual-phosphorylated Erk (pTpY-Erk)
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showed that untreated proliferating WEHI-231 ceils displayed sustained and 
cyclic activation of Erk-MAPK (figure 3.9A). Ligation of the BCR enhanced early 
Erk signals but suppressed prolonged MAPK activation (figure 3 .9 B). These 
results agree with previous observations (appendix 2 ) and indicate the cells 
used in this experiment were undergoing the regular pattern of Erk-MAPK 
activation.
Western blotting for pY-Erk indicated that the pattern of expression of pY- 
Erk paralleled that of pTpY-Erk (figure 3.9). Single-phosphorylated pY-Erk was 
therefore most abundant at < 1  hr and 4-24 hr in untreated cells. In anti-lg- 
treated cells pY-Erk was present at ^4 hr but as with pTpY-Erk, sustained pY~ 
Erk signals were suppressed by ligation of the BCR. This suggests that WEHI- 
231 cells contain a reservoir of pY-Erk at times when Erk is highly active. This 
pool of single-phosphorylated Erk may represent an intermediate step in the 
generation of dual-phosphorylated Erk. However, the kinetics of accumulation of 
pY-Erk and pTpY-Erk were not identical in WEHI-231 cells. For example, in 
untreated cells the level of pTpY-Erk was roughly equal in 24 hr and 48 hr 
samples whereas the levels of pY-Erk were significantly lower after 48 hr 
compared to levels at 24 hr (figure 3.9A). These observations suggest that pY- 
Erk may have a functional significance that is independent of its potential role 
as an intermediate step in the generation of dual-phosphorylated Erk. Indeed, 
recent reports have suggested that single-phosphorylated forms of Erk retain 
partial activity (379) therefore the pool of pY-Erk in WEHI-231 cells might 
represent a pool of partially active Erk that may be functionally distinct from 
dual-phosphorylated Erk. The ability of anti-lg to induce a loss of pY-Erk in 
WEHI-231 cells suggests that the function of this species of Erk is antagonised 
by ligation of the BCR.
Single-phosphorylated pT-Erk was also detected in untreated and anti-lg- 
treated WEHI-231 cells. Phospho-T-Erk, like pY-Erk, was detected at times 
when pTpY-Erk was abundant but this might reflect the ability of the pT-Erk 
antibody to bind to dual-phosphorylated Erk, as indicated by the recombinant 
dual-phosphorylated Erk2 control. Nonetheless, Western blotting for pT-Erk 
showed clearly that the expression of pT-Erk in WEHI-231 cells was very 
different to that of pY-Erk or pTpY-Erk. Indeed, a significant pT-Erk signal was 
detected in both untreated and anti-lg-stimulated cells at times when dual-
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phosphorylated Erk levels were low. For example, in untreated cells a strong 
pT-Erk signal was obtained at 2 hr and 48 hr despite the presence of very weak 
pY-Erk and pTpY-Erk signals at these times (figure 3.9A). This suggests that 
untreated WEHI-231 cells contain a reservoir of pT-Erk that is present when 
other phosphorylated forms of Erk are absent. The precise function of this pool 
of pT-Erk is not understood but, as with pY-Erk, pT-Erk is partially active (379) 
therefore it might represent a distinct reservoir of partially active Erk. 
Furthermore, treatment of WEHI-231 cells with anti-lg did not diminish the levels 
of pT-Erk despite ligation of the BCR being able to suppress pY-Erk and pTpY- 
Erk signals (figure 3.9B). Indeed, high levels of pT-Erk were detected between 8  
hr and 48 hr in anti-lg-treated WEHI-231 cells indicating the function of pT-Erk 
is not suppressed by ligation of the BCR.
The results presented in figure 3.9 therefore indicate that WEHI-231 cells 
contain single-phosphorylated forms of Erk in addition to their dual- 
phosphorylated and non-phosphorylated forms. Since pT-Erk and pY-Erk are 
known to have kinase activities that are 2-3 orders of magnitude higher than 
non-phosphorylated Erk (379), these species of Erk are likely to have unique 
signalling functions in WEHI-231 cells. However, the activities of pT-Erk and pY- 
Erk are 1 - 2  orders of magnitude less than pTpY-Erk (379) therefore the 
formation of single-phosphorylated forms of Erk is likely to represent an 
alternative mechanism to PAC-1-mediated suppression of Erk activity in both 
proliferating and anti-lg-stimulated WEHI-231 cells. For example, the 
abundance of pT-Erk at times when dual-phosphorylated Erk is barely 
detectable may be caused by the activation of tyrosine-specific protein 
phosphatases. Furthermore, the presence of high levels of pT-Erk in 8-48 hr 
samples of anti-lg-treated WEHI-231 cells suggests that the synthesis of this 
single phosphorylated form of Erk may be activated by ligation of the BCR.
3.12.10 SHF tyrosine phosphatases interact with Erk1/2 in WEHI-231 cells
The tyrosine-specific protein phosphatases SHP-1 and SHP-2 are known 
mediators of BCR signalling in mature B lymphocytes (110, 117, 132, 134, 165) 
(see section 3.8). The function of these protein phosphatases in immature B 
cells is less well understood. The results of figure 3.9 implicated tyrosine 
phosphatases as potential mediators of Erk signalling in WEHI-231 cells. The
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role of SHP proteins in regulating Erk-MAPK was thus investigated by 
determining the association of Erk and SHP in untreated and stimulated WEHI- 
231 cells. To do this, Erk1/2 immune complexes were prepared from WEHI-231 
whole cell lysates and these were analysed by Western blotting for SHP-1 or 
SHP-2.
SHP-1 was found to be constitutively associated with Erk in untreated and 
anti-CD40-treated WEHI-231 cells over a period of 48 hr (figure 3.10A and D). 
This suggests that WEHI-231 cells can survive and proliferate when SHP-1 
interacts with Erk. SHP-1 was also found to interact with Erk1/2 in anti-lg- 
treated WEHI-231 cells (figure 3.1 OB). However, a dissociation of SHP-1 from 
Erk was observed in the 8  hr sample suggesting ligation of the BCR can 
regulate the interaction of these two proteins. Similarly, in cells treated with anti- 
lg plus anti-CD40, SHP-1 was detected in Erk immune complexes except 
between 2 hr and 8  hr where there was a dissociation of SHP-1 and Erk (figure 
3.IOC). Co-ligation of CD40 therefore can also regulate the interaction of SHP-1 
and Erk.
The results of figure 3.9 implicated a role for tyrosine phosphatases in 
BCR-mediated suppression of sustained Erk signals. Figure 3.10A-D shows 
that SHP-1 and Erk can indeed interact in WEHI-231 cells and this can be 
regulated by ligation of the BCR or CD40. However, unlike the binding of PAC- 1  
to Erk, the association of SHP-1 and Erk was not specifically enhanced by 
ligation of the BCR suggesting the interaction of SHP- 1  and Erk may not 
mediate BCR-dependent inhibition of cyclic Erk signals. Furthermore, co-ligation 
of CD40 prevented the binding of PAC-1 and Erk suggesting a potential 
mechanism of CD40-mediated enhancement of Erk signals. However, at times 
when dual-phosphorylated Erk levels were most suppressed by treatment with 
anti-lg (12-48 hr), anti-CD40 did not prevent SHP-1 and Erk interacting. It is 
thus unclear what precise purpose is served by the interaction of SHP- 1  and 
Erk in WEHI-231 cells. One aspect of this interaction that requires further 
investigation is to determine the activity of SHP-1 in Erk immune complexes, in 
the cytosol, the activity of SHP-1 is normally suppressed by autoinhibition since 
an N-terminal SH2  domain of SHP binds to a C-terminal phospho-tyrosine 
residue thus blocking the catalytic domain (figure 3.4). SHP can be activated by 
the binding of its SH2 domains to tyrosine phosphorylated proteins (133). The
129
mechanism by which SHP-1 interacts with Erk is unclear and it is possible that 
activation of SHP- 1  in this complex requires the SH2 domain of SHP-1 to 
interact with an additional protein to form a multicomponent complex. The 
interaction of SHP- 1  with additional proteins may also serve to anchor SHP- 
1/Erk at a particular intracellular location. Furthermore, the influence of SHP-1 
on Erk activity is unclear since Erk is not generally considered to be a substrate 
of SHP- 1  (380, 381). However, it has recently been suggested that upstream 
activators, substrates and negative regulators of Erk-MAPK can compete with 
each other for binding to Erk-MAPK (376). The formation of Erk-SHP-1 
complexes therefore might influence the activity of Erk by regulating the 
interaction of Erk and other proteins including additional regulators or 
substrates.
SHP-2 is structurally very similar to SHP-1 but is functionally distinct. For 
example, SHP-1 is generally considered to be a negative regulator of BCR 
signalling in mature B lymphocytes but SHP-2 can enhance BCR-mediated 
activation of Erk-MAPK via its interaction with Grb-2 (110, 117, 132, 165, 419). 
The role of SHP-2 in regulating Erk in WEHI-231 cells was investigated by 
detection of SHP-2-Erk complexes in WEHI-231 cells. The association of Erk1/2 
with SHP-2 was studied by preparing immune complexes of Erk 1/2 from WEHI- 
231 cell lysates and Western blotting with an anti-SHP- 2  antibody. In untreated 
WEHI-231 cells, SHP-2 strongly associated with Erk1/2 especially between 0  
and 1 hr although the association was also observed at later times including 4 - 8  
hr and 24 hr (figure 3.1 OE). A sustained, cyclic pattern of SHP-2-Erk association 
was also observed in anti-CD40-treated cells (figure 3.1 OH).
In contrast, a strong association of SHP- 2  and Erk in anti-lg-treated WEHI- 
231 cells was exclusively observed between 0 and 1 hr suggesting that ligation 
of the BCR causes SHP- 2  to dissociate from Erk (figure 3.1 OF). However, co­
culture with anti-lg plus anti-CD40 impaired the early binding of Erk1/2 and 
SHP-2 whilst enhancing the sustained interaction of these signalling molecules 
(figure 3.10G).
These observations show that SHP-2 can associate with Erk1 / 2  in WEHI- 
231 cells and this can be regulated by ligation of the BCR and CD40. 
Furthermore, the interaction of SHP- 2  and Erk has distinct parallels with the 
pattern of Erk activation in WEHI-231 cells (appendix 2). Indeed, the SHP-2-Erk
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complex was most abundant when the highest levels of pTpY-Erk could be 
detected. This suggests that SHP- 2  does not mediate the dephosphorylation of 
pTpY-Erk but instead may increase the activity of Erk-MAPK.
The activation of Erk by SHP-2 has already been observed downstream of 
the BCR in mature B lymphocytes. However, in this system SHP- 2  is recruited 
to the BCR complex via Gab-1 and SHP-2 can then associate with Grb-2 
leading to the recruitment of SOS and the stimulation of Erk-MAPK (110, 117, 
132, 165). A similar situation has been observed in Jurkat T cells downstream 
of the TCR (420). Furthermore, the association of Gab- 1  and SHP-2 /Grb- 2  has 
been observed downstream of the receptors for EGF and PDGF and this 
interaction was specifically required for the sustained activation of Erk 1 / 2  (166). 
SHP-2, via its association with Grb2, can therefore be a positive regulator of Erk 
signalling. However, it is not known if SHP-2 can also directly associate with Erk 
in these systems and hence in WEHI-231 cells it is unclear how the activity of 
Erk is regulated by the direct interaction of SHP- 2  and Erk.
Furthermore, the intracellular location of the Erk-SHP-2 complex in WEHI- 
231 cells has not been established. The interaction between SHP-2 and Gab-1 
occurs within the cytosol but SHP- 2  can also enter the nuclei of cells and has 
been found in association with STAT-1 in the nuclei of A431 cells (397). 
Identification of the intracellular location of Erk-SHP-2 in WEHI-231 cells might 
indicate whether SHP-2 is a regulator of cytosolic or nuclear Erk-MAPK.
Taken together, these results show that Erk can bind either directly or 
indirectly via complexes to SHP-1 and SHP-2 tyrosine phosphatases in WEHI- 
231 cells. However, the kinetics of this interaction do not directly implicate SHP- 
1 as a regulator of Erk downstream of the BCR and CD40 and SHP-2 appears 
to be a positive mediator of Erk-MAPK signalling in WEHI-231 cells. The 
regulation of Erk-MAPK in WEHI-231 cells is thus incompletely understood. 
Protein phosphatases other than PAC-1 are likely to be involved in mediating 
BCR-driven suppression of cyclic Erk signals but further investigations are 
required to identify these phosphatases. Studies in T cells may prove useful in 
directing these additional studies since several protein phosphatases including 
PAC-1, MKP-1, MKP-2, MKP-3, MKP-6 , VHR, VHX and HePTP are known to 
regulate the activity of Erk in these cells. For example, the tyrosine phosphatase 
HePTP and the dual-specificity phosphatase MKP-1 are cytosolic phosphatases
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that suppress Erk activity in unstimulated T cells but ligation of the TCR 
stimulates Erk-MAPK and in turn Erk can induce PAC- 1  leading to a termination 
of the Erk signal. However PAC-1 de novo synthesis is optimal 30-60 min after 
TCR stimulation and the suppression of later Erk signals requires the more 
sustained accumulation of additional MAPK phosphatases including VHR (382, 
418).
3.12.11 Ras can stimulate Erk via Raf or PI-3-K in WEHI-231 cells
The regulation of Erk-MAPK in WEHI-231 cells is critical for determining 
the survival and proliferation of these cells. The mechanisms used by the BCR 
and CD40 to couple to Erk-MAPK are incompletely understood. The results 
presented above indicate that activation of an early Erk signal correlates with 
the presence of MEK-Erk complexes. However, sustained and cyclic activation 
of Erk can be regulated independently of upstream activators.
The classical Erk-MAPK cascade (figure 3.1) can be initiated by the 
monomeric G-protein Ras (see section 3.4.2), However, Ras has several 
effectors including Raf, PI-3-K and RalGDS (see section 3.5). The role of Ras in 
regulating the activity of Erk-MAPK in WEHI-231 cells was investigated using 
WEHI-231 cells transfected by electroporation with a pcDNAS.I plasmid 
containing a RasV^^ construct (RasV^^ WEHI-231), a RasV^^S^® construct 
(RasV^^S^^ WEHI-231), a RasV^^C^° construct (RasV^^C^° WEHI-231) or an 
empty plasmid (pcDNAS.I WEHI-231) (see table 2.18 and section 3.5 for 
details of these mutations). To further investigate the importance of the Erk- 
MAPK cascade an additional mutant WEHI-231 cell line was generated by 
transfecting cells by electroporation with either a pcDNAS.I plasmid containing 
a AMEKK3 construct (AMEKK3 WEHI-231) or an empty plasmid (pcDNAS.I 
WEHI-231). The AMEKK3 construct encodes a constitutively active form of 
MEKK3 and was a generous gift from Dr. S. J. Cook (The Babraham Institute, 
Cambridge, UK). MEKK3 is a MAPKKK that can activate several different types 
of MAPK. MEKK3 can stimulate p38 via MKK3/6 and JNK via MKK4/7 (421, 
422). MEKK3 also stimulates MEK1/2 and Erk 1/2 and can activate Erk5 via 
MEK5 (423-425). Transfection of cells with AMEKK3 can be used to determine 
the effect of simultaneously activating multiple types of MAPK.
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Expression of RasV^^, RasV^^S^^ or RasV^^C^® induced a general increase 
in the activity of Erk in WEHI-231 cells indicating Ras is an important upstream 
activator of Erk in these cells (figure 3.11). Furthermore, Ras was able to 
stimulate Erk via at least two distinct pathways since RasV^^S^® couples only to 
Raf whilst RasV^^C^° only binds to PI-3-K. Ras can thus stimulate Erk via Raf-1 
or PI-3-K in WEHI-231 cells. AMEKK3 WEHI-231 cells also had enhanced 
activation of Erk (figure 3.11E), which is consistent with MEKK3 being an 
activator of Erk1/2 (423).
Untreated or CD40-stimulated WEHI-231 cells transfected with the empty 
vector pcDNAS.I underwent sustained cyclic activation of Erk-MAPK (figure 
3.11A). Although transfection of these cells with RasV^^, RasV^^S^® or 
RasV^^C" °^ enhanced the activity of Erk (figure 3.11B-D), they still displayed 
cyclic activation of Erk over the 24 hr time period. This shows that the 
constitutive activation of Raf and/or PI-3-K by Ras was insufficient to sustain 
constitutively active Erk signals. Interestingly, untreated or CD40-stimu!ated 
WEHI-231 cells that were transfected with either RasV^^S^® or RasV^^C^° had 
greater Erk activity than cells transfected with RasV^^. This suggests that 
restricting the downstream effectors of Ras can actually increase the activation 
of Erk, further supporting the observation that Ras can stimulate Erk via Raf-1 
or PI-3-K in WEHI-231 cells.
Ligation of the BCR on RasV^^ WEHI-231 cells enhanced the early (1 hr) 
Erk activity but suppressed the activation of Erk between 8  hr and 24 hr (figure 
3.1 IB). Stimulation of the BCR therefore induces negative regulatory 
mechanisms that can suppress Erk activity even in the presence of constitutive 
activation of Raf-1 and P1-3-K by Ras. This is consistent with observations 
suggesting BCR-dependent inhibition of sustained and cyclic activation of Erk is 
mediated by the induction of MAPK phosphatases rather than the inhibition of 
upstream activators of Erk (figure 3.8 and appendix 5) and that these 
phosphatases may be Erk-dependent Similarly, transfection of WEHI-231 cells 
with either RasV^^S^® or RasV^ ^C'^ ® did not prevent BCR-driven inhibition of Erk 
(figure 3.11C-D).
Co-ligation of CD40 on BCR-stimulated pcDNA3.1 WEHI-231 cells 
restored cyclic activation of Erk, with optimal levels of dual-phosphorylated Erk 
being detected at 1 hr and 24 hr (figure 3.11 A). Cyclic patterns of Erk activation
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were also observed in RasV^^ transfected WEHI-231 cells that were treated with 
anti-lg plus anti-CD40 (figure 3.1 IB). In contrast, RasV^^S^® and RasV’’^C'^ ° 
WEHI-231 cells treated with anti-lg plus anti-CD40 displayed slightly impaired 
Erk activation at 24 hr (figure 3.11C-D). Indeed, these WEHI-231 cells had less 
dual-phosphorylated Erk than the equivalent pcDNA3.1 WEHI-231 cells. This 
suggests that CD40-mediated restoration of sustained Erk signals in BCR- 
stimulated WEHI-231 cells requires Ras-dependent activation of both Raf and 
P1-3-K.
3.12.12 Constitutive activation of Ras partially protects WEHI-231 cells 
from BCR-driven growth arrest and apoptosis
To investigate the functional significance of these observations, the DNA 
synthesis and apoptosis of RasV^^, RasV^^S^ ,^ RasV^^C" °^ and AMEKK3 WEHI- 
231 cells was measured. The level of DNA synthesis was determined by 
measuring the incorporation of [^H] thymidine. After 24 hr, anti-lg induced 
growth arrest of pcDNA3. 1 WEHI-231 cells in a dose-dependent manner (figure 
3.12A). However, WEHI-231 cells that were transfected with RasV^^, RasV^^S^^ 
or RasV^^C^° were completely protected from anti-lg-induced growth arrest after 
24 hr. Expression of constitutively active Ras therefore protects WEHI-231 cells 
from anti-lg-dependent growth arrest and it does so via the activation of Raf 
and/or PI-3-K. These observations agree with previous data that showed Erk- 
MAPK promotes proliferation of WEHI-231 cells (appendices 2-4). However, 
expression of these constitutively active forms of Ras did not substantially 
increase the levels of dual-phosphorylated Erk at 24 hr in anti-lg-treated cells 
(figure 3.11) suggesting Ras might be promoting proliferation of WEHI-231 cells 
via an alternative mechanism.
Interestingly, expression of AMEKK3 was significantly less effective than 
the constitutively active forms of Ras at protecting WEHI-231 cells from BCR- 
driven growth arrest at 24 hr (figure 3.12A). This agrees with previous 
observations suggesting Erk-MAPK and not JNK or p38, is specifically required 
for proliferation of WEHI-231 cells (326) and suggests that JNK or p38 may 
have a role in suppressing proliferation of WEHI-231 cells.
DNA synthesis was also measured in RasV^^ WEHI-231 cell lines after 48 
hr and 72 hr. In contrast to the protection observed after 24 hr, expression of
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RasV^^, RasV^^S^^ RasV^^C'^® or AMEKK3 did not prevent anti-lg-induced 
growth arrest after 48 hr or 72 hr (figure 3.12B-C). A small amount of protection 
was enabled by expression of RasV^^ or RasV^^C'^® suggesting that Ras- 
dependent activation of PI-3-K might have a greater role in promoting 
proliferation than Ras-dependent stimulation of Raf-1 . Furthermore, CD40- 
mediated rescue was greatest in RasV^C"^® WEHI-231 cells (figure 3 .1 2 D) 
although expression of each of the RasV^^ vectors induced a slight increase in 
proliferation compared to pcDNA3.1 WEHI-231 cells treated with anti-lg plus 
anti-CD40. These observations were unexpected since CD40-mediated 
restoration of sustained Erk signals was slightly impaired in RasV^^S^^ and 
RasV'‘^C'^ ° WEHI-231 cells. This further suggests that Ras can induce 
proliferation of WEHI-231 cells via an alternative mechanism(s).
Expression of RasV^^ vectors therefore partially protects WEHI-231 cells 
from anti-lg-induced growth arrest. To determine whether this was due to 
increased proliferation or merely reflected enhanced survival of the cells, the 
sub-diploid DNA content of these cells was analysed (figure 3.12E). After 48 hr, 
10 pg/ml anti-lg doubled the number of pcDNAS.I WEHI-231 cells with sub­
diploid DNA (figure 3.12E) but expression of vectors containing RasV^^, 
RasV^^S^® or RasV^ ^C"^ ® reduced the ability of anti-lg to induce apoptosis. This 
suggests that Ras can stimulate survival signals in WEHI-231 cells via the 
activation of Raf and/or PI-3-K. However, expression of RasV^^S^® offered least 
protection indicating Ras-dependent activation of PI-3 -K is more effective at 
rescuing WEHI-231 cells from BCR-driven apoptosis than Ras-dependent 
stimulation of Raf. These observations are consistent with the thymidine assay 
data suggesting Ras can promote survival and proliferation of WEHI-231 cells 
and this can be mediated by the activation of either Raf- 1  or PI-3-K. Moreover, 
CD40-dependent rescue from BCR-driven apoptosis was slightly impaired in 
RasV^^S^® WEHI-231 cells, confirming PI-3-K is the more effective mediator of 
Ras-dependent rescue. Constitutive activation of Ras can thus increase the 
survival of WEHI-231 cells and this may contribute to the inhibition of BCR- 
driven growth arrest observed in WEHI-231 cells expressing constitutively 
active forms of Ras.
BCR-driven apoptosis was also impaired in AMEKK3  WEHI-231 cells 
despite these cells being relatively sensitive to anti-lg-induced growth arrest.
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This suggests that the simultaneous activation of Erk1/2 with JNK, p38 or Erk5 
may reduce pro-apoptotic signals in WEHI-231 cells. This is consistent with 
previous observations that have implicated JNK/p38 as mediators of immature 
B cell survival (306-309).
3.12.13 Ras-dependent activation of PI-3-K does not stimulate Akt
To investigate the mechanism of Ras-dependent and MEKK3-mediated 
survival of WEHI-231 cells, the activity of Akt in transfected WEHI-231 cells was 
determined since PI-3-K-dependent activation of Akt can promote the survival of 
many different cell types including mature splenic B lymphocytes (see section 
1.6.3.1) (184, 186, 188, 189, 193-195). Furthermore, Akt has been implicated 
as an effector of Ras-dependent PI-3-K signalling downstream of TCR (426).
The activity of Akt is regulated by phosphorylation; in particular, Akt must 
be phosphorylated at Thr^ °® and Ser'^ ^  ^for activation (184). The activity of Akt in 
lysates prepared from RasV^^, RasV^^S^®, RasV^^C^® and AMEKK3 WEHI-231 
cells was determined by Western blotting with phosphorylation-sensitive 
antibodies that specifically recognise Akt with phospho-Thr^°® (pTAkt) or 
phospho-Ser"^^^ (pSAkt). Positive controls for phosphorylated and non- 
phosphorylated Akt (purchased from New England Biolabs) were included in all 
the Western blots.
In general, pcDNAS.I WEHI-231 cells had very low levels of pTAkt and 
pSAkt indicating WEHI-231 cells do not normally have high Akt activity (figure 
3.ISA). Furthermore, ligation of the BCR and/or CD40 did not greatly enhance 
the phosphorylation of Akt and the only condition that appeared to induce 
phosphorylation of both Thr^ *^  ^ and Ser'^^  ^ was treatment with anti-CD40. 
However, the levels of pTAkt and pSAkt in CD40-stimulated cells were very low 
and may not reflect a true Akt signal. These observations suggest WEHI-231 
cells have low Akt activity and this is unlikely to be affected by ligation of the 
BCR and/or CD40.
Transfection of WEHI-231 cells with RasV^^, RasV^^S^^, RasV^^C'^  ^ or 
AMEKK3 did not greatly enhance the activation of Akt (figure 3.13B-E). As with 
pcDNAS.I cells, the only condition that induced phosphorylation of both Thr^ °® 
and Ser'^^  ^ was CD40 stimulation. Surprisingly, the highest levels of 
phosphorylated Akt were observed in RasV^^S^® WEHI-231 cells and this form
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of Ras cannot couple to PI-3-K. This result must be treated with some caution 
since the levels of pTAkt were lower than or equal to those of the non- 
phosphorylated Akt control cell extract (figure 3.13C, anti-CD40-treatment, 
compare lane 5 to lanes 1-4). Overall, these observations suggest that the 
activity of Akt is low in WEHI-231 cells and Akt is unlikely to be a significant 
mediator of Ras-dependent or MEKKS-mediated survival and proliferation of 
these cells. Alternative effectors of PI-3-K thus appear to be responsible for 
enhancing the viability of RasV^^C"^  ^WEHI-231 cells.
3.12.14 Ras can in d u c e  B c I-X l in WEHI-231 cells especially via the 
activation of PI-3-K
To further investigate the enhanced survival potential of WEHI-231 cells 
transfected with constitutively active Ras mutants, the expression of B c I-x l  was 
determined by Western blotting of lysates prepared from these cells. B c I-x l  is 
known to be an important survival factor of WEHI-231 immature B cells that can 
be induced by CD40 to suppress BCR-dependent apoptosis (see section 1.9.3 
and chapter 4 for further details) (292, 293, 306, 427). The mechanisms that 
regulate the expression of B c I-xl  in WEHI-231 cells are incompletely 
understood.
Bc I-xl levels were low in untreated and anti-lg-stimulated pcDNA3.1 
WEHI-231 cells but ligation of CD40, in the presence or absence of anti-lg, 
greatly enhanced the expression of B c I-x l , especially between 8 hr and 48 hr 
(figure 3.14A). This is consistent with previous studies that have identified B c I-xl  
as a key mediator of CD40-driven survival (292, 293, 427).
Expression of RasV^^ or AMEKK3 induced a general increase in the levels 
of Bc I-Xl detected in WEHI-231 cells without altering the pattern of expression 
(figure 3.14B and E). B c I-x l  was thus most abundant in CD40-stimulated cells 
and between 8  hr and 48 hr. Constitutive activation of Ras or MEKK3 therefore 
can overcome some of the negative regulatory mechanisms that prevent B c I-xl  
induction in unstimulated and anti-lg-treated WEHI-231 cells to allow a slight 
increase in B c I-xl  expression. This is likely to contribute to the increased 
survival of RasV^^ or AMEKK3 WEHI-231 cells observed in figure 3.12E.
However, expression of RasV^^S^^ or RasV^^C"^  ^ substantially increased 
the levels of B c I-Xl in untreated WEHI-231 cells (figure 3.14C-D). This suggests
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Ras can induce B c 1-x l  in unstimulated cells via Raf or PI-3-K but this process 
was impaired by activation of both of these pathways (figure 3.14B). 
Interestingly, expression of RasV^ ^C"^ ® also increased the expression of Bc I-xl  in 
anti-lg-stimulated cells suggesting Ras-dependent activation of P1-3-K can 
either induce B c I-x l  expression or overcome the BCR-mediated negative 
regulation of Bc !-xl  expression. Furthermore, these observations are consistent 
with the results of figure 3.12, which showed RasV^^C^° WEHI-231 cells were 
partially protected from BCR-driven apoptosis. Ras-dependent activation of Raf 
or PI-3-K can thus induce B c I-x l  in unstimulated WEHI-231 cells. However, the 
activation of PI-3-K alone can increase Bc I-xl  levels in anti-lg-stimulated cells. 
Interestingly, expression of constitutively active forms of Ras did not lead to the 
constitutive induction of B c !-Xl in CD40-stimulated cells, suggesting signalling 
pathways other than Ras and its effectors are likely to contribute to CD40- 
dependent induction of B c I-x l . This is consistent with the observation that 
inhibition of MEK did not impair CD40-dependent survival (appendix 3B).
3.12.15 Inhibition of Dok can increase the activity of Erk in BCR-stimulated 
WEHI-231 cells
Dok-1 is an adaptor protein that has multiple functions including the 
regulation of Ras via RasGAP (see section 3.10). For example, in mature B 
cells Dok- 1  is phosphorylated following co-ligation of the BCR and FcyRIIB and 
this leads to the activation of RasGAP and inhibition of Ras (244). To 
investigate the role of Doki in WEHI-231 cell signalling, WEHI-231 cells were 
retrovirally transfected with pMXI-egfp vectors containing Dok-PH/PTB (Dok- 
PH/PTB WEHI-231) or empty vector (pMXI WEHI-231). Expression of Dok- 
PH/PTB can suppress wild-type Doki since it prevents proteins from binding to 
the PH and PTB domains of cellular D oki. Expression of Dok-PH/PTB therefore 
is expected to inhibit RasGAP in WEHI-231 cells and increase the activation of 
Ras.
The activity of Erk-MAPK in WEHI-231 cells transfected with Dok-PH/PTB 
was investigated by Western blotting. Expression of Dok-PH/PTB enhanced the 
activity of Erk in untreated and BCR-stimulated WEHI-231 cells (figure 3.15A-
B). Of particular interest, inhibition of Dok appeared to prevent BCR-dependent 
suppression of sustained Erk signals, implicating Doki as a mediator of BCR-
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driven suppression of Erk-MAPK. Interestingly, expression Dok-PH/PTB did not 
increase the levels of phospho-Erk in anti-CD40-treated WEHI-231 cells despite 
CD40 inducing Erk in pMXI WEHI-231 cells. This observation may reflect an 
ability of CD40 to suppress Doki in WEHI-231 cells.
Expression of Dok-PH/PTB did not substantially increase the activity of Akt 
in untreated or stimulated WEHI-231 cells (figure 3.15C-D). Furthermore, in 
contrast to the RasV^^ mutants, the expression of B c 1-xl was slightly impaired in 
Dok-PH/PTB WEHI-231 cells (figure 3.15E-F). The phenotype of Dok-PH/PTB 
WEHI-231 cells reflected these observations since expression of Dok-PH/PTB 
did not significantly protect WEHI-231 cells from BCR-driven apoptosis after 24 
hr or 48 hr (figure 3.16A-B). Furthermore, despite being able to increase the 
expression of Erk in untreated and BCR-stimulated WEHI-231 cells, expression 
of Dok-PH/PTB did not impair BCR-driven growth arrest of WEHI-231 cells after 
24, 48 or 72 hr (figure 3.16C-E). This is likely to be due to these cells being 
susceptible to BCR-driven apoptosis. Expression of Dok-PH/PTB also did not 
affect CD40-dependent rescue from BCR-driven growth arrest (figure 3.16F).
Inhibition of Dok via the expression of Dok-PH/PTB in WEHI-231 cells 
therefore enhances Erk signalling. However, Dok-PH/PTB is unable to induce 
pro-survival proteins and consequently does not appear to enhance the survival 
or proliferation of WEHI-231 cells. Dok thus appears to be a regulator of Erk in 
WEHI-231 cells and it may be involved in mediating BCR-dependent 
suppression of sustained Erk signals. Precisely how Dok impairs Erk signalling 
in WEHI-231 cells is unknown but in other systems. Doki mediates its effects 
by regulating the activity of RasGAP (244). However, constitutive activation of 
Ras did not substantially increase sustained Erk signals in BCR-stimulated 
WEHI-231 cells (figure 3.11) suggesting Dok may inhibit Erk downstream of the 
BCR via an alternative effector. In T lymphocytes Crk is an effector of Dok and 
Crk can interact with C3G, an activator of Rap-1 (399, 403). The induction of 
Rap-1 can lead to the activation or inhibition of Erk-MAPK independently of Ras 
(figure 1.17). The role of Crk/C3G/Rap-1 in mediating Doki signalling in WEHI- 
231 cells has not been explored but preliminary data suggests that untreated 
WEHI-231 cells display cyclic activation of Rapi (428).
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3.12.16 Inhibition of SHIP increases Erk activation but cannot induce 
constitutive Erk signalling
Analysis of the RasV^^C^° WEHI-231 cells indicated PI-3-K is an important 
effector of Ras. To further investigate the role of PI-3-K in WEHI-231 cell 
signalling, WEHI-231 cells were retrovirally transfected with pMXI-egfp vectors 
containing SHIP-Cl (SHIP-CI WEHI-231), SHIP-SH2 (SHIP-SH2  WEHI-231) or 
empty vector (pMXI WEHI-231). SHIP-CI is a catalytically inactive form of SHIP 
whilst SHIP-SH2  encodes the SH2  domain of SHIP and hence it competes with 
wild-type SHIP to prevent its attachment to phospho-tyrosine residues. SHIP is 
a phosphatase that removes the 5’ phosphate from the inositol ring, enabling it 
to reduce the levels of PI-3, 4, 5 -P3 and antagonise the function of PI-3-K (see 
sections 1.7.2 and 3.9). Transfection of WEHI-231 cells with dominant negative 
SHIP mutants therefore should enhance PI-3-K signalling.
The activity of Erk-MAPK in WEHI-231 cells transfected with empty vector 
(pMXl-egfp), SHIP-CI or SHIP-SH2 was investigated by Western blotting of 
lysates prepared from these cells. In general, the activity of Erk was reduced in 
retrovirally transfected WEHI-231 cells including pMXI WEHI-231 cells 
suggesting this method of transfection impairs Erk activation. Nonetheless, 
proliferating pMXI WEHI-231 cells underwent cyclic activation of Erk whilst BCR 
stimulation enhanced early (1 hr) Erk signals without elevating sustained levels 
of phospho-Erk and co-ligation of the BCR and CD40 restored sustained and 
cyclic activation of Erk (figure 3.17A).
Expression of SHIP-CI or SHIP-SH2-containing vectors did not greatly 
alter the pattern of Erk activation in untreated or stimulated cells (figure 3.17B-
C) but consistent with the results of figure 3.1 ID, Erk signalling was slightly 
enhanced in these cells. These results further agree with the observations of 
figure 3.11 by showing enhanced PI-3-K function is insufficient to override the 
negative regulatory mechanisms that normally suppress Erk activity in WEHI- 
231 cells. For example, stimulation of SHIP-CI or SH1P-SH2 WEHI-231 cells 
with anti-lg plus anti-CD40 induced a cyclic pattern of Erk activation with Erk 
being inhibited at 8  hr. Enhanced PI-3-K signalling therefore increases the 
activation of Erk at times of high Erk activity but cannot overcome the negatively 
regulatory mechanisms that normally suppress Erk signalling.
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3.12.17 Expression of SHIP partially protects WEHI-231 cells from BCR- 
driven growth arrest and apoptosis
To further examine the role of PI-3-K signalling in WEHI-231 cells, the 
proliferation and apoptosis of SHIP-CI and SH1P-SH2 WEHI-231 cells was 
determined. Proliferation was investigated by measuring the DNA synthesis of 
populations of cells cultured for 24, 48 or 72 hr (figure 3.18A-C). Ligation of the 
BCR on pMXI WEHI-231 cells induced growth arrest in a dose-dependent 
manner. Furthermore, expression of SHIP-CI did not protect the cells from 
BCR-driven growth arrest. In contrast, anti-lg-induced growth arrest was slightly 
impaired in SHIP-SH2 WEHI-231 cells, especially after 72 hr. For example, 
treatment of WEHI-231 cells with 1 pg/ml anti-lg for 72 hr induced a 88% 
decrease in the percentage of DNA synthesis in pMXI WEHI-231 cells but the 
DNA synthesis was only decreased by 60% in SHIP-SH2 WEHI-231 cells 
(figure 3.18C). This agrees with the observations of figure 3.12 in which Ras- 
dependent activation of PI-3-K partially protected WEHI-231 cells from anti-lg- 
induced growth arrest. Furthermore, the antagonism of PI-3-K by SHIP appears 
to require interactions mediated by the SH2 domain of SHIP. However, CD40- 
mediated rescue from anti-lg-induced growth arrest was relatively unaffected by 
expression of SHIP-CI or SHIP-SH2 (figure 3.18D), suggesting SHIP does not 
normally impair CD40-dependent restoration of proliferation.
Apoptosis of SHIP-CI and SHIP-SH2 WEHI-231 cells was also measured. 
As with previous experiments, anti-lg did not induce a significant amount of 
apoptosis after 24 hr (figure 3.18E). However, the 24 hr cultures do suggest that 
expression of SHIP-CI or SHIP-SH2 increased the basal level of survival of 
WEHI-231 cells, implicating PI-3-K activation as a pro-survival factor of 
proliferating cells. After 48 hr, anti-lg induced apoptosis of pMXI WEHI-231 and 
SH1P-SH2 WEHI-231 cells (figure 3.18F). However, expression of SHIP-CI 
partially protected WEHI-231 cells from BCR-driven apoptosis. This was slightly 
unexpected since SHIP-CI did not appear to prevent BCR-driven proliferation 
and SHIP-SH2 did reduce the level of anti-lg-induced growth arrest. CD40- 
mediated rescue from BCR-driven apoptosis was not significantly affected by 
expression of either SHIP mutant.
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3.12.18 Inhibition of SHIP does not activate Akt but can induce B c I-xl
To further investigate the signals downstream of SHIP and PI-3-K, the 
activity of Akt was measured by Western blotting of lysates prepared from 
SHIP-CI and SH1P-SH2 WEHI-231 cells. However, no activation of Akt could be 
detected in unstimulated or stimulated pMXI WEHI-231, SHIP-CI WEHI-231 or 
SHIP-SH2 WEHI-231 cells (figure 3.19A-C). This is consistent with the 
observations of figure 3.13 and further suggests that Akt is unlikely to be a 
significant survival factor of unstimulated, BCR-activated or CD40-stimulated 
WEHI-231 cells.
However, expression of SHIP-CI and SHIP-SH2 did induce a slight 
increase in the expression of B c !-xl  in untreated and BCR-stimulated WEHI-231 
cells (figure 3.19D-F). This is likely to explain the general reduction in apoptosis 
observed in WEHI-231 cultures after 24 hr (figure 3.18E). Furthermore, these 
results agree with those of figure 3.14 in which Ras-dependent activation of Pl- 
3-K induced B c I-x l  in untreated WEHI-231 cells. Moreover, CD40-mediated 
induction of Bc I-xl  was not significantly affected by inhibition of SHIP.
Overall, the inhibition of SHIP appears to induce Bc I-xl in untreated and 
possibly BCR-stimulated WEHI-231 cells and this contributes to the increased 
survival of these cells. These observations confirm those of the Ras mutants in 
which Ras-dependent activation of PI-3-K was implicated as an important 
survival factor of unstimulated or BCR-activated WEHI-231 cells via the 
induction of B c I-x l .
3.13 Conclusions
Ligation of the BCR on WEHI-231 cells induced growth arrest at G0/G1 
phase of the cell cycle and apoptosis in a dose-dependent manner (figures 3.5- 
3.6). Co-ligation of CD40 rescued the cells from growth arrest and apoptosis. To 
investigate the signalling mechanisms used to regulate survival and proliferation 
of WEHI-231 cells, the activity of MAPK was determined. Anti-lg induced early 
Erk signals with optimal stimulation at 30 min and this was reduced by co­
ligation of CD40 (appendix 1). In contrast, ligation of the BCR or CD40 did not 
induce significant levels of p38 or JNK activity(328).
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The functional significance of early Erk signals was investigated using 
pharmacological inhibitors of MEK to inhibit Erk activity. MEK inhibitors 
abrogated BCR-driven apoptosis (appendix 1E) and reduced the ability of the 
BCR to induce arachidonic acid production (328) in WEHI-231 cells. Previous 
data has suggested that the BCR induces apoptosis via the induction of cPLAz 
and arachidonic acid (102). Taken together, this suggests that ligation of the 
BCR induces early Erk signals that stimulate CPLA2 , leading to the production of 
arachidonic acid and the onset of apoptosis (figure 3.20A).
However, additional functions for Erk-MAPK were suggested by the 
observation that proliferating WEHI-231 cells undergo sustained and cyclic 
activation of Erk (appendix 2). Furthermore, ligation of the BCR disrupted cyclic 
activation of Erk by inhibiting sustained Erk signals whilst co-ligation of CD40 
restored prolonged Erk signalling (appendix 2). The functional significance of 
these signals was investigated via the repeated application of MEK inhibitors to 
suppress Erk activation. Inhibition of sustained Erk signals inhibited basal and 
CD40-mediated proliferation and prevented CD40-dependent rescue from BCR- 
driven growth arrest (appendix 3). However, MEK inhibitors did not abrogate 
CD40-mediated rescue from BCR-driven apoptosis (appendix 3B) thus 
suggesting cyclic activation of Erk is particularly required for proliferation of 
WEHI-231 cells. Furthermore, laser scanning cytometry was used to show 
WEHI-231 cells undergoing cell cycle progression have high concentrations of 
phospho-Erk that is reduced by ligation of the BCR or the addition of cell cycle 
inhibitors but can be restored by CD40-dependent signals (appendix 4). Taken 
together, these observations strongly suggested that sustained and cyclic 
activation of Erk is required for proliferation of WEHI-231 cells. Disruption of 
these signals can be mediated by the BCR to induce growth arrest whilst CD40 
can enable the cells to proliferate by restoring the sustained and cyclic Erk 
signals (figure 3.20A).
To investigate the mechanism of BCR-dependent inhibition of sustained 
Erk signals, the activity of MEK was determined. Ligation of the BCR did not 
dissociate MEK-Erk complexes and did not dephosphorylate key of residues of 
MEK that must be phosphorylated for activation of the kinase (figure 3.7), 
Furthermore, the activity of MEK was determined using an in vitro MEK assay 
and this showed that ligation of BCR does not inhibit sustained MEK signals
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(figure 3.8). These observations indicate the BCR does not uncouple Erk from 
its upstream activators and hence the BCR must inhibit Erk via an alternative 
pathway.
The activation of Erk requires phosphorylation of a T-E-Y motif in the 
activation loop and dephosphorylation of these residues inhibits Erk (figure 3.3). 
Indeed, Erk can induce its own inhibition via the induction of the dual-specificity 
MAPK phosphatase PAC-1 (385). The role of PAC-1 in regulating Erk in WEHI- 
231 cells was investigated. Ligation of the BCR increased the expression of 
PAC-1 and enhanced the formation of PAC-1-Erk complexes (appendix 5). 
Furthermore, CD40 caused PAC-1 and Erk to dissociate. These observations 
strongly suggest that the BCR can inhibit Erk via the induction of PAC-1 
enabling Erk activity to be suppressed despite the presence of active MEK 
(figure 3.20B). However, PAC-1 is unlikely to be the only inhibitor of Erk in 
WEHI-231 cells since WEHI-231 cells were found to contain pY-Erk and pT-Erk 
in addition to the dual-phosphorylated and non-phosphorylated forms (figure 
3.9). This suggests that MAPK may also be regulated by threonine and tyrosine 
phosphatases.
The interaction of Erk with the tyrosine phosphatases SHP-1 and SHP-2 
was thus investigated. Interestingly both phosphatases were found in 
association with Erk (figure 3.10). However, the kinetics of the association of 
SHP-1 and Erk did not directly implicate SHP-1 as a regulator of Erk 
downstream of the BCR and CD40 and further experiments are required to 
explore the functional significance of this interaction. In contrast, the association 
of SHP-2 and Erk did seem to be regulated by the BCR and CD40 and the 
SHP-2-Erk complexes were most abundant at times of high Erk activity 
suggesting a role for SHP-2 as a positive regulator of Erk in WEHI-231 cells.
The mechanism of Erk activation in WEHI-231 cells was further 
investigated by transfection of cells with constitutively active forms of Ras. 
Expression of active Ras induced a general increase in Erk activity in WEHI-231 
cells (figure 3.11). However, constitutive activation of Ras did not lead to 
constitutive Erk activity, which is consistent with the activity of Erk being 
negatively regulated by MAPK phosphatases. Interestingly, mutagenesis of Ras 
to restrict its interaction with downstream effectors indicated Ras could 
stimulate Erk via the activation of Raf-1 and/or PI-3-K (figure 3.11C-D).
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Furthermore, expression of active Ras partially protected WEHI-231 cells from 
anti-lg-induced growth arrest and apoptosis and this was particularly evident in 
the RasV^^C'^  ^mutant which can only couple to PI-3-K (figure 3.12). Moreover, 
Ras was found to increase the expression of B c I-x l  in untreated and anti-lg- 
stimulated WEHI-231 cells (figure 3.14) and this was most effective when Ras 
was coupled to PI-3-K (figure 3.20B).
To confirm the importance of Ras and PI-3-K in promoting survival and 
proliferation of WEHI-231 cells, additional experiments were performed on cells 
expressing mutant forms of SHIP and Dok. Inhibition of SHIP supported the 
RasV^ ^C'^ ® data, which suggested PI-3-K has a role in regulating the survival 
and proliferation of WEHI-231 cells (figures 3.17-3.19). In particular, the 
induction of PI-3-K seems to be able to induce Bc I-xl in unstimulated and anti- 
lg-treated cells (figure 3.19D-F) although the mechanism of this has not been 
explored. Inhibition of Dok did not enhance Bc I-xl expression but it did implicate 
Dok as an inhibitor of Erk in untreated and anti-lg-stimulated WEHI-231 cells 
(figure 3.15). Dok is a known activator of RasGAP (244) but inhibition of Dok did 
not mimic constitutive activation of Ras suggesting the activity of Erk can be 
regulated by Ras-dependent and Ras-independent mechanisms in WEHI-231 
cells.
The differential regulation of Erk-MAPK in WEHI-231 cells is thus critical 
for the survival and proliferation of WEHI-231 cells. Early Erk signals can induce 
a pro-apoptotic pathway involving arachidonic acid production whilst sustained 
Erk signals are critical for proliferation of WEHI-231 cells (figure 3.20A). 
Inhibition of sustained and cyclic Erk activation is critical for BCR-driven growth 
arrest and this is not mediated by uncoupling Erk from its upstream activators 
but instead requires the induction of MAPK phosphatases. However, the 
regulation of Erk in WEHI-231 cells is a complex process and is influenced by 
non-classical effectors of Erk including P1-3-K (figure 3.20B).
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Figure 3.1. MAPKs are activated in response to a wide variety of stimuli via a 
conserved signalling network. MAP kinase proteins (Erk1/2, ErkS, JNK1-3 and 
p38) are activated via a conserved signalling cascade that is initiated by 
upstream signals that activate MKKKs (MAP kinase kinase kinases) leading to 
the stimulation of MKKs (MAP kinase kinases) which can then activate 
members of the MAPK family. MAP kinase proteins target both cytoplasmic and 
nuclear proteins including transcription factors.
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Figure 3.2. Regulation of Raf-1 activity. (1) In unstimulated cells, Raf-1 is 
inhibited by the binding of its amino terminal to its kinase domain and this is 
stabilised by phosphorylation of Ser^ ®® and Ser®^\ which interact with 14-3-3 
proteins. (2) Activation of Raf-1 requires it to translocate to the plasma 
membrane where it can associate with Ras-GTP. (3) PP2A dephosphorylates 
Ser^ ^® causing 14-3-3 proteins to be displaced and enhancing the association of 
Raf-1 to Ras-GTP and MEK. Raf-1 is also phosphorylated at Ser^ ^® and Tyr^ "^  ^
to assist the activation of Raf-1, perhaps by removing the N-terminai inhibitory 
region from the Raf-1 kinase domain. Phosphorylation of Ser^ ^® and also 
increases the association of Raf-1 and MEK. Raf-1 can activate MEK by 
phosphorylation. (4) The inactivation of Raf-1 is mediated by phosphorylation of 
Ser'^ ®, catalysed by protein kinase A, since this causes Raf-1 and Ras to 
dissociate. Akt can also catalyse the phosphorylation of Ser^ ®®, providing a 
docking site for 14-3-3 proteins.
147
Plasma membrane
F W
3 3 3 8
,Y341
Active Raf-1
PS43_____ ,8 2 5 9'
)S621
Inactive Raf-1 14-3-3
Figure 3.3. Inhibition of Erk-MAPK by protein phosphatases. MAPKs can be 
inactivated by the action of three different types of protein phosphatases: dual­
specificity phosphatases, threonine phosphatases and tyrosine phosphatases. 
Erk1/2 that lacks phosphorylation of the T-E-Y motif is inactive. Erk is stimulated 
by phosphorylation of the threonine and tyrosine residues of the T-E-Y motif. 
Three different types of protein phosphatases can inhibit Erk. Dual-specificity 
phosphatases remove the phosphate from both the threonine and tyrosine 
residues of T-E-Y generating inactive Erk. Threonine phosphatases only 
dephosphorylate the threonine residue and tyrosine phosphatases only 
dephosphorylate the threonine residue. Both phosphatases can generate 
partially active forms of Erk.
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Figure 3.4. Activation of SHP. SHP tyrosine phosphatases are retained in an 
inactive conformation by the binding of their N-terminal SH2 domain to 
phospho-tyrosine residues in the C-terminal region of the protein. Autoinhibition 
is relieved by the binding of the SH2 domains of SHP to phosphorylated 
peptides including ITlM-containing proteins. This induces a conformational 
change in SHP that results in its activation.
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Figure 3.6. Ligation of the BCR on WEHI-231 cells induces growth arrest. (A) 
WEHI-231 cells (1 x10* cells/well) were cultured in the presence of increasing 
concentrations of anti-ig (0-10 pg/ml). Proliferation was assessed by measuring 
the incorporation of [^H] thymidine at 48 hr. Values are the mean counts per 
minute (cpm) ± standard deviation of triplicate wells. Data are representative of 
at least twelve independent experiments. (B) WEHI-231 cells (1x10* cells/well) 
were cultured in the presence of media (untreated), anti-ig (10 pg/ml), anti- 
CD40 (10 pg/ml) or a combination of anti-lg plus anti-CD40 (both at 10 pg/ml). 
Proliferation was assessed by measuring the incorporation of [^H] thymidine at 
48 hr. Values are the mean counts per minute (cpm) ± standard deviation of 
triplicate wells. Data are representative of at least twelve independent 
experiments.
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Figure 3.6. Ligation of the BCR on WEHI-231 cells induces apoptosis. WEHI- 
231 cells (5x10® cells/ml) were cultured for 24 hr with medium (untreated) (A), 
anti-lg (10 pg/ml) (B), a combination of anti-lg plus anti-CD40 (both at 10 pg/ml)
(C) or anti-CD40 alone (10 pg/ml) (D). Levels of apoptosis were indicated by 
measuring the number of cells with sub-diploid DMA and this was determined by 
Pl-staining and FACS analysis (FL3 fluorescence). Data are representative of at 
least ten independent experiments. WEHI-231 cells (5 x 10® cells/ml) were 
cultured for 48 hr with medium (untreated) (E), anti-lg (10 pg/ml) (F), a 
combination of anti-lg plus anti-CD40 (both at 10 pg/ml) (G) or anti-CD40 alone 
(10 pg/ml) (H). Levels of apoptosis were indicated by measuring the number of 
cells with sub-diploid DNA and this was determined by Pl-staining and FACS 
analysis (FL3 fluorescence). Data are representative of at least ten independent 
experiments.
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Figure 3.7. BCR-mediated downregulation of Erk activity does not Involve a 
dissociation of MEK1/2 from Erk1/2. WEHI-231 cells (1 x 10® cells/ml) were 
cultured for up to 48 hr with (A) medium (untreated), (B) anti-lg (10 pg/ml), (C) 
anti-CD40 (10 pg/ml) or (D) a combination of anti-lg plus anti-CD40 (both at 10 
pg/ml) before preparing cell lysates. Erk1/2-containing immune complexes were 
prepared from 100 pg lysate and were analysed by Western blotting, using the 
NuPAGE system of gel electrophoresis, with anti-MEK1/2 antibody. Erk1/2 
levels in the immune complexes were determined by dot blot analysis with 
Western blotting using the same anti-Erk1/2 antibody as was used to prepare 
the immune complexes. Ligation of the BCR does not decrease the levels of 
phospho-MEK1/2 in WEHI-231 cells. WEHI-231 cells (1 x 10® cells/ml) were 
cultured for up to 48 hr with (E) medium (untreated), (F) anti-lg (10 pg/ml), (G) 
anti-CD40 (10 pg/ml) or (H) a combination of anti-lg plus anti-CD40 (both at 10 
pg/ml) before preparing cell lysates. Whole cell lysates (50 pg/lane) were run on 
10% Tris-HCL gels using the BioRad system of gel electrophoresis. Levels of 
phospho-MEK (pMEK1/2) and total Erk (Erk1/2) were determined by Western 
blotting using phospho-MEK1/2 (pS^^ /^pS^^^) and Erk1/2-MAPK antibodies, 
respectively.
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Figure 3.8. BCR-mediated downregulation of Erk activity does not reflect 
suppression of MEK activation. WEHI-231 cells (1 x 10® cells/ml) were cultured 
for up to 48 hr with either medium (untreated) (A) or 10 pg/ml anti-ig (B) before 
preparing cell lysates. MEK-containing immune complexes were prepared from 
100 pg lysate and in vitro MEK kinase assays were conducted using 
recombinant Erk-GST fusion protein as substrate and Western blotting using 
the BioRad electrophoresis system. A positive control for this assay is illustrated 
in lane +ve and reflected an in vitro kinase assay using recombinant human 
activated MEK1 (0.5 U) and the Erk-GST substrate. In addition, MEK kinase 
activity was supported by analysis of MEK activation by Western blotting using 
anti-phospho-MEK1/2 (pMEK1/2) antibodies that recognise the active form of 
MEK. Loading control for Erk-GST and MEK are also shown. Data are 
representative of at least two independent experiments.
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Figure 3.9. Erk is differentially phosphorylated at the T-E-Y motif of the 
activation loop. WEHI-231 cells (1 x 10® cells/ml) were stimulated with medium 
(untreated) (A) or 10 pg/ml anti-lg (B) for up to 48 hr and whole cell lysates 
were prepared. Differential phosphorylation of the regulatory Thr and Tyr 
residues of Erk was determined by Western blotting of whole cell lysates (100 
pg protein/lane), using 10% Bis-Tris gels on the NuPAGE electrophoresis 
system (Invitrogen) with recombinant non-phosphorytated Erk2 (w) and 
recombinant dual-phosphorylated Erk2 (p) control proteins. Phosphorylation- 
sensitive antibodies for Erk-MAP kinase were used in Western blotting. Single 
phosphorylated forms of Erk were detected using anti-phospho-Tyr^®'^-p44/p42 
MAPK (pY-Erk) and anti-phospho-Thr^®®-p44/p42 MAPK (pT-Erk) antibodies. 
The anti-phospho-Thr^antibody detected some dual-phosphorylated Erk, as 
indicated by its ability to detect control protein p. Anti-phospho-p44/p42 MAPK 
(Thr202/Tyr204) (pjpy-Erk) and p44/p42 MAPK (Erk) antibodies were used to 
detect dual phosphorylated and total Erk levels, respectively.
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Figure 3.10. SHP-1 and SHP-2 interact with Erk1/2 in WEHI-231 cells. WEHI- 
231 cells (1 X 10® cells/ml) were cultured for up to 48 hr with medium 
(untreated) (A), anti-lg (10 pg/ml) (B), anti-lg plus anti-CD40 (both at 10 pg/ml) 
(C) or anti-CD40 (10 pg/ml) (D) before preparing cell lysates. Erk1/2-containlng 
immune complexes were prepared from 100 pg lysate and were analysed by 
Western blotting, using the NuPAGE system of gel electrophoresis, with anti- 
SHP-1 antibody. Erk1/2 levels in the immune complexes were determined by 
dot blot analysis with Western blotting using the same anti-Erk1/2 antibody as 
was used to prepare the immune complexes. WEHI-231 cells (1 x 10® cells/ml) 
were cultured for up to 48 hr with medium (untreated) (E), anti-lg (10 pg/ml) (F), 
anti-lg plus anti-CD40 (both at 10 pg/ml) (G) oranti-CD40 (10 pg/ml) (H) before 
preparing cell lysates. Erk1/2-containing immune complexes were prepared 
from 100 pg lysate and were analysed by Western blotting, using the NuPAGE 
system of gel electrophoresis, with anti-SHP-2 antibody. Erk1/2 levels in the 
immune complexes were determined by dot blot analysis with Western blotting 
using the same anti-Erk1/2 antibody as was used to prepare the immune 
complexes.
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Figure 3.11. Ras can stimulate Erk via Raf or P1-3-K in WEHI-231 cells. WEHI- 
231 cells (1 X 10® cells/ml) transfected with empty pcDNA3.1 vector (A), 
RasV^^-containing vector (B), RasV^^S®®-containing vector (C), RasV^^C^®- 
containing vector (D) or AMEKKS-containing vector (E) were cultured for up to 
24 hr with medium (untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 
pg/ml) or anti-lg plus anti-CD40 (a-lg + a-CD40, both at 10 pg/ml) before 
preparing cell lysates. Whole cell lysates (50 pg/lane) were analysed by 
Western blotting, using the NuPAGE system of gel electrophoresis. Levels of 
dual-phosphorylated Erk (pErk) and total Erk (Erk) were determined by Western 
blotting. All pErk Western blots were developed on the same piece of film and 
all Erk Western blots were developed on a single piece of film. The pErk signal 
was relatively weak in pcDNA3.1 cells therefore a longer exposure to 
photographic film has also been shown (upper pErk panel in figure 3.11 A). Data 
are representative of at least two independent experiments.
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Figure 3.12. Constitutive activation of Ras partially protects WEHI-231 cells 
from BCR-driven growth arrest and apoptosis. WEHI-231 cells (1 x 10"^  
cells/well) transfected with empty pcDNA3.1 vector, RasV^^-containing vector, 
RasV^^S®®-containing vector, RasV^^C'^®-containing vector or AM EKK3- 
containing vector were cultured in the presence of increasing concentrations of 
anti-lg (0-10 pg/ml). Proliferation was assessed by measuring the incorporation 
of [®H] thymidine at 24 hr (A), 48 hr (B) or 72 hr (C). Values are the mean % 
control (pcDNA3.1 WEHI-231 cells without anti-lg) thymidine uptake ± sem, n=4 
individual experiments, each performed in triplicate. (D) WEHI-231 cells (1 x 10  ^
cells/well) transfected with empty pcDNA3.1 vector, Ras^-containing vector, 
RasV^^S®®-containing vector, RasV^^C^®-containing vector or AMEKKS- 
containing vector were cultured in the presence of media (untreated), anti-lg (a- 
Ig, 10 pg/ml), or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, both at 
10 pg/ml). Proliferation was assessed by measuring the incorporation of [®H] 
thymidine at 48 hr. Values are the mean % control (pcDNA3.1 WEHI-231 cells 
without anti-lg or anti-CD40) thymidine uptake ± sem, n=4 individual 
experiments, each performed in triplicate. (E) WEHI-231 cells (5x10® cells/ml) 
transfected with empty pcDNAS.I vector, RasV^^-containing vector, RasV^ ^S®®- 
containing vector, RasV^^C^®-containing vector or AMEKKS-containing vector 
were cultured for 48 hr with medium (untreated), anti-lg (a-lg, 10 pg/ml), anti- 
CD40 (a-CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a- 
CD40, both at 10 pg/ml). Levels of apoptosis were indicated by the % sub­
diploid cells and this was determined by Pl-staining and FACS analysis (FL2 
fluorescence).
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Figure 3.13. Ras-dependent activation of PI-3-K does not stimulate Akt. WEHI- 
231 cells (1 X 10® cells/ml) transfected with empty pcDNAS.I vector (A), 
Ras^-containing vector (B), RasV^^S®®-containing vector (C), RasV^^C^°- 
containing vector (D) or AMEKKS-containing vector (E) were cultured for up to 
48 hr with medium (untreated), anti-ig (a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 
pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, both at 10 
pg/ml) before preparing cell lysates. Whole cell lysates (50 pg/lane) were 
analysed by Western blotting, using the NuPAGE system of gel electrophoresis. 
Gel loading was as follows: lane 1 1 hr, lane 2 8 hr, lane 3 24 hr, lane 4 48 hr, 
lane 5 non-phosphorylated Akt control (total cell extracts from Jurkat cells 
treated with PI-3-K inhibitor LY294002), lane 6 phosphorylated Akt control (total 
cell extracts prepared from untreated Jurkat cells). Levels of phospho-Thr®°® Akt 
(pTAkt), phospho-Ser^^® Akt (pSAkt) and total Akt (Akt) were determined by 
Western blotting. Data are representative of at least two independent 
experiments.
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Figure 3 .1 4 .  Ras can induce B c I-Xl in WEHI-231 cells especially via the 
activation of PI-3-K. WEHI-231 cells (1 x 10® cells/ml) transfected with empty 
pcDNAS.I vector (A), RasV^^-containing vector (B), RasV^^S^®-containing 
vector (C), RasV^^C'^^-containing vector (D) or AMEKK3-containing vector (E) 
were cultured for up to 48 hr with medium (untreated), anti-lg (a-lg, 10 pg/mi), 
anti-CD40 (a-CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + 
a-CD40, both at 10 pg/ml) before preparing cell lysates. Whole cell lysates (50 
pg/lane) were analysed by Western blotting, using the NuPAGE system of gel 
electrophoresis. Levels of B c I-x l  and total Erk (Erk) were determined by 
Western blotting. Total Erk was detected to check the gel loading. Data are 
representative of at least two independent experiments.
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Figure 3.15. inhibition of Dok can increase the activity of Erk but does not 
stimulate Akt or Bc I-xl in BCR-stimulated WEHI-231 cells. WEHI-231 cells (1 x 
10® cells/ml) transfected with empty pMXI-egfp vector (A) or Dok-PH/PTB- 
containing vector (B) were cultured for up to 48 hr with medium (untreated), 
anti-lg (10 pg/ml), anti-CD40 (10 pg/ml) or a combination of anti-lg plus anti- 
CD40 (both at 10 pg/ml) before preparing cell lysates. Whole cell lysates (50 
pg/lane) were analysed by Western blotting, using the NuPAGE system of gel 
electrophoresis. Levels of dual-phosphorylated Erk (pErk) and total Erk (Erk) 
were determined by Western blotting. WEHI-231 cells (1 x 10® cells/ml) 
transfected with empty pMXI-egfp vector (0) or Dok-PH/PTB-containing vector
(D) were cultured for up to 48 hr with medium (untreated), anti-lg (10 pg/ml), 
anti-CD40 (10 pg/ml) or a combination of anti-lg plus anti-CD40 (both at 10 
pg/ml) before preparing cell lysates. Whole cell lysates (50 pg/lane) were 
analysed by Western blotting, using the NuPAGE system of gel electrophoresis. 
Gel loading was as follows: lane 1 1 hr, lane 2 8 hr, lane 3 24 hr, lane 4 48 hr, 
lane 5 phosphorylated Akt control (total cell extracts from untreated Jurkat 
cells), lane 6 non-phosphorylated Akt control (total cell extracts from Jurkat cells 
treated with P1-3-K inhibitor LY294002). Levels of phospho-Thr®®® Akt (pTAkt), 
phospho-Ser"^^® Akt (pSAkt) and total Akt (Akt) were determined by Western 
blotting. WEHI-231 cells (1 x 10® cells/ml) transfected with empty pMXl-egfp 
vector (E) or Dok-PH/PTB-containing vector (F) were cultured for up to 48 hr 
with medium (untreated), anti-lg (10 pg/ml), anti-CD40 (10 pg/ml) or a 
combination of anti-lg plus anti-CD40 (both at 10 pg/ml) before preparing cell 
lysates. Whole cell lysates (50 pg/lane) were analysed by Western blotting, 
using the NuPAGE system of gel electrophoresis. Levels of Bc I-x l  and total Erk 
(Erk) were determined by Western blotting. Total Erk was detected to check the 
gel loading. Data are representative of at least two independent experiments.
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Figure 3.16. Inhibition of Dok does not substantially protect WEHI-231 cells 
from BCR-driven growth arrest and apoptosis. WEHI-231 cells (5x10® cells/ml) 
transfected with empty pMXI-egfp vector or Dok-PH/PTB-containing vector were 
cultured for 24 hr (A) or 48 hr (B) with medium (untreated), anti-lg (10 pg/ml), 
anti-CD40 (10 pg/ml) or a combination of anti-lg plus anti-GD40 (both at 10 
pg/ml). Levels of apoptosis were indicated by the % sub-diploid cells and this 
was determined by Pl-staining and FAGS analysis (FL2 fluorescence). WEHI- 
231 cells (1 X 10  ^cells/well) transfected with empty pMXI-egfp vector or Dok- 
PH/PTB-containing vector were cultured in the presence of increasing 
concentrations of anti-lg (0-10 pg/ml). Proliferation was assessed by measuring 
the incorporation of [®H] thymidine at 24 hr (0), 48 hr (D) or 72 hr (E). Values 
are the mean % control (pMXI-egfp WEHI-231 cells without anti-lg) thymidine 
uptake ± sem, n=4 individual experiments, each performed in triplicate. (F) 
WEHI-231 cells (1 x 10"^  cells/well) transfected with empty pMXI-egfp vector or 
Dok-PH/PTB-containing vector were cultured in the presence of media 
(untreated), anti-lg (10 pg/ml), or a combination of anti-lg plus anti-GD40 (both 
at 10 pg/ml). Proliferation was assessed by measuring the incorporation of [®H] 
thymidine at 48 hr. Values are the mean % control (pMXI-egfp WEHI-231 cells 
without anti-lg or anti-GD40) thymidine uptake ± sem, n=4 individual 
experiments, each performed in triplicate.
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Figure 3.17. inhibition of SHIP increases Erk activation but cannot induce 
constitutive Erk signalling. WEHI-231 cells (1x10® cells/ml) transfected with 
empty pMXI-egfp vector (A), SHIP-CI-containing vector (B) or SHIP-SH2- 
containing vector (C) were cultured for up to 48 hr with medium (untreated), 
anti-lg (10 pg/ml), anti-CD40 (10 pg/ml) or anti-lg plus anti-CD40 (both at 10 
pg/ml) before preparing cell lysates. Whole cell lysates (50 pg/lane) were 
analysed by Western blotting, using the NuPAGE system of gel electrophoresis. 
Levels of dual-phosphorylated Erk (pErk) and total Erk (Erk) were determined 
by Western blotting. Data are representative of at least two independent 
experiments.
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Figure 3.18. Expression of SHIP partially protects WEHI-231 cells from BCR- 
driven growth arrest and apoptosis. WEHI-231 cells (1 x 10  ^ cells/well) 
transfected with empty pMXI-egfp vector, SHIP-CI-containing vector or SHIP- 
SH2-containing vector were cultured in the presence of increasing 
concentrations of anti-lg (0-10 pg/ml). Proliferation was assessed by measuring 
the incorporation of [®H] thymidine at 24 hr (A), 48 hr (B) or 72 hr (C). Values 
are the mean % control (pMXI-egfp WEHI-231 cells without anti-lg) thymidine 
uptake ± sem, n=4 individual experiments, each performed in triplicate. (D) 
WEHI-231 cells (1x10"^ cells/well) transfected with empty pMXI-egfp vector, 
SHIP-CI-containing vector or SHIP-SH2-containing vector were cultured in the 
presence of media (untreated), anti-lg (10 pg/ml), or a combination of anti-lg 
plus anti-CD40 (both at 10 pg/ml). Proliferation was assessed by measuring the 
incorporation of [®H] thymidine at 48 hr. Values are the mean % control (pMXI- 
egfp WEHI-231 cells without anti-lg or anti-CD40) thymidine uptake ± sem, n=4 
individual experiments, each performed in triplicate. WEHI-231 cells (5x10® 
cells/ml) transfected with empty pMXI-egfp vector, SHIP-CI-containing vector or 
SHIP-SH2-containing vector were cultured for 24 hr (E) or 48 hr (F) with 
medium (untreated), anti-lg (10 pg/ml), anti-CD40 (10 pg/ml) or a combination 
of anti-lg plus anti-CD40 (both at 10 pg/ml). Levels of apoptosis were indicated 
by the % sub-diploid cells and this was determined by Pl-staining and FACS 
analysis (FL2 fluorescence).
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Figure 3.19. Inhibition of SHIP does not activate Akt but can induce B c I-x l . 
WEHI-231 cells (1 x 10® ceils/ml) transfected with empty pMXI-egfp vector (A), 
SHIP-CI-containing vector (B) or SHIP-SH2-containing vector (0) were cultured 
for up to 48 hr with medium (untreated), anti-lg (10 pg/ml), anti-CD40 (10 pg/ml) 
or a combination of anti-lg plus anti-CD40 (both at 10 pg/ml) before preparing 
cell lysates. Whole cell lysates (50 pg/lane) were analysed by Western blotting, 
using the NuPAGE system of gel electrophoresis. Gel loading was as follows: 
lane 1 1 hr, lane 2 8 hr, lane 3 24 hr, lane 4 48 hr, lane 5 phosphorylated Akt 
control (total cell extracts from untreated Jurkat cells), lane 6 non- 
phosphorylated Akt control (total cell extracts from Jurkat cells treated with PI-3- 
K inhibitor LY294002). Levels of phospho-Thr^°® Akt (pTAkt), phospho-Ser"^^® 
Akt (pSAkt) and total Akt (Akt) were determined by Western blotting. Data are 
representative of at least two independent experiments. WEHI-231 cells (1 x 
10® cells/ml) transfected with empty pMXI-egfp vector (D), SHIP-CI-containing 
vector (E) or SHIP-SH2-containing vector (F) were cultured for up to 48 hr with 
medium (untreated), anti-lg (10 pg/ml), anti-CD40 (10 pg/ml) or a combination 
of anti-lg plus anti-CD40 (both at 10 pg/ml) before preparing cell lysates. Whole 
cell lysates (50 pg/lane) were analysed by Western blotting, using the NuPAGE 
system of gel electrophoresis. Levels of B c I-xl  and total Erk (Erk) were 
determined by Western blotting. Total Erk was detected to check the gel 
loading. Data are representative of at least two independent experiments.
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Figure 3.20. Models of differential regulation of Erk by the BCR and CD40. (A) 
Ligation of the BCR induces early (^4 hr) Erk signals that lead to the production 
of arachidonic acid and induction of apoptosis. WEHI-231 cells also undergo 
sustained and cyclic activation of Erk that is inhibited by the BCR but can be 
restored by co-ligation of CD40. These sustained Erk signals are necessary for 
proliferation of the cells. (B) The regulation of sustained Erk signals is a 
complex process. Ras can activate sustained Erk via Raf-1 or P1-3-K. The BCR 
does not inhibit sustained Erk signals by suppressing upstream regulators of 
Erk but instead induces PAC-1 and other MARK phosphatases. PI-3-K might 
induce Erk directly or may prevent the induction of MAPK phosphatases. PI-3-K 
is also important for inducing B c I-x l  to impair the BCR-driven apoptotic 
pathway. Additional molecules are likely to regulate the activity of Erk including 
Dok, which may be activated by the BCR to suppress Erk and SHP-2, which 
might enhance Erk activation.
165
(A)
BC
CD40
Arachidonic acid 
production Apoptosis I
ustain
Erk1
Proliferation
Apoptosis &
CD40
SHP-2
ustain
^  VErk1/2
PAC-1 + other 
phosphatases
Proliferation
CHAPTER 4  - Role of B c I-Xl in CD40’-mecliated rescue from BCR-driven 
growth arrest and apoptosis 
4.1 Regulation of apoptosis in immature B cells
Apoptosis plays a key role in the removal of self-reactive clones of newly 
developed B lymphocytes. WEHI-231 cells are widely used as a model of clonal 
deletion of immature B cells since ligation of the BCR induces growth arrest and 
apoptosis whilst cells can be rescued by T cell-dependent factors such as co­
ligation of CD40 (108, 292, 305). However, the precise mechanisms of BCR- 
driven clonal deletion and CD40-mediated rescue are incompletely understood.
Recently (102) it has been shown that ligation of the BCR on immature B 
cells leads to the activation of mitochondrial PLA2 and subsequent arachidonic 
acid-mediated disruption of mitochondrial membrane potential and function. 
This causes the cellular levels of ATP to be depleted and apoptosis to be 
induced. Moreover, WEHI-231 cells can be protected from BCR-driven 
apoptosis using stabilisers of the mitochondrial membrane potential or by 
CD40-mediated signalling (102).
It has also been shown that post-mitochondrial execution of such BCR- 
driven apoptosis is not dependent on caspase activation since BCR-driven 
disruption of the mitochondria does not cause cytochrome c to be released into 
the cytoplasm and effector caspases do not appear to be activated. 
Furthermore, BCR-driven loss of mitochondria! membrane potential and 
commitment to apoptosis can proceed in the presence of caspase inhibitors. In 
contrast, cathepsin B is stimulated by ligation of the BCR and inhibition of 
cathepsin B using EST prevents post-mitochondrial induction of apoptosis in 
WEHI-231 cells (102). Figure 1.22 summarises this pathway of BCR-driven 
apoptosis also see section 1.10.1 for further details.
4.2 Regulation of proliferation in immature B cells
As discussed in chapter 3, BCR-driven apoptosis of WEHI-231 cells 
requires the activation of early Erk signals that probably function to stimulate 
CPLA2 . In contrast, sustained and cyclic activation of Erk is observed in 
proliferating WEHI-231 cells. Ligation of the BCR suppresses sustained Erk
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signals leading to the induction of growth arrest whilst co-ligation of CD40 
restores these Erk signals and enables the cells to proliferate (328). Sustained 
and cyclic activation of Erk is thus necessary for proliferation of WEHI-231 B 
cells but precisely how these signals enable proliferation is incompletely 
understood.
As discussed in section 1.10.2, the BCR and CD40 can differentially 
regulate several proteins involved in controlling cell cycle progression. For 
example, in BCR-stimulated immature B cells Cdk4/cyclin D2  is induced, 
allowing the cells to progress through the early stages of G1 phase but these 
cells cannot induce Cdk2/cyclin E and hence are unable to progress through the 
G1 to S phase transition (33). Furthermore, ligation of the BCR on WEHI-231 
cells increases the levels of p21 and p27 inhibitors of Cdk proteins and of p53, 
leading to growth arrest and promoting apoptosis. Moreover, Rb is 
hypophosphorylated in BCR-activated WEHI-231 cells, leading to the formation 
of Rb-E2F complexes and hence an inhibition of E2F. This causes cyclin A to 
be downregulated to further prevent S phase entry. However, co-ligation of 
CD40 results in the phosphorylation and inhibition of Rb and rescues the cells 
from BCR-driven growth arrest (53, 56, 58).
4.3 CD40-mediated rescue
CD40 can prevent BCR-driven growth arrest and apoptosis of immature B 
cells (102, 328). Although the mechanism of CD40-mediated rescue of BCR- 
stimulated WEHI-231 cells is incompletely understood, CD40-dependent 
survival Is likely to involve the induction of pro-survival Bcl- 2  family members 
(see sections 1.4.1 and 1.10.1.1). For example, CD40 induces an upregulation 
of B c I-xl  without enhancing the expression of Bcl-2 or Bax (290, 292, 293) and 
overexpression of B c 1-x l  in WEHI-231 cells protects the cells from BCR-driven 
apoptosis (292, 311). The upregulation of Bc I-x l  can thus protect immature B 
cells from BCR-driven apoptosis. Furthermore, the region of CD40 that is 
required for the induction of Bc I-xl  is also necessary for the prevention of BCR- 
driven apoptosis (312).
However, additional anti-apoptotic Bcl-2 family members, especially A1 
and Mcl-1, may also contribute to the survival of immature 8  cells (302). For 
example, stimulation of WEHI-231 cells at CD40 can upregulate the expression
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of the a1 gene and overexpression of A1 can partially protect the cells from 
BCR-driven apoptosis (304). However, A1 seems to protect the immature B 
cells by suppressing the activation of caspase 7 to impair BCR-dependent DNA 
laddering (317). A1 therefore may not prevent cPLA2-mediated apoptosis in 
BCR-stimulated immature B cells.
4.4 Phosphofipase Az
The hydrolysis of membrane phospholipids is an important source of lipid 
second messengers. The phospholipase Az (PLAz) family of enzymes hydrolyse 
phospholipids to generate free fatty acid. There are three types of PLAz 
enzymes: secretory PLAz, calcium-independent PLAg and cytosolic PLAg 
(cPLAg). Secretory PLAg is a 14 kD, ubiquitously expressed and calcium- 
dependent enzyme that can release several fatty acids including sn - 2  
arachidonic acid (429, 430). Calcium-independent PLAg also has broad 
substrate specificity but it does not require calcium for its activation, it exists as 
26 kD and 8 6  kD forms. Cytosolic PLAg is an 85 kD enzyme that does not share 
any homology to secreted or calcium-independent PLAg enzymes and it 
preferentially hydrolyses sn- 2  arachidonic acid from membrane phospholipids 
(429). Arachidonic acid is an important second messenger and is a precursor of 
eicosanoids.
The activation of cPLAg requires both calcium and Erk-MAPK-mediated 
phosphorylation. Calcium binds to the N-terminal region of cPLAg, enabling it to 
translocate from the cytosol to the plasma membrane and other intracellular 
membranes (289). This brings cPLAg into close proximity to its lipid substrates 
but this alone is insufficient to promote prolonged activation of cPLAg and 
arachidonic acid production. Sustained activation of cPLAg requires Erk-MAPK- 
mediated phosphorylation of Ser®°®. Indeed, phosphorylation of Ser®®® and 
calcium binding synergistically mediate the activation of cPLAg (222, 289).
Additional mechanisms of regulation of cPLAg may also exist since protein 
kinase A (PKA) and PKC can also phosphorylate cPLAg in vitro although the 
functional significance of this is not fully understood. Furthermore, in the long 
term, cPLAg can be regulated at the transcriptional level. For example, 
glucocorticoids can suppress the transcription of cPLAg whilst in epithelial cells 
IFNy can increase the expression of cPLAg (431).
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Cytosolic PLAg had been proposed to be a ubiquitously expressed enzyme 
but it is not found in mature B and T cells and its expression cannot be induced 
following culture with a variety of different cytokines. In contrast, immature B 
cells and thymocytes do express cPLAg and it is activated under conditions that 
lead to clonal deletion (see section 4.1) (102, 218, 222, 288). Furthermore, IL-4 
and CD40 can rescue immature B cells from BCR-driven apoptosis by reducing 
the activity of cPLAg (102, 288).
In addition to its pro-apoptotic functions, arachidonic acid is also a 
substrate for cyclooxygenase and lipoxygenase enzymes leading to the 
production of prostaglandins and leukotrienes, respectively. Prostaglandins and 
leukotrienes are eicosanoids and are important mediators of inflammation.
4.5 Cyclooxygenase
Cyclooxygenase (Cox) enzymes catalyse the rate-limiting step in the 
formation of prostaglandins and thromboxanes, collectively known as 
prostanoids, from arachidonic acid. Two isoforms of Cox have been 
characterised: Coxi is constitutively expressed and is responsible for basal and 
constitutive prostanoid synthesis; Cox2 is an inducible enzyme that is encoded 
by an immediate early gene that is expressed in response to cytokines, 
mitogens and endotoxins (432, 433). The promoter of the Cox2 gene has 
binding sites for AP-1, NF-kB and cAMP response element binding protein 
(CREB) therefore the transcription of Cox2 can be regulated by several 
members of the MAPK family. For example, arachidonic acid production is 
stimulated in U937 cells treated with platelet microparticles leading to the 
activation of PI-3-K. PI-3-K then induces p38 and JNK MAPKs and PKC- 
dependent stimulation of Erk-MAPK. The activation of MAPKs leads to the 
induction of c-Jun and Elk-1 and the expression of Cox2 is increased resulting 
in the production of eicosanoids (434).
The initial stage of prostanoid generation involves the conversion of 
arachidonic acid to the common intermediate prostaglandin Hg (PGHg) and this 
is catalysed by PGH synthase. PGH synthase has peroxidase and Cox activity 
therefore prostanoid production is limited by the synthesis of PGHg (432, 433). 
PGHg is converted to prostanoids (prostaglandin Eg, prostaglandin Dg, 
prostaglandin Fg^ , 6 -keto prostaglandin Fi,^  and thromboxane Bg) by terminal
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prostanoid synthase enzymes (figure 4.1) (435). For example, PGE synthase is 
a terminal prostanoid synthase that catalyses the synthesis of prostaglandin Eg 
(PGEg) from PGHg. The differential expression of terminal prostanoid synthase 
enzymes determines the profile of prostanoid production in any particular cell 
and some terminal prostanoid synthase enzymes are inducible therefore 
extracellular ligands can determine which prostanoids are synthesised within a 
cell (433).
Prostanoids generally regulate cellular function by binding to specific G- 
protein-coupled receptors and the expression of these receptors depends on 
the cell type and the developmental stage of the cell. The different receptors for 
prostanoids are coupled to different G-proteins therefore prostanoids can 
mediate a broad range of effects. For example, the main prostanoid receptors 
expressed in B lymphocytes are EP1-4. These receptors all recognise PGEg but 
EP1 and one isoform of EP3 are coupled to Gi whilst EP2, the other isoform of 
EP3 and EP4 are coupled to Gs (433) therefore PGEg can mediate several 
functions in B cells. Indeed, in B lymphocytes PGEg has been associated with 
inducing growth arrest, especially at early stages of B cell development (436, 
437). However, more recent evidence suggests exogenous PGEg can also 
function in synergy with various co-receptors including CD40, IL-4 and IL-10 to 
promote proliferation of B cells (438).
Prostanoids are mediators of inflammation, can regulate vascular function 
and have been associated with promoting cancer (433, 435, 439, 440). For 
example, in IL-4 and lipopolysaccharide-stimulated murine splenic B cells, 
PGEg promotes an inflammatory response by enhancing the production of IgE 
and lgGi whilst decreasing the synthesis of IgM and IgGs (441). Furthermore, 
overexpression of Cox2  in epidermal cells can elevate the levels of several 
prostaglandins including PGEg, rendering the cells hypersensitive to the 
development of cancer upon exposure to carcinogens (439).
Indeed, Cox2 has been associated with promoting cell survival in several 
systems. For example, overexpression of Cox2 can protect human lung 
adenocarcinoma cells from apoptosis induced by anti-cancer drugs and UV 
radiation. It does so by increasing PGEg production, leading to the activation of 
PI-3-K and Akt, which then promote cellular survival (442). Cox2 can also 
suppress p53-mediated apoptosis possibly via increasing the expression of the
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pro-survival protein B c I-xl  (59). Furthermore, overexpression of Cox2 in 
epithelial cells leads to the production of PGEg and subsequent upregulation of 
Bcl-2 and stimulation of Erk-MAPK thus promoting cell survival and potentially 
inducing proliferation (443).
The action of Cox and the production of PGEg have thus been associated 
with several diseases including cancer, inflammation and heart disease. 
Manipulation of prostaglandin synthesis therefore has therapeutic potential for 
treating these disease states (440). For example, nonsteroidal anti-inflammatory 
drugs prevent prostaglandin biosynthesis by inhibiting Cox resulting in a 
suppression of inflammation and reduced risk of certain types of cancer (439, 
444).
4.6 Lipoxygenase
Lipoxygenase (Lox) enzymes catalyse the oxidation of arachidonic acid to 
generate leukotrienes and other metabolites and these are important mediators 
of inflammation. At least three families of Lox enzymes have been 
characterised: 5-Lox, 12-Lox and 15-Lox. Each family of Lox enzymes oxidises 
arachidonic acid at a different position and so produces different metabolites of 
arachidonic add (445).
5-Lox catalyses the initial stages in the production of leukotrienes and 
lipoxins, which are important inflammatory mediators. The activity of 5-Lox is 
enhanced by several protein kinases including Ca^Vcalmodulin kinase II, 
rendering the activity of 5-Lox sensitive to calcium, and PKA. However, 5-Lox 
can also be stimulated independently of calcium using unsaturated fatty acids 
including arachidonic acid. For example, arachidonic acid increases the ability 
of MK2 , a p38 MAPK-activated protein kinase, to phosphorylate and stimulate 
5-Lox (446). The activity of 5-Lox is also sensitive to the cellular redox status. 
For example, in B lymphocytes reactive oxygen species can stimulate 5-Lox by 
producing hydrogen peroxide and hydroperoxides. Once activated, 5-Lox can 
generate leukotriene B4 and this can stimulate B cell activation, proliferation and 
differentiation (447). Furthermore, in acute pre-B lymphocytic leukemia, 
peripheral B lymphoblasts often have elevated expression of 5-Lox implicating 
the action of this enzyme in promoting cell survival and proliferation (448).
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The action of 15-Lox enzymes can also regulate cell survival by 
determining the activity of Erk-MAPK and Akt. For example, in prostate cancer 
cells expression of 15-Lox-1 is often high whilst 15-Lox-2 is downregulated. 15- 
Lox- 1  catalyses the release of 13-(S)-hydroxyoctadecadienoic acid leading to 
the activation of Erk and Akt. In contrast, 15-Lox~2 catalyses the release of 15- 
(S)-hydroxyeicosatetraenoic acid, which inhibits Erk1/2 and Akt (449). Different 
members of the 15-Lox family therefore have distinct functions. Furthermore, 
the action of 12-Lox has also been associated with promoting cancer. 
Cancerous cells that produce high levels of 12(S)-hydroxy-5, 8 , 10, 14- 
eicosatetraenoic acid are prone to metastasis perhaps due to the ability of this 
metabolite to stimulate PKC resulting in the release of cathepsin B from 
malignant cells (445).
4.7 Aims and objectives
CD4G signalling can prevent BCR-driven induction of cPLAg, arachidonic 
acid production, loss of mitochondrial function and ultimately apoptosis of 
WEHI-231 cells (102, 328). Ligation of CD40 on immature B cells induces B c I-Xl 
and overexpression of Bc I-xl  in WEHI-231 cells can protect them from BCR- 
driven apoptosis (290, 292, 293, 311). The aim of this investigation was to 
further examine the role of Bc I-x l  in CD40-mediated rescue of WEHI-231 cells 
from BCR-driven mitochondrial death pathway.
The specific objectives of this investigation were;
1. to determine the effect of expression of B c I-Xl on the survival and 
proliferation of BCR-stimulated WEHI-231 cells
2. to investigate the mechanisms of Bcl-xt-dependent regulation of survival 
and proliferation of WEHI-231 cells and in particular, to analyse the effect of 
Bc I-xl  on the cPLAg-mediated death pathway
3. to explore the function of arachidonic acid and its metabolites in 
regulating immature B cell survival and proliferation
4. to examine the signalling mechanisms used by metabolites of 
arachidonic acid to regulate the survival and proliferation of WEHI-231 cells.
172
4.8 Results and Discussion
4.8.1 B c I-xl  is upregulated downstream of CD40 in WEHI-231 cells
Ligation of the BCR on WEHI-231 immature B cells leads to growth arrest 
and apoptosis that can be rescued by co-stimulation of CD40 (figures 3.5-3.6). 
An important mediator of CD40-dependent rescue is the pro-survival Bcl- 2  
family protein B c I-Xl (290, 292, 293, 312). In collaboration with Elad Katz, 
Western blotting was used to measure the levels of Bc I-x l  in whole cell lysates 
prepared from WEHI-231 cells. In general, ligation of the BCR reduced the 
levels of B c I-xl  in WEHI-231 cells over a  48 hr time period (Appendix 6 ). 
However, ligation of CD40 or co-ligation of the BCR plus CD40 restored levels 
to greater than or equal to the amount of B c I-xl found in untreated WEHI-231 
cells (Appendix 6 ). Indeed, anti-CD40-treated WEHI-231 cells had high levels of 
B c I-xl  especially between 4  hr and 48 hr (figure 4.2A). However, anti-lg-treated 
WEHI-231 cells had substantially lower levels of B c I-Xl throughout the 48 hr 
time period (figure 4.2B) indicating ligation of the BCR on WEHI-231 cells 
impaired the expression of B c I-x l . Nonetheless, co-ligation of the BCR and 
CD40 on WEHI-231 cells restored B c I-x l  signalling and enabled Bcl-xt to be 
upregulated between 8  hr and 48 hr (figure 4.2C). This is a very important time 
for CD40-mediated rescue since WEHI-231 cells can only be rescued from 
BCR-driven growth arrest and apoptosis if they are stimulated at CD40 within 
the first 8  hr of anti-lg exposure (328). These observations suggest that B c I-xl  is 
a mediator of CD40-dependent rescue of BCR-stimulated WEHI-231 cells. 
Indeed, CD40-mediated upregulation of B c I-xl  has been observed previously 
and has been implicated in promoting immature B cell survival (290, 292, 293, 
311).
4.8.2 Transfection of WEHI-231 cells with the bct-xi gene can mimic the 
upregulation of B c I-x l  following ligation of CD40
The significance of B c I-Xl as a mediator of CD40 signalling was studied
using WEHI-231 cells transfected with the pSFFV-Neo plasmid containing the
human b c l-X t  gene (B c I-x l WEHI-231) or empty plasmid as control (Neo WEHI-
231). Western blot analysis of wild-type WEHI-231 cells treated with anti-CD40
or anti-lg plus anti-CD40 showed expression of BcI-xl in CD40-stimulated
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WEHI-231 cells was similar to that of untreated B c I-Xl WEHI-231 cells (figure 
4.2A and C). B c I-X l WEHI-231 cells therefore mimic CD40-mediated 
upregulation of B c I-x l .
4.8.3 Overexpression of B c I-x l  protects WEHI-231 cells from BCR-driven 
apoptosis
To determine the function of CD40-mediated induction of Bc I-x l , the effect 
of overexpression of Bcl-xu on BCR-driven apoptosis was determined. 
Apoptosis of Neo and B c I-x l  WEHI-231 cells was studied using Pl-staining and 
FACS analysis. The BCR and CD40 were stimulated using anti-lg and anti- 
CD40, respectively. To determine the optimal concentration of anti-lg for BCR- 
mediated apoptosis, Neo and B c !-Xl WEHI-231 cells were stimulated with 
increasing concentrations of anti-lg and the % sub-diploid cells was measured. 
After 24 hr, anti-lg induced apoptosis of Neo WEHI-231 cells with optimal levels 
of apoptosis being obtained between 1 and 1 0  pg/ml anti-lg (figure 4.3A). 
However, after 48 hr, optimal apoptosis was not achieved in Neo WEHI-231 
cells treated with 1 pg/ml anti-lg, suggesting 1 0  pg/ml anti-lg was a preferable 
concentration of anti-lg for studying BCR-driven apoptosis (figure 4.3B). 
Furthermore, 10 pg/ml anti-CD40 was able to protect Neo WEHI-231 cells from 
apoptosis induced by 10 pg/ml anti-lg after 24 hr or 48 hr indicating this was 
also a suitable concentration of anti-lg to study CD40-mediated rescue.
Interestingly, overexpression of Bc I-x l  almost completely abrogated BCR- 
driven apoptosis of WEHI-231 cells at all concentrations of anti-lg (0-10 pg/ml) 
after 24 hr and 48 hr (figure 4.3). Indeed, after 24 hr, anti-lg (10 pg/ml) 
increased the percentage of Neo WEHI-231 cells with sub-diploid DNA from 6 % 
to 18% indicating anti-lg had induced apoptosis whilst co-culture with anti-CD40 
(10 pg/ml) rescued the cells from apoptosis (figure 4.4A). In contrast, treatment 
of B c I-xl  WEHI-231 with anti-lg (10 pg/ml) for 24 hr only caused the percentage 
of sub-diploid cells to increase from 4% to 6 % (figure 4.4B) indicating 
overexpression of B c I~Xl can protect WEHI-231 cells from anti-lg-induced 
apoptosis.
After 48 hr, the effects of anti-lg and anti-CD40 on Neo and Bc I-Xl WEHI- 
231 cells were even more pronounced (figure 4.5). After 48 hr, anti-lg increased 
the percentage of apoptotic Neo WEHI-231 cells from 10% to 40% (figure 4.6A).
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In contrast, B c I-xl  WEHI-231 cells remained resistant to anti-lg-induced 
apoptosis after 48 hr since 10 pg/ml anti-lg only increased the percentage of 
B c I-xl  WEHI-231 cells with sub-diploid DNA from 6 % to 1 1 % (figure 4.5B). 
Expression of B c 1-Xl therefore protects WEHI-231 cells from BCR-driven 
apoptosis.
Interestingly, the ability of B c I-xl  WEHI-231 cells to resist BCR-driven 
apoptosis was reproducibly slightly enhanced by ligation of CD40 (figures 4.3- 
4.5). For example, after 48 hr, co-ligation of CD40 on anti-lg-treated B c I-xl  
WEHI-231 cells reduced the percentage of sub-diploid cells from 11% to 8 % in 
this experiment (figure 4.5B). This suggests that although overexpression of 
B c I-Xl is highly effective at preventing BCR-driven apoptosis, CD40 might 
initiate additional signals to further improve the survival of immature B cells. 
One possibility is ligation of CD40 on B c I-xl  WEHI-231 cells might further 
increase the expression of B c I-xl  in these cells to amplify this pro-survival 
signal.
4.8.4 Overexpression of Bc1-xl does not protect WEHI-231 cells from BCR- 
driven growth arrest
Ligation of the BCR on WEHI-231 cells induces growth arrest and 
apoptosis of the cells that can be rescued by co-ligation of CD40. The results of 
figures 4.3-4.5 strongly implicate B c I-xl  as a  key mediator of CD40-dependent 
rescue from BCR-driven apoptosis. To further explore the role of B c I-Xl in 
mediating CD40-dependent rescue, the effect of Bc 1-xl  on the proliferation of 
WEHI-231 cells was examined by analysing the cell cycle of BCR-stimulated 
WEHI-231 cells using Pl-staining and FAGS analysis. Furthermore, the levels of 
DNA synthesis were determined by measuring the incorporation of [®H] 
thymidine.
Neo and B c I -xl  WEHI-231 cells were treated with increasing 
concentrations of anti-lg to determine the optimal concentration of anti-lg 
required for BCR-driven growth arrest. After 48 hr, DNA synthesis was 
measured in Neo and B c I-xl  WEHI-231 cells. Ligation of the BCR induced 
complete growth arrest of Neo WEHI-231 cells with optimal growth arrest being 
observed between 1 and 10 pg/ml anti-lg (figure 4.6 A). Co-ligation of CD40 was 
able to restore DNA synthesis to Neo WEHI-231 cells treated with 10 pg/ml anti-
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Ig indicating this concentration of anti-lg was appropriate for the study of BCR- 
driven growth arrest and CD40-mediated restoration of proliferation.
To determine the role of B c I-X l in the regulation of immature B cell 
proliferation, the proliferation of Neo and B c I-xl  WEHI-231 cells was compared. 
In untreated WEHI-231 cells, the level of DNA synthesis in Bc I-x l  WEHI-231 
cells was consistently lower than that of untreated Neo WEHI-231 cells. A 
possible explanation for this is the increased survival of Bc I-xl  WEHI-231 cells 
results In a  slower turnover rate of the cells and hence the level of DNA 
synthesis in a population of B c I-xl  WEHI-231 cells is reduced. Interestingly, 
treatment of B c I-xl  WEHI-231 cells with increasing concentrations of anti-lg also 
suppressed DNA synthesis in a dose-dependent manner (figure 4.6A). This 
suggests B c I-xl cannot prevent BCR-driven growth arrest despite being able to 
protect WEHI-231 cells from BCR-dependent apoptosis. Furthermore, by 
measuring the DNA synthesis of WEHI-231 cells, B c I-xl  WEHI-231 cells appear 
to be more sensitive to BCR-driven growth arrest than Neo WEHI-231 cells 
since 0 . 1  pg/ml anti-lg was sufficient to induce optimal growth arrest of B c I-xl  
WEHI-231 cells (figure 4.6A). Overexpression of Bc I-xl  therefore did not appear 
to prevent BCR-driven growth arrest. Moreover, co-culture with anti-CD40 
rescued both Neo and B c I-xl  WEHI-231 cells from BCR-dependent growth 
arrest indicating signals other than Bc I-x l  are required for CD40-mediated 
induction of proliferation.
Previously it has been shown that ligation of the BCR on immature B cells 
induces growth arrest at G0/G1 phase of the cell cycle (figure 3.6) therefore the 
percentage of cells in G0 /G 1 phase of the cell cycle was determined by Pl- 
staining and FACS analysis. After 24 hr, anti-lg enhanced the G0/G1 population 
of Neo and B c I-xl  WEHI-231 cells in a dose-dependent manner with optimal 
enrichment of G0/G1 cells being observed at 1 - 1 0  pg/ml anti-lg (figure 4.6B). In 
agreement with the thymidine assay data, B c I-xl  WEHI-231 cells were slightly 
more sensitive than Neo WEHI-231 cells to cell cycle arrest at G0/G1 (figure 
4.6B). After 48 hr, the G0/G1 population of B c I-Xl WEHI-231 cells was further 
enriched by anti-lg; for example, 77% of cells treated with 10 pg/ml anti-lg for 
48 hr were in G0/G1 phase (figure 4.SB and 4.6C). However, in Neo WEHI-231 
cells, exposure to 10 pg/ml anti-lg for 48 hr was less effective at enriching the 
number of cells in G0 /G 1 phase, presumably reflecting the high degree of anti-
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Ig-induced apoptosis in Neo WEHI-231 cultures (figure 4.5A). Nonetheless, co­
ligation of CD40 reduced the number of Neo and B c I-xl  WEHI-231 cells in 
G0/G1 phase indicating CD40 can efficiently protect these cells from BCR- 
driven cell cycle arrest (figures 4.4-4.6 ). Furthermore, this suggests that CD40 
abrogates BCR-driven growth arrest via the induction of pathways other than 
B c I-Xl.
Ligation of the BCR on WEHI-231 cells therefore potently induces growth 
arrest at G0/G1 phase of the cell cycle that cannot be prevented by 
overexpression of Bc I-x l . The level of growth arrest can be further corroborated 
by examination of the percentage of cells in S phase and G2/M. After 24 hr, 
anti-lg dramatically reduced the number of Neo WEHI-231 cells in S phase with 
optimal growth arrest being observed at 1-10 pg/ml anti-lg (figure 4.7A). 
Furthermore, the number of Neo WEHI-231 cells in G2/M was reduced by anti- 
lg in a dose-dependent manner with maximal growth arrest being induced by 1 0  
pg/ml anti-lg. For example, treatment of Neo WEHI-231 cells with 10 pg/ml anti- 
lg for 24 hr, enhanced the percentage of cells in G0/G1 phase from 34% to 49% 
whilst reducing the number of S phase cells from 28% to 11% and G2 /M phase 
cells from 24% to 15% (figure 4.4A). Ligation of the BCR therefore potently 
induced cell cycle arrest of Neo WEHI-231 cells at G0/G1 phase within 24 hr. 
However, co-ligation of CD40 completely protected Neo WEHI-231 cells from 
BCR-driven grov\4h arrest (figures 4.4A and 4.7A).
Similarly, treatment of B c I-Xl WEHI-231 ceils with anti-lg for 24 hr also 
reduced the number of cells in S phase in a dose-dependent manner (figure 
4.7A). For example, 10 pg/ml anti-lg increased the percentage of Bc I-xl  WEHI- 
231 cells in GQ/G1 from 43% to 52% whilst reducing the S phase population 
from 30% to 16% (figure 4.48). Overexpression of B c I-Xl therefore was unable 
to prevent BCR-driven cell cycle arrest at G0/G1 phase. However, B c I-xl  might 
offer some protection or delay the onset of growth arrest since treatment of Bcl- 
x l WEHI-231 cells with 10 pg/ml anti-lg for 24 hr did not diminish the number of 
cells in G2/M phase (figures 4.7A and 4.4B). Nonetheless, co-ligation of CD40 
on Bc I-Xl WEHI-231 cells restored proliferation, as indicated by the reduction in 
the number of G0 /G1 cells and the enrichment of the S phase population.
After 48 hr, similar observations were made although the levels of growth 
arrest were generally higher and 1 0  pg/ml anti-lg was most effective at inducing
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cell cycle arrest (figure 4.7B). For example, after 48 hr, 10 pg/ml anti-lg potently 
induced growth arrest of Neo WEHI-231 cells since the percentage G0 /G 1 cells 
increased from 33% to 44%, the percentage of S phase cells decreased from 
35% to 8 % and the percentage G2/IVI cells fell from 22% to 3% (figure 4.5A). 
Bc I-xl  WEHI-231 cells were also highly sensitive to BCR-driven growth arrest 
after 48 hr. For example, after 48 hr, 77% of B c I-x l  WEHI-231 cells treated with 
10 pg/ml anti-lg were in G0/G1 phase of the cell cycle and just 5% of cells were 
in G2 /IVI phase indicating ligation of the BCR potently induced growth arrest of 
B c I-Xl WEHI-231 cells at G0/G1 phase (figure 4.5B). Expression of B c I-Xl 
therefore protects WEHI-231 cells from BCR-driven apoptosis but cannot 
prevent BCR-driven growth arrest.
Moreover, co-culture with anti-CD40 protected both Neo and Bc I-x l  WEHI- 
231 cells from BCR-driven growth arrest, even after 48 hr (figures 4.4-4.7 ). 
These results agree with previous observations that suggested overexpression 
of B c1-Xl in WEHI-231 cells can protect them from anti-lg-induced apoptosis but 
not growth arrest (292, 311). CD40-mediated rescue from BCR-driven 
apoptosis is thus likely to involve the upregulation of B c I-xl  but CD40- 
dependent rescue from anti-lg-induced growth arrest requires signals that are 
additional to Bc I-x l .
4.8.5 Arachidonic acid induces apoptosis of WEHI-231 cells
Bc I-xl  is thus a key survival factor of WEHI-231 cells and overexpression 
of B c I-Xl can abrogate BCR-driven apoptosis without preventing BCR-mediated 
growth arrest. The mechanism of BCR-driven apoptosis has previously been 
investigated in WEHI-231 cells (102, 218, 328) (see section 4.1) and this 
showed that ligation of the BCR induces an early Erk signal that contributes to 
the activation of CPLA2 leading to the production of arachidonic acid at the 
mitochondria. The production of arachidonic acid precedes disruption of the 
mitochondrial membrane potential and death of the cell. Co-ligation of CD40 
prevents BCR-dependent apoptosis by suppressing BCR-driven induction of 
CPLA2 and subsequent production of arachidonic acid (1 0 2 , 218).
To further investigate the role of B c I-Xl in CD40-mediated rescue from 
BCR-driven apoptosis, the effect of B c I-xl on growth arrest and apoptosis 
induced by exogenous arachidonic acid was determined. The cell cycle of Neo
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and Bel-XL WEHI-231 cells treated with exogenous arachidonic acid (AA) was 
investigated by Pl-staining and FACS analysis. Treatment of Neo WEHI-231 
cells with 10 pg/ml anti-lg and/or 100 pM AA dramatically increased the number 
of cells with sub-diploid DNA indicating these agents potently induce apoptosis 
of Neo WEHI-231 cells (figure 4.8A). In contrast, overexpression of B c I-x l  
impaired both anti-lg and AA-mediated apoptosis (figure 4.8A), suggesting Bcl- 
x l targets the AA-mediated apoptotic pathway. However, B c I-xl  was unable to 
completely prevent apoptosis induced by these agents especially when Bc I-xl 
WEHI-231 cells were treated with a combination of 100 pM AA plus 10 pg/ml 
anti-lg, suggesting the Bcl-xt-mediated rescue pathway could be overwhelmed 
by a combination of these agents.
AA-dependent apoptosis was also impaired by ligation of CD40. Indeed, 
anti-CD40 and B c I-x l  provided a similar level of protection from AA-mediated 
apoptosis. Furthermore, as with overexpression of Bc I-x l , ligation of CD40 did 
not completely prevent AA-induced apoptosis (figure 4.8B). These observations 
suggest that B c I-xl  and CD40 act via a common survival pathway. However, 
ligation of CD40 on Bc I-xl  WEHI-231 cells increased their ability to resist AA- 
mediated apoptosis suggesting CD40 signalling might further enhance the 
induction of B c I-xl  or initiate Bcl-xu-independent survival signals.
Furthermore, CD40 alone was unable to prevent apoptosis of Neo WEHI- 
231 cells treated with a combination of anti-lg plus A A  but CD40 stimulation of 
Bc I-xl  WEHI-231 cells impaired the ability of these agents to induce apoptosis 
(figure 4.8C). These observations are consistent with published data that 
implicates arachidonic acid as a key mediator of BCR-driven apoptosis (102). 
Moreover, they suggest that CD40 and B c I-xl  both prevent apoptosis induced 
by anti-lg and exogenous A A , which is consistent with B c I-xl being a key 
mediator of CD40-dependent survival. Furthermore, these results imply B c I-xl  
prevents BCR-driven apoptosis downstream of arachidonic acid. This is 
consistent with arachidonic acid-dependent apoptosis being mediated by 
inducing a loss of mitochondrial membrane potential (102) since B c I-xl  is known 
to protect the integrity of intracellular organelles including the mitochondria (73).
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4.8.6 Arachidonic acid induces growth arrest of WEHI-231 cells
To further investigate the role of Bc I-xl and arachidonic acid in WEHI-231 
cell signalling, the effect of B c I-xl  on growth arrest induced by exogenous 
arachidonic acid was determined. Exogenous arachidonic acid was added to 
WEHI-231 cells and proliferation was assessed by measuring the DNA 
synthesis. The addition of exogenous AA to WEHI-231 cells for 48 hr induced 
growth arrest in a dose-dependent manner (figure 4.9A). This might reflect the 
ability of AA to induce apoptosis of WEHI-231 cells. Overexpression of Bc I-Xl 
slightly impaired but did not prevent AA-mediated cell cycle arrest in WEHI-231 
cells (figure 4.9A). The apparent reduced sensitivity to apoptosis may have 
been due to the increased survival of B c I-xl  WEHI-231 cells.
Proliferation of WEHI-231 cells treated with exogenous AA was further 
studied by staining the cells with PI followed by FACS analysis. Exogenous AA 
reduced the number of S phase cells to a similar extent as treatment of WEHI- 
231 cells with 10 pg/ml anti-lg (figure 4.9B). Furthermore, AA and anti-lg both 
depleted the G2/M population of Neo-WEHi-231 cells to a similar extent (figure 
4.9B). Interestingly, overexpression of Bc I-Xl impaired AA and anti-lg-mediated 
depletion of S phase cells. This may reflect the increased survival of these cells 
since anti-lg and AA efficiently depleted the G2/M population of B c I-xl  WEHI- 
231 cells (figure 4.9B). Overexpression of B c I-xl  is thus inefficient at preventing 
BCR- or AA-mediated depletion of cycling WEHI-231 cells. However, ligation of 
CD40 partially protected B c1-x l  WEHI-231 cells from AA-induced growth arrest 
and 10 pg/ml anti-CD40 raised the IC50 of AA from 38 pM to 55 pM (figure 
4.9C). CD40 therefore protects WEHI-231 cells from apoptosis and cell cycle 
arrest induced by ligation of the BCR or exposure to exogenous AA. B c I-xl  
mimics CD40 in enabling the cells to survive in the presence of AA but it does 
not restore proliferation as efficiently as CD40, which is consistent with B c I-xl  
mediating CD40-dependent rescue from BCR-driven apoptosis but not growth 
arrest.
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4.8.7 Overexpression of B c I-x l  suppresses coupling of the BCR to 
mitochondrial PLA2 activation
The finding that B c I-xl  expression can impair AA-induced apoptosis of 
WEHI-231 cells suggested that this anti-apoptotic pathway was likely to act 
downstream of PLA2 and presumably by protecting the integrity of the 
mitochondrial membranes (73). However, arachidonic acid is itself an activator 
of PLA2 and can increase mitochondrial PLA2 activity in untreated or anti-lg- 
stimulated immature B cells (appendix 7A) (427) and this has also been 
reported by various other groups (429, 450). These observations raised the 
possibility that Bc 1-Xl may also prevent BCR-driven apoptosis by suppressing 
mitochondrial PLA2 activity. This possibility was investigated in collaboration 
with Elad Katz and Caroline Lord (427) by determining the activity of PLA2 in 
isolated mitochondria of anti-lg-stimuiated Neo and B c I-xl WEHI-231 cells. 
Indeed, these investigations revealed B c I-x l  does prevent AA-mediated 
activation of PLA2 in WEHI-231 cells (appendix 7B). To eliminate the possibility 
that the observed PLAa activity was induced by mitochondrial dysfunction, the 
activity of PLA2 was determined in mitochondria isolated from WEHI-231 cells 
treated with the mitochondrial stabilisers oligomycin or cyclosporin A. These 
stabilisers have previously been shown to prevent BCR-driven apoptosis by 
abrogating anti-lg-mediated disruption of mitochondrial membrane potential and 
depletion of cellular ATP (appendix 7C and (102)). However, they did not 
prevent BCR-mediated induction of mitochondrial PLA2 activity (appendix 7D) 
indicating the observed PLA2 activity in Neo and Bc I-Xl WEHI-231 cells was not 
caused by disruption of the mitochondria. These observations therefore suggest 
Bc I-xl  suppresses mitochondrial PLA2 activity independently of its regulation of 
mitochondrial membrane potential.
4.8.8 Overexpression of B c !-x l  antagonises arachidonic acid- and BCR- 
mediated disruption of inner mitochondrial membrane potential
Previously it has been shown that treatment of WEHI-231 cells with 
exogenous arachidonic acid can mimic BCR-mediated disruption of 
mitochondrial membrane integrity thus committing the cell to later stages of 
apoptosis (102). To further investigate the mechanism of Bcl-xu-mediated
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protection of WEHI-231 cells from BCR- and AA-induced apoptosis, the effect of 
overexpression of Bc I-Xl on mitochondrial membrane potential was determined. 
In collaboration with Elad Katz, the mitochondrial membrane potential was 
measured by analysing the uptake of the lipophilic dye DiOCe since the uptake 
of this dye is directly proportional to the mitochondrial transmembrane potential. 
Treatment of Neo WEHI-231 cells with anti-lg (10 pg/ml) or AA (100 pM) 
induced a profound loss of mitochondrial membrane potential that was maximal 
by 20-24 hr (appendix 7E). However, Bc 1-Xl WEHI-231 cells were partially 
protected from anti-lg- and AA-induced disruption of mitochondrial membrane 
potential. This is consistent with Bc I-x l  having roles in protecting the integrity of 
the mitochondria and suppressing apoptosis induced by these agents.
4.8.9 B c I-X l antagonises the post-mitochondrial induction of the 
executioner protease, cathepsin B in WEHI-231 cells
Previously it has been shown that ligation of the BCR mediates the post- 
mitochondrial induction of cathepsin B and this contributes to the executioner 
protease activity of apoptosis in WEHI-231 cells (102). In collaboration with Elad 
Katz and Caroline Lord, the effect of B c I-x l  on cathepsin B activity was 
determined in WEHI-231 cells. In keeping with the ability of Bc I-xl  to prevent 
anti-lg- or AA-induced collapse of mitochondrial membrane potential and 
induction of apoptosis, B c I-xl  also abrogated BCR-driven activation of cathepsin 
B (appendix 7F). B c I-xl  therefore impairs multiple stages of BCR- and AA- 
driven apoptosis including the activation of mitochondrial PLA2 , disruption of 
mitochondrial membrane integrity and the activation of effector caspases.
4.8.10 Overexpression of B c I-x l  does not restore sustained cycling Erk 
activation required for proliferation in WEHI-231 cells
Although B c I-Xl expression can mimic CD40-dependent rescue from BCR-
driven apoptosis (figures 4.3-4.5), expression of BcI-xl cannot substitute for
CD40-signalling in the reversal of anti-lg-induced growth arrest of WEHI-231
cells (figures 4.4-4.7) (311, 312). The upstream mechanisms underlying CD40-
dependent rescue of anti-lg-induced growth arrest are incompletely understood
but, as discussed in Chapter 3, a key event of CD40-mediated rescue is the
restoration of sustained cyclic activation of Erk-MAPK, which is required for celt
182
cycle progression (328). To further investigate the function of B c I-x l  in the 
rescue of BCR-stimulated WEHI-231 cells the effect of Bc I-xl  on E rk  activity 
was determined.
The activation of Erk-MAPK in Neo and B c !-xl  WEHI-231 cells was 
investigated using Western blotting with antibodies that specifically recognise 
dual-phosphorylated Erk 1/2. in general, expression of B c I-xl did not alter the 
temporal pattern of Erk activation (figure 4.10), In particular, overexpression of 
B c I-xl  did not restore sustained, cycling Erk activation to anti-lg-treated WEHI- 
231 cells. In contrast, co-culture with anti-CD40 was able to restore sustained 
Erk signalling to Neo and B c I-Xl WEHI-231 cells. The expression of Bc I-Xl is 
thus insufficient to prevent BCR-mediated inhibition of sustained Erk signalling. 
This is consistent with B c I-x l  being unable to prevent BCR-driven growth arrest 
since restoration of this signal is necessary for proliferation of WEHI-231 cells. 
CD40-mediated restoration of sustained and cycling Erk activation and the 
induction of proliferation therefore requires signals in addition to B c I-x l . 
Furthermore, it has previously been shown that transient transfection of B c I-xl  
WEHI-231 cells with E2F1 or viral El A can protect the cells from BCR-driven 
growth arrest (52). This suggests that a possible function of sustained Erk 
signals is to induce E2F, perhaps via the suppression of Rb. Rb is inhibited by 
phosphorylation catalysed by cyclin/Cdk complexes (50) and BCR-stimulated 
immature B cells particularly lack cyclin E/Cdk2 complexes (33) therefore 
sustained Erk signals might function to induce cyclin E/Cdk2 leading to a 
suppression of Rb. However, additional experiments must be performed to 
show a direct link between sustained Erk signalling and the induction of E2F.
4.8.11 Cox and Lox inhibitors implicate a key role for arachidonic acid in 
mediating the mitochondrial death pathway in WEHI-231 ceils
Exogenous arachidonic acid can mimic BCR-driven disruption of 
mitochondrial function and subsequent induction of apoptosis. Furthermore, Bcl- 
x l can suppress BCR-mediated activation of PLAg, mitochondrial malfunction 
and apoptosis that is induced by either BCR-ligation or exogenous AA. These 
findings strongly imply that the BCR induces apoptosis via the activation of 
PLA2 leading to the disruption of mitochondrial function. However, it has not 
been possible to show that PLA2-mediated production of AA is actually the
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cause of BCR-driven disruption of the mitochondria since inhibitors of cPLAg are 
non-metaboiisable analogues of arachidonic acid and they themselves induce 
apoptosis of WEHI-231 cells (451). Consequently, it was necessary to regulate 
AA metabolism via an alternative mechanism involving inhibitors of 
cyclooxygenase (Cox) and lipoxygenase (Lox). AA is a substrate of Cox and 
Lox enzymes, leading to the production of prostaglandins and leukotrienes, 
respectively. Inhibitors of Cox2 (NS-398) and Lox (LOI) should therefore 
prevent AA metabolism and enhance AA signalling.
The Cox2 selective inhibitor, NS-398 (N-[2-(cyclohexyloxy)-4- 
nitrophenyljmethanesulfonamide) and the 12-Lox/15-Lox inhibitor, LOI (ethyl- 
3,4-dihydroxybenzylidenecyanoacetate) were used to explore the role of AA in 
BCR-mediated induction of the mitochondrial death pathway. Inhibition of Cox 
and Lox, enhanced BCR-driven apoptosis of Neo WEHI-231 cells, as indicated 
by the observed increase in the number of cells with sub-diploid DNA (figure 
4.11). These inhibitors also enhanced disruption of the mitochondrial membrane 
potential (appendix 8). The BCR-driven mitochondrial death pathway of WEHI- 
231 cells is thus enhanced under conditions in which arachidonic acid cannot 
be metabolised to prostaglandins and leukotrienes. Furthermore, this 
enhancement of BCR-driven apoptosis was prevented by co-ligation of CD40, 
which is consistent with CD40 being able to suppress BCR- and AA-driven 
apoptosis (figure 4.11). Moreover, overexpression of Bcl-xu mimicked CD40 in 
suppressing anti-lg- and NS-398/LOl-driven apoptosis. Apoptosis was further 
suppressed by ligation of CD40 on Bc I-Xl WEHI-231 cells (figure 4 .1 1 ) , which is 
consistent with previous observations showing CD40 and B c I-Xl can both 
protect WEHI-231 cells from BCR-driven apoptosis (figures 4.3-4.5). NS-398- 
mediated disruption of the mitochondrial membrane potential was also impaired 
by expression of B c I-X l (appendix 8). Enhancement of arachidonic acid 
signalling via the inhibition of Cox and Lox therefore induces apoptosis of 
unstimulated and anti-lg-treated WEHI-231 cells that can be suppressed by 
ligation of CD40 or overexpression of B c I-x l . Taken together, these 
observations implicate a causal role for BCR-dependent arachidonic acid 
generation in mediating the mitochondrial death pathway and this pathway can 
be inhibited by induction of B c I-x l .
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4.8.12 Inhibition of Cox and Lox impairs proliferation of WEHI-231 cells
The inhibition of Cox and Lox enhanced BCR-driven apoptosis suggesting 
the formation of prostaglandins and leukotrienes can inhibit apoptosis by 
reducing the cellular levels of AA. However, prostaglandins and leukotrienes 
can also function as signalling molecules and they have been associated with 
promoting inflammation, regulating vascular function and assisting 
carcinogenesis (433, 435, 439, 440). Inhibition of Cox2 and Lox in WEHI-231 
cells therefore prevents prostaglandin and leukotriene signalling in addition to 
enhancing AA signals. To further explore the role of eicosanoids in WEHI-231 
cells, the effect of Cox and Lox inhibitors on proliferation of WEHI-231 cells was 
determined.
Treatment of Neo WEHI-231 cells with NS-398, LOI or a combination of 
these two inhibitors suppressed DNA synthesis in a dose-dependent manner 
(figure 4.12A). Furthermore, treatment of Neo WEHI-231 cells with these 
inhibitors enhanced BCR-driven growth arrest in a concentration-dependent 
manner. NS-398 was less effective than LOI at inducing growth arrest and the 
combined exposure to NS-398 and LOI suppressed DNA synthesis more 
potently than treatment of the cells with a single inhibitor. Furthermore, Pl- 
staining and FACS analysis of Neo WEHI-231 cells showed that NS-398 and 
LOI slightly enhanced BCR-driven depletion of S phase and G2/M cells (figure 
4.13A-B). Inhibition of Cox and/or Lox therefore suppresses proliferation and 
enhances BCR-driven growth arrest.
Consistent with the observation that upregulation of B c I-Xl does not 
prevent BCR-driven growth arrest (figures 4.4-4.7), expression of B c I-xl  did not 
protect WEHI-231 cells from growth arrest induced by NS-398 and/or LOI 
(figure 4.12B). However, NS-398 and LOI also impaired CD40-mediated rescue 
from BCR-driven growth arrest (figure 4.13C-D) suggesting CD40-mediated 
restoration of proliferation might involve the activation of Cox2/Lox and hence 
metabolites of AA may promote proliferation of WEHI-231 cells, indeed, 
inhibitors of Cox2 and Lox were found to promote growth arrest and apoptosis 
of WEHI-231 cells. Taken together, these observations suggest that the 
metabolism of arachidonic acid to produce prostaglandins and leukotrienes may 
play a role in switching off the AA-mediated death pathway and/or promoting 
proliferation of WEHI-231 cells.
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4.8.13 Anti-lg inhibits the production of prostaglandin Eg in WEHI-231 cells
The observation that Cox2 and Lox inhibitors impaired proliferation of 
WEHI-231 cells and compromised CD40-mediated rescue from BCR-driven 
growth arrest suggested prostaglandins and leukotrienes might promote 
proliferation of WEHI-231 cells. The role of one particular eicosanoid, 
prostaglandin E2 (PGE2), in regulating the proliferation of WEHI-231 cells was 
investigated since PGE2 has previously been associated with regulating 
proliferation of B lymphocytes. Early reports suggested that PGE2 was 
associated with the induction of growth arrest of B lymphocytes, especially 
during early stages of B cell development (436, 437). However, more recent 
evidence suggests exogenous PGE2 can function in synergy with various co­
receptors including CD40, IL-4 and IL-10 to promote proliferation of B cells 
(438).
In studies initiated by Stephen Gauld, the levels of PGE2 were measured 
in WEHI-231 cells using a PGE2 competitive binding immunoassay kit (Cayman 
Chemical) (427). Ligation of the BCR reduced the levels of intracellular PGE2 
whilst co-ligation of CD40 partially restored PGE2 levels (appendix 9). Such 
PGE2 production appears to be exclusively intracellular since no PGE2 could be 
detected in cell supernatants (data not shown). Moreover, CD40-dependent 
rescue of PGE2 levels was independent of B c I~xl  expression since BCR- 
signalling suppressed PGE2 generation equally well in Neo and B c I-Xl WEHI- 
231 cells (figure 4.14A).
The mechanisms regulating PGE2 production in WEHI-231 cells are 
incompletely understood but the expression of Cox2 correlated with PGE2  
production (Western blot panel in appendix 9). Cox2 levels were thus depleted 
in BCR-activated cells but co-ligation of CD40 enabled Cox2 levels to be 
restored. Indeed, the expression of Cox2 and subsequent PGE2 production has 
been observed downstream of CD40-ligation in lung fibroblast cells (462) 
suggesting CD40 can induce Cox2 in several systems.
4.8.14 Regulation of Erk-MAPK by arachidonic acid and its metabolites
The mechanism of prostaglandin/leukotrlene-dependent regulation of 
WEHI-231 survival and proliferation is incompletely understood but eicosanoids
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are known to regulate the activity of key signalling molecules such as MARK to 
determine the survival, activity and proliferation of various types of cells. For 
example, Lox1 activity is enhanced in the PCS prostate cancer cell line and this 
leads to increased release of 13-(S)-hydroxyoctadecadienoic acid, which can 
stimulate MARK and Akt (449). Since the survival and proliferation of WEHI-231 
cells is critically dependent on the differential regulation of Erk-MAPK, the effect 
of Cox and Lox inhibitors on the activity of Erk was investigated.
Treatment of proliferating Neo or B c I-xl WEHI-231 cells with NS-398/L01 
suppressed sustained (8-48 hr) Erk signals (figure 4.14B). This is consistent 
with these signals being necessary for proliferation of WEHI-231 cells and with 
the observation that NS398/LOI can induce growth arrest of WEHI-231 cells. 
NS-398/LOI-dependent growth arrest may therefore be mediated by a 
suppression of sustained and cyclic Erk activation in WEHI-231 cells. 
Furthermore, coupled with the knowledge that the BCR and CD40 differentially 
regulate PGE2 levels in WEHI-231 cells, these observations suggest a possible 
function of PGE2 is to enhance sustained Erk signalling in WEHI-231 cells.
NS-398 and LOI also induced a general enhancement of early (< 4 hr) 
Erk-MAPK signals in Neo WEHI-231 cells (figure 4.ISA). This may contribute to 
the ability of these inhibitors to induce apoptosis of WEHI-231 ceils. 
Furthermore, these observations show that early Erk signals can be amplified 
under conditions in which AA is allowed to accumulate suggesting AA- 
dependent induction of cPLAa (appendix 7A) may be mediated by the activation 
of Erk. Moreover, NS-398 and LOI were less effective at enhancing early Erk 
signals in CD40-stimulated WEHI-231 cells. However, overexpression of Bc I-xl  
did not mimic CD40 in protecting WEHI-231 cells from NS-398/LOI-dependent 
enhancement of early Erk signals (figure 4.1 SB) suggesting Bc I-xl is acting 
downstream of Erk to impair AA-mediated induction of CPLA2 and BCR-driven 
apoptosis. These results suggest that the accumulation of arachidonic acid may 
increase early Erk signals and this is impaired by ligation of CD40 but probably 
independently of Bc I-Xl expression.
To investigate this possibility further, WEHI-231 ceils were cultured with 
exogenous arachidonic acid and the activity of Erk in lysates prepared from 
these cells was determined by Western blotting. In unstimulated and anti-lg- 
treated Neo WEHI-231 cells, AA enhanced the activity of Erk between 0 and 4
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hr, suggesting AA can induce Erk in WEHI-231 cells (figure 4.16A). In contrast, 
Erk signalling in CD40-stimulated WEHI-231 cells was not enhanced by 
exposure to AA, implying CD40 can impair AA-dependent activation of Erk 
(figure 4.16A). These results suggest AA can enhance early (0-4 hr) Erk 
signals, which is likely to contribute to AA-dependent activation of cPLAa but 
ligation of CD40 can protect WEHI-231 cells from AA-mediated induction of Erk. 
However, anti-CD40 was insufficient to prevent AA-mediated Erk activation in 
BCR-stimulated Neo WEHI-231 cells (figure 4.16A). This is consistent with the 
observations of figure 4.8C that showed CD40 was unable to prevent apoptosis 
induced by a combination of anti-lg plus AA.
Furthermore, consistent with the results of figure 4.15, expression of Bc I-xl  
only impaired the ability of AA to enhance early Erk signals when B c I-x l  WEHI- 
231 cells were stimulated at CD40 (figure 4.16B). Taken together, these 
observations suggest that arachidonic acid can enhance early (0-4 hr) Erk 
activity in WEHI-231 cells and this is assisted by ligation of the BCR. However, 
ligation of CD40 can impair the ability of AA to induce Erk signalling and it 
seems to do so independently of B c I-x l . Conditions that Increase the levels of 
AA therefore seem to promote early Erk signals and this could lead to an 
enhancement of the mitochondrial death pathway. Furthermore, the activation 
of Erk by AA might amplify arachidonic acid signalling since CPLA2 can be 
stimulated by Erk and inhibitors of MEK are known to impair BCR-dependent 
arachidonic acid production (328).
4.9 Conclusions
Ligation of CD40 on WEHI-231 cells induced B c I-xl  and this was mimicked 
by transfection of WEHI-231 cells with a pSFFV-Neo plasmid containing the 
human gene for B c I-xl  (figure 4.2). Overexpression of B c I-x l  protected WEHI- 
231 cells from BCR-driven apoptosis suggesting CD40-dependent survival is 
mediated by Bc I-xl  (figures 4.3-4.5 ). In contrast, overexpression of Bc I-x l  did 
not prevent BCR-driven growth arrest but ligation of CD40 on Bc I-xl  WEHI-231 
cells restored proliferation to BCR-stimulated cells (figures 4.4-4.7). This 
suggests that CD40-dependent rescue from BCR-driven growth arrest requires 
signals that are additional to B c I-x l .
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To further investigate the mechanism of Bct-XL-mediated rescue of BCR- 
stimulated WEHI-231 cells, the effect of expression of B c I -xl  on the 
mitochondrial death pathway was explored. BCR-driven apoptosis can be 
mimicked by treatment of WEHI-231 cells with exogenous arachidonic acid 
(figure 4.8). Overexpression of B c I-xl  or ligation of CD40 impaired AA- 
dependent apoptosis of WEHI-231 cells and protection was enhanced by a 
combination of B c I-xl  expression and treatment with anti-CD40 (figure 4.8). 
These observations are consistent with AA being a key mediator of BCR-driven 
apoptosis and they show B c I-x l  and CD40 can suppress apoptosis induced by 
ligation of the BCR or exposure to AA. This is consistent with B c1-xl  being a key 
mediator of CD40-dependent survival. These observations also suggest that 
B c I-Xl prevents BCR/AA-driven apoptosis downstream of arachidonic acid and 
this is likely to be mediated by Bcl-xt-dependent protection of mitochondrial 
integrity.
However, AA can stimulate CPLA2 activity to enhance arachidonic acid 
production in WEHI-231 cells. Overexpression of Bc I-Xl prevented AA-mediated 
induction of AA production and this was not impaired by mitochondrial 
stabilisers (appendix 7). B c I-X l therefore can suppress BCR/AA-dependent 
apoptosis by inhibiting AA-mediated induction of PLA2 . Moreover, Bc I-xl  
protected WEHI-231 cells from BCR-driven disruption of mitochondrial 
membrane potential (appendix 7E), which is consistent with B c 1-xl  having a role 
in retaining the integrity of the mitochondria. Furthermore, BCR-dependent 
activation of cathepsin B was impaired by expression of Bcl-xu (appendix 7F). 
Overexpression of B c I-x l  therefore impaired the BCR-driven apoptotic pathway 
by suppressing AA-dependent induction of PLA2 and protecting the 
mitochondria from AA-mediated disruption. Consequently, B c I-Xl prevented 
BCR-dependent induction of effector proteases and resultant apoptosis.
In contrast, expression of B c I-xl  did not prevent BCR- or AA-induced 
growth arrest (figures 4.4-4.7 and 4.9). Furthermore, expression of Bc I-x l  was 
unable to restore sustained and cyclic activation of Erk to BCR-stimulated 
WEHI-231 cells (figure 4.10). This is consistent with sustained Erk signalling 
being necessary for proliferation of WEHI-231 ceils and with the observation 
that CD40-dependent proliferation requires signalling pathways other than Bcl-
Xl.
189
To further understand the role of AA and its metabolites in determining the 
survival and proliferation of WEHI-231 cells the metabolism of AA was inhibited 
using Cox2 and Lox inhibitors. In this way intracellular AA levels were elevated, 
resulting in enhanced BCR-dependent disruption of mitochondrial membrane 
potential and BCR-driven apoptosis (figure 4.11 and appendix 8 ). The 
mitochondrial death pathway was thus amplified under conditions in which AA 
was able to accumulate. However, expression of B c I-xl  or ligation of C D 4 0  
impaired these effects. Taken together, these observations implicate a causal 
role for BCR-dependent arachidonic acid production in mediating the 
mitochondrial death pathway and this can be inhibited by ligation of CD40 or 
induction of B c I-x l .
The metabolism of AA to prostaglandins and leukotrienes can thus impair 
BCR-driven apoptosis by reducing the levels of AA. However, a mitogenic role 
for metabolites of AA was also implicated using Cox2 and Lox inhibitors since 
these inhibitors impaired proliferation of WEHI-231 cells (figure 4.12). This was 
not rescued by expression of B c I-x l , which is consistent with B c I-xl  being 
unable to restore proliferation to BCR-stimulated WEHI-231 cells. However, 
CD40-mediated rescue from BCR-driven growth arrest was also impaired by 
Cox2/Lox inhibitors (figure 4.13) suggesting proliferation of WEHI-231 cells 
might require the production of eicosanoids. Consistent with this, anti-lg 
inhibited PGE2 production in WEHI-231 cells but co-ligation of CD40 restored 
PGE2 production (appendix 9). In contrast, Bc I-xl  was unable to restore PGE2 
production to anti-lg-treated cells (figure 4.14A) thus suggesting PGE2 is 
associated with promoting proliferation rather than survival of WEHI-231 cells. A 
possible mechanism for regulating PGE2 production in WEHI-231 cells was 
implicated by the observation that Cox2  expression correlated with PGE2 levels 
(appendix 9) indicating the BCR may promote growth arrest by downregulating 
Cox2 levels.
The significance of PGE2 and other eicosanoids was investigated by 
determining the effect of Cox2/Lox inhibitors on the activity of Erk in WEHI-231 
cells. Inhibition of Cox2/Lox suppressed sustained Erk signals and this is likely 
to contribute to the induction of growth arrest (figure 4.14B). Cox2/Lox inhibitors 
also enhanced early (<4 hr) Erk signals (figure 4.15) suggesting a possible 
mechanism for NS-398/LOI-induced apoptosis since early Erk signals can
190
induce cPLAg to enhance AA-dependent disruption of mitochondrial function. 
Furthermore, treatment of unstimulated or BCR-activated WEHI-231 cells with 
exogenous AA enhanced Erk activity between 0 and 4 hr whereas ligation of 
CD40 impaired AA-mediated induction of Erk (figure 4.16). Conditions that 
increase the levels of AA therefore appear to promote early Erk signals and this 
might lead to the induction of CPLA2 to further elevate AA levels leading to an 
enhancement of the mitochondrial death pathway.
Ligation of the BCR therefore induces early Erk signals that contribute to 
the activation of CPLA2 and arachidonic acid production. Arachidonic acid can 
enhance early Erk signals, possibly leading to an induction of CPLA2 and an 
elevation of AA levels. The accumulation of AA leads to a loss of mitochondrial 
membrane potential and commitment of the cell to apoptosis. However, BCR- 
driven apoptosis can be prevented by ligation of CD40. Bc I-x l  is a key mediator 
of CD40-dependent survival and it does so by suppressing AA-mediated 
induction of CPLA2 activity and by protecting the mitochondria from AA- 
dependent disruption. The induction of Bc I-Xl by CD40 therefore impairs BCR- 
driven activation of cathepsin B and subsequent apoptosis. However, 
expression of B c I-x l  cannot mimic CD40-dependent rescue from BCR-driven 
growth arrest. The precise mechanism of CD40-dependent proliferation is 
incompletely understood but it is likely to involve the induction of Cox2. This 
could impair BCR-driven apoptosis by diminishing the levels of arachidonic acid 
and could promote proliferation via the production of PGE2 . Indeed, PGE2 and 
other eicosanoids may promote proliferation of WEHI-231 cells via the induction 
of sustained and cyclic activation of Erk. A model of these findings is presented 
in figure 4.17.
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Figure 4.1. Generation of prostaglandins. Arachidonic acid is generated by 
CPLA2 and is converted to the common intermediate prostaglandin H2 (PGH2) 
by prostaglandin H synthase. Prostaglandin H synthase has peroxidase and 
cyclooxygenase activity. PGH2 is converted to prostaglandins (PGE2 , PGD2 , 
PGp2a, thromboxane 8 2  and 6 -keto PGP2« by terminal prostanoid synthases. * 
The rate limiting step of prostaglandin synthesis is catalysed by Cox.
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Figure 4.2. B c 1-xl  is upregulated downstream of CD40 and this can be 
mimicked by transfection of WEHI-231 cells with the bcl-xt gene. Wild-type 
WEHI-231 cells (1 x 1 0 ® cells/ml) were cultured for up to 48 hr with (A) anti- 
CD40 (10 pg/ml), (B) anti-lg (10 pg/ml) or (C) a combination of anti-lg plus anti- 
CD40 (both at 10 pg/ml) before preparing cell lysates. Whole cell lysates were 
analysed by Western blotting (50 pg/well), using the NuPAGE system of gel 
electrophoresis, with anti-Bci-xus antibody. Expression of B c I-Xl in anti-CD40- 
treated wild-type WEHI-231 cells was compared to that of unstimulated WEHI- 
231 cells transfected with empty vector (Neo) or overexpressing B c I-x l  (Bel). 
Recombinant p42 Erk2 was also loaded as an additional standard. Data are 
representative of at least three independent experiments.
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Figure 4.3. Overexpression of Bc I-Xl protects WEHI-231 cells from BCR-driven 
apoptosis. Neo or B c I-xl  WEHI-231 B cells (5x10® cells/ml) were cultured for 
24 hr (A) or 48 hr (B) with anti-lg (0-10 pg/ml, as indicated), anti-CD40 (a-CD40, 
1 0  pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, both at 10 
pg/ml). Levels of apoptosis were indicated by the number of cells with sub­
diploid DNA and this was determined by Pl-staining and FACS analysis (FL2 
fluorescence). Data are representative of at least six independent experiments.
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Figure 4.4. Overexpression of Bc 1-xl  protects WEHI-231 cells from BCR-driven 
apoptosis but not growth arrest after 24 hr. Neo (A) or Bcl-xu (B) WEHI-231 B 
cells (5x10® cells/ml) were cultured for 24 hr with medium (untreated), anti-lg 
(10 pg/ml) or a combination of anti-lg plus anti-CD40 (both at 10 pg/ml). The 
cell cycle progression of WEHI-231 cells was analysed by Pl-staining and FACS 
analysis (FL2 fluorescence). Data are representative of at least six independent 
experiments.
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Figure 4.6. Overexpression of Bo I-xl  protects WEHI-231 cells from BCR-driven 
apoptosis but not growth arrest after 48 hr. Neo (A) or B c 1-x l  (B) WEHI-231 B 
cells (5 X 10® cells/ml) were cultured for 48 hr with medium (untreated), anti-lg 
(10 pg/ml) or a combination of anti-lg plus anti-CD40 (both at 10 pg/ml). The 
cell cycle progression of WEHI-231 cells was analysed by Pl-staining and FACS 
analysis (FL2 fluorescence). Data are representative of at least six independent 
experiments.
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Figure 4.6. Overexpression of Bc I-xl does not protect WEHI-231 cells from 
BCR-driven growth arrest at G0/G1 phase. (A) Neo or Bc I-xl WEHI-231 cells (1 
X 10* cells/well) were cultured in the presence of increasing concentrations of 
anti-lg (0-10 pg/ml, as indicated), anti-CD40 (10 pg/ml) or anti-lg plus anti-CD40 
(both at 10 pg/ml). Proliferation was assessed by measuring the incorporation 
of [^H] thymidine at 48 hr. Values are the mean counts per minute (cpm) ± 
standard deviation of triplicate wells. Data are representative of at least six 
independent experiments. (B) Neo or Bcl-xi. WEHI-231 cells (5x10® cells/ml) 
were cultured for 24 hr with increasing concentrations of anti-lg (0-10 jjg/ml, as 
indicated), anti-CD40 (10 pg/ml) or a combination of anti-lg plus anti-CD40 
(both at 10 pg/ml). The number of cells in G0/G1 phase of the cell cycle was 
determined by Pl-staining and FACS analysis (FL2 fluorescence). Data are 
representative of at least six independent experiments. (C) Neo or Bc I-xl WEHI- 
231 B cells (5 X 10® cells/ml) were cultured for 48 hr with increasing 
concentrations of anti-lg (0-10 pg/ml, as indicated), anti-CD40 (10 pg/ml) or a 
combination of anti-lg plus anti-CD40 (both at 10 pg/ml). The number of cells in 
G0/G1 phase of the cell cycle was determined by Pl-staining and FACS 
analysis (FL2 fluorescence). Data are representative of at least six independent 
experiments.
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Figure 4.7. Overexpression of B c I-x l  does not protect WEHI-231 ceils from 
BCR-driven depletion of S phase and G  2/M phase cells. (A) Neo or B c I-xl  
WEHI-231 cells (6 x 10® cells/ml) were cultured for 24 hr with anti-lg (0-10 
pg/ml, as indicated), anti-CD40 (10 pg/ml) or a combination of anti-lg plus anti- 
CD40 (both at 10 pg/ml). The number of cells in S phase and G2/M were 
determined by Pl-staining and FACS analysis (FL2 fluorescence). Data are 
representative of at least six independent experiments. (B) Neo or B c I-Xl WEHI- 
231 cells (5 X 10® cells/ml) were cultured for 48 hr with anti-lg (0-10 pg/ml, as 
indicated), anti-CD40 (10 pg/ml) or a combination of anti-lg plus anti-CD40 
(both at 10 pg/ml). The number of cells in 3 phase and G2/M were determined 
by Pl-staining and FACS analysis (FL2 fluorescence). Data are representative 
of at least six independent experiments.
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Figure 4.8. Arachidonic acid induces apoptosis of WEHI-231 cells. (A) Neo or 
Bc I-Xl WEHI-231 cells (5x10® cells/ml) were cultured for 48 hr with medium 
(untreated), 100 pM arachidonic acid (AA), 10 pg/ml anti-lg (a-lg) or a 
combination of 100 pM arachidonic acid plus 10 pg/ml anti-lg (a-lg + AA). 
Levels of apoptosis were determined by Pl-staining and FACS analysis (FL3 
fluorescence). Data are representative of at least three independent 
experiments. (B) Neo or Bc I-xl  WEHI-231 cells (5 x 10® cells/ml) were cultured 
for 48 hr with medium (untreated), 100 pM arachidonic acid (AA), 10 pg/ml anti- 
CD40 (a-CD40) or a combination of 100 pM arachidonic acid plus 10 pg/ml anti- 
CD40 (a-CD40 + AA). Levels of apoptosis were determined by Pl-staining and 
FACS analysis (FL3 fluorescence). Data are representative of at least three 
independent experiments. ( 0 )  Neo or B c I-xl  WEHI-231 cells (5  x 10® cells/ml) 
were cultured for 48 hr with medium (untreated), 100 pM arachidonic acid (AA), 
a combination of anti-lg plus anti-CD40 (a-l/C, both at 10 pg/ml) or a 
combination of 100 pM arachidonic acid plus 10 pg/ml anti-lg plus 10 pg/ml anti- 
CD40 (a-l/C + AA). Levels of apoptosis were determined by Pl-staining and 
FACS analysis (FL3 fluorescence). Data are representative of at least three 
independent experiments.
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Figure 4.9. Arachidonic acid Induces growth arrest of WEHI-231 cells. (A) Neo 
or Bel-XL WEHI-231 cells (1 x 10* cells/well) were cultured in the presence of 
increasing concentrations of arachidonic acid (0-100 pM). Proliferation was 
assessed by measuring the incorporation of pH] thymidine at 48 hr. Values are 
the mean counts per minute (cpm) ± standard deviation of triplicate wells. Data 
are representative of at least three independent experiments. (B) Neo or Bc I-xl 
WEHI-231 cells (5 x 10  ^ cells/ml) were cultured for 48 hr with medium 
(untreated), arachidonic acid (AA, 100 pM), anti-lg (a-lg, 10 pg/ml) or a 
combination of arachidonic acid (100 pM) plus anti-lg (10 pg/ml) (a-lg + AA). 
The number of cells in S phase and G2/M were determined by Pl-staining and 
FACS analysis (FL3 fluorescence). Data are representative of at least three 
independent experiments. (C) B c I-xl WEHI-231 cells (1 x 10* cells/well) were 
cultured in the presence of increasing concentrations of arachidonic acid (0-100 
pM, as indicated) with medium (no a-CD40), 1 pg/ml anti-CD40 or 10 pg/ml 
anti-CD40. Proliferation was assessed by measuring the incorporation of pH] 
thymidine at 48 hr. Values are the mean counts per minute (cpm) ± standard 
deviation of triplicate wells. Data are representative of at least three 
independent experiments.
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Figure 4.10. Overexpression of Bc I-Xl does not restore sustained cycling Erk 
activation required for proliferation in WEHI-231 cells. Neo or B c I-x l  WEHI-231 
cells (1 X 10® cells/ml) were cultured for up to 24 hr with medium (untreated), 
anti-lg (10 pg/ml), anti-CD40 (10 pg/ml) or a combination of anti-lg plus anti- 
CD40 (both at 10 pg/ml) before preparing cell lysates. Whole cell lysates (50 
pg/lane) were run on 10% Bis-Tris gels using the NuPAGE system of gel 
electrophoresis. Levels of dual-phosphorylated Erk (pErk) and total Erk (Erk) 
were determined by Western blotting. Data are representative of at least six 
independent experiments.
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Figure 4.11. Cox and Lox inhibitors enhance BCR-mediated apoptosis of 
WEHI-231 cells. Neo or B c I-x l  WEHI-231 cells (5x10® cells/ml) were cultured 
for 48 hr with medium (untreated), a combination of NS-398 plus LOI (NS + 
LOI), anti-lg (a-lg). a combination of anti-lg plus NS-398 plus LOI (a-lg + NS + 
LOI), a combination of anti-lg plus anti-CD40 (a-lg + a-CD40) or a combination 
of anti-lg plus anti-CD40 plus NS-398 plus LOI (a-lg + a-CD40 + NS + LOI). The 
same concentrations of antibodies and inhibitors were used throughout: anti-lg 
10 pg/ml, anti-CD40 10 pg/ml, NS-398 10 pM and LOI 10 pM. Levels of 
apoptosis were determined by measuring the sub-diploid DNA content using Pl- 
staining and FACS analysis (FL3 fluorescence). Data are representative of at 
least three independent experiments.
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Figure 4.12. Inhibition of Cox and Lox impairs proliferation of WEHI-231 cells. 
Neo (A) or B c I -xl (B) WEHI-231 cells were stimulated with increasing 
concentrations of anti-lg (0-1 pg/ml, as indicated) plus NS-398 (0, 1 or 10 pM), 
LOI (0, 1 or 10 pM) or a combination of NS-398 plus LOI (both at 10 pM) for 48 
hr. Proliferation was assessed by measuring the incorporation of [^H] thymidine 
at 48 hr. Values are the mean counts per minute (cpm) ± standard deviation of 
triplicate wells and data are presented as % of control (Neo (A) or Bc I-x l  (B) 
WEHI-231 cells in the absence of anti-lg and inhibitor) mean cpm ± standard 
deviation. Data are representative of at least three independent experiments.
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Figure 4.13. Inhibition of Cox and Lox impairs proliferation and CD40-mediated 
rescue of WEHI-231 cells. Neo WEHI-231 (5x10® cells/ml) were cultured for 48 
hr with medium (untreated), a combination of NS-398 plus LOI (both at 10 pM), 
anti-lg (10 pg/ml) or a combination of anti-lg (10 pg/ml) plus NS-398 (10 pM) 
plus LOI (10 pM). The number of cells In S phase (A) or G2/M phase (B) were 
determined by Pl-staining and FACS analysis (FL3 fluorescence). Data are 
representative of at least three independent experiments. (C) Neo WEHI-231 
cells were stimulated for 48 hr with medium (untreated), anti-lg (10 pg/ml), anti- 
CD40 (10 pg/ml) or a combination of anti-lg plus anti-CD40 (10 pg/ml) and for 
each of these conditions cells were also treated with medium (no inhibitor), NS- 
398 (10 pM), LOI (10 pM) or a combination of NS-398 plus LOI (both at 10 pM). 
Proliferation was assessed by measuring the incorporation of [®H] thymidine at 
48 hr. Values are the mean counts per minute (cpm) ± standard deviation of 
triplicate wells and data are presented as % of control (untreated Neo WEHI- 
231 cells in the absence of inhibitor) mean cpm ± standard deviation. Data are 
representative of at least three independent experiments. (D) B c I-xl  WEHI-231 
cells were stimulated for 48 hr with medium (untreated), anti-lg (10 pg/ml), anti- 
CD40 (10 pg/ml) or a combination of anti-lg plus anti-CD40 (10 pg/ml) and for 
each of these conditions cells were also treated with medium (no inhibitor), NS- 
398 (10 pM), LOI (10 pM) or a combination of NS-398 plus LOI (both at 10 pM). 
Proliferation was assessed by measuring the incorporation of [®H] thymidine at 
48 hr. Values are the mean counts per minute (cpm) ± standard deviation of 
triplicate wells and data are presented as % of control (untreated B c I-x l  WEHI- 
231 cells in the absence of inhibitor) mean cpm ± standard deviation. Data are 
representative of at least three independent experiments.
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Figure 4.14. B c I-xl  does not prevent anti-ig-dependent inhibition of PGEz 
production in WEHI-231 cells and inhibition of Cox/Lox impairs CD40-mediated 
activation of sustained Erk signals. (A) Neo or B c !-x l  WEHI-231 cells (1x10® 
cells/ml) were cultured for up to 48 hr in the presence or absence of anti-lg (1 
pg/ml) before preparing cell lysates and determining the levels of PGE2 using a 
PGE2 competitive binding immunoassay kit (Cayman Chemical). Each anti-lg- 
treated time point sample is expressed as a % of its unstimulated control and 
data are presented as means ± standard deviation, n=3. (B) Treatment of 
proliferating Neo or B c I-x l  WEHI-231 cells with NS-398/LOI suppresses 
sustained (8-48 hr) Erk signals. Neo or Bc I-Xl WEHI-231 cells (1x10® cells/ml) 
were cultured for up to 48 hr with anti-CD40 (10 pg/ml) in the presence (NS- 
398/LOI) or absence (no inhibitor) of NS-398 plus LOI (both at 10 pM) before 
preparing cell lysates. Whole cell lysates (50 pg/lane) were run on 10% Bis-Tris 
gels using the NuPAGE system of gel electrophoresis. Levels of dual- 
phosphorylated Erk (pErk) and total Erk (Erk) were determined by Western 
blotting.
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Figure 4.15. Inhibition of Cox2 plus Lox enhances early (<4 hr) Erk-MAPK 
signals in WEHI-231 cells. Neo (A) or Bc I-xl (B) WEHI-231 cells (1 x 10® 
cells/ml) were cultured for up to 4 hr with medium (untreated), anti-lg (10 pg/ml), 
anti-CD40 (10 pg/ml) or a combination of anti-lg plus anti-CD40 (both at 10 
pg/ml) in the presence (NS-398/LOI) or absence (no inhibitor) of NS-398 plus 
LOI (both at 10 pM) before preparing cell lysates. Whole cell lysates (50 
pg/lane) were run on 10% Bis-Tris gels using the NuPAGE system of gel 
electrophoresis. Levels of dual-phosphorylated Erk (pErk) and total Erk (Erk) 
were determined by Western blotting.
206
(A) No Inhibitor
Untreated
NS-398/LOI
Anti-lg
Anti-CD40
Anti-lg + 
Anti-CD40
Time (hr) 0 1 2  4
(B) No Inhibitor
Untreated
Anti-lg
Anti-CD40
Anti-lg + 
Anti-CD40
pErk
Erk
pErk
Erk
pErk
Erk
pErk
Erk
pErk
Erk
pErk
Erk
pErk
Erk
pErk
Erk
0 1 2  4 
NS-398/LOI
Time (hr) 0 1 2  4 0 1 2  4
Figure 4.16. Arachidonic acid enhances the activity of Erk between 0 and 4 hr 
and this is impaired by ligation of CD40. Neo (A) or B c I-xl  (B) WEHI-231 cells 
(1 X 10® cells/ml) were cultured for up to 4 hr with medium (untreated), anti-lg 
(10 pg/ml), anti-CD40 (10 pg/ml) or a combination of anti-lg plus anti-CD40 
(both at 10 pg/ml) in the presence (+ AA) or absence (- AA) of arachidonic acid 
(100 pM) before preparing cell lysates. Whole cell lysates (50 pg/lane) were run 
on 10% Bis-Tris gels using the NuPAGE system of gel electrophoresis. Levels 
of dual-phosphorylated Erk (pErk) and total Erk (Erk) were determined by 
Western blotting.
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Figure 4.17. Model of Bci-XL-dependent rescue of BCR-stimulated WEHI-231 
cells. Ligation of the BCR induces early Erk signals that contribute to the 
activation of PLA2 and arachidonic acid production. The accumulation of 
arachidonic acid leads to a loss of mitochondrial membrane potential and 
commitment of the cell to apoptosis. Ligation of CD40 prevents BCR-driven 
apoptosis via the induction of BcI-xl. BcI-xl is a key mediator of CD40- 
dependent survival and it does so by suppressing AA-mediated induction of 
cPLAz activity and by protecting the mitochondria from AA-dependent 
disruption. The induction of BcI-xl by CD40 therefore impairs BCR-driven 
activation of cathepsin B and subsequent apoptosis. However, expression of 
Bc1-Xl cannot protect WEHI-231 cells from BCR-driven growth arrest. The 
precise mechanism of CD40-dependent proliferation is incompletely understood 
but it involves the induction of sustained and cyclic Erk signals. The induction of 
Cox2 and subsequent production of PGE2 downstream of CD40 appears to 
contribute to the activation of sustained Erk signals and hence proliferation. 
However, CD40 may also induce the production of additional eicosanoids to 
further promote proliferation of WEHI-231 cells.
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CHAPTER 5 - Role of sphingosine kinase in regulating survival and 
proliferation of WEHI-231 cells
5.1 Sphingolipids and ceramide
Sphingolipids are a diverse family of phospholipids and glycolipids that are 
characterised by their sphingoid backbone. The sphingoid backbone is based 
on the lipid ceramide. Ceramide can be generated by two distinct mechanisms: 
by de novo biosynthesis (figure 5.1 A) or by the conversion of sphingolipids to 
ceramide using specific enzymes. For example, sphingomyelin can be 
converted to ceramide using sphingomyelinase enzymes. There are three 
classes of sphingomyelinases: acidic (lysosomal) sphingomyelinase (optimal pH 
of this enzyme is 5), magnesium-dependent sphingomyelinase (membrane- 
bound enzyme with neutral optimal pH) and magnesium-independent 
sphingomyelinase (cytosolic enzyme with neutral optimal pH). The activity of 
sphingomyelinases can be regulated by extracellular ligands: for example, 
TNFa elevates the cellular levels of ceramide by stimulating neutral 
sphingomyelinases and by inducing de novo biosynthesis (453).
De novo biosynthesis of ceramide (figure 5.1 A) takes place in the 
endoplasmic reticulum and begins with the condensation of serine and paimitoyl 
CoA to form 3-ketosphinganine, which is then reduced to form 
dihydrosphingosine (sphinganine). Dihydrosphingosine can be converted to 
dihydroceramide via the attachment of a fatty acyl group using an amide link. 
Dihydroceramide can then be converted to ceramide using desaturase (453- 
455). Newly synthesised ceramide translocates from the endoplasmic reticulum 
to the Golgi in vesicles and the Golgi can then transport ceramide to other 
membranes within the cell (265).
Ceramide has several functions within a cell. Firstly, it is a structural
component of membranes and is particularly enriched in lipid rafts (272).
Secondly, ceramide can function as a second messenger especially via the
activation of ceramide-activated protein kinases and protein phosphatases.
Ceramide-activated protein phosphatases can induce growth arrest by
dephosphorylating Rb and c-Jun. Ceramide-activated protein phosphatases
also promote apoptosis by activating caspases and inhibiting PKCa and Bci-2
(456). Ceramide-activated protein kinases may promote growth arrest and
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apoptosis by inhibiting Ras and its downstream effectors (MARK and PI-3-K) 
(463). For example, ceramide induces apoptosis in dendritic cells by inhibiting 
PI-3-K and the downstream effectors Akt, N F -k B and Bc I-xl (457). Other targets 
of ceramide may include Raf-1, cathepsin D, cPLAa, PKCt and MEKK/JNK 
(458-460). Ceramide thus functions as a second messenger that promotes 
growth arrest and apoptosis.
A third function of ceramide is to act as a substrate for specific enzymes 
that can convert ceramide into other sphingolipids (figure 5.1 A) (453). The 
simplest alteration of ceramide is its phosphorylation catalysed by ceramide 
kinase to form ceramide-1-phosphate (461). The reverse reaction is catalysed 
by ceramide phosphatase. By contrast, a series of chemical reactions are 
required to convert ceramide to glycosphingolipids, gangliosides and 
sulphatides. These lipids are involved in cell-to-cel! interactions and may 
regulate the activities of receptor tyrosine kinases (462). Ceramide can also be 
converted to sphingomyelin using sphingomyelin synthase. Sphingomyelin is an 
important component of cellular membranes that differentially affects the 
properties of membranes depending on its fatty acyl composition. About 50% of 
cellular sphingomyelin is found in the plasma membrane and it is particularly 
abundant in lipid rafts.
Another important sphingolipid that can be formed from ceramide is 
sphingosine, which is the precursor for sphingosine-1 -phosphate (SPP). The 
interconversion of ceramide, sphingosine and SPP, referred to as the SPP 
rheostat, can determine the fate of a cell (figure 6.1 B). The reversible 
conversion of ceramide to sphingosine and sphingosine-1 -phosphate is 
particularly important since sphingosine and sphingosine-1 -phosphate can also 
function as signalling molecules. Ceramide is hydrolysed by ceramidase to form 
sphingosine. Sphingosine is generally considered to be a pro-apoptotic 
signalling molecule since it can mediate the activation of cathepsins and 
caspases (103). Sphingosine also inhibits PKC-dependent activation of Erk 
(463). In contrast to sphingosine and ceramide, SPP is generally considered to 
favour survival and proliferation of cells.
5.2 Sphingosine kinase
Sphingosine kinase catalyses the phosphorylation of sphingosine to
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generate SPP (figure 5.1B). Two mammalian sphingosine kinases have been 
cloned and they have been found to be evolutionarily conserved lipid kinases 
that can be detected in multiple tissues with highest levels being found in the 
lung and spleen (464). Inside the cell, sphingosine kinase has been detected in 
both cytosolic and membrane fractions (465). The activity of sphingosine kinase 
can be regulated by multiple extracellular ligands. Indeed, sphingosine kinase 
has at least three consensus sequences for Ca^'^/calmodulin-binding indicating 
it is a calcium-sensitive enzyme. Sphingosine kinase also has multiple potential 
phosphorylation sites including one for PKA, two for casein kinase II and eight 
for PKC (464). Cellular levels of SPP can be depleted by converting SPP back 
to sphingosine using SPP phosphatase or by degrading SPP using SPP lyase 
to form palmitaldehyde and phosphoethanolamine (466, 467). However, the 
accumulation of SPP generally involves the activation of sphingosine kinase 
rather than the inhibition of degradation pathways (465).
5.3 Sphingosine-1-phosphate
SPP is thought to be a mediator of mitogenesis in multiple cellular systems 
in response to a wide variety of stimuli (463, 468). For example, constitutive 
expression of sphingosine kinase in NIH-3T3 cells enhances their proliferation 
and stimulates transformation (469). Furthermore, in C3H10T1/2 murine 
fibroblasts PDGF and fibroblast growth factor can both stimulate ceramidase 
and sphingosine kinase to elevate SPP levels and this is required for cellular 
survival, proliferation and differentiation (470).
However, an additional layer of diversity in SPP signalling was unravelled 
with the discovery that SPP can function as both an intracellular and an 
extracellular signalling molecule (463, 468, 471). As an extracellular ligand SPP 
is recognised by members of the EDG (endothelial-differentiation gene) family 
of G-protein-coupled receptors including EDG1, EDG3, EDG5, EDG6  and 
EDG8  (472). These receptors can couple SPP to several different types of G- 
proteins including Gi, Gq and G12/13 (463).
Attempts have been made to attribute specific functions to different SPP- 
sensitive EDG receptors but these receptors are widely expressed in most cells 
and tissues and activation of any one of these receptors is likely to have 
multiple biological effects (471, 473). For example, in human T lymphoblastoma
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cells SPP stimulates EDG3 or EDG5 and decreases the levels of Bax to prevent 
apoptosis (474). Furthermore, in airway smooth muscle cells SPP can stimulate 
EDG1, a Gi-coupled receptor, resulting in the activation of c-Src and Grb-2/PI~3- 
K leading to the stimulation of Erk1/2 and this can be enhanced by co­
stimulation with PDGF resulting in increased DNA synthesis (475). Moreover, 
the SPP-mediated activation of EDG6, which is largely expressed in lymphoid 
and hematopoietic tissues, can activate Erk1/2 and PLC via Gi thus coupling 
extracellular SPP to MAPK and to calcium mobilisation (468). Calcium 
mobilisation is also observed downstream of EDG3 and EDG5 in C2C12 
myoblast cells (476). SPP therefore regulates multiple signalling networks 
downstream of EDG receptors including calcium mobilisation, PI-3-K and Erk- 
MAPK. In general, this leads to enhanced survival and proliferation of the cells. 
However, in human myofibroblasts SPP can suppress proliferation via the 
activation of EDG1, EDG3 and EDG5 (477). Furthermore, Rac/Cdc42-mediated 
stimulation of JNK has been implicated in coupling SPP-sensitive EDG 
receptors to the activation of caspases and apoptosis (463). The signals 
induced by extracellular SPP are thus diverse and can potentially regulate the 
survival, proliferation and differentiation of cells.
In addition to its role as an extracellular ligand, increasing evidence 
suggests SPP can function independently of EDG receptors as an intracellular 
second messenger (463, 468, 471). Initial studies suggesting SPP is an 
intracellular second messenger used pertussis toxin to inhibit Gi-coupled 
receptors but the discovery of Gq- and G i2/i3“Coupled EDG receptors showed 
that pertussis toxin-insensitive effects of SPP are not necessarily due to SPP 
functioning as an intracellular signalling molecule. More convincing evidence 
that SPP is an intracellular signalling molecule came from the use of dihydro- 
SPP, which can bind to and activate all SPP-sensitive EDG receptors but is 
unable to mimic all the effects of SPP. Furthermore, microinjection of SPP or 
caged SPP can elevate intracellular calcium levels and promote survival and 
proliferation of cells. Moreover, yeast lack G-protein-coupled receptors and yet 
phosphorylated sphingolipids and possibly SPP can mobilise calcium in yeast.
Intracellular SPP is believed to regulate a variety of signalling pathways 
including MAPK activation, Ca^ "^  signalling and PLD. For example, in 
C3H10T1/2 fibroblast cells ceramide activates apoptosis via JNK but the
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conversion of ceramide to SPP stimulates Erk-MAPK and promotes survival, 
proliferation and differentiation of the cells (470). Furthermore, in U937 cells 
FcyRI activates sphingosine kinase resulting in the mobilisation of calcium 
independently of PLC stimulation and IP 3 production (478). SPP is also likely to 
amplify existing Ca^^ signals since sphingosine kinase has at least three 
Ga^'"/calmodulin-binding consensus sequences (463, 465). Moreover, ceramide 
can inhibit PLD but SPP is an activator of PLD so can increase the cellular 
levels of phosphatidic acid (479). Phosphatidic acid can stimulate PI-4-kinase, 
Ras and Raf and can be converted to DAG to stimulate phorbol ester-sensitive 
isoforms of PKC (480).
In general intracellular SPP promotes survival and proliferation of cells. 
For example, in U937 cells SPP can suppress apoptosis induced by TNFa, anti- 
Fas antibodies, serum deprivation and exogenous ceramide by suppressing the 
release of mitochondrial factors including cytochrome c and Smac/DIABLO and 
hence preventing the activation of executioner caspases. A similar protective 
effect can be observed in U937 cells that overexpress B c I-x l but SPP does not 
mediate its effects by increasing the expression of B c I-x l, B cI-2  or Mcl-1 (8 4 ).  
Furthermore, in Swiss 3T3 cells PDGF can stimulate sphingosine kinase 
resulting in SPP production. SPP then promotes G1 to S phase transition to 
enhance proliferation of the cells. In this system sphingosine kinase and SPP 
are found in the nucleoplasm and nuclear envelope, indicating sphingosine 
kinase is a nuclear-associated enzyme that can mediate the production of SPP 
specifically at the nucleus. However, the signalling mechanisms used by 
nuclear SPP to promote cell cycle progression have not yet been deciphered 
(4 8 1 ).
5.4 SPP rheostat and sphingolipid signalling in B lymphocytes
The SPP rheostat describes the interconversion of ceramide, sphingosine 
and SPP (figure 5.1B). Each of these molecules regulates a complex network of 
signalling pathways but ceramide and sphingosine are generally associated 
with growth arrest and apoptosis whilst SPP favours survival and proliferation. 
The relative balance of these lipids can thus determine the survival and 
proliferation of a cell.
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Under apoptotic conditions, ligation of the BCR on WEHI-231 cells can 
elevate the cellular levels of ceramide (305). The activity of sphingosine kinase 
can also be regulated by the BCR and by CD40. Indeed, ligation of the BCR on 
immature B cells has been shown to induce a rapid but transient (^10 min) peak 
of sphingosine kinase activity whereas co-ligation of CD40 produces a more 
sustained activation of sphingosine kinase (428). The functional significance of 
the BCR-coupled transient peak of sphingosine kinase activity has not been 
explored but one possibility is it has a role in promoting calcium mobilisation to 
enhance PLA2 activity and hence arachidonic acid production. Interestingly, the 
BCR of mature B lymphocytes is also coupled to SPP production but the 
kinetics are different to those of WEHI-231 cells. In particular, mature B cells 
display a delayed but prolonged accumulation of SPP (428). Since ligation of 
the BCR on mature B cells leads to proliferation and activation, prolonged SPP 
production may be more associated with promoting survival and proliferation of 
B cells.
Indeed, over a 48 hr time period, unstimulated proliferating WEHI-231 
cells accumulate SPP. However, ligation of the BCR impairs SPP production in 
WEHI-231 cells whilst co-ligation of CD40 appears to restore SPP levels (428). 
Prolonged elevation of SPP therefore correlates with conditions that favour the 
survival and proliferation of WEHI-231 cells. Consistent with this, inhibition of 
sphingosine kinase impairs proliferation of WEHI-231 cells. Furthermore, SPP 
appears to function exclusively as an intracellular signalling molecule in WEHI- 
231 cells since no SPP can be detected in supernatants of these cells (428). 
The SPP rheostat therefore seems to be regulated by the BCR and CD40 in 
WEHI-231 cells and it is likely to affect the proliferation of the cells. However, 
the mechanism of SPP signalling in immature B cells is poorly understood.
5.5 Aims and objectives
Previous investigations have shown that ligation of the BCR and CD40 on 
WEHI-231 cells can regulate the activity sphingosine kinase and hence the 
cellular levels of SPP (428). However, the role of sphingosine kinase and SPP 
in regulating the survival and proliferation of WEHI-231 cells is incompletely 
understood.
The objectives of this investigation were;
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1. to determine the effect of inhibition of sphingosine kinase on the survival 
and proliferation of WEHI-231 cells
2. to examine the effect of inhibition of sphingosine kinase on BCR-driven 
growth arrest and apoptosis
3. to investigate the signalling mechanisms used by SPP to determine the 
survival and proliferation of WEHI-231 cells by analysing the effect of inhibition 
of sphingosine kinase on the activity of Erk-MAPK and the levels of Bc I-x l .
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5.6 Results and Discussion
5.6.1 Inhibition of sphingosine kinase in WEHI-231 cells induces growth 
arrest and apoptosis
The cellular levels of SPP can be increased by various ligands and they 
generally do so by stimulating sphingosine kinase rather than by suppressing 
the degradation of SPP (465). However, the levels of sphingosine in 
mammalian cells are substantially lower than the levels of ceramide therefore 
the accumulation of SPP generally requires the simultaneous activation of 
sphingosine kinase and ceramidase (453, 460, 465, 470). Inhibition of 
sphingosine kinase can thus deplete the cell of SPP. QMS (N, N-Dimethyl-D- 
erythro-sphingosine) is a competitive inhibitor of sphingosine kinase 1 and a 
non-competitive inhibitor of sphingosine kinase 2 (482) with few non-specific 
toxic effects. WEHI-231 cells were treated with QMS to assess the role of 
sphingosine kinase and SPP in regulating survival and proliferation of immature 
B cells.
The effect of QMS on the cell cycle progression of WEHI-231 cells was 
determined using Pl-staining and FACS analysis of DMS-treated cells. 
Treatment of WEHI-231 cells with DMS induced growth arrest and apoptosis 
after 24 hr and 48 hr in a dose-dependent manner (figure 5.2-5.S). Indeed, after 
24 hr DMS enriched the G0/G1 population of cells (figure 5.3B) and diminished 
the number of cells in S phase (figure 5.30) and G2/M (figure 5.3D), indicating 
DMS induces growth arrest at G0/G1 phase of the cell cycle. For example, after 
24 hr, 2.5 pM DMS increased the percentage of G0/G1 cells from 34% to 50% 
whilst decreasing the percentage of cells in S phase from 28% to 6% and 
diminishing the G2/M population from 24% to 6% (figure 5.2A). After 48 hr, the 
number of cells in S phase and G2/M was decreased by DMS in a dose- 
dependent manner but DMS also depleted the G0/G1 population of cells (figure 
5.3B-D). This is likely to reflect the high levels of apoptosis in the cultures of 
WEHI-231 cells treated with DMS for 48 hr. Indeed, DMS greatly enriched the 
sub-diploid population of cells, especially at 48 hr, indicating the inhibition of 
sphingosine kinase induces apoptosis of WEHI-231 cells (figure 5.3A). For 
example, 78% of WEHI-231 cells treated with 2.5 pM DMS for 48 hr had sub­
diploid DNA. Interestingly, >1 pM DMS was required for the potent induction of
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apoptosis whereas >0.25 pM DMS was adequate for significant induction of 
growth arrest of WEHI-231 cells (figure 5.3A-D). This suggests that the 
induction of growth arrest by DMS may not simply reflect the onset of apoptosis 
in these WEHI-231 cells. Treatment of WEHI-231 cells with DMS alone 
therefore induces growth arrest at G0/G1 phase of the cell cycle and causes the 
cells to undergo apoptosis.
To confirm the ability of DMS to induce growth arrest of WEHI-231 cells 
the effect of DMS on DNA synthesis of WEHI-231 cells was determined by 
measuring the incorporation of [^H] thymidine after 48 hr. In agreement with the 
cell cycle data, DMS inhibited DNA synthesis in a dose-dependent manner with 
complete growth arrest being observed following exposure to 2.5 pM DMS for 
48 hr (figure 5.3E). These observations therefore suggest that the conversion of 
ceramide and sphingosine to SPP by sphingosine kinase is important for the 
survival and proliferation of unstimulated WEHI-231 cells. This is consistent with 
published data that has associated these lipids with regulating survival and 
proliferation of multiple cell types (456, 463, 468). For example, SPP is required 
for cell cycle progression from GI to S phase in PDGF-stimulated Swiss 3T3 
cells (481).
5.6.2 Inhibition of sphingosine kinase enhances BCR-driven growth arrest
Previous investigations have suggested that the BCR of mature and 
immature B cells can regulate the activity of sphingosine kinase (428). To 
further explore the role of sphingosine kinase in BCR signalling, the effect of 
DMS on the cell cycle progression of anti-lg-treated WEHI-231 cells was 
determined by Pl-staining and FACS analysis.
After 24 hr and 48 hr, anti-lg and DMS were both capable of inducing 
growth arrest of WEHI-231 cells in a dose-dependent manner (figure 5.4). 
However, treatment of WEHI-231 cells with a combination of anti-lg plus DMS 
further enhanced the induction of growth arrest (figure 5.4). Furthermore, anti-lg 
and/or DMS induced growth arrest at G0/G1 phase of the cell cycle since this 
population of cells was enriched by these agents whilst the number of cells in S 
phase and G2/M was diminished (compare figures 5.4A and D to 5.4B-C and 
5.4E-F). This is consistent with the observations of figure 3.6 and figures 5.2-5.3 
in which anti-lg or DMS were shown to induce G0/G1 cell cycle arrest-
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Moreover, analysis of DNA synthesis by measuring the incorporation of [^H] 
thymidine after 48 hr also showed that DMS enhanced BCR-driven growth 
arrest (figure 5.5).
Furthermore, analysis of number of cells in S phase and G2/M suggested 
that anti-lg and DMS synergistically induced growth arrest of WEHI-231 cells. 
For example, in the absence of DMS, treatment of WEHI-231 cells with 1 pg/ml 
anti-lg for 48 hr reduced the percentage of S phase cells from 35% to 20% 
(15% difference) and in the absence of anti-lg, 0.25 pM DMS reduced the 
number of S phase cells from 35% to 33% (2% difference). However, treatment 
of WEHI-231 cells with a combination of 1 pg/ml anti-lg plus 0.25 pM DMS for 
48 hr reduced the percentage of S phase cells from 35% to 9% (26% 
difference) (figure 5.4E). The effect of anti-lg plus DMS was therefore greater 
than the sum of the effects of the two single inhibitors indicating anti-lg and 
DMS synergistically reduced the number of cells in S phase. Furthermore, 
analysis of the G2/M population of cells also indicated anti-lg and DMS were 
acting in synergy. For example, in the absence of DMS, treatment of WEHI-231 
cells with 1 pg/ml anti-lg for 48 hr reduced the number of cells in G2/M from 
22% to 10% (12% difference) and in the absence of anti-lg, 0.25 pM DMS 
reduced the percentage of cells in G2/M from 22% to 21% (1% difference) 
(figure 5.4F). However, treatment of WEHI-231 cells with 1 pM DMS plus 1 
pg/ml anti-lg for 48 hr reduced the percentage of G2/M cells from 22% to 4% 
(18% difference). These results show anti-lg and DMS synergistically induce 
growth arrest implying both agents may affect the same signalling pathway to 
regulate proliferation of WEHI-231 cells. Furthermore, these observations 
suggest that BCR-driven growth arrest may involve the suppression of 
sphingosine kinase. Consistent with this, previous investigations have shown 
that ligation of the BCR on WEHI-231 cells can suppress sustained SPP signals 
(428).
6.6.3 Inhibition of sphingosine kinase enhances BCR-driven apoptosis
To further investigate the role of sphingosine kinase in BCR signalling, the 
effect of DMS on BCR-dependent apoptosis was determined by Pl-staining of 
antl-lg/DMS-treated WEHI-231 cells followed by FACS analysis. Both anti-lg 
and DMS can induce apoptosis of WEHI-231 cells in a dose-dependent manner
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(figure 3.6 and 5.2-5.3), Furthermore, treatment of WEHI-231 cells with DMS 
enhanced BCR-driven apoptosis after 24 hr and 48 hr (figure 5.6A-B). For 
example, after 24 hr, 1 pg/ml anti-lg increased the percentage of cells with sub­
diploid DNA from 6% to 19% (13% difference) and treatment with 2.5 pM DMS 
increased the percentage of sub-diploid cells from 6% to 31% (25% difference) 
(figure 5.6A). However, exposure of WEHI-231 cells to 1 pg/ml anti-lg plus 2.5 
pM DMS for 24 hr increased the percentage of apoptotic cells from 6% to 58% 
(52% difference) indicating anti-lg and DMS synergistically induce apoptosis of 
WEHI-231 cells.
A similar situation was observed after 48 hr culture with anti-lg and DMS. 
For example, after 48 hr, 1 pg/ml anti-lg increased the percentage of apoptotic 
cells from 10% to 25% (15% difference) and 1 pM DMS increased the number 
of sub-diploid cells from 10% to 12% (2% difference) (figure 5.6B). However, 
co-culture with 1 pg/ml anti-lg plus 1 pM DMS increased the number of cells 
with sub-diploid DNA from 10% to 58% (48% difference). Anti-lg and DMS 
therefore synergistically induced apoptosis of WEHI-231 cells suggesting DMS 
can regulate the activation of the BCR-driven apoptotic pathway. Previously it 
has been shown that exogenous ceramide can induce apoptosis of WEHI-231 
cells via the classical caspase-dependent pathway (102, 320) whilst BCR-driven 
apoptosis of WEHI-231 cells does not involve the release of cytochrome c from 
the mitochondria and is mediated by cathepsins (102). The observation that 
anti-lg and DMS synergistically induced apoptosis of WEHI-231 cells suggests 
that DMS-mediated apoptosis may not be exclusively caused by the 
accumulation of ceramide.
Furthermore, previous investigations have shown that unstimulated WEHI- 
231 cells produce SPP over a 48 hr period with optimal levels being observed 
between 8 hr and 24 hr. Ligation of the BCR decreases the levels SPP 
throughout the 48 hr time period whilst co-ligation of CD40 can restore SPP 
levels (428). These observations show that SPP is a signalling molecule of 
WEHI-231 cells that can be differentially regulated by the BCR and CD40. 
Taken together, these observations suggest that BCR-dependent apoptosis 
may require the inhibition of sphingosine kinase and/or sphingosine kinase 
might be activated by CD40 to suppress BCR-driven apoptosis.
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5.6.4 Ligation of CD40 partially protects WEHI-231 cells from DMS-driven 
apoptosis
To further investigate the role of sphingosine kinase in regulating BCR- 
driven apoptosis, the effect of DMS on CD40-mediated rescue from anti-lg- 
induced apoptosis of WEHI-231 cells was examined. The sub-diploid DNA 
content of cells treated with anti-lg, anti-CD40 and DMS was determined by Pl- 
staining and FACS analysis.
As shown above, after 24 hr, DMS induced apoptosis of unstimulated 
WEHI-231 cells in a dose-dependent manner (figure 5.6C). Furthermore, DMS 
more potently induced apoptosis of anti-lg-treated WEHI-231 cells. These 
observations are consistent with earlier data (figures 5.2-5.3 and 5.6A). 
However, after 24 hr, DMS (0-2.5 pM) did not induce apoptosis of anti-CD40 
treated WEHI-231 cells, indicating ligation of CD40 can protect WEHI-231 cells 
from DMS-driven apoptosis (figure 5.6C). This is consistent with the theory that 
DMS enhances the BCR-driven apoptotic pathway since CD40 is known to 
protect WEHI-231 cells from BCR-driven apoptosis. Furthermore, after 24 hr, 
CD40 almost completely prevented apoptosis induced by a combination of anti- 
lg plus DMS (figure 5.6C). Ligation of CD40 can therefore impair BCR- and 
DMS-driven apoptosis of WEHI-231 cells. This finding suggests that CD40- 
mediated survival may not require the activation of sphingosine kinase. 
However, after 48 hr, ligation of CD40 was unable to protect WEHI-231 cells 
from apoptosis induced by DMS, especially at 2.5 pM DMS (figure 5.6D). This 
suggests that inhibition of sphingosine kinase ultimately impairs CD40-mediated 
survival and hence implies that this kinase may have a role in promoting pro­
survival signals or suppressing pro-apoptotic pathways in WEHI-231 cells.
5.6.5 CD40 partially protects WEHI-231 cells from DMS-induced growth 
arrest
To further investigate the role of sphingosine kinase in CD40~mediated 
rescue of BCR-stimulated WEHI-231 cells, the effect of DMS on CD40- 
dependent proliferation was explored. The level of DNA synthesis in DMS- 
treated WEHI-231 cells was determined by measuring the incorporation of [^H] 
thymidine after 48 hr. In agreement with previous observations (figure 3.6 and
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figures 5.2-5.5), anti-lg and DMS both induced growth arrest of WEHI-231 cells 
(figure 5.7A). Furthermore, ligation of CD40 was inefficient at preventing DMS- 
mediated inhibition of DNA synthesis after 48 hr (figure 5.7A). For example, 
CD40 slightly impaired the inhibition of DNA synthesis by 1 pM DMS but was 
unable to prevent growth arrest induced by >1 pM DMS. Similarly, after 48 hr 
anti-CD40 was inefficient at preventing DMS-mediated growth arrest of BCR- 
activated WEHI-231 cells and DMS appeared to slightly impair CD40-mediated 
rescue from anti-lg-induced growth arrest (figure 5.7A).
To further analyse the effect of DMS on CD40-mediated rescue from BCR- 
driven growth arrest, the cell cycle of WEHI-231 cells was analysed by Pl- 
staining and FACS analysis. After 24 hr, ligation of CD40, in the presence or 
absence of BCR-stimulation, partially protected WEHI-231 cells from DMS- 
dependent depletion of S phase (figure 5.7B) and G2/M phase (figure 5.7C) 
populations of cells. Similarly, after 48 hr, anti~CD40 was able to partially protect 
WEHI-231 cells from DMS-driven depletion of S phase (figure 5.7D) and G2/M 
phase (figure 5.7E) cells. This was especially evident when cells were treated 
with 2.5 pM DMS. For example, after 48 hr, 2.5 pM DMS reduced the 
percentage of cells in S phase from 35% to 3% (32% difference) but in the 
presence of anti-CD40, 2.5 pM DMS only decreased the percentage of S phase 
cells from 35% to 11% (24% difference). Furthermore, after 48 hr, 2.5 pM DMS 
decreased the number of cells in G2/M from 22% to 1% (21% difference) but in 
CD40-stimulated cells, 2.5 pM DMS only reduced the percentage of G2/M cells 
from 22% to 6% (16% difference). Taken together, these observations suggest 
that ligation of CD40 can partially protect WEHI-231 cells from DMS-driven 
growth arrest but CD40 was unable to fully protect the ceils.
5.6.6 Overexpression of B c I-x l  protects WEHI-231 cells from DMS-driven 
apoptosis
B c 1-xl seems to be a key mediator of CD40-dependent survival therefore 
Bc I-xl  WEHI-231 cells were used to further investigate the role of sphingosine 
kinase in CD40-mediated rescue of BCR-stimulated WEHI-231 cells. The effect 
of DMS on the sub-diploid DNA content of Neo and Bcl-xu WEHI-231 cells was 
determined by Pl-staining and FACS analysis. As shown previously (figures 5,2- 
5.3), DMS induced apoptosis of Neo WEHI-231 cells in a dose-dependent
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manner, especially at >1 pM DMS (figure 5.8). In contrast, B c I-x l  WEHI-231 
cells were protected from DMS-driven apoptosis after 24 hr and 48 hr (figure 
5.8A-B). For example, after 48 hr, 77% of Neo WEHI-231 cells treated with 2.5 
pM DMS had sub-diploid DNA whilst 17% of B c I-Xl WEHI-231 cells were 
apoptotic when exposed to the same conditions (figure 5.SB). Expression of 
Bc I-xl  therefore protects WEHI-231 cells from DMS-driven apoptosis. This is 
consistent with DMS amplifying BCR-driven apoptosis since B c I-xl  has 
previously been shown to suppress this pro-apoptotic pathway (427).
Furthermore, expression of B c I-xl  protected WEHI-231 cells from 
apoptosis induced by a combination of anti-lg plus DMS (figure 5.9). For 
example, after 24 hr, 31% of Neo WEHI-231 cells treated with 2.5 pM DMS had 
sub-diploid DNA and co-culture with 10 pg/ml anti-lg increased this percentage 
to 55%. In contrast, only 7% of B c I-Xl WEHI-231 cells treated with 2.5 pM DMS 
had sub-diploid DNA and co-culture with 10 pg/ml anti-lg increased this 
percentage to just 12% (figure 5.9A). Similarly, after 48 hr, overexpression of 
Bc I-xl  greatly reduced the level of apoptosis induced by a combination of anti-lg 
plus DMS (figure 5.9B). Nonetheless, Bc I-xl  WEHI-231 cells treated with 2.5 pM 
DMS for 48 hr were slightly susceptible to anti-lg-induced apoptosis suggesting 
these cells no longer had complete protection against these pro-apoptotic 
agents. This is consistent with previous observations where it was shown that 
the protective effects of Bc I-xl  could be overridden by amplification of the BCR- 
driven pro-apoptotic pathway (figure 4.8).
Taken together, this data strongly suggests that expression of B c I-x l can 
protect WEHI-231 cells from anti-lg-induced and DMS-mediated apoptosis. This 
is consistent with Bcl-xu being an important pro-survival factor of WEHI-231 
cells. Interestingly, a comparison of CD40-dependent and Bcl-XL-mediated 
rescue from DMS-driven apoptosis showed that expression of B c I-x l was more 
effective than ligation of CD40 at enabling WEHI-231 cells to survive in the 
presence of DMS (figure 5.90). For example, 63% of Neo WEHI-231 cells 
treated with 2.5 pM DMS plus anti-GD40 for 48 hr had sub-diploid DNA. In 
contrast, only 16% of B c I-x l  WEHI-231 cells were apoptotic when treated with
2.5 pM DMS in the absence of CD40. Bcl-xt was thus significantly more 
effective than anti-CD40 at protecting WEHI-231 cells from DMS-induced
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apoptosis. This implies that CD40-mediated survival is impaired by DMS and 
this can be overcome by expression of Bc 1-x l .
6.6.7 DMS impairs B c I-Xl expression in WEHI-231 cells
To further investigate the mechanism of DMS-driven apoptosis, the effect 
of DMS on Bel-XL expression was examined since B c 1-x l  seems to be a key 
mediator of CD40-dependent survival (see chapter 4) and DMS appears to 
impair CD40-mediated survival in a manner that can be overcome by 
expression of B c I-x l . This suggests that DMS might impair CD40-mediated 
induction of B c 1-xl in WEHI-231 cells and hence the expression of B c I-xl  in 
DMS-treated WEHI-231 cells was investigated by Western blotting.
B c I-Xl was detected in untreated WEHI-231 cells, especially in 24 hr and 
48 hr lysates (figure 5.10A). However, treatment of these unstimulated WEHI- 
231 cells with DMS reduced the levels of Bc I-x l  in a dose-dependent manner. 
Inhibition of sphingosine kinase therefore impaired Bc I-xl expression suggesting 
the activity of this kinase, which is cycling in untreated cells (428), contributes to 
the induction of Bc I-xl  in unstimulated WEHI-231 cells. B c I-Xl is an important 
survival factor of WEHI-231 cells (292, 311) therefore this is likely to explain, at 
least in part, why DMS induces apoptosis of these cells.
The effect of DMS on CD40-mediated induction of B c I-Xl was also 
examined since ligation of CD40 is known to upregulate B c I-Xl in WEHI-231 
cells (figure 4.2) and this is important for CD40-dependent survival. As with 
unstimulated WEHI-231 cells, treatment of anti-CD40-treated WEHI-231 cells 
with DMS reduced the levels of B c I-xl  in the cells (figure 5.108). Indeed, 0.5 pM 
DMS was able to reduce the levels of B c I-xl to a similar extent as exposure to 
10 pg/ml anti-lg. Moreover, B c I~x l  levels were further reduced by treatment of 
WEHI-231 cells with a combination of anti-lg plus DMS. This is consistent with 
the high levels of apoptosis observed in these cells (figure 5.6). Furthermore, 
WEHI-231 cells treated with a combination of anti-lg plus anti-CD40 were less 
sensitive to DMS-dependent suppression of Bc 1-Xl than cells treated with anti-lg 
alone but they still had lower levels of B c I-xl  than cells cultured in the absence 
of DMS (figure 5.1 OB). DMS therefore impaired the induction of B c I-xl  in 
unstimulated and CD40-activated WEHI-231 cells and this is likely to contribute
223
to the observations of figure 5.6 in which CD40 was only able to partially protect 
Neo WEHI-231 cells from DMS-driven apoptosis.
These observations suggest that DMS-dependent apoptosis is likely to be 
mediated, at least in part, by reducing B c I-xl  levels. This may reflect a 
mechanism used by the BCR to suppress pro-survival pathways since previous 
investigations have suggested that the BCR can impair SPP production (428). 
The BCR may therefore inhibit sphingosine kinase to reduce SPP levels and 
hence prevent the induction of Bc I-x l . Alternatively, the BCR may impair B c I-xl  
signalling by allowing ceramide to accumulate since ceramide is known to 
decrease the expression of pro-survival Bcl-2-family members including Bcl-2 
(456) and Bc I-xl  (457) in other cellular systems.
These observations can also account for the impaired CD40-mediated 
survival observed in DMS-treated cells (figure 5.6) since B c I-x l  is an important 
mediator of CD40-dependent survival. Moreover, these observations implicate 
sphingosine kinase as a CD40-regulated enzyme whose action contributes to 
the upregulation of Bc I-xl  and hence to CD40-mediated survival.
5.6.8 Ligation of CD40 enhances the survival of DMS-treated B c I -x l  WEHi- 
231 cells
To further explore the mechanism of CD40-mediated survival of anti-lg- 
and DMS-treated WEHI-231 cells, the effect of ligation of CD40 on the survival 
of B c I-xl  WEHI-231 cells was examined. Apoptosis of B c I-Xl WEHI-231 cells 
was measured by determining their sub-diploid DNA content using Pl-staining 
and FACS analysis.
In agreement with earlier observations (figures 4.3 and 5.8-5.9), overexpression 
of B c I~x l  was found to impair anti-lg and DMS-driven apoptosis (figure 5.11). 
However, Bc 1-xl  WEHI-231 cells did display enhanced sub-diploid DNA content 
when treated with a combination of anti-lg (10 pg/ml) plus high concentrations 
of DMS (2.5 pM), especially after 48 hr (figure 5.11). Interestingly, treatment of 
these cells with anti-CD40 impaired the ability of anti-lg and DMS to induce 
apoptosis after 24 hr and 48 hr (figure 5.11A-B). Indeed, treatment with anti- 
CD40 enhanced the protective capacity of B c I-xl  WEHI-231 cells and enabled 
full protection from apoptosis induced by a combination of 10 pg/ml anti-lg plus
2.5 pM DMS. These observations indicate that despite DMS suppressing CD40-
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mediated induction of B c I-x l , CD40 was able to improve the survival of anti- 
Ig/DMS-treated WEHI-231 cells. CD40 is therefore likely to stimulate DMS- 
insensitive pro-survival signals in addition to the DMS-sensitive pathway of 
inducing B c I-x l . The nature of these signals remains unknown but one 
possibility is CD40 can upregulate Bc I-x l  via sphingosine kinase-dependent and 
independent pathways. Alternatively, CD40 may induce Bcl-XL-independent 
survival signals. However, these observations may also reflect the ability of 
DMS to promote cell death via more than one signalling pathway. For example, 
DMS may also promote caspase-dependent apoptosis by elevating ceramide 
levels (102).
5.6.9 Overexpression of B c !-xl  does not protect WEHI-231 cells from DMS- 
induced growth arrest
To further examine the role of Bc I-xl in protecting DMS-treated WEHI-231 
cells, the proliferation of DMS-treated Neo and B c I-xl  WEHI-231 cells was 
examined by measuring the incorporation of f  H] thymidine and hence the level 
of DNA synthesis. Cell cycle progression of Neo and B c1-x l  WEHI-231 cells was 
also analysed by Pl-staining and FACS analysis.
Treatment of Neo WEHI-231 cells with DMS inhibited DNA synthesis in a 
dose-dependent manner and this was not prevented by the expression of Bc I-xl 
(figure 5.12A). Furthermore, after 24 hr, Bc I-xl  was unable to prevent DMS- 
mediated depletion of S phase and G2/M phase populations of cells (figure 
5.12B). For example, after 24 hr, in the absence of DMS 28% of Neo WEHI-231 
cells were in S phase but treatment with 2.5 pM DMS reduced the number of 
cells in S phase to 6%. Similarly, in the absence of DMS 30% of B c I-xl  WEHI- 
231 cells were in S phase but exposure to 2.5 pM DMS reduced the number of 
S phase cells to 5%. Likewise, after 48 hr expression of Bcl-xu was unable to 
protect WEHI-231 cells from DMS-mediated depletion of S phase and G2/M 
phase cells (figure 5.12C). This suggests that inhibition of sphingosine kinase 
impairs proliferation of WEHI-231 cells and this cannot be prevented by 
expression of Bc I-Xl.
Furthermore, the ability of anti-lg and DMS to co-ordinately suppress 
proliferation of WEHI-231 cells was not prevented by overexpression of Bc I-xl  
(figure 5 .1 3 A -B ). B c I-x l  WEHI-231 cells were more sensitive to anti-lg-induced
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growth arrest but overexpression of B c I-xl  did not alter the susceptibility of 
WEHI-231 cells to DMS-driven growth arrest. These observations suggest that 
sphingosine kinase may promote proliferation of WEHI-231 cells independently 
of its role in inducing Bcl-XL-mediated survival. Similarly, distinct mechanisms 
appear to regulate the survival and proliferation of WEHI-231 cells downstream 
of the BCR and CD40 (102, 328, 427).
5.6.10 Overexpression of B c I-X l slightly enhances CD40-dependent rescue 
of DMS-driven growth arrest
To further investigate the regulation of proliferation of WEHI-231 cells by 
DMS, the effect of ligation of CD4Q was explored. The number of cells in S 
phase was determined by Pl-staining and FACS analysis of DMS-treated Neo 
and B c I-X l WEHI-231 cells. After 24 hr, DMS decreased the number of 
untreated Neo WEHI-231 cells in S phase in a dose-dependent manner (figure 
5.14A). However, ligation of CD4Q on Neo WEHI-231 cells impaired DMS- 
mediated growth arrest. In contrast, overexpression of B c I-x l  did not protect 
WEHI-231 cells from DMS-driven growth arrest but ligation of CD40 on B c 1-xl  
WEHI-231 cells did prevent DMS-mediated depletion of S phase cells. Analysis 
of the number of cells in G2/M gave similar results (data not shown). These 
observations suggest CD40 can protect WEHI-231 cells from DMS-driven 
growth arrest after 24 hr but this cannot be mimicked by expression of B c I-Xl.
However, after 48 hr, CD40 was less effective at protecting Neo WEHI- 
231 cells from DMS-dependent growth arrest (figure 5.14B). Similarly, 
expression of Bc I-Xl was relatively ineffective at protecting WEHI-231 cells from 
DMS-mediated depletion of S phase cells. However, ligation of CD40 on B c I-Xl 
WEHI-231 cells did impair DMS-mediated growth arrest. To further explore 
these observations, the level of DNA synthesis in WEHI-231 cells was 
determined by measuring the incorporation of [^H] thymidine. Supporting the 
cell cycle data, the combination of overexpression of B c I-xl  and ligation of 
CD40, albeit to a lesser degree than observed with cell cycle analysis, partially 
protected WEHI-231 cells from DMS-dependent inhibition of DNA synthesis 
after 48 hr (figure 5.14C).
These observations therefore show that after 24 hr, ligation of CD40 can 
impair DMS-dependent growth arrest whereas expression of B c I-x l  is
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insufficient to sustain proliferation of the cells. This indicates that CD40 
signalling but not B c I-xl expression can prevent DMS-mediated growth arrest. 
However, after 48 hr CD40 was inefficient at preventing DMS-driven growth 
arrest unless B c I-xl  was overexpressed. A  possible explanation for this relates 
to the observation that DMS impaired CD40-mediated survival by suppressing 
the induction of B c I-x l . Ligation of CD40 alone therefore might be adequate to 
prevent DMS-mediated growth arrest but it was not able to prevent apoptosis 
and hence cell cycle progression was impaired. Moreover, expression of Bc I-x l  
was unable to restore proliferation to DMS-treated WEHI-231 cells but it did 
protect the cells from apoptosis. Consequently, protection of WEHI-231 cells 
from DMS-induced growth arrest required the expression of B c I-xl to prevent 
apoptosis and CD40-mediated, Bcl-XL-independent signals to prevent cell cycle 
arrest.
5.6.11 DMS does not prevent CD40-mediated rescue of WEHI-231 cells 
from BCR-driven growth arrest
Bc I-Xl WEHI-231 cells were treated with DMS to investigate the role of 
sphingosine kinase in GD40-mediated rescue from BCR-driven growth arrest. 
Bc I-Xl WEHI-231 cells were used since Bc I-xl  can protect WEHI-231 cells from 
DMS-driven apoptosis (figure 5.9). Proliferation was assessed by analysing the 
cell cycle using Pl-staining and FACS analysis. Consistent with previous 
observations (figure 4.4-4.7) anti-lg diminished the number of cells in S phase 
and G2/M indicating ligation of the BCR induced growth arrest of B c I-Xl WEHI- 
231 cells after 24 hr and 48 hr (figure 5.15). However, co-ligation of CD40 
replenished the S phase and G2/M phase populations of cells indicating CD40 
can prevent BCR-driven growth arrest of Bc I-xl  WEHI-231 cells. Furthermore, 
the addition of DMS (0-2.5 pM) did not prevent CD40-mediated rescue from 
BCR-driven growth arrest after 24 hr or 48 hr (figure 5.15A-B). For example 
after 48 hr, in the absence of DMS, 20% of cells treated with anti-lg plus anti- 
CD40 were in G2/M phase whereas 17% of cells treated with 2.5 pM DMS were 
in G2/M. DMS therefore slightly impaired but did not prevent CD40-mediated 
rescue from BCR-driven growth arrest. This suggests that CD40-mediated 
rescue from BCR-dependent growth arrest is not exclusively dependent on the 
activation of sphingosine kinase.
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5.6.12 DMS does not alter sustained cyclic activation of Erk-MAPK in 
WEHI-231 cells
To investigate the mechanism of DMS-dependent growth arrest of WEHI- 
231 cells, the effect of DMS on Erk activity was determined since sustained 
activation of Erk is required for proliferation of WEHI-231 cells (328). 
Furthermore, it is well recognised that ceramide, sphingosine and SPP can 
differentially regulate the activity of MAPK in multiple systems (453, 458, 463, 
471). For example, in C3H10T1/2 cells SPP is an activator of Erk-MAPK and 
this is believed to be important for the induction of proliferation (470). 
Conversely, in airway smooth muscle cells sphingosine can inhibit Erk1/2 and 
induce growth arrest (463). Furthermore, WEHI-231 cells appear to have similar 
patterns of SPP production and Erk activation. For example, over a 48 hr time 
period prolonged SPP production can be observed in unstimulated WEHI-231 
cells with maximal levels being obtained after 8 hr, Anti-lg suppresses the 8 hr 
peak of SPP production but anti-CD40 restores the signal (428). Similarly, 
un stimulated WEHI-231 cells have prolonged and cyclic activation of Erk over a 
48 hr time period and this is suppressed by ligation of the BCR but is restored 
by co-ligation of CD40 (appendix 2). However, the signalling mechanisms used 
to regulate sustained Erk signals are incompletely understood. The regulation of 
Erk-MAPK by sphingosine kinase was thus investigated by Western blotting of 
lysates prepared from DMS-treated WEHI-231 cells.
Consistent with previous observations, unstimulated WEHI-231 cells 
displayed sustained cyclic activation of Erk-MAPK that was disrupted by ligation 
of the BCR but restored by co-ligation of CD40 (figure 5.16). However, 
treatment of WEHI-231 cells with DMS did not mimic anti-lg in that it was unable 
to suppress sustained Erk signalling in untreated WEHI-231 cells (figure 5.16). 
This suggests that DMS-dependent growth arrest is not mediated by an 
inhibition of Erk-MAPK and sphingosine kinase does not appear to be required 
for sustained Erk signalling in WEHI-231 cells. Furthermore, inhibition of 
sphingosine kinase did not prevent CD40-mediated restoration of sustained and 
cyclic Erk signals in anti-lg-treated WEHI-231 cells (figure 5.16). This implies 
that sphingosine kinase is not required for CD40-mediated activation of 
sustained Erk signals in WEHI-231 cells. This agrees with the observation that
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DMS did not prevent CD40-dependent rescue from BCR-driven growth arrest 
(figure 5.15).
Taken together, this data shows that DMS does not induce growth arrest 
of WEHI-231 cells by suppressing sustained Erk signals and DMS does not 
impair CD40-dependent restoration of prolonged Erk signals in BCR-stimulated 
cells. This suggests that BCR-dependent suppression of sustained Erk signals 
is not mediated by an inhibition of sphingosine kinase and depletion of SPP 
levels. Furthermore, CD40-dependent restoration of sustained Erk signals does 
not require the induction of sphingosine kinase.
Previously it has been shown that WEHI-231 cells have both early and 
sustained SPP signals (428). The function of the early (<1 hr) signal is not 
known. The activity of Erk was measured in WEHI-231 cells in which the early 
SPP signal was permitted but the sustained (>8 hr) SPP signal was inhibited by 
adding DMS to the WEHI-231 cultures after 4 hr. The inhibition of prolonged 
SPP production did not affect the activation of Erk-MAPK in unstimulated or 
anti-CD40-treated WEHI-231 cells (figure 6.17) supporting the proposal that 
sphingosine kinase is not necessary for inducing prolonged Erk signalling in 
WEHI-231 cells.
5.6.13 DMS does not alter the activity of MEK in WEHI-231 cells
Previous data has suggested that BCR-dependent inhibition of sustained 
Erk signalling does not require the inhibition of the upstream activator MEK 
(figures 3.7-3.8) but is instead mediated by MAPK phosphatases (appendix 5 
and figure 3.9). To confirm the data of figure 5.16, which suggested sphingosine 
kinase was not required for BCR-dependent inhibition of Erk, the effect of DMS 
on the activity of MEK was determined in WEHI-231 cells. MEK is activated by 
phosphorylation of Ser i^7/218 Ser^^\ catalysed by upstream kinases 
including Raf-1 (372) therefore the activity of MEK was determined by Western 
blotting using an antibody that only recognises MEK when it is phosphorylated 
at these residues.
In the absence of DMS (left hand side of figure 5.18) untreated WEHI-231 
cells had high levels of phospho-MEK1/2 at late time points (8-48 hr) indicating 
the presence of sustained MEK activation. Stimulation of WEHI-231 cells with 
anti-lg, anti-CD40 or a combination of anti-lg plus anti-CD40 did not abolish
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sustained MEK signalling. Furthermore, the addition of 0.5 pM DMS (right hand 
side of figure 5.18) did not alter the levels of phospho-MEK in unstimulated or 
stimulated WEHI-231 cells. This is consistent with the observation that DMS 
does not affect sustained Erk signalling (figure 5.16). The BCR and CD4G 
therefore do not require sphingosine kinase to regulate sustained MEK or Erk 
signals in WEHI-231 cells.
Nonetheless, inhibition of sphingosine kinase using DMS does enhance 
BCR-driven growth arrest. A potential role for sphingosine kinase in stimulating 
proliferation of WEHI-231 cells downstream of Erk is suggested by studies on 
N1H3T3 fibroblast cells. Transfection of N1H3T3 cells with RasV^^, a 
constitutively active form of Ras, induces cellular transformation, inhibition of 
sphingosine kinase using DMS or overexpression of a kinase dead mutant of 
sphingosine kinase can impair RasV^^-dependent transformation: for example,
2.5 pM DMS reduced the cellular transformation by 41%. These results show 
that sphingosine kinase can signal downstream of Ras to promote cellular 
transformation and hence proliferation (469). Furthermore, it has recently been 
reported that sphingosine kinase can be directly phosphorylated by Erk1/2 and 
this enhances the activity of sphingosine kinase and promotes Its translocation 
from the cytosol to the plasma membrane (483). Similarly, in WEHI-231 cells 
sphingosine kinase may function downstream of Erk-MAPK to increase SPP 
production and to promote proliferation since proliferation of WEHI-231 cells is 
known to be dependent on sustained Erk signals and these can be differentially 
regulated by the BCR and CD40 (328). To investigate this possibility further, the 
activity of sphingosine kinase could be measured in WEHI-231 cells treated with 
MEK inhibitors such as PD98059 and U0126.
5.6.14 DMS does not alter phospho-Erk signalling in B c I-xl  WEHI-231 cells
To further examine the role of sphingosine kinase in CD40-mediated 
rescue from BCR-driven growth arrest the activity of Erk was measured in Bcl- 
x l WEHI-231 cells treated with DMS. B c I-xl  WEHI-231 cells were used since 
Bc I-Xl can prevent DMS-dependent apoptosis therefore these cells enable 
DMS-dependent growth arrest to proceed without the complicating factor of 
DMS-mediated apoptosis. The activation of Erk-MAPK was investigated in Neo 
and B c I-xl  WEHI-231 cells using Western blotting for dual-phosphorylated Erk
230
(figure 5.19). In the absence of DMS, untreated Neo WEHI-231 cells had 
highest levels of phospho-Erk between 24 hr and 48 hr and these sustained Erk 
signals were inhibited by ligation of the BCR. However, co-ligation of CD40 
restored Erk activation between 24 hr and 48 hr. Overexpression of B c1-x l  in the 
absence of DMS did not alter the temporal pattern of Erk activation. This is 
consistent with the observations of figure 4.10 in which expression of Bcl-xu was 
shown to be unable to restore sustained Erk signalling to BCR-stimulated 
WEHI-231 cells.
In general, the addition of 0.5 pM DMS (lanes 4-6 of figure 5.19) to Neo or 
Bc I-Xl WEHI-231 cells did not affect the temporal pattern or the intensity of 
phospho-Erk signalling in unstimulated cells or cells treated with anti-lg in the 
presence or absence of anti-CD40, These observations show that 0.5 pM DMS 
does not affect Erk signalling in cells protected from DMS-mediated apoptosis. 
Taken together, the results of figures 5.16-5.19 indicate 0.5 pM DMS does not 
mimic anti-lg in suppressing sustained Erk signalling and does not impair CD40- 
mediated restoration of sustained Erk signals.
However, exposure of Neo and Bc I-xl  WEHI-231 cells to 5 pM DMS (lanes 
7-9 of figure 5.19) did cause a general suppression of phospho-Erk signalling, 
especially between 24 hr and 48 hr. This observation was not altogether 
surprising since high concentrations of DMS very potently induce growth arrest 
and apoptosis of WEHI-231 cells (figure 5.2) suggesting many of the cells used 
to prepare these lysates may have been undergoing growth arrest and 
apoptosis. Consequently, very few cells will have been cycling and hence 
signals associated with cell cycle progression such as sustained Erk signalling 
will have been suspended.
However, an interesting observation was made in the total Erk Western 
blots of the lysates prepared from Neo and Bc I-xl  WEHI-231 cells treated with 6 
pM DMS (figure 5.19). The detection of total Erk (non-phosphorylated plus 
phosphorylated Erk) is often used as a loading control for phospho-Erk Western 
blotting but WEHI-231 cells treated with 5 pM DMS appeared to have reduced 
levels of total Erk. This was more evident in Neo WEHI-231 cells than in B c I-xl  
WEHI-231 cells and total Erk levels seemed to be enhanced by ligation of 
CD40, suggesting the depletion in total Erk levels correlated with increased cell 
death. Nonetheless, these observations are unlikely to be an artefact caused by
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inadequate protein loading since B c 1-xl  levels were constant in ail lysates 
prepared from Bc I-Xl WEHI-231 cells including those in which total Erk levels 
were depleted. Bc 1-x l  WEHI-231 cells are transfected with a vector that causes 
them to constitutively express Bc I-xl  therefore Western blotting for Bc I-xl  can be 
used as a loading control for these cells.
These observations are representative of a single experiment and hence 
must be repeated to confirm these findings but they suggest that high 
concentrations of DMS may downregulate cellular levels of total Erk and this 
can be inhibited by anti-CD40, expression of Bc I-xl  or a combination of these 
two factors. Expression of B c I-x l  and ligation of CD40 are both known to 
increase the survival of WEHI-231 cells therefore the reduced levels of total Erk 
observed in figure 5.19 are likely to be caused by the onset of apoptosis in 
these cells. However, these results also implicate a role for sphingosine kinase 
in increasing or sustaining total Erk levels in WEHI-231 cells, perhaps by 
preventing the degradation of Erk or by promoting the expression of the erk 
gene.
5.7 Conclusions
The role of sphingosine kinase in regulating survival and proliferation of 
WEHI-231 cells was investigated using the sphingosine kinase inhibitor DMS. 
DMS induced cell cycle arrest at G0/G1 phase and caused WEHI-231 cells to 
undergo apoptosis (figures 5.2-5.3). Furthermore, DMS and anti-lg 
synergistically induced growth arrest and apoptosis (figures 5.4-5.6) suggesting 
DMS can regulate the pathways used by the BCR to induce growth arrest and 
apoptosis. This is consistent with previous observations, which showed that the 
BCR of WEHI-231 cells is coupled to sphingosine kinase and can suppress 
sustained SPP signals. Taken together, this suggests that the BCR of WEHI- 
231 cells is likely to be coupled to SPP signalling and may regulate SPP 
production to affect the survival and proliferation of the cells (figure 5.20).
Anti-lg induced growth arrest and apoptosis can be prevented by co­
ligation of CD40, However, CD40 only partially protected WEHI-231 cells from 
DMS-mediated growth arrest and apoptosis (figures 5.6-5.7). Nonetheless, 
overexpression of Bc 1-x l  did protect WEHI-231 cells from apoptosis but not 
growth arrest induced by DMS and/or anti-lg (figures 5.8-5.9). Indeed,
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expression of B c I-xl  was more effective than ligation of CD40 at preventing 
apoptosis of DMS-treated WEHI-231 cells (figure 5.9C) suggesting CD40- 
dependent survival was impaired by DMS and this could be overcome by 
expression of B c I-x l . Consistent with this, DMS was found to reduce the levels 
of B c I-Xl in unstimulated WEHI-231 cells and cells treated with anti-lg and/or 
anti-CD40 (figure 5.10). This suggests that sphingosine kinase is likely to 
contribute to the induction of B c I-x l  in unstimulated and anti-CD40-treated 
WEHI-231 cells, enabling the BCR-driven mitochondrial death pathway to be 
suppressed (figure 5.20). However, ligation of CD40 enhanced the survival of 
DM S/anti-1 g-treated Bc I-x l  WEHI-231 cells (figure 5.11) suggesting CD40 may 
stimulate B c I-xl  via sphingosine kinase-dependent and independent 
mechanisms or CD40 may promote survival of WEHI-231 cells via B c I-Xl- 
independent mechanisms.
Expression of B c I-xl  did not prevent anti-lg- or DMS-dependent growth 
arrest (figures 5.12-5.13) but ligation of CD40 did impair DMS-mediated growth 
arrest of Bc I-xl  WEHI-231 cells (figures 5.14-5.15). This suggests that CD40 
can stimulate mitogenic pathways that can overcome DMS-mediated growth 
arrest. To further investigate the mechanism of DMS-mediated growth arrest, 
the effect of DMS on sustained Erk signalling was explored since the BCR and 
CD40 differentially regulate Erk1/2 and this is important for determining the 
proliferation of WEHI-231 cells. This showed that DMS-dependent growth arrest 
was not mediated by an inhibition of sustained Erk signals since DMS did not 
mimic anti-lg in suppressing these signals (figure 5.16). BCR-dependent 
suppression of sustained Erk signals therefore is unlikely to involve an inhibition 
of sphingosine kinase. Furthermore, DMS did not impair CD40-mediated 
restoration of sustained Erk signals to anti-lg-treated WEHI-231 cells indicating 
sphingosine kinase is not required for CD40-dependent induction of prolonged 
Erk signals. However, recent reports suggest that sphingosine kinase may 
actually be regulated downstream of Erk1/2 therefore sphingosine kinase may 
promote proliferation of WEHI-231 cells downstream of Erk-MAPK (figure 5.20). 
Finally, high levels of DMS appeared to reduce the cellular levels of Erk 1/2 
(figure 5.19) suggesting sphingosine kinase may also have a role in ensuring 
constant levels of Erk can be found in WEHI-231 cells.
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Figure 5.1. Sphingolipid biosynthesis and the SPP rheostat. (A) Sphingolipid 
biosynthesis. Ceramide is biosynthesised via a series of reactions catalysed by 
specific enzymes (enzymes are shown in blue). Ceramide forms the backbone 
of sphingolipids. Ceramide can be converted to sphingomyelin via the action of 
sphingomyelin synthase (1). This is a reversible reaction; sphingomyelin can be 
converted to ceramide using sphingomyelinase (2). Ceramide can form 
sphingosine using ceramidase (3) and the reverse reaction is catalysed by 
ceramide synthase (4). Ceramide can be phosphorylated by ceramide kinase 
(5) to form ceramide-1-phosphate and ceramide-1-phosphate is 
dephosphorylated by ceramide phosphatase (6) to form ceramide. Ceramide 
can also be converted to glycosphingolipids, gangliosides and sulphatides via a 
series of reactions catalysed by various enzymes. (B) The SPP rheostat. SPP 
rheostat describes the interconversion of ceramide, sphingosine and SPP. 
Ceramide can be formed from sphingomyelin using sphingomyelinase. 
Ceramide can then be converted to sphingosine by ceramidase and 
sphingosine can be phosphorylated to form SPP. Each of these reactions is 
reversible therefore SPP can be converted to sphingosine and sphingosine to 
ceramide. In general, ceramide and sphingosine are pro-apoptotic signalling 
molecules whilst SPP promotes survival and proliferation therefore the relative 
balance of ceramide/sphingosine and SPP can determine the survival and 
proliferation of the cell.
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Figure 5.2. Inhibition of sphingosine kinase in WEHl-231 cells induces growth 
arrest and apoptosis. Neo WEHl-231 cells (5x10® cells/ml) were cultured for 24 
hr or 48 hr with medium (no DMS) or increasing concentrations of DMS (0.25, 1 
or 2.5 pM). The cells were then stained with PI and analysed by FACS analysis 
(FL2 fluorescence). Data are representative of at least three independent 
experiments.
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Figure 5.3. Inhibition of sphingosine kinase in WEHl-231 cells induces growth 
arrest and apoptosis. Neo WEHl-231 cells (5 x 10® cells/ml) were cultured for 24 
hr or 48 hr with increasing concentrations of DMS (0-2.5 pM). Cells were then 
stained with PI and analysed by FACS analysis (FL2 fluorescence) to determine 
the number of cells with sub-diploid DNA (apoptotic cells) (A) and the number of 
cells in G0/G1 phase (B), S phase (C) and G2/M phase (D) of the cell cycle. 
Data are representative of at least three independent experiments. (E) Wild- 
type WEHl-231 cells (1 X 10* cells/well) were cultured in the presence of 
increasing concentrations of DMS (0-5 pM). Proliferation was assessed by 
measuring the incorporation of [®H] thymidine at 48 hr. Values are the mean 
counts per minute (cpm) ± standard deviation of triplicate wells. Data are 
representative of at least three independent experiments.
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Figure 5.4. Inhibition of sphingosine kinase enhances BCR-driven growth 
arrest. Neo WEHl-231 cells (5 x 10® cells/ml) were cultured with increasing 
concentrations of anti-lg (0-10 pg/ml) in the presence of increasing 
concentrations of DMS (0-2.5 pM, as indicated) for 24 hr or 48 hr. Cells were 
then stained with PI and analysed by FACS analysis (FL2 fluorescence) to 
determine the number of cells in G0/G1 phase, S phase and G2/M phase of the 
cell cycle. (A) shows % G0/G1 cells after 24 hr, (B) is % S phase cells after 24 
hr (C) is % G2/M cells after 24 hr, (D) is % G0/G1 cells after 48 hr, (E) is % S 
phase cells after 48 hr and (F) is % G2/M cells after 48 hr. Data are 
representative of at least three independent experiments.
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Figure 5.5. Inhibition of sphingosine kinase enhances BCR-driven growth 
arrest. Neo WEHl-231 cells (1 xIO^ cells/well) were cultured in the presence of 
increasing concentrations of anti-lg (0-10 pg/ml) in the presence of increasing 
concentrations of DMS (0-2.5 pM, as indicated). Proliferation was assessed by 
measuring the incorporation of [^H] thymidine at 48 hr. Values are the mean 
counts per minute (cpm) ± standard deviation of triplicate wells. Data are 
representative of at least three independent experiments.
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Figure 5.6. Inhibition of sphingosine kinase enhances BCR-driven apoptosis 
but CD40-ligation partially protects WEHl-231 cells from DMS-driven apoptosis. 
Neo WEHl-231 ceils (5 x 10® cells/ml) were cultured with increasing 
concentrations of anti-lg (0-10 pg/ml) in the presence of increasing 
concentrations of DMS (0-2.5 pM) for 24 hr (A) or 48 hr (B). Cells were then 
stained with PI and analysed by FACS analysis (FL2 fluorescence) to determine 
the number of cells with sub-diploid DNA (apoptotic cells). Neo WEHl-231 cells 
(5x10® cells/ml) were cultured with medium (untreated), anti-lg (a-lg, 10 pg/ml), 
anti-CD40 (a-CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + 
a-CD40, both at 10 pg/ml) in the presence of increasing concentrations of DMS 
(0-2.5 pM) for 24 hr (C) or 48 hr (D). Cells were then stained with PI and 
analysed by FACS analysis (FL2 fluorescence) to determine the number of cells 
with sub-diploid DNA (apoptotic cells). Data are representative of at least three 
independent experiments.
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Figure 6.7. CD40 partially protects WEHl-231 cells from DMS-induced growth 
arrest. (A) Neo WEHl-231 cells (1 x lO'* cells/well) were cultured in the 
presence of medium (untreated), anti-lg (a-lg, 1 pg/ml), anti-CD40 (a-CD40, 10 
pg/ml) or a combination of anti-lg (1 pg/ml) plus anti-CD40 (10 pg/ml) in the 
presence of increasing concentrations of DMS (0-5 pM, as Indicated). 
Proliferation was assessed by measuring the incorporation of [^H] thymidine at 
48 hr. Values are the mean counts per minute (cpm) ± standard deviation of 
triplicate wells. Data are representative of at least three independent 
experiments. Neo WEHl-231 cells (5x10® cells/ml) were cultured with medium 
(untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a 
combination of anti-lg plus anti-CD40 (a-lg + a-CD40, both at 10 pg/ml) In the 
presence of increasing concentrations of DMS (0-2.5 pM) for 24 hr or 48 hr. 
Cells were then stained with PI and analysed by FACS analysis (FL2 
fluorescence) to determine the number of cells in S phase and G2/M phase of 
the cell cycle. (B) shows the % S phase cells after 24 hr, (C) is % G2/M phase 
cells after 24 hr, (D) is % S phase cells after 48 hr and (E) is % G2/M phase 
cells after 48 hr. Data are representative of at least three independent 
experiments.
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Figure 5.8. Overexpression of B c I-x l  protects WEHl-231 cells from DMS-driven 
apoptosis. Neo or B c I-x l  WEHl-231 cells (5x10® cells/ml) were cultured for 24 
hr (A) or 48 hr (B) with increasing concentrations of DMS (0-2.5 pM). The cells 
were then stained with PI and analysed by FACS analysis (FL2 fluorescence) to 
determine the number of cells with sub-diploid DNA (apoptotic cells). Data are 
representative of at least three independent experiments.
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Figure 5.9. Overexpression of B c I-xl protects WEHl-231 cells from BCR- and 
DMS-driven apoptosis. Neo or Bcl-xu WEHl-231 cells (5x10® cells/ml) were 
cultured for 24 hr (A) or 48 hr (B) with increasing concentrations of anti-lg (0-10 
pg/ml) in the presence of increasing concentrations of DMS (0-2.5 pM, as 
indicated). The cells were then stained with PI and analysed by FACS analysis 
(FL2 fluorescence) to determine the number of cells with sub-diploid DNA 
(apoptotic cells). Data are representative of at least three independent 
experiments. (C) Neo or Bc I-xl  WEHl-231 cells (5x10® cells/ml) were cultured 
for 48 hr with medium (untreated) or anti-CD40 (a-CD40, 10 pg/ml) plus 
increasing concentrations of DMS (0-2.5 pM, as indicated). The cells were then 
stained with PI and analysed by FACS analysis (FL2 fluorescence) to determine 
the number of cells with sub-diploid DNA (apoptotic cells).
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Figure 5.10. DMS impairs Bc I -Xl expression in WEHl-231 cells. (A) Neo WEHl- 
231 cells (1 X 10® cells/ml) were cultured for 0, 24 or 48 hr with several 
concentrations of DMS (0, 0.5 pM or 5 pM) before preparing cell lysates. Levels 
of Bc I-xl  were determined by Western blotting using the NuPAGE system of gel 
electrophoresis with 10% Bis-Tris gels. Gels were loaded (30 pg protein/lane) 
as follows: lane 1, no DMS time 0 lysate; lane 2, no DMS 24 hr lysate; lane 3, 
no DMS 48 hr lysate; lane 4, DMS 0.5 pM time 0 lysate; lane 5, DMS 0.5 pM 24 
hr lysate; lane 6, DMS 0.5 pM 48 hr lysate; lane 7, DMS 5 pM time 0 lysate; 
lane 8, DMS 5 pM 24 hr lysate; lane 9, DMS 5 pM 48 hr lysate; lane 10, no 
DMS unstimulated time 0 B c1-xl  WEHl-231 lysate ( B c I-xl  positive control). (B) 
Wild-type WEHl-231 cells (1 x 10® cells/ml) were cultured for up to 48 hr with 
anti-CD40 (10 pg/ml), anti-lg (10 pg/ml) or a combination of anti-lg plus anti- 
CD40 (both at 10 pg/ml) in the presence or absence of DMS (0.5 pM) before 
preparing cell lysates. Whole cell lysates (50 pg/lane) were run on 10% Tris-HCI 
gels using the BioRad system of gel electrophoresis. B c I -Xl positive and 
negative controls were also included on the gels: n is no DMS unstimulated time 
0 Neo WEHl-231 lysate (Bcl-xu negative control) and b is no DMS unstimulated 
time 0 B c I-xl  WEHl-231 lysate ( Bc I-xl  positive control). Levels of Bc I-Xl and total 
Erk (Erk) were determined by Western blotting.
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Figure 5.11. Ligation of CD40 enhances the survival of DMS-treated B c I-x l  
WEHl-231 cells. Bc I-Xl WEHl-231 cells (5x10® cells/ml) were cultured for 24 hr 
(A) or 48 hr (B) with medium (untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a- 
CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, 
both at 10 pg/ml) in the presence of increasing concentrations of DMS (0-2.5 
pM, as indicated). The cells were then stained with PI and analysed by FACS 
analysis (FL2 fluorescence) to determine the number of cells with sub-diploid 
DNA (apoptotic cells). Data are representative of at least three independent 
experiments.
244
(A)  24 hr
no DMS n  DMS 0.25 pM n  DMS 1 pM m DMS 2.5 pM
untreated 
(B) 48 hr
a-CD40 a-lg + 
a-CD40
no DMS g  DMS 0.25 pM a  DMS 1 pM ■  DMS 2.5 pM
untreated a-lg a-CD40 a-lg + a-CD40
Figure 5.12. Overexpression of B c I-Xl does not protect WEHl-231 cells from 
DMS-induced cell cycle arrest (A) Neo or Bc I-Xl WEHl-231 cells (1 x 10* 
cells/well) were cultured in the presence of increasing concentrations of DMS 
(0-5 pM). Proliferation was assessed by measuring the incorporation of [^H] 
thymidine at 48 hr. Values are the mean counts per minute (cpm) ± standard 
deviation of triplicate wells. Neo or Bc I-Xl WEHl-231 cells (5x10® cells/ml) were 
cultured with increasing concentrations of DMS (0-2.5 pM) for 24 hr (B) or 48 hr
(C). Cells were then stained with Pi and analysed by FACS analysis (FL2 
fluorescence) to determine the number of cells in S phase and G2/M phase of 
the cell cycle. Data are representative of at least three independent 
experiments.
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F ig u re  5 .1 3 . Overexpression of Bo I-xl does not protect WEHl-231 cells from 
DMS-induced growth arrest Neo (A) or Bc I-x l (B ) WEHl-231 cells (1 x 10  ^
cells/well) were cultured in the presence of increasing concentrations of anti-lg 
(0-10 pg/ml) in the presence of increasing concentrations of DMS (0-2.5 pM). 
Proliferation was assessed by measuring the incorporation of [^H] thymidine at 
48 hr. Values are the mean counts per minute (cpm) ± standard deviation of 
triplicate wells.
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Figure 5.14. Overexpression of B c I-x l  enhances CD40-dependent rescue of 
DMS-driven growth arrest. Neo or Bc I-xl WEHI-231 cells (5x10^ cells/ml) were 
cultured with medium (untreated) or anti-CD40 (a-CD40, 10 pg/ml) in the 
presence of increasing concentrations of DMS (0-2.5 pM, as indicated) for 24 hr
(A) or 48 hr (B). Cells were then stained with PI and analysed by FACS analysis 
(FL2 fluorescence) to determine the number of cells in S phase of the cell cycle. 
Data are representative of at least three independent experiments. (0) Neo or 
B c I-xl WEHI-231 cells (1 xIO* cells/well) were cultured with medium (untreated) 
or anti-CD40 (a-CD40, 10 pg/ml) in the presence of increasing concentrations 
of DMS (0-2.6 pM, as indicated). Proliferation was assessed by measuring the 
incorporation of [^H] thymidine at 48 hr. Values are the mean counts per minute 
(cpm) ± standard deviation of triplicate wells.
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Figure 5.15. DMS does not prevent CD40-mediated rescue of WEHI-231 cells 
from BCR-driven growth arrest. Bc I-xl WEHI-231 cells (5x10® cells/ml) were 
cultured with medium (untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a-CD40, 
10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, both at 10 
pg/ml) in the presence of increasing concentrations of DMS (0-2.5 pM) for 24 hr 
(A) or 48 hr (B). Cells were then stained with PI and analysed by FACS analysis 
(FL2 fluorescence) to determine the number of cells in S phase and G2/M 
phase of the cell cycle. Data are representative of at least three independent 
experiments.
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Figure 5.16. DMS does not alter sustained cyclic activation of Erk-MAPK in 
WEHI-231 cells. Wild-type WEHI-231 cells (1 x 10® cells/ml) were cultured for 
up to 48 hr with medium (untreated), anti-lg (10 pg/ml), anti-CD40 (10 pg/ml) or 
a combination of anti-lg plus anti-CD40 (both at 10 pg/ml) in the presence or 
absence of 0.6 pM DMS before preparing cell lysates. Whole cell lysates (50 
pg/lane) were run on 10% Tris-HCI gels using the BioRad system of gel 
electrophoresis. Levels of duai-phosphorylated Erk (pErk) and total Erk (Erk) 
were determined by Western blotting.
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Figure 5.17. Inhibition of sphingosine kinase after 4 hr does not alter sustained 
cyclic activation of Erk-MAPK in WEHI-231 cells. Wild-type WEHI-231 cells (1 x 
10® cells/ml) were cultured for up to 48 hr with medium (untreated) or anti-CD40 
(10 pg/ml) and after 4 hr of culture cells were also treated with medium (no 
DMS) or DMS (0.5 pM) before preparing cell lysates. Whole cell lysates (50 
pg/lane) were run on 10% Bis-Tris gels using the NuPAGE system of gel 
electrophoresis. Recombinant non-phosphorylated Erk2 (w) and recombinant 
phosphorylated Erk2 (p) were used as positive controls. Levels of dual- 
phosphorylated Erk (pErk) and total Erk (Erk) were determined by Western 
blotting.
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Figure 5.18. DMS does not alter the activity of MEK in WEHI-231 cells. Wild- 
type WEHI-231 cells (1 x 10® cells/ml) were cultured for up to 48 hr with medium 
(untreated), anti-lg (10 pg/ml), anti-CD40 (10 pg/ml) or a combination of anti-lg 
plus anti-CD40 (both at 10 pg/ml) in the presence or absence of 0.5 pM DMS 
before preparing cell lysates. Whole cell lysates (50 pg/lane) were run on 10% 
Tris-HCI gels using the BioRad system of gel electrophoresis. Levels of 
phosphorylated MEK (pMEK) and total Erk (Erk) were determined by Western 
blotting.
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Figure 5.19. DMS does not alter phospho-Erk signalling in B c I-xl WEHI-231 
cells. Neo or Bc I-Xl WEHI-231 cells (1 x 10® cells/ml) were cultured for up to 48 
hr with DMS (0 , 0.5 pM or 5 pM) and medium (untreated), anti-lg (1 pg/ml) or a 
combination of anti-lg (1 pg/ml) plus anti-CD40 (10 pg/ml) before preparing cell 
lysates. Whole cell lysates (30 pg/lane) were run on 10% Bis-Tris gels using the 
NuPAGE system of gel electrophoresis. Gels were loaded as follows: lane 1, no 
DMS time 0 lysate; lane 2, no DMS 24 hr lysate; lane 3, no DMS 48 hr lysate; 
lane 4, DMS 0.5 pM time 0 lysate; lane 5, DMS 0,5 pM 24 hr lysate; lane 6, 
DMS 0.5 pM 48 hr lysate; lane 7, DMS 5 pM time 0 lysate; lane 8, DMS 5 pM 
24 hr lysate; lane 9, DMS 5 pM 48 hr lysate; lane 10, no DMS unstimulated time 
0 B c I-xl WEHI-231 lysate (Bcl-xu positive control); lane 11, recombinant 
phospho-Erk positive control (New England Biolabs). Levels of dual- 
phosphorylated Erk (pErk), total Erk (Erk) and Bcl-X|_ were determined by 
Western blotting.
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Figure 6.20. Model showing role of sphingosine kinase signalling in regulating 
survival and proliferation of WEHI-231 cells. DMS (shown in red) is an inhibitor 
of sphingosine kinase with few non-specific toxic effects therefore it prevents 
the formation of SPP from sphingosine. WEHI-231 cells were treated with DMS 
to assess the role of sphingosine kinase and SPP in regulating survival and 
proliferation of immature B cells. Sphingosine kinase and hence SPP production 
is differentially regulated by the BCR and CD40. SPP contributes to the 
induction of B c I-x l  and hence can suppress BCR-driven induction of cathepsin 
B-mediated apoptosis. Additional pathways may also induce B c I-x l  downstream 
of CD40. Inhibition of sphingosine kinase induces growth arrest of WEHI-231 
cells suggesting SPP is also likely to promote proliferation of WEHI-231 cells. 
However, inhibition of sphingosine kinase did not alter Erk activity in WEHI-231 
cells suggesting sphingosine kinase might be activated downstream of 
sustained Erk signals.
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CHAPTER 6 - Role of PKC in regulating the survival and proliferation of 
WEHI-231 cells
6.1 Protein kinase C
Protein kinase C (PKC) comprises a large family of kinases that can be 
categorised into three subclasses: conventional PKC (a, pi, pH and y), novel 
PKC (Ô, 8 , 0, T], v) and atypical PKC (^, i/X) (204, 208). Each PKC enzyme 
contains several conserved domains with specific functions (figure 6.1 A). The 
C1 region is found in all PKC enzymes and includes a pseudosubstrate site that 
binds to the catalytic domain to inactivate the kinase. To activate PKC, the 
pseudosubstrate site must dissociate from the kinase domain. This can be 
mediated by the binding of PKC to membranes. The membrane attachment of 
conventional and novel PKC enzymes is enhanced by their association with 
DAG and phorbol ester. The DAG/phorbol ester-binding site of these 
subclasses of PKC enzymes is mediated by a region in the C l domain that has 
two zinc-finger domains. Atypical PKC isoforms have a single zinc-finger 
domain and are unresponsive to DAG and phorbol ester.
The C2 domain of PKC enzymes also enhances their membrane 
attachment. For example, the C2 domain of conventional PKCs contains a 
calcium and lipid-binding domain that enables these enzymes to associate with 
phosphatidylserine in a Ca^^-dependent manner. In contrast, the C2 domain of 
novel and atypical PKCs lacks one or more aspartate residues and cannot bind 
to calcium. However, the C2 domain of each subclass of PKC enzymes can 
bind to RACKS (receptor for activated C kinase). RACKs are not substrates of 
PKC but instead they are anchoring proteins that target PKC enzymes to 
particular Intracellular locations. The intracellular location of PKC enzymes is 
also influenced by a V5 domain that is located at the C-terminus of PKC. The 
V5 domain is separated from the C l and C2 domains by a hinge region and the 
kinase domain. The kinase domain contains binding sites for substrates and for 
ATP (204).
The different subclasses of PKC can be distinguished by their regulatory
mechanisms and these are dependent on the structure of the enzymes.
Conventional PKC (cPKC) isoforms are targeted to membranes by associating
with phosphatidylserine in a Ca^^-dependent manner. This contributes to their
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activation but they also require DAG, which binds to the enzyme to increase its 
affinity for phosphatidylserine and calcium. Novel PKC (nPKC) isoforms are 
Ca^^-insensitive but do require phosphatidylserine and DAG for activation. 
Atypical PKC (aPKC) isoforms are Ca^^-insensitive and do not require DAG for 
stimulation (484). Phorbol ester can be used to mimic DAG and stimulate cPKC 
and nPKC isoforms.
The activity of all PKC enzymes can also be regulated by phosphorylation. 
In particular phosphorylation of a conserved threonine residue, Thr'^ ®^  of PKCa 
(485), in the activation loop helps to align the activation loop for substrate 
binding. At the plasma membrane, this residue can be phosphorylated by PDK- 
1 (phosphoinositide-dependent kinase-1) (486). Additional sites of 
phosphorylation include a ser/thr residue, Thr®'^  ^ of PKCpil (484), in a turn motif 
of the C-terminal segment of PKC. Phosphorylation of this residue stabilises the 
PKC enzyme. Conventional and novel PKC isoforms are further stabilised by 
the phosphorylation of a ser/thr residue flanked by a hydrophobic residue. In 
cPKCs and PKCe phosphorylation of the turn motif and the hydrophobic motif is 
mediated by autophosphorylation (484). PKC enzymes are also subject to 
tyrosine phosphorylation but the residues involved are specific to particular PKC 
isoforms.
PKC isoforms can also be regulated by proteolytic cleavage since this 
releases and activates the catalytic domain. PKCa, p and y are cleaved by 
calpains whilst PKCô, 0 and ^ can be cleaved by caspases. The activation of 
PKC by proteolytic cleavage is one mechanism by which these cysteine 
proteases can promote apoptosis. For example, in the rat pituitary cell line 
GH3B6 genotoxic stress results in the stimulation of calpains and caspases and 
the active catalytic domains of PKCô, PKCe and PKCa can accumulate at 
particular intracellular organelles including the mitochondria. At the 
mitochondria, the active catalytic domains of PKCô and PKCe promote 
cytochrome c release and caspase 3 stimulation leading to enhanced 
apoptosis. The active catalytic domain of PKCa also promotes apoptosis but it 
does so independently of inducing cytochrome c release or caspase 3 
stimulation (487).
PKC enzymes can further influence the survival and proliferation of cells 
by regulating additional intracellular signalling networks. For example, in HEK-
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293 cells phorbol ester-sensitive isoforms of PKC can increase the production 
of SPP by promoting the translocation of sphingosine kinase to the plasma 
membrane leading to its phosphorylation and activation (488).
Furthermore, PKC enzymes from all three subclasses can regulate the 
activity of Erk-MAPK. However, the regulation of Erk1/2 by PKC is complex 
since PKC can target several signalling molecules in the MAPK cascade 
depending on the system being studied. For example, phorbol ester-sensitive 
PKC enzymes enhance the activity of Ras in growth factor-stimulated NIH3T3 
and Swiss 3T3 fibroblasts and this is necessary for the activation of Erk. PKC- 
dependent activation of Ras in these systems can be suppressed by calmodulin 
suggesting cPKC enzymes are responsible for the induction of Ras (489). 
Furthermore, in IL-3-stimulated murine hematopoietic cells phorbol ester- 
sensitive isoforms of PKC can directly phosphorylate and activate Raf-1 (209). 
The indirect stimulation of Raf-1 by PKC has also been observed in 
immortalised embryonic rat hippocampal cells. In this system cPKC and aPKC 
isoforms can phosphorylate Ser^ ®^  of RKIP leading to a dissociation of RKIP 
and Raf-1 thus enhancing the ability of Raf-1 to stimulate MEK and Erk (490). In 
addition, transient transfection of Cos7 cells with members from all three 
subclasses of PKC enzymes indicated cPKC and nPKC isoforms can stimulate 
Raf-1 and hence Erk whilst aPKC enzymes activate MEK/Erk by a Raf-1- 
independent mechanism (491). Moreover, in erythroid cells Erk can be activated 
by MEK-dependent and MEK-independent mechanisms and this is necessary 
for erythropoietin-mediated proliferation. PKC is at least required for MEK- 
independent stimulation of Erk and PKC is essential for the induction of 
proliferation (492). PKC can also negatively regulate Erk-MAPK; for example, 
PKCe induces MKP-1 in lipopolysaccharide-stimulated macrophages leading to 
the inhibition of Erk1/2 (493). Different isoforms of PKC can thus positively or 
negatively regulate the Erk-MAPK cascade at multiple stages depending on the 
particular cellular system.
6.2 Protein kinase C in B lymphocytes
Immature B cells have diminished PKC signalling compared to mature B 
lymphocytes suggesting PKC may contribute to the differential response of 
distinct developmental stages of B cells to ligation of the BCR. For example,
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ligation of the BCR on mature B cells leads to PIP2 hydrolysis, Ca^  ^mobilisation 
and stimulation of PKC. In contrast, ligation of the BCR on immature B cells can 
mobilise calcium but PIP2 hydrolysis and subsequent PKC activation are 
significantly reduced.
Furthermore, PKCp has been implicated as a mediator of mature B cell 
activation since PKCp  ^ mice have reduced humoral immune responses and 
their B lymphocytes have impaired activation downstream of the BCR (2 1 0 ). 
More specifically, mature B lymphocytes from PKCp' '^ mice are less able to 
activate BcI-xl and Bcl-2 and hence are prone to apoptosis (199, 290). The 
expression of pro-survival Bcl-2 family members is also an important survival 
signal in immature B cells (290-293, 317, 427) therefore the impaired activation 
of PKC in BCR-stimulated immature B cells could increase their sensitivity to 
apoptosis. Indeed, treatment of primary splenic immature B cells or WEHI-231 
cells with phorbol ester can prevent BCR-driven apoptosis suggesting the 
diminished BCR-coupled activation of cPKC and nPKC isoforms in immature B 
cells contributes to their cell death (294, 295).
Moreover, PKC further promotes survival of mature B cells by inducing 
NF-kB since NF-kB can regulate the transcription of c-Myc, BcI-xl and Bcl-2 
(193, 199, 2 1 1 ). In contrast, ligation of the BCR on immature B ceils cannot 
sustain NF-kB activation, perhaps due to the defective stimulation of PKC. This 
is likely to contribute to cell death since NF-kB signalling is enhanced under 
conditions that favour cell survival, including CD40 co-stimulation (261, 296, 
297).
Previous studies have shown that the BCR and CD40 on immature B cells 
can regulate the expression of multiple PKC isoforms. In particular, PKCa, 
PKCô and PKC^ were highlighted as potential mediators of CD40-dependent 
rescue from anti-lg-induced growth arrest. Furthermore, untreated WEHI-231 
cells appeared to express multiple isoforms of PKC including, PKCa, PKCô, 
PKCe and PKC^ (unpublished observations). Consequently, these four PKC 
isoforms were selected for further analysis.
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6.3 PKCa
PKCa is an 82 kD cPKC isoform therefore it has a C1 domain that 
contains two zinc-finger domains to allow binding to DAG and phorbol ester. 
PKCa is activated synergistically by DAG and Ca '^" and hence can be 
stimulated downstream of PLCy. Calcium binds to the C2 domain of PKCa 
since this is rich in aspartate residues. The activation of PKCa requires it to 
translocate to the membrane and this is enabled by PKCa binding to 
phosphatidylserine in a calcium-dependent manner (204).
PKCa is further regulated by phosphorylation of several residues. For 
example, Thr"^ ®^  is located in the activation loop of PKCa and this residue must 
be phosphorylated for enzymic activity. Thr®^ ® can also be phosphorylated 
although this is not directly required for activation of the enzyme but lack of 
phosphorylation causes PKCa to be hypersensitive to protein phosphatases 
and hence dephosphorylation and inhibition. Phosphorylation of Thr®^ ® therefore 
can regulate the duration of PKCa activation (485). Similarly, the 
phosphorylation of Ser®®^  can protect PKCa from phosphatases and hence this 
residue also affects the duration of PKCa activation (494).
The activation of PKCa can induce apoptosis of cells by inhibiting Akt. For 
example, in LNCaP prostate cancer cells the induction of PKCa leads to the 
activation of PP2A, which can dephosphorylate and inhibit Akt (495). PKCa can 
also mediate its effects via the activation of Ras. For example, in mast cells, 
ligation of FceRI leads to the induction of Syk, which can phosphorylate Tyr®^  ^of 
PKCa and Tyr®®^  of PKCp1. The resultant phospho-tyrosine residues can 
interact with the SH2 domain of Grb-2 and hence promote the formation of the 
Grb-2 /SOS complex, leading to the induction of Ras and downstream effectors 
including Erk-MAPK (496). The activation of PKCa therefore leads to cell-type- 
specific effects.
6.4 PKCô
PKCô is a 78 kD nPKC isoform that is widely distributed among cells and 
tissues. The C-terminal half of PKCô contains the catalytic domain and the 
regulatory region is in the N-terminal half. PKCô has a C1 domain for DAG-
258
binding therefore it can be stimulated downstream of PLCy. However, PKCô 
lacks a classical C2 domain therefore it is regulated independently of Ca^ .^ 
Nonetheless, the C2-like domain of nPKC enzymes can still bind to RACKs and 
this has important targeting functions. (204).
The activation of PKCô is also promoted by binding to PIP2 or PIP3. 
Furthermore, PKCô can be regulated by phosphorylation of Ser °^® in the 
activation loop, Ser®"^  ^ in the turn motif and Ser®®^  in the hydrophobic motif 
(497). Phosphorylation of can be catalysed by PDK-1 and it is not
necessary for activation of PKCô but it functions to stabilise the enzyme. Ser®"^  ^
of PKCô can be autophosphorylated whilst Ser®®^  is phosphorylated by an 
upstream kinase. PKC^ is a component of the signalling cascade leading to the 
phosphorylation of Ser®®^  of PKCô but it is not clear if PKCô is a direct substrate 
of PKC^. PKCô can also be phosphorylated at tyrosine residues and this can be 
catalysed by various kinases including Src, Lyn, Fyn, Abl, PYK2, Lck and 
growth factor receptors. Tyrosine phosphorylation of PKCô can increase its 
activity but DAG is required for full activation (497).
PKCô can also be stimulated by caspase-dependent cleavage resulting in 
a free, active kinase domain. This is particularly important for promoting 
apoptosis (487). For example, in LNCaP prostate cancer cells apoptosis is 
mediated by a biphasic production of ceramide. Sustained ceramide production 
enables PKCô-activation and translocation to the mitochondria where it can 
induce the release of cytochrome c resulting in the stimulation of caspase 9 
(498, 499). In this system PKCô also promotes apoptosis via the induction of 
p38 MAPK (495).
PKCô has also been implicated as a negative regulator of B lymphocytes 
since PKCô' '^ mice have enhanced mature B cell proliferation, elevated antibody 
production and are prone to autoimmunity. PKCô therefore appears to suppress 
proliferation of mature B cells and may also assist negative selection of 
immature B cells (199, 497).
6.5 PKCe
PKCe is a 90 kD nPKC isoform that is regulated in a similar way to PKCô. 
PKCe has a C1 domain that binds to DAG and other lipids but lacks a classical
259
C2 domain and hence is insensitive to calcium but can still interact with RACKs. 
The activation of PKCe is promoted by binding to PIP2 and P IP 3. PKCe is also 
regulated by phosphorylation of Thr®®® in the activation loop, Ser^^° in the turn 
motif and Ser^ ^® in the hydrophobic motif. Ser^^  ^can be autophosphorylated. In 
addition, PKCe can be stimulated by proteolysis catalysed by caspase 3, 
caspase 7 or calpains. However, one unique feature of PKCe is it has an actin- 
binding motif and the binding of PKCe to actin is promoted by DAG and 
arachidonic acid. This has two effects: firstly, it anchors PKCe to a particular 
subcellular location and secondly, it can maintain PKCe in a catalytically active 
conformation (206).
PKCe is expressed in many different cells and tissues but is especially 
abundant in cells of the immune system and neuronal cells. For example, PKCe 
is required in macrophages therefore mice that lack PKCe have severely 
impaired macrophage survival and function resulting in an increased 
susceptibility to bacterial infection. A possible role for PKCe in promoting cell 
survival was suggested by the observation that PKCe can activate NF-kB (206).
PKCe is also a regulator of the Erk-MAPK cascade. For example, PKCe 
stimulates the MEK/Erk cascade in thrombin-stimulated Jurkat T cells (206). 
Furthermore, in cholecystokinin-stimulated pancreatic cells PLCy-mediated 
activation of PKCe can enhance the Ras/Raf-1-mediated induction of Erk (500). 
Moreover, PKCe can mediate the activation of Erk by PI-3-K and this can 
promote mitogenesis of SW480 colon carcinoma cells (501). In addition, PKCe 
has Rap-1 guanine nucleotide exchange factor activity therefore it can stimulate 
Rap-1 to activate or inhibit Erk, depending on the cellular levels of B-Raf (502). 
PKCe has also been observed to negatively regulate Erk via the induction of 
MAPK phosphatases for example, in lipopolysaccharide-stimulated 
macrophages PKCe can suppress Erk by stimulating MKP-1 (493).
6.6 PKCÇ
PKCC is a 72 kD aPKC isoform that is activated independently of calcium 
and DAG. Alternative lipids mediate the translocation of PKC^ to membranes 
including phosphatidylinositol lipids such as PIP3. PKCC can thus be activated 
downstream of PI-3-K. PKCC can also be targeted to specific subcellular
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compartments via the binding of its C2 domain to RACKs. PKC^ is further 
regulated by phosphorylation but as with other aPKCs, PKC^ has only two sites 
of ser/thr phosphorylation since a glutamate residue replaces the a
phosphorylation site in the C-terminal hydrophobic motif (204).
In vascular smooth muscle cells PKC^ is activated downstream of ]ceramide leading to a direct inhibition of Akt and a suppression of proliferation 
(603). In contrast, PKCÇ promotes cell survival in danorubicin-stimulated U937 
cells since it mediates PI-3-K-dependent activation of Raf-1 and MEK/Erk (504). 
PI-3-K-dependent activation of PKC^ also increases Erk activity in 
lysophosphatidic acid-treated CHO cells (505). PKCC can thus mediate PI-3-K- 
dependent activation of Erk in multiple systems suggesting it may also couple 
PI-3-K to Erk downstream of the BCR. Indeed, splenic B lymphocytes of PKCC^" 
mice have impaired BCR signalling including decreased activation of Erk and 
NF-k B (506). Mature B lymphocytes from PKC "^ "^ mice therefore undergo 
spontaneous apoptosis and have defective activation, including reduced 
proliferation and impaired ability to produce antibody (199). PKC^ thus seems to 
have an important role in promoting survival and activation of mature B cells. 
Furthermore, the number of immature B cells in PKCC^" mice is greater than 
normal mice suggesting PKCÇ may also be required for negative selection of 
immature B cells (506).
6.7 Aims and objectives
Several PKC isoforms have been associated with promoting survival and 
proliferation of mature B cells since they can induce pro-survival Bcl-2 family 
proteins and NF-k B (193, 199, 210, 211, 290). Immature B cells display 
impaired PKC signalling compared to mature B cells but treatment of primary 
splenic immature B cells or WEHI-231 cells with phorbol ester can prevent 
BCR-driven apoptosis suggesting the diminished activation of cPKC and nPKC 
isoforms in immature B cells contributes to their cell death (294, 295). Indeed, 
previous studies have shown that the BCR and CD40 on immature B cells can 
regulate the expression of multiple PKC isoforms. In particular, PKCa, PKCô 
and PKC^ were highlighted as potential mediators of CD40-dependent rescue 
from anti-lg-induced growth arrest (unpublished observations).
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The aims of this investigation were:
1. to investigate the role of PKCa, PKCô, PKCe and PKC^ in regulating the 
survival and proliferation of WEHI-231 cells
2. to explore the role of these PKC isoforms in regulating the activity of 
Erk-MAPK in WEHI-231 cells since PKC can regulate the activity of Erk in 
several other cellular systems (501, 504, 505) and, as discussed in previous 
chapters, Erk-MAPK signalling is important for determining the survival and 
proliferation of WEHI-231 cells
3. to examine the role of PKCa, PKCô, PKCe and PKC^ in regulating the 
induction of the pro-survival proteins B c I-xl and Akt in WEHI-231 cells.
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6.8 Results and Discussion
6.8.1 PKCa partially protects WEHI-231 cells from BCR-driven growth 
arrest and apoptosis
Previous studies using antisense oligonucleotides to PKCa showed that 
PKCa may help to promote proliferation of WEHI-231 cells (unpublished 
observations). To further investigate the role of PKCa in WEHI-231 cell 
signalling, WEHI-231 cells were transfected by electroporation with the 
pcDNA3.1 plasmid containing a constitutively active form of PKCa (PKCaCAT 
WEHI-231), a kinase inactive form of PKCa (PKCaKR WEHI-231) or an empty 
plasmid as control (pcDNA3.1 WEHI-231), The PKCaCAT construct encoded 
residues 326-674, which encompasses the kinase region of PKCa. The 
PKCaKR construct encoded most of PKCa (residues 2-672) but the kinase was 
inactivated via a point mutation, K^ ®®R. Figure 6.1B illustrates the general 
structure of PKC-CAT and PKC-KR forms of PKC.
To determine the role of PKCa in regulating proliferation of WEHI-231 
cells the DNA synthesis of cells transfected with PKCaCAT and PKCaKR was 
determined by measuring the incorporation of [^H] thymidine. After 24 hr, anti-lg 
induced growth arrest of pcDNAS.I WEHI-231 cells in a dose-dependent 
manner (figure 6.2A). This is consistent with the observed response of wild-type 
WEHI-231 cells (figure 3.5) and shows that the empty pcDNA3.1 vector did not 
impair BCR-driven growth arrest of WEHI-231 cells. In contrast to pcDNA3.1 
WEHI-231 cells, PKCaCAT WEHI-231 cells were protected from BCR- 
dependent inhibition of DNA synthesis after 24 hr (figure 6.2A). This suggests 
that PKCa prevents growth arrest and/or induces proliferation in WEHI-231 
cells. This is consistent with earlier studies that implicated PKCa as a mediator 
of CD40-dependent rescue from anti-lg-induced growth arrest (unpublished 
observations). However, expression of PKCaKR also protected WEHI-231 cells 
from anti-lg-induced inhibition of DNA synthesis after 24 hr (figure 6.2A). This 
observation was unexpected and suggests that PKCa impairs BCR-driven 
growth arrest but PKCa catalytic activity does not appear to be essential.
After 48-72 hr, expression of PKCaCAT or PKCaKR in WEHI-231 cells 
provided partial protection from BCR-dependent inhibition of DNA synthesis
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(figure 6.2B). Furthermore, expression of either PKCaCAT or PKCaKR may 
also slightly enhance CD40-mediated rescue from BCR-driven growth arrest 
after 48 hr (figure 6.2C). Taken together, these observations suggest that PKCa 
may have a role in promoting proliferation and/or in preventing growth arrest of 
WEHI-231 cells but the catalytic activity of PKCa does not seem to be essential 
for these effects.
To further investigate the role of PKCa in regulating proliferation of WEHI- 
231 cells, the cell cycle and apoptotic status of PKCaCAT and PKCaKR WEHI- 
231 cells was analysed by Pl-staining and FACS analysis. The proliferation of 
WEHI-231 cells was measured by determining the number of cells in S phase 
plus G2/M since ligation of the BCR induces growth arrest at G0/G1 phase of 
the cell cycle and hence depletes the populations of S phase and G2/M phase 
cells (figure 3.6). After 24 hr and 48 hr, treatment of pcDNA3.1 WEHI-231 cells 
with anti-lg increased the number of cells in G0/G1 phase but reduced the 
number of cells in S phase and G2/M whereas co-culture with anti-CD40 
replenished these populations of cells (figure 6.2D-E and data not shown). 
Expression of PKCaCAT and PKCaKR did not have a dramatic effect on the 
number of cells in S phase and G2/M (figure 6.2D-E). Nonetheless, expression 
of PKCaCAT did partially protect WEHI-231 cells from BCR-dependent cell 
cycle arrest. For example, after 48 hr, treatment of pcDNA3.1 WEHI-231 cells 
with 10 pg/ml anti-lg reduced the percentage of S phase plus G2/IVI phase cells 
from 41% to 17% and co-culture with 10 pg/ml anti-CD40 restored this 
population of cells to 41%. However, treatment of PKCaCAT WEHI-231 cells 
with 10 pg/ml anti-lg only reduced the percentage of S phase plus G2/M phase 
cells to 24% and co-culture with anti-CD40 restored this population of cells to 
40% (figure 6.2E). Similarly, expression of PKCaKR impaired BCR-driven 
growth arrest of WEHI-231 cells. For example, after 24 hr, 10 pg/ml anti-lg 
reduced the percentage of pcDNA3.1 cells in 8 phase plus G2/M phase from 
31% to 23% and co-culture with anti-CD40 restored this population of cells to 
39%. However, 31% of PKCaKR WEHI-231 cells treated with 10 pg/ml anti-lg 
were in S phase plus G2/M and co-ligation of CD40 increased this percentage 
to 46% (figure 6.2D). These observations therefore support the thymidine assay 
data, which suggested that PKCa can promote proliferation of WEHI-231 cells 
but this does not require the kinase to be active.
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In addition, ceil cycle analysis of PKCaCAT and PKCoiKR WEHI-231 cells 
indicated that expression of both of these mutant forms of PKCa also slightly 
impaired anti-lg-induced apoptosis after 24 hr and 48 hr (figure 6.2F-G). 
Moreover, expression of PKCaKR was slightly more effective than expression 
of PKCaCAT at preventing anti-lg-induced apoptosis, indicating PKCa kinase 
activity was not essential for increasing the survival of WEHI-231 cells. 
Furthermore, expression of PKCaCAT or PKCaKR also slightly reduced the 
number of cells with sub-diploid DNA that had been cultured with anti-lg plus 
anti-CD40 indicating PKCa may also improve CD40-mediated survival. PKCa 
therefore appears to increase the survival and the proliferation of BCR- 
stimulated and anti-CD40-treated WEHI-231 cells and PKCa kinase activity is 
not essential for these effects.
This is not an isolated example of PKCa signalling that is independent of 
kinase activity. For example, in IFNy-primed U937 cells, PKCa assists the 
activation of PLD1 following ligation of FcyRI by directly binding to PLD1 in a 
PKCa kinase-independent manner. Indeed, inhibition of PKCa kinase activity 
does not prevent FcyRI-mediated induction of PLD1 whereas down regulation of 
PKCa levels does impair PLD1 activation. FcyRI-dependent induction of PLD1 
thus requires the recruitment of PKCa but PKCa kinase activity is not 
necessary (507) indicating PKCa can perform important signalling functions 
independently of its kinase activity.
6.8.2 Expression of PKCaCAT increases sustained Erk signalling in WEHI- 
231 cells
To investigate the mechanism of PKCa-mediated enhancement of 
proliferation in WEHI-231 cells the effect of PKCa on Erk signalling was 
explored since the induction of sustained and cyclic Erk signals is important for 
proliferation of WEHI-231 celts. Furthermore, many PKC isoforms including 
PKCa can regulate the activity of Erk1/2 (see sections 6.1 and 6.3). The activity 
of Erk in PKCaCAT and PKCaKR WEHI-231 cells was determined by Western 
blotting using antibodies that recognise dual-phosphorylated Erk 1/2.
Unstimulated pcDNA3.1 WEHI-231 cells displayed cycling Erk signals 
over a 48 hr time period (figure 6.3A). However, ligation of the BCR suppressed
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sustained Erk signals whilst co-ligation of CD40 restored prolonged Erk signals 
(figure 6.3A). This is consistent with previous observations of Erk signalling in 
wild-type WEHI-231 cells (appendix 2). A similar pattern of Erk signalling was 
observed in PKCaKR WEHI-231 cells (figure 6.3B) indicating expression of 
PKCaKR did not increase the survival and proliferation of WEHI-231 cells by 
regulating the activity of Erk.
In contrast, expression of PKCaCAT did alter sustained Erk signals in 
WEHI-231 cells (figure 6.3C). In particular, ligation of the BCR on PKCaCAT 
WEHI-231 cells prevented anti-lg-induced inhibition of sustained (48 hr) Erk 
signals. This is likely to contribute to the increased proliferation of PKCaCAT 
WEHI-231 cells. However, the mechanism of PKCaCAT-mediated induction of 
Erk1/2 has not been investigated. Nonetheless, in FceRI-stimulated mast celts 
PKCa can induce Grb-2/SOS and hence Ras (496) therefore PKCaCAT may 
also regulate Erk in WEHI-231 cells by increasing the activation of Ras. 
However, expression of constitutively active Ras in BCR-stimulated WEHI-231 
cells did not substantially increase sustained Erk signals (figure 3.11) 
suggesting PKCa may activate Erk via Ras-independent mechanisms such as 
inhibiting MAPK phosphatase activity.
Nonetheless, these observations indicate PKCaCAT and PKCaKR can 
increase the proliferation of WEHI-231 cells but they appear to do so via distinct 
mechanisms. Indeed, expression of PKCaCAT impairs BCR-mediated inhibition 
of sustained Erk signalling whilst expression of PKCaKR did not alter Erk 
signalling in WEHI-231 cells. The mechanism used by PKCaKR to increase the 
proliferation of WEHI-231 cells has not been determined but it may act 
downstream or in parallel to Erk and hence diminish the need for sustained Erk 
signals in proliferating cells.
6.8.3 Expression of PKCa can induce B c I-X l in WEHI-231 cells
To further explore the mechanism of PKCa-mediated survival and 
proliferation of WEHI-231 cells, the levels of Bc I-x l  in cells expressing PKCaKR 
or PKCaCAT were determined since, as discussed in chapter 4, B c I-xl  is an 
important survival factor of WEHI-231 cells. Moreover, cPKCs have previously 
been associated with inducing B c I-x l  in mature B lymphocytes since peripheral
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B cells from PKC(3"^ ‘ mice are less able to activate Bc I-Xl and Bcl-2 (199, 290). 
Levels of B c I-x l  in WEHI-231 cells were determined by Western blotting using 
anti-Bcl-xus antibodies.
Expression of PKCaKR or PKCaCAT enhanced the levels of Bc !-Xl in 
CD40-stimulated WEHI-231 cells (figure 6.4A-C). This is consistent with figure 
6.2F-G in which CD40-stimulated PKCaKR and PKCaCAT WEHI-231 cells had 
a slightly lower sub-diploid DNA content than the equivalent pcDNAS.I WEHI- 
231 cells. However, expression of PKCaCAT also enhanced the levels of B c 1-xl  
in untreated and BCR-stimulated WEHI-231 cells (figure 6.4C) indicating PKCa 
can induce Bc I-x l  in the absence of CD40 stimulation. Furthermore, it is likely 
that this requires PKCa kinase activity since PKCaKR WEHI-231 cells did not 
display increased levels of B c I-x l  in cells that had not been stimulated with 
CD40. This suggests that CD40 may enhance PKCa kinase activity to suppress 
BCR-driven apoptosis or the BCR may inhibit this kinase to enhance apoptosis 
of WEHI-231 cells.
However, expression of PKCaKR also increased the survival of untreated 
and BCR-stimulated WEHI-231 cells (figure 6.2F-G) suggesting PKCaKR can 
initiate additional pro-survival signals. The activity of Akt was thus investigated 
in PKCaKR and PKCaCAT WEHI-231 cells since Akt is an important survival 
factor of many cell types including mature splenic B lymphocytes (see section 
1.6.3.1) (184, 186, 188, 189, 193-195). The activity of Akt was determined by 
Western blotting using phosphorylation-sensitive antibodies that specifically 
recognise Akt that is phosphorylated at Thr °^® (pTAkt) or Ser^^  ^ (pSAkt). 
Positive controls for phosphorylated and non-phosphorylated Akt (purchased 
from New England Biolabs) were included in all the Western blots.
In general the activity of Akt was very low in WEHI-231 cells and pTAkt
and pSAkt were not detected in unstimulated or anti-lg-treated pcDNA3.1,
PKCaKR or PKCaCAT WEHI-231 cells (figure 6.4D-F). This is consistent with
the results of figures 3.13, 3.15 and 3.19 in which Akt was barely detectable in
WEHI-231 cells even when they were expressing a constitutively active form of
Ras that specifically couples to PI-3-K (figure 3.13D). However, expression of
PKCaCAT or PKCaKR in cells treated with anti-lg plus anti-CD40 did slightly
increase the levels of pTAkt and pSAkt indicating PKCa might induce Akt in
BCR and CD40 co-stimulated WEHI-231 cells (figure 6.4E-F). Furthermore, this
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does not appear to require PKCa kinase activity since it was observed in ceils 
expressing constitutively active and inactive forms of PKCa. Potentially the 
induction of Akt could increase the survival of WEHI-231 cells but it is not clear 
whether or not PKCa-mediated induction of Akt exists in wild-type WEHI-231 
cells since this was only observed in cells that were constitutively expressing 
PKCa.
Taken together, these findings indicate there may be two distinct 
mechanisms of PKCa signalling: one that requires kinase activity and one that 
functions independently of active kinase. In WEHI-231 cells either mechanism 
of PKCa signalling appears to promote survival and proliferation of the cells but 
the signalling pathways that are regulated by PKCa depend on whether or not 
the kinase is active. In particular, PKCa kinase activity can induce Bc I-xl  in the 
presence or absence of anti-lg and/or anti-CD40 whereas PKCa that lacks 
catalytic activity can only induce B c I-Xl in CD40-stimulated cells. Additional 
PKCaKR-dependent survival pathways are thus likely to exist. Furthermore. 
PKCa kinase activity can enhance sustained Erk signals presumably to 
Increase proliferation of WEHI-231 cells and impair BCR-driven growth arrest. 
However, expression of PKCaKR cannot enrich sustained Erk signals and 
hence must use alternative, as yet unidentified, signals to increase the 
proliferation of WEHI-231 cells.
6.8.4 PKCÔ partially protects WEHI-231 cells from BCR-driven growth 
arrest and apoptosis
To further explore the use of PKC in WEHI-231 signalling, the role of the 
nPKC isoform PKCô was investigated using WEHI-231 ceils transfected by 
electroporation with the pcDNA3.1 plasmid containing a constitutively active 
form of PKCô (PKCôCAT WEHI-231). a kinase inactive form of PKCô (PKCôKR 
WEHI-231) or an empty plasmid as control (pcDNAS.I WEHI-231). The 
PKCôCAT construct encoded residues 334-674, which encompasses the kinase 
region of PKCô. The PKCôKR construct encoded most of PKCô (residues 2- 
674) but the kinase was inactivated via a point mutation, K^ ^®R.
The role of PKCô in regulating the proliferation of WEHI-231 cells was 
examined by measuring the DNA synthesis of ceils transfected with PKCô
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constructs. The level of DNA synthesis was determined by measuring the 
incorporation of [^H] thymidine. After 24 hr, anti-lg decreased the level of DNA 
synthesis in pcDNA3.1 WEHI-231 cells in a dose-dependent manner (figure 
6.5A). However, expression of PKCôCAT prevented BCR-driven inhibition of 
DNA synthesis (figure 6.5A) suggesting PKCô can protect WEHI-231 cells from 
BCR-driven growth arrest. This is consistent with previous antisense 
observations that implicated PKCô as a mediator of CD40-dependent rescue 
from anti-lg-induced growth arrest (unpublished observations). Furthermore, 
expression of PKCôKR also inhibited BCR-driven growth arrest and it appeared 
to slightly increase the amount proliferation above basal levels (figure 6.5A). 
These observations suggest that after 24 hr PKCô can protect WEHI-231 celts 
from BCR-driven growth arrest but PKCô kinase activity does not seem to be 
essential.
After 48-72 hr, expression of PKCôCAT did not prevent BCR-driven 
growth arrest and expression of PKCôKR only slightly impaired anti-lg-induced 
growth arrest of WEHI-231 cells (figure 6.5B). This suggests that expression of 
PKCô was insufficient to prevent growth arrest of WEHI-231 cells induced by 
prolonged exposure to anti-lg. However, cell cycle analysis of PKCôCAT and 
PKCôKR WEHI-231 cells showed that expression of either of these constructs 
slightly impaired anti-lg-induced depletion of S phase plus G2/M phase cells 
after 24 hr and 48 hr (figure 6.5D-E). Taken together, these observations 
implicate PKCô as a mitogenic signalling molecule in WEHI-231 cells that can 
impair BCR-driven growth arrest. However, expression of PKCôCAT or 
PKCôKR only had slight effects on the proliferation of CD40-stimulated WEHI- 
231 cells (figure 6.5C-E).
Expression of PKCôKR did not affect the survival of unstimulated WEHI- 
231 cells or cells treated with anti-lg and/or anti-CD40. Nonetheless, expression 
of PKCôCAT slightly reduced the number of cells with sub-diploid DNA (figure 
6.5F-G). This suggests that PKCô may improve the survival of WEHI-231 cells 
but this is likely to require PKCô kinase activity. This observation is different to 
that of WEHI-231 cells expressing PKCa constructs since PKCa kinase activity 
was not essential for improving survival of WEHI-231 cells and this shows that 
different isoforms of PKC have distinct roles in WEHI-231 cell signalling.
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Taken together, these observations suggest that PKCô can promote the 
survival and proliferation of WEHI-231 cells. However, analysis of PKCô^ mice 
implicated PKCô as a negative regulator of mature B cell proliferation (199, 
497). Nonetheless, this is consistent with the observation that the BCRs of 
mature and immature B cells are generally coupled to the same signalling 
pathways despite having very different effects on the phenotype of the cell. It is 
possible that the amplitude, duration or intracellular location of PKCô is 
dependent on the developmental stage of the cell.
6.8.5 Expression of PKCÔCAT increases sustained Erk signalling in WEHI- 
231 cells
To investigate the mechanism of PKCÔ-mediated enhancement of 
proliferation of WEHI-231 cells, the activity of Erk in PKCôCAT and PKCôKR 
WEHI-231 cells was determined by Western blotting with antibodies that 
specifically recognise dual-phosphorylated Erk1/2. In general, expression of 
PKCôCAT or PKCôKR slightly enhanced Erk signalling in cells treated with anti- 
lg and/or anti-CD40 (figure 6.6), suggesting that expression of PKCô favoured 
the activation of Erk. However, expression of PKCôKR was not able to prevent 
BCR-mediated inhibition of sustained Erk signals (figure 6.6B). PKCôKR 
therefore did not impair BCR-driven growth arrest by enhancing sustained Erk 
signals. In contrast, expression of PKCôCAT did enhance sustained Erk signals 
in anti-lg-treated WEHI-231 cells (figure 6.6C) suggesting PKCô can impair 
BCR-mediated inhibition of sustained Erk signals but this requires PKCô kinase 
activity. PKCôCAT therefore is likely to increase the proliferation of WEHI-231 
cells by enhancing sustained Erk1/2 signals. Furthermore, these observations 
suggest that the BCR may inhibit PKCô kinase activity to suppress sustained 
Erk signals or CD40 might induce this kinase to enhance Erk signalling and 
hence regulate the proliferation of WEHI-231 cells.
However, in anti-CD40-treated WEHI-231 cells expression of either 
PKCôKR or PKCôCAT increased sustained Erk signals (figure 6.6) suggesting 
PKCÔ can enrich Erk signals independently of PKCô kinase activity in CD40- 
activated cells. Furthermore, expression of PKCôKR but not PKCôCAT 
increased sustained Erk signals in cells treated with anti-lg plus anti-CD40. This
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shows that PKCô can stimulate sustained Erk signals independently of PKCô 
kinase activity but only in CD40-activated WEHI-231 cells. Furthermore, the 
regulatory regions of PKCÔ appear to be specifically required for the induction of 
sustained Erk signals in WEHI-231 cells treated with anti-lg plus anti-CD40.
6.8.6 Expression of PKCÔ can induce B c I-x l  but cannot increase the 
activity of Akt
To investigate the mechanism of PKCô-dependent survival, the activity of 
Akt was determined by Western blotting with phosphorylation-sensitive Akt 
antibodies. As with previous experiments, very low levels of pTAkt and pSAkt 
were detected in WEHI-231 cells. Furthermore, the activity of Akt was relatively 
unaffected by expression of PKCôKR or PKCôCAT suggesting PKCô does not 
directly affect Akt activity in WEHI-231 cells (figure 6.7A-C). The induction of Akt 
therefore is unlikely to be responsible for the improved survival of PKCôCAT 
WEHI-231 cells.
To further investigate the signalling mechanism of PKCô-mediated survival 
of WEHI-231 cells, the levels of B c I-xl  were determined by Western blotting of 
lysates prepared from PKCôCAT and PKCÔKR WEHI-231 cells (figure 6.7D-F). 
Expression of PKCôKR induced a slight increase in the levels of B c I-x l  in 
untreated WEHI-231 cells but did not induce Bc I-Xl in anti-lg-treated cells (figure 
6.7E). This is consistent with the observations of figure 6.5F-G in which 
expression of PKCôKR was shown to be insufficient to increase the survival of 
WEHI-231 cells. In contrast, expression of PKCôCAT did slightly increase the 
survival of WEHI-231 cells. Furthermore, expression of PKCÔCAT increased the 
expression of Bc I-Xl, especially in anti-lg-treated WEHI-231 cells (figure 6.7F). 
This suggests that PKCô can increase the survival of WEHI-231 cells, even in 
the presence of anti-lg, via the induction of Bc I-x l . Moreover, this requires PKCô 
kinase activity although the substrates of PKCô that are involved in this process 
have not been identified. These observations implicate PKCô as an upstream 
mediator of Bc I-xl signalling in WEHI-231 cells and suggest that ligation of the 
BCR might suppress this pro-survival signal by inhibiting PKCô kinase activity.
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6.8.7 PKCe partially protects WEHI-231 cells from BCR-driven growth 
arrest
To further investigate the use of PKC in WEHI-231 cell signalling, the role 
of the nPKC isoform PKCe was investigated using WEHI-231 cells transfected 
by electroporation with the pcDNA3.1 plasmid containing a constitutively active 
form of PKCe (PKCeCAT WEHI-231), a kinase inactive form of PKCe (PKCeKR 
WEHI-231) or an empty plasmid as control (pcDNA3.1 WEHI-231). The 
PKCe CAT construct encoded residues 395-737, which encompasses the kinase 
region of PKCe. The PKCeKR construct encoded most of PKCe (residues 2- 
732) but the kinase was inactivated via a point mutation, K'^ ^^ R.
The role of PKCe in regulating proliferation of WEHI-231 cells was 
investigated by measuring the DNA synthesis and analysing the cell cycle of 
PKCeCAT and PKCeKR WEHI-231 celts. After 24 hr, expression of PKCeCAT 
prevented anti-lg-dependent inhibition of DNA synthesis and actually induced 
proliferation of BCR-stimulated cells (figure 6.8A). Furthermore, expression of 
PKCeKR also prevented BCR-driven inhibition of DNA synthesis but it did not 
increase proliferation above basal levels. These observations show that PKCe 
can block BCR-driven growth arrest pathways and/or induce proliferative 
signals in WEHI-231 cells. This suggests that PKCe may be inhibited by the 
BCR to regulate proliferation of WEHI-231 cells. Furthermore, the kinase activity 
of PKCe is not essential for these effects but the presence of active kinase 
enables PKCe to induce proliferation more effectively.
However, after 48-72 hr, expression of PKCeCAT or PKCeKR was no 
longer able to protect WEHI-231 ceils from anti-lg-induced inhibition of DNA 
synthesis (figure 6.8B). The protective effects of PKCe can thus be overcome by 
prolonged exposure to anti-lg. Furthermore, cell cycle analysis of PKCeCAT and 
PKCeKR WEHI-231 cells (figure 6.8D-E) showed that expression PKCe slightly 
increased the percentage of anti-lg-treated cells in S phase and G2/M after 24 
hr. However, after 48 hr protection was virtually abrogated. Moreover, in 
general, expression of PKCeCAT or PKCeKR did not greatly affect CD40- 
mediated rescue of WEHI-231 cells from BCR-driven growth arrest (figure 6.8C- 
E).
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6.8.8 PKCe can induce Erk in BCR-stimulated WEHI-231 cells
To investigate the mechanism of PKCe-dependent rescue from BCR- 
driven growth arrest, the activity of Erk in PKCeCAT and PKCeKR WEHI-231 
cells was determined by Western blotting. Expression of PKCeCAT, but not 
PKCeKR, in untreated WEHI-231 cells slightly increased the levels of phospho- 
Erk between 24 hr and 48 hr (figure 6.9) suggesting PKCe kinase activity may 
induce Erk in unstimulated cells. Furthermore, the expression of PKCeCAT or 
PKCeKR induced a general increase in Erk activity in CD40-stimulated WEHI- 
231 cells (figure 6.9).
Moreover, expression of either PKCeCAT or PKCeKR slightly increased 
the activity of Erk at 48 hr in anti-lg-treated WEHI-231 cells (figure 6.9B-C). The 
presence of this signal has previously been associated with induction of 
proliferation in WEHI-231 cells (328) therefore the ability of PKCe to increase 
this signal is likely to contribute to PKCe-dependent protection from BCR-driven 
growth arrest. Furthermore, the observation that both PKCeCAT and PKCeKR 
can induce sustained Erk signals in BCR-activated WEHI-231 cells suggests 
that PKCe kinase activity was not essential. These observations are consistent 
with the thymidine assay data (figure 6.8A-C), which implicated PKCe as a 
mitogenic signal of WEHI-231 cells and suggests that the BCR may impair 
proliferation of WEHI-231 cells by inhibiting PKCe signalling.
PKCe can thus slightly increase sustained Erk signals in BCR-activated
WEHI-231 cells presumably resulting in enhanced proliferation. The mechanism
of PKCeCAT- or PKCeKR-mediated induction of Erk has not been explored.
However, PKCe has been shown to regulate the activity of Erk via several
different mechanisms in other cellular systems (see section 6.5). Of particular
interest, PKCe has been shown to enhance the Ras/Raf-1-mediated induction of
Erk and to couple P1-3-K to Erk (500, 501). Data presented in chapter 3
suggests that Ras is an important upstream activator of Erk in WEHI-231 cells
and it can do so via Raf-1 and PI-3-K (see section 3.12.11) therefore PKCe may
help to amplify Ras-dependent activation of Erk. To further investigate the role
of PKCe in mediating Ras-dependent activation of Erk, WEHI-231 cells could be
generated with mutations in both PKCe and Ras. Furthermore, BCR-dependent
inhibition of sustained Erk signals can be mediated by the induction of MAPK
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phosphatases and PKCe has been associated with regulating MAPK 
phosphatases in other systems. For example, in lipopolysaccharide-stimulated 
macrophages PKCe can induce MKP-1 to suppress Erk (493) suggesting PKCe 
may also regulate MAPK phosphatases in other systems, possibly even in a 
negative manner.
6.8.9 PKCe cannot induce BcI-Xl or Akt and does not protect WEHI-231 
cells from BCR-driven apoptosis
PKCe therefore can impair anti-lg-induced growth arrest of WEHI-231 cells 
and this does not absolutely require PKCe kinase activity. In contrast, 
expression of PKCeCAT or PKCeKR did not appear to protect WEHI-231 cells 
from BCR-driven apoptosis since the number of cells with sub-diploid DNA was 
not reduced by expression of PKCe (figure 6.10A-B). These observations 
implicate PKCe as specifically affecting the proliferation of WEHI-231 cells.
Furthermore, analysis of the levels of Bc 1-x l  in WEHI-231 cells showed 
that expression of PKCeCAT or PKCeKR did not substantially enhance the 
levels of Bel-XL in anti-lg-treated WEHI-231 cells (figure 6.10C-E). Moreover, 
expression of PKCeCAT did not increase the activity of Akt, as indicated by 
Western blotting for pTAkt and pSAkt (figure 6.11A and C). However, the levels 
of pTAkt and pSAkt were slightly elevated by expression of PKCeKR in 
untreated and anti-lg-treated WEHI-231 cells (figure 6.1 IB).
Taken together, these observations suggest that PKCe does not 
substantially modulate B c I-x l  expression or Akt activity in WEHI-231 cells. 
Consequently, expression of PKCeCAT or PKCeKR did not increase the survival 
of WEHI-231 cells and did not prevent BCR-driven apoptosis. PKCe therefore 
appears to specifically regulate proliferation rather than survival of WEHI-231 
cells. This is in contrast to the observed role of PKCô in WEHI-231 cells despite 
PKCe and PKCÔ both being nPKC isoforms and hence being sensitive to the 
same upstream activators. The functions of PKCe and PKCô in WEHI-231 cells 
are thus likely to be distinct, which is consistent with analysis of these PKC 
isoforms in other systems. For example, in the androgen-dependent LNCaP cell 
line PKCô and PKCa both promote apoptosis whereas PKCe can suppress 
apoptosis and induce proliferation (495). Different isoforms of the same
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subclass of PKC enzymes can thus mediate distinct functions in several 
systems including WEHI-231 cells. One explanation for this is PKCô and PKCe 
may have different intracellular locations in WEHI-231 cells since PKC enzymes 
can reside in particular intracellular locations via their interaction with RACKs. 
Furthermore, PKCe has an actin-binding motif that provides a unique anchoring 
point for this enzyme and the association of PKCe to actin is enhanced by 
arachidonic acid (206) therefore the production of arachidonic acid in WEHI-231 
cells may influence the intracellular location of PKCe but not other PKC 
isoforms. However, the intracellular location of PKC enzymes has yet to be 
examined in WEHI-231 cells.
6.8.10 PKCÇ partially protects WEHI-231 cells from BCR-driven growth 
arrest and apoptosis
To further explore the use of PKC in WEHI-231 signalling, the role of an 
aPKC isoform, PKC^ was investigated since PKC^ can be activated 
downstream of PI-3-K and Ras seems to be able to activate Erk via PI-3-K in 
WEHI-231 cells (section 3.12.11). Furthermore, PKCC" mice have impaired 
mature B cell survival and activation and have elevated numbers of immature B 
cells suggesting PKCÇ can regulate the survival of mature and immature B cells 
(199, 506). The role of PKC^ in WEHI-231 cells was explored using WEHI-231 
cells transfected by electroporation with the pcDNA3.1 plasmid containing a 
constitutively active form of PKC^ (PKCACAT WEHI-231), a kinase inactive 
form of PKC'ç (PKCAKR WEHI-231) or an empty plasmid as control (pcDNA3.1 
WEHI-231). The PKCACAT construct encoded residues 239-592, which 
encompasses the kinase region of PKC^. The PKCAKR construct encoded most 
of PKC^ (residues 2-592) but the kinase was inactivated via a point mutation,
k“ ’m .
The role of PKCÇ in regulating proliferation of WEHI-231 cells was 
examined by measuring the DNA synthesis of PKCACAT and PKCAKR WEHI- 
231 cells and by analysing the cell cycle of these cells. Measurement of the 
DNA synthesis of WEHI-231 cells after 24 hr showed that expression of 
PKCACAT or PKCAKR significantly reduced BCR-driven growth arrest (figure 
6.12A). This suggests that PKC^ may be inhibited by the BCR to induce growth
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arrest or may be stimulated by CD40 to enable proliferation of WEHI-231 cells. 
This is consistent with previous observations that implicated PKC^ as a 
mediator of CD40-dependent rescue from anti-lg-induced growth arrest 
(unpublished observation). Moreover, PKCÇ kinase activity did not appear to be 
necessary for preventing growth arrest of anti-lg-treated WEHI-231 cells. In 
contrast, expression of PKCACAT or PKCAKR was insufficient to protect WEHI- 
231 cells from BCR-driven Inhibition of DNA synthesis after 48-72 hr indicating 
prolonged exposure to anti-lg overcame the protection offered by PKCC (figure 
6.12B). Furthermore, expression of PKCÇ did not appear to affect proliferation 
of cells treated with anti-lg plus anti-CD40, suggesting PKC^ did not increase 
the proliferation of CD40-stimulated WEHI-231 cells (figure 6.12C-E).
Analysis of the cell cycle status of PKCACAT and PKCAKR WEHI-231 cells 
suggested PKCC might promote proliferation of anti-lg-treated WEHI-231 cells 
(figure 6.12D-E). Furthermore, expression of PKCACAT and PKCAKR appeared 
to be equally effective at promoting proliferation of WEHI-231 cells. Analysis of 
the proliferation of PKCACAT and PKCAKR WEHI-231 cells therefore suggests 
that PKC^ might induce proliferation and/or inhibit BCR-driven growth arrest of 
WEHI-231 cells and the kinase activity of PKC^ does not seem to be essential 
for these effects.
In addition, cell cycle analysis of PKCACAT and PKCAKR WEHI-231 cells 
also suggested that PKCt might increase the survival of WEHI-231 cells since 
expression of either of these PKCt enzymes slightly reduced the number of 
anti-lg-treated WEHI-231 cells with sub-diploid DNA (figure 6.12F-G). 
Furthermore, expression of PKCAKR was more effective than expression of 
PKCACAT at reducing the number of WEHI-231 cells with sub-diploid DNA. This 
suggests that PKC^ catalytic activity was not essential for PKC^-mediated 
reduction in apoptosis of WEHI-231 cells. PKC^ can thus promote survival and 
proliferation of WEHI-231 cells but the kinase activity of PKC^ is not always 
essential for these processes.
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6.8.11 PKCÇ slightly increases the activity of Erk-MAPK in BCR-stimulated 
WEHI-231 cells
The activation of sustained and cyclic Erk signals is associated with the 
induction of proliferation in WEHI-231 cells. Furthermore, Ras is an important 
upstream activator of Erk and it can mediate the activation of Erk via Raf-1 or 
FI-3-K (discussed in chapter 3). Previous studies have shown that PKCÇ can 
induce the Erk-MAPK cascade. In particular, PKCt can mediate P1-3-K- 
dependent activation of Erk 1/2. For example, PI-3-K-dependent activation of 
PKCC increases Erk activity in lysophosphatidic acid-treated OHO cells and in 
danorubicin-stimulated U937 cells (504, 505).
To investigate the role of PKCÇ in regulating the activity of Erk and hence 
the mechanism of PKC^-dependent promotion of proliferation in WEHI-231 
cells, the activity of Erk in PKCACAT and PKCAKR WEHI-231 cells was 
determined by Western blotting using antibodies to dual-phosphorylated Erk1/2. 
Expression of either PKCAKR or PKCACAT slightly increased the levels of dual- 
phosphorylated Erk at 48 hr in BCR-stimulated WEHI-231 cells (figure 6.13). 
This is consistent with expression of PKCACAT and PKCAKR being able to 
partially protect WEHI-231 cells from BCR-driven growth arrest (figure 6.12). 
This suggests that PKC^ may promote proliferation of WEHI-231 cells by 
inducing sustained Erk signals but the kinase activity of PKCÇ does not appear 
to be necessary for these effects.
6.8.12 Expression of PK C Ç  does not induce B c I-x l or Akt in WEHI-231 c e lls
To investigate the mechanism of PKC^-dependent increase in survival of 
WEHI-231 cells, the effect of expression of PKCACAT or PKCAKR on the levels 
of B c I-xl  in WEHI-231 cells was determined since B c I-xl  is an important survival 
factor of WEHI-231 cells. In untreated and anti-lg-stimulated WEHI-231 cells, 
expression of PKCACAT or PKCAKR did not affect the levels of Bc I-Xl (figure 
6.14A-C), indicating the ability of PKCC to impair BCR-driven apoptosis (figure 
6.12G) was not mediated by enhancing B c !-xl  levels. Expression of PKCAKR 
was more effective than expression of PKCACAT at protecting WEHI-231 cells 
from BCR-driven apoptosis and yet expression of PKCAKR did not enhance
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CD40-mediated induction of B c I-Xl in WEHI-231 cells (figure 6.14B). PKCAKR 
therefore does not induce B c I-x l  indicating PKCAKR increases the survival of 
WEHI-231 cells by acting downstream of Bc I-xl or independently of Bc I-x l .
In contrast, expression of PKCACAT did induce a slight enhancement of 
B c1-xl levels in CD40-stimulated cells (figure 6.14C) suggesting active PKCt, 
kinase can promote the CD40-dependent pathway of inducing Bc I-Xl. However, 
the inability of PKCACAT to induce B c I-Xl in the absence of CD40-stimuiation 
indicates PKCt kinase activity is insufficient to directly induce B c I-xl signalling.
To further explore the mechanism of PKCC-dependent survival of WEHI- 
231 cells, the effect of PKCÇCAT and PKCAKR on Akt activity was determined 
since PKC^ can regulate the activity of Akt in other cellular systems (503). The 
activity of Akt was estimated by Western blotting with antibodies that were 
sensitive to the phosphorylation-state of Akt. However, as with previous 
experiments, the levels of pTAkt and pSAkt in WEHI-231 cells were 
exceptionally low and expression of PKCACAT or PKCAKR did not enhance the 
activation of Akt (figure 6.14D-F). In particular, no pSAkt could be detected in 
PKCACAT and PKCAKR WEHI-231 cells despite obtaining a strong signal in the 
positive control samples (figure 6.18E-F, lane 5). These observations suggest 
that PKCt cannot induce Akt in WEHI-231 cells and hence PKCÇ-dependent 
survival of these cells is not mediated by the induction of Akt.
6.9 Conclusions
Previous studies have suggested that PKCa, PKCô and PKC^ have a role 
in CD40-med iated rescue of WEHI-231 cells from BCR-driven growth arrest 
(unpublished observations). Indeed, analysis of WEHI-231 cells expressing 
constitutively active or kinase inactive PKC isoforms showed that PKCa, PKCÔ, 
PKCe and PKCÇ can all impair BCR-driven growth arrest (figures 6.2, 6.5, 6.8 
and 6.12). Furthermore, expression of constitutively active PKCe actually 
increased proliferation of anti-lg-treated WEHI-231 cells. Moreover, each of 
these isoforms of PKC can promote proliferation when expressed as either a 
constitutively active catalytic domain (PKC-CAT) or when expressed as a 
complete PKC enzyme with a point mutation inactivating the kinase (PKC-KR).
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These observations suggest that in WEHI-231 cells the catalytic activity of PKC 
is not always essential for PKC-mediated functions.
Furthermore, analysis of the activity of Erk in WEHI-231 cells that were 
expressing mutant forms of PKC showed that expression of PKCaCAT, 
PKCôCAT, PKCeCAT, PKCeKR, PKCACAT or PKCAKR can all impair BCR- 
driven suppression of sustained (48 hr) Erk signals (figures 6.3, 6.6, 6.9 and 
6.13). The increased proliferation observed in PKCaCAT, PKCôCAT, 
PKCeCAT, PKCeKR, PKCACAT and PKCAKR WEHI-231 cells is thus likely to 
be caused, at least in part, by the enhancement of sustained Erk signals (figure
6.15). Furthermore, these observations suggest that PKCa, PKCÔ, PKCe and 
PKCC may be inhibited by the BCR and/or induced by CD40 to regulate Erk and 
hence proliferation of WEHI-231 cells. However, expression of PKCaKR or 
PKCôKR did not prevent BCR-mediated suppression of sustained Erk signals 
(figures 6.3 and 6.6) suggesting these isoforms of PKC impair BCR-driven 
growth arrest via a different mechanism although the details of this have not 
been explored. However, these observations show that PKC-CAT and PKC-KR 
mutants of the same PKC isoform are likely to use distinct signalling 
mechanisms to promote proliferation of WEHI-231 cells. To further explore the 
need for PKC kinase activity versus PKC regulatory regions it would be 
Interesting to transfect WEHI-231 cells with additional PKC-containing 
constructs including mutants that encode the same region as the PKC-CAT 
mutants but with a point mutation to inhibit the kinase activity.
In addition to promoting proliferation of WEHI-231 cells, expression of 
some isoforms of PKC can also slightly improve the survival of the cells (figure
6.15). In particular, expression of PKCaCAT, PKCaKR, PKCôCAT, PKCACAT 
or PKCAKR reduced the number of WEHI-231 cells with sub-diploid DNA 
(figures 6.2, 6.5 and 6.12). However, PKCe was unable to increase the survival 
of WEHI-231 cells (figure 6.10) suggesting this isoform is specifically involved in 
regulating proliferation. PKCôKR was also unable to increase the survival of 
WEHI-231 cells despite PKCôCAT reducing the level of apoptosis (figure 6.5). 
This further supports the theory that PKC-CAT and PKC-KR mediate their 
effects via distinct signalling mechanisms.
The mechanism of PKC-dependent survival was investigated by 
determining the effect of PKC on the induction of BcI-xl and Akt. None of the
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PKC isoforms were able to substantially alter the activity of Akt (figures 6.4, 6.7,
6.11 and 6.14). This is consistent with the Akt studies in chapter 3, which 
showed that WEHI-231 cells have low Akt activity and it does not appear to be 
regulated by the BCR or CD40. However, a possible mechanism of PKC- 
dependent survival was suggested by the observation that specific PKC 
isoforms can induce B c I-x l in WEHI-231 cells (figure 6.15). Indeed, expression 
of either PKCaCAT or PKCaKR increased the levels of B c I-x l in CD40- 
sti mu Iated WEHI-231 cells (figure 6.4). This suggests that PKCa-dependent 
survival is likely to be mediated, at least in part, by the induction of B c I-x l and 
that PKCa kinase activity is not essential for the induction of B c I-x l in CD40- 
sti mu Iated WEHI-231 cells. However, PKCa kinase activity was essential for 
PKCa-dependent induction of B c I-X l in untreated and BCR-stimulated WEHI- 
231 cells (figure 6.4). This suggests that PKCa kinase activity can induce B c I-x l 
and hence survival of WEHI-231 cells implying this may represent a mechanism 
of CD40-dependent survival or this pathway may be inhibited by the BCR to 
promote apoptosis. These observations also indicate that PKCaCAT is either 
more effective at activating the pathway that increases B c1-x l levels or 
PKCaCAT and PKCaKR use distinct mechanisms for inducing B o I-x l. 
Furthermore, the inability of PKCaKR to induce Bc1-xl in untreated and anti-lg- 
stimulated WEHI-231 cells suggests PKCa may also promote survival via Bcl- 
XL-independent mechanisms.
The levels of B c I-x l in WEHI-231 cells were also increased by expression 
of either PKCôKR or PKCôCAT (figure 6.7). However, as with PKCa-dependent 
induction of B cI-x l, PKCô kinase activity was essential for upregulating B c I-x l in 
anti-lg-treated WEHI-231 cells. PKCa and PKCô-dependent survival of WEHI- 
231 cells thus seem to be mediated, at least in part, by the induction of B c I-x l. 
This suggests that the BCR may inhibit PKCa and/or PKCô kinase activity to 
impair B c !-x l signalling or CD40 might increase the activity of these kinases to 
promote survival of WEHI-231 cells. Nonetheless, additional mechanisms of 
PKCa and PKCô-dependent survival are likely to exist. Furthermore, expression 
of PKC^was unable to induce B c I-x l (figure 6.14) suggesting PKC^-dependent 
promotion of WEHI-231 cell survival is also mediated by signalling mechanisms 
that are independent of B cI-X l or function in parallel to B cI-x l.
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Taken together, these observations show that expression of PKCa, PKCô, 
PKCe and PKC^ can promote proliferation of WEHI-231 cells suggesting the 
suppression of these PKC enzymes may be induced by the BCR to promote 
growth arrest. Alternatively, these isoforms of PKC may be activated by CD40 
to increase the proliferation of WEHI-231 cells. Furthermore, expression of each 
of these isoforms, except PKCe, can also increase the survival of WEHI-231 
cells (figure 6.15) suggesting PKCa, PKCô and PKCÇ may be differentially 
regulated by the BCR and CD40 to determine the survival of WEHI-231 cells. 
Moreover, these effects can be mediated in a PKC-kinase dependent manner 
but some of them can also be performed in kinase inactive PKC mutants 
suggesting PKC also has signalling functions in WEHI-231 cells that do not 
require the phosphorylation of substrates.
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Figure 6.1. Structure of PKC. (A) There are three subclasses of PKC enzymes, 
conventional PKC (cPKC), novel PKC (nPKC) and atypical PKC (aPKC). They 
contain several conserved domains with specific functions. The C1 region of all 
PKCs contains a pseudosubstrate site and the C1 domain of conventional and 
novel PKC enzymes, but not atypical PKCs, also has two zinc-finger domains 
that can bind to DAG and phorbol ester. The C2 domain contains a calcium and 
lipid-binding domain that can bind to calcium in cPKCs and the C2 domain of all 
PKC enzymes can interact with RACKs. A hinge region of PKC attaches the C1 
and C2 domains to the kinase domain. The kinase domain contains binding 
sites for substrates and for ATP. Attached to the kinase domain is a V5 domain 
that can determine the intracellular location of PKC enzymes. (B) Mutant forms 
of PKCa, Ô, E and t  were generated to study the role of PKC in WEHI-231 cell 
signalling. PKC-CAT mutants are constitutively active and lack a regulatory 
region. PKC-KR mutants contain full length PKC but have a point mutation in 
the kinase domain to inactivate the PKC catalytic activity.
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Figure 6.2. PKCa partially protects WEHI-231 cells from BCR-driven growth 
arrest and apoptosis. PKCaCAT, PKCaKR or pcDNA3.1 WEHI-231 cells (1 x 
10  ^ cells/well) were cultured in the presence of increasing concentrations of 
anti-lg (0-10 pg/ml). Proliferation was assessed by measuring the incorporation 
of [^H] thymidine at 24 hr (A) or 48-72 hr (B). Values are the mean % control 
(pcDNA3.1 WEHI-231 cells without anti-lg) thymidine uptake ± sem, n=3 
individual experiments, each performed in triplicate. (0) PKCaCAT, PKCaKR or 
pcDNAS.I WEHI-231 cells (1 x 10  ^cells/well) were cultured in the presence of 
medium (untreated), anti-lg (10 pg/ml) or a combination of anti-lg plus anti- 
CD40 (both at 10 pg/ml). Proliferation was assessed by measuring the 
incorporation of [^H] thymidine at 48 hr. Values are the mean % control 
(pcDNAS.I WEHI-231 cells without anti-lg or anti-CD40) thymidine uptake ± 
sem, n=4 individual experiments, each performed in triplicate. PKCaCAT, 
PKCaKR or pcDNAS.I WEHI-231 cells (5x10® cells/ml) were cultured for 24 hr 
(D) or 48 hr (E) with medium (untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a- 
CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, 
both at 10 pg/ml). The number of mitogenic cells (S phase plus G2/M phase) 
was determined by Pl-staining and FACS analysis (FL2 fluorescence). 
PKCaCAT, PKCaKR or pcDNAS.I WEHI-231 cells (5 x 10® cells/ml) were 
cultured for 24 hr (F) or 48 hr (G) with medium (untreated), anti-lg (a-lg, 10 
pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 
(a-lg + a-CD40, both at 10 pg/ml). Levels of apoptosis were indicated by the % 
sub-diploid cells and this was determined by Pl-staining and FACS analysis 
(FL2 fluorescence).
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Figure 6.3. Expression of PKCaCAT increases sustained Erk signalling in 
WEHI-231 cells. pcDNAS.I (A), PKCaKR (B) or PKCaCAT (0) WEHI-231 cells 
(1x10® cells/ml) were cultured for up to 48 hr with medium (untreated), anti-lg 
(a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a combination of anti-lg plus 
anti-CD40 (a-lg + a-CD40, both at 10 pg/ml) before preparing cell lysates. 
Whole cell lysates (50 pg/lane) were analysed by Western blotting, using the 
NuPAGE system of gel electrophoresis. Levels of dual-phosphorylated Erk 
(pErk) and total Erk (Erk) were determined by Western blotting.
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Figure 6.4. Expression of PKCa can induce Bci-xu but does not activate Akt in 
WEHI-231 cells. pcDNA3.1 (A), PKCaKR (B) or PKCaCAT (C) WEHI-231 cells 
(1 X 10® cells/ml) were cultured for up to 48 hr with medium (untreated), anti-lg 
(a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a combination of anti-lg plus 
anti-CD40 (a-lg + a-CD40, both at 10 pg/ml) before preparing cell lysates. 
Whole cell lysates (50 pg/lane) were analysed by Western blotting, using the 
NuPAGE system of gel electrophoresis. Levels of B c I-x l and total Erk (Erk) 
were determined by Western blotting. pcDNA3.1 (D), PKCaKR (E) or 
PKCaCAT (F) WEHI-231 cells (1 x 10® cells/ml) were cultured for up to 48 hr 
with medium (untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 pg/ml) 
or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, both at 10 pg/ml) 
before preparing cell lysates. Whole cell lysates (50 pg/lane) were analysed by 
Western blotting, using the NuPAGE system of gel electrophoresis. Gel loading 
was as follows: lane f, 1 hr; lane 2, 8 hr; lane 3, 24 hr; lane 4, 48 hr; lane 5, 
phosphorylated Akt control (total cell extracts from untreated Jurkat cells); lane 
6, non-phosphorylated Akt control (total cell extracts from Jurkat cells treated 
with PI-3-K inhibitor LY294002). Levels of phospho-Thr®°® Akt (pTAkt), 
phospho-Ser^^® Akt (pSAkt) and total Akt (Akt) were determined by Western 
blotting.
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Figure 6.5. PKCô partially protects WEH1-231 cells from BCR-driven growth 
arrest and apoptosis. PKCôCAT, PKCôKR or pcDNAS.I WEHl-231 ceils (1 x 
10  ^ cells/well) were cultured in the presence of increasing concentrations of 
anti-lg (0-10 pg/ml). Proliferation was assessed by measuring the incorporation 
of f  H] thymidine at 24 hr (A) or 48-72 hr (B). Values are the mean % control 
(pcDNA3.1 WEHl-231 cells without anti-lg) thymidine uptake ± sem, n=3 
individual experiments, each performed in triplicate. (0) PKCôCAT, PKCôKR or 
pcDNAS.I WEHl-231 cells (1 xIO^ cells/well) were cultured in the presence of 
medium (untreated), anti-lg (10 pg/ml) or a combination of anti-lg plus anti- 
CD40 (both at 10 pg/ml). Proliferation was assessed by measuring the 
incorporation of [^H] thymidine at 48 hr. Values are the mean % control 
(pcDNA3.1 WEHl-231 cells without anti-lg or anti-CD40) thymidine uptake ± 
sem, n=4 individual experiments, each performed in triplicate. PKCôCAT, 
PKCôKR or pcDNAS.I WEHl-231 cells (5x10® cells/ml) were cultured for 24 hr
(D) or 48 hr(E) with medium (untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a- 
CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, 
both at 10 pg/ml). The number of mitogenic cells (S phase plus G2/M phase) 
was determined by Pl-staining and FACS analysis (FL2 fluorescence). 
PKCôCAT, PKCôKR or pcDNAS.I WEHl-231 cells (5 x 10® cells/ml) were 
cultured for 24 hr (F) or 48 hr (G) with medium (untreated), anti-lg (a-lg, 10 
pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 
(a-lg + a-CD40, both at 10 pg/ml). Levels of apoptosis were indicated by the % 
sub-diploid cells and this was determined by Pl-staining and FACS analysis 
(FL2 fluorescence).
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F ig u re  6 .6 . Expression of PKCôCAT increases sustained Erk signalling in 
WEHl-231 cells. pcDNAS.I (A), PKCôKR (B) or PKCôCAT (C) WEHl-231 cells 
(1x10® cells/ml) were cultured for up to 48 hr with medium (untreated), anti-lg 
(a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a combination of anti-lg plus 
anti-CD40 (a-lg + a-CD40, both at 10 pg/ml) before preparing cell lysates. 
Whole cell lysates (60 pg/lane) were analysed by Western blotting, using the 
NuPAGE system of gel electrophoresis. Levels of dual-phosphorylated Erk 
(pErk) and total Erk (Erk) were determined by Western blotting.
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Figure 6.7. Expression of PKCô cannot activate Akt but can induce B c I-X l in 
WEHl-231 cells. pcDNAS.I (A), PKCôKR (B) or PKCôCAT (C) WEHl-231 cells 
(1 x 10® cells/ml) were cultured for up to 48 hr with medium (untreated), anti-lg 
(a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a combination of anti-lg plus 
anti-CD40 (a-lg + a-CD40, both at 10 pg/ml) before preparing cell lysates. 
Whole cell lysates (50 pg/lane) were analysed by Western blotting, using the 
NuPAGE system of gel electrophoresis. Gel loading was as follows: lane 1, 1 
hr; lane 2, 8 hr; lane 3, 24 hr; lane 4, 48 hr; lane 5, phosphorylated Akt control 
(total cell extracts from untreated Jurkat cells); lane 6, non-phosphorylated Akt 
control (total cell extracts from Jurkat cells treated with PI-3-K inhibitor 
LY294002). Levels of phospho-Thr®°® Akt (pTAkt), phospho-Ser"^^® Akt (pSAkt) 
and total Akt (Akt) were determined by Western blotting. pcDNAS.I (D), 
PKCôKR (E) or PKCÔCAT (F) WEHl-231 cells (1 x 10® celts/ml) were cultured 
for up to 48 hr with medium (untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a- 
CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, 
both at 10 pg/ml) before preparing cell lysates. Whole cell lysates (50 pg/lane) 
were analysed by Western blotting, using the NuPAGE system of gel 
electrophoresis. Levels of B c I-x l and total Erk (Erk) were determined by 
Western blotting.
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Figure 6.8. PKCe partially protects WEHl-231 cells from BCR-driven growth 
arrest. PKCeCAT, PKCbKR or poDNA3.1 WEHl-231 cells (1 x 10^ cells/well) 
were cultured in the presence of increasing concentrations of anti-lg (0-10 
pg/ml). Proliferation was assessed by measuring the incorporation of [®H] 
thymidine at 24 hr (A) or 48-72 hr (B). Values are the mean % control 
(pcDNA3.1 WEHl-231 cells without anti-lg) thymidine uptake ± sem, n=3 
individual experiments, each performed in triplicate. (0) PKCeCAT, PKCeKR or 
pcDNAS.I WEHl-231 cells (1 xIO* cells/well) were cultured in the presence of 
medium (untreated), anti-lg (10 pg/ml) or a combination of anti-lg plus anti- 
CD40 (both at 10 pg/ml). Proliferation was assessed by measuring the 
incorporation of [®H] thymidine at 48 hr. Values are the mean % control 
(pcDNAS.I WEHl-231 cells without anti-lg or anti-CD40) thymidine uptake ± 
sem, n=4 individual experiments, each performed in triplicate. PKCeCAT, 
PKCeKR or pcDNAS.I WEHl-231 cells (5x10® cells/ml) were cultured for 24 hr
(D) or 48 hr (E) with medium (untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a- 
CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, 
both at 10 pg/ml). The number of mitogenic cells (S phase plus G2/M phase) 
was determined by Pl-staining and FACS analysis (FL2 fluorescence).
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Figure 6.9. PKCe can induce Erk in BCR-stimulated WEHl-231 cells. pcDNAS.I
(A), PKCeKR (B) or PKCeCAT (C) WEHl-231 cells (1 x 10® cells/ml) were 
cultured for up to 48 hr with medium (untreated), anti-lg (a-lg, 10 pg/ml), antl- 
CD40 (a-CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a- 
CD40, both at 10 pg/ml) before preparing cell lysates. Whole cell lysates (60 
pg/lane) were analysed by Western blotting, using the NuPAGE system of gel 
electrophoresis. Levels of dual-phosphorylated Erk (pErk) and total Erk (Erk) 
were determined by Western blotting.
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Figure 6.10. PKCe does not protect WEHl-231 cells from BCR-driven apoptosis 
and cannot induce B c I-x l. PKCeCAT, PKCeKR or pcDNAS.I WEHl-231 cells (5 
X 10® cells/ml) were cultured for 24 hr (A) or 48 hr (B) with medium (untreated), 
anti-lg (a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a combination of anti- 
lg plus anti-CD40 (a-lg + a-CD40, both at 10 pg/ml). Levels of apoptosis were 
indicated by the % sub-diploid cells and this was determined by Pl-staining and 
FACS analysis (FL2 fluorescence). pcDNAS.I (0), PKCeKR (D) or PKCeCAT
(E) WEHl-231 cells (1 x 10® cells/ml) were cultured for up to 48 hr with medium 
(untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a 
combination of anti-lg plus anti-CD40 (a-lg + a-CD40, both at 10 pg/ml) before 
preparing cell lysates. Whole cell lysates (50 pg/lane) were analysed by 
Western blotting, using the NuPAGE system of gel electrophoresis. Levels of 
B cI-X l and total Erk (Erk) were determined by Western blotting.
291
(A) 24 hr
40 ipcDNA3.1 nPKCeCAT 1 PKCeKR 
35
S  25
îS 10
untreated a-lg a-CD40 a-lg + 
a-CD40
(C) PCDNA3.1
(B) 48 hr
pcDNA3.1 DPKCeCAT BPKOeKR
untreated a-lg a-CD40 a-lg + 
a-CD40
mmm w * 4m,
BcI-Xl
Erk
Time (hr) 1 8 24 48 1 8 24 48 1 8 24 48 1 8 24 48
Untreated a-lg a-CD40 a-lg + a-CD40
(D) PKCeKR
« • « N t M m r n m m.. ..2 . «# # # .# # # # # # # *
«m» «"Ar-##*#
mmmm i—i w
BcI-Xl
Erk
Time (hr) 1 8 24 48 1 8 24 48 1 8 24 48 1 8 24 48Untreated a-lg a-CD40 a-lg + a-CD40
(E) PKCeCAT
#'41 # #
aw# " -  — mm <*Mw,
BcI-Xl
Erk
Time (hr) 1 8 24 48 1 8 24 48 1 8 24 48 1 8 24 48
Untreated a-lg a-CD40 a-lg + a-CD40
Figure 6.11. PKCe cannot induce Akt in WEHl-231 cells. pcDNAS.I (A), 
PKCeKR (B) or PKCeCAT (C) WEHl-231 cells (1 x 10® cells/ml) were cultured 
for up to 48 hr with medium (untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a- 
CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, 
both at 10 pg/ml) before preparing cell lysates. Whole cell lysates (50 pg/lane) 
were analysed by Western blotting, using the NuPAGE system of gel 
electrophoresis. Gel loading was as follows: lane 1, 1 hr; lane 2, 8 hr; lane 3, 24 
hr; lane 4, 48 hr; lane 5, phosphorylated Akt control (total cell extracts from 
untreated Jurkat cells); lane 6, non-phosphorylated Akt control (total cell 
extracts from Jurkat cells treated with P1-3-K inhibitor LY294002). Levels of 
phospho-Thr®°® Akt (pTAkt), phospho-Ser'^^® Akt (pSAkt) and total Akt (Akt) 
were determined by Western blotting.
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Figure 6.12. PKCt partially protects WEHl-231 cells from BCR-driven growth 
arrest and apoptosis. PKCECAT, PKCEKR or pcDNAS.I WEHl-231 cells (1 x 
10  ^ cells/well) were cultured in the presence of increasing concentrations of 
anti-lg (0-10 pg/ml). Proliferation was assessed by measuring the incorporation 
of [^H] thymidine at 24 hr (A) or 48-72 hr (B). Values are the mean % control 
(pcDNAS.I WEHl-231 cells without anti-lg) thymidine uptake ± sem, n=3 
individual experiments, each performed in triplicate. (C) PKCECAT, PKCEKR or 
pcDNAS.1 WEHl-231 cells (1 x 10  ^cells/well) were cultured in the presence of 
medium (untreated), anti-lg (10 pg/ml) or a combination of anti-lg plus anti- 
CD40 (both at 10 pg/ml). Proliferation was assessed by measuring the 
incorporation of [®H] thymidine at 48 hr. Values are the mean % control 
(pcDNAS.I WEHl-231 cells without anti-lg or anti-CD40) thymidine uptake ± 
sem, n=4 individual experiments, each performed in triplicate. PKCECAT, 
PKCEKR or pcDNAS.I WEHl-231 cells (5x10® cells/ml) were cultured for 24 hr 
(D) or 48 hr (E) with medium (untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a- 
CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 (a-lg + a-CD40, 
both at 10 pg/ml). The number of mitogenic cells (S phase plus G2/M phase) 
was determined by Pl-staining and FACS analysis (FL2 fluorescence). 
PKCECAT, PKCEKR or pcDNAS.I WEHl-231 cells (5 x 10® cells/ml) were 
cultured for 24 hr (F) or 48 hr (G) with medium (untreated), anti-lg (a-lg, 10 
pg/ml), anti-CD40 (a-CD40, 10 pg/ml) ora combination of anti-lg plus anti-CD40 
(a-lg + a-CD40, both at 10 pg/ml). Levels of apoptosis were indicated by the % 
sub-diploid cells and this was determined by Pl-staining and FACS analysis 
(FL2 fluorescence).
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Figure 6.13. PKCÇ slightly increases the activity of Erk-MAPK in BCR- 
stimulated WEHl-231 cells. pcDNAS.I (A). PKCEKR (B) or PKCECAT (C) 
WEHl-231 cells (1 x 10® cells/ml) were cultured for up to 48 hr with medium 
(untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a 
combination of anti-lg plus anti-CD40 (a-lg + a-CD40, both at 10 pg/ml) before 
preparing cell lysates. Whole cell lysates (50 pg/lane) were analysed by 
Western blotting, using the NuPAGE system of gel electrophoresis. Levels of 
dual-phosphorylated Erk (pErk) and total Erk (Erk) were determined by Western 
blotting.
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Figure 6.14. Expression of PKCÇ does not induce B c I-x l or Akt in WEHl-231 
cells. PCDNA3.1 (A), PKCÇKR (B) or PKCÇCAT (C) WEHl-231 cells (1x10® 
cells/ml) were cultured for up to 48 hr with medium (untreated), anti-lg (a-lg, 10 
pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a combination of anti-lg plus anti-CD40 
(a-lg + a-CD40, both at 10 pg/ml) before preparing cell lysates. Whole cell 
lysates (50 pg/lane) were analysed by Western blotting, using the NuPAGE 
system of gel electrophoresis. Levels of B c I-x l and total Erk (Erk) were 
determined by Western blotting. pcDNAS.I (D), PKCEKR (E) or PKCECAT (F) 
WEHl-231 cells (1x10® cells/ml) were cultured for up to 48 hr with medium 
(untreated), anti-lg (a-lg, 10 pg/ml), anti-CD40 (a-CD40, 10 pg/ml) or a 
combination of anti-lg plus anti-CD40 (a-lg + a-CD40, both at 10 pg/ml) before 
preparing cell lysates. Whole cell lysates (50 pg/lane) were analysed by 
Western blotting, using the NuPAGE system of gel electrophoresis. Gel loading 
was as follows: lane 1, 1 hr; lane 2, 8 hr; lane 3, 24 hr; lane 4, 48 hr; lane 5, 
phosphorylated Akt control (total cell extracts from untreated Jurkat cells); lane 
5, non-phosphorylated Akt control (total cell extracts from Jurkat cells treated 
with P1-3-K inhibitor LY294002). Levels of phospho-Thr®°® Akt (pTAkt), 
phospho-Ser^^® Akt (pSAkt) and total Akt (Akt) were determined by Western 
blotting.
295
(A) PCDNA3.1
mm BcI-Xl
Erk
Time (hr) 1 8 24 48 1 8 24 48 1 8 24 48 1 8 24 48
Untreated a-lg a-CD40 a-lg + a-CD40
(B) PKCÇKR
BcI-Xl
Erk
Time (hr) 1 8 24 48 1 8 24 48 1 8 24 48 1 8 24 48
Untreated a-lg a-CD40 a-lg + a-CD40
(C) PKCECAT
BcI-Xl
Erk
Time (hr) 1 8 24 48 1 8 24 48 1 8 24 48 1 8 24 48
Untreated a-lg a-CD40 a-lg + a-CD40
(D) PCDNA3.1
A mm E l pTAkt 
pSAkt 
Akt
1 2 3 4 5 6  1 2 3 4  56 1 2 3 4 5 6  1 2 3 4  56  
Untreated a-lg a-CD40 a-lg + a-CD40
(E) PKCÇKR
pSAkt
Akt
1 2 3 4  56 1 2  3 4  56 1 2 3 4 5 6  1 2 3 4  56  
Untreated a-lg a-CD40 a-lg + a-CD40
(F) PKCÇCAT
pTAkt
pSAkt
Akt
1 2 3 4 5 6  1 2 3 4 5 6  1 2 3 4 5 6  1 2 3 4  56
Untreated a-lg a-CD40 a-lg + a-CD40
Figure 6.15. Model showing the role of PKCa, PKCô, PKCe and PKCC in 
regulating survival and proliferation of WEHl-231 cells. Expression of PKCa, 
PKCô, PKCe or PKC^ can increase the proliferation of WEHl-231 cells and 
impair BCR-driven growth arrest. Furthermore, expression of each of these 
PKC isoforms as constitutively active kinases can impair BCR-driven inhibition 
of sustained Erk signals. Expression of kinase inactivated forms of PKCe and 
PKC^ can also increase sustained Erk signals. The ability of certain PKC 
isoforms to impair BCR-driven inhibition of sustained Erk signals is likely to 
contribute to the enhanced proliferation observed in cells expressing these PKC 
isoforms. However, additional mechanisms of PKC-dependent induction of 
mitogenesis are likely to exist since expression of kinase inactivate forms of 
PKCa and PKCô also increased proliferation of WEHl-231 cells but did not 
enhance sustained Erk signals. Expression of PKCa, PKCô and PKC^ can also 
slightly increase the survival and impair BCR-driven apoptosis of WEHl-231 
cells. PKCa and PKCô can increase the levels of B c I-x l  in WEHl-231 cells and 
this is likely to increase the survival of the cells. The mechanism of PKC^- 
dependent survival has not been determined but it does not appear to induce 
B c I-xl  or stimulate Akt in WEHl-231 cells.
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CHAPTER 7 " General Discussion
The immune system has developed mechanisms to protect against the 
generation of autoimmune B lymphocytes. Thus, immature B cells are 
programmed to be sensitive to the process of negative selection such that 
ligation of the BCR by antigen on these cells induces growth arrest and 
apoptosis. However, T cell-derived signals, generated in response to cognate 
antigen, such as co-ligation of CD40 can rescue the immature B cells and 
enable them to survive and proliferate. This investigation has explored the 
signalling mechanisms used by the BCR and CD40 to differentially regulate the 
survival and proliferation of immature B cells. In particular, the role of Erk-MAPK 
in controlling these processes was examined using the WEHl-231 immature B 
cell line.
7,1 Dual role for Erk-MAPK in regulating BCR-driven apoptosis and CD40- 
mediated rescue of WEHl-231 immature B cells
Evidence is presented in this investigation to show that the BCR and 
CD40 differentially regulate the activity of Erk-MAPK in WEHl-231 cells 
(appendices 1-2). In particular, the BCR couples to an early (< 2 hr) transient 
Erk signal that is impaired by ligation of CD40. This early Erk signal is important 
for the induction of apoptosis of WEHl-231 cells (328). Indeed, inhibition of early 
Erk signals using pharmacological inhibitors of MEK can suppress BCR-driven 
apoptosis (appendix IE). This is consistent with the observation that ligation of 
the BCR on immature B cells can induce apoptosis via the induction of CPLA2 , a 
MAPK-sensitive enzyme (102). Cytosolic PLA2 is activated by Erk1/2 and Ca^  ^
downstream of the BCR in WEHl-231 cells and this leads to the production of 
arachidonic acid. Arachidonic acid can disrupt the mitochondrial membrane 
potential leading to the activation of executioner proteases and apoptosis of the 
cell (102). Indeed, it has been observed that inhibition of early Erk1/2 activity in 
BCR-stimulated WEHl-231 cells can also prevent anti-lg-induced activation of 
CPLA2 , as indicated by measuring the production of arachidonic acid (328). The 
BCR is thus coupled to an early (^2 hr) Erk1/2 signal that plays a key role in 
committing WEHl-231 cells to apoptosis.
297
However, this investigation has also identified a second role for Erk-MAPK 
in promoting survival and proliferation of WEHl-231 cells. Indeed, in addition to 
the early (<2 hr) pro-apoptotic Erk-MAPK signal, proliferating WEHl-231 cells 
display sustained (12-48 hr) and cyclic activation of Erk (appendix 2). Ligation of 
the BCR inhibits sustained Erk signals despite enhancing early pro-apoptotic 
Erk1/2 activity (appendix 2). However, co-ligation of CD40 can restore 
sustained Erk signals and data is presented in this study to suggest that this is 
important for CD40-dependent rescue from BCR-driven growth arrest.
Indeed, inhibition of sustained Erk signals using pharmacological inhibitors 
of MEK can induce growth arrest and apoptosis of proliferating WEHl-231 cells 
(appendix 3). In addition, they can impair CD40-dependent rescue from anti-lg- 
induced growth arrest despite enabling CD40-mediated rescue from BCR- 
driven apoptosis. Furthermore, the combined analysis of cell cycle progression 
and intracellular phospho-Erk levels using laser scanning cytometry showed 
that cycling (G1, S and G2/M phase) WEHl-231 cells have high levels of 
phospho-Erk whereas newly formed daughter cells have significantly lower 
levels of phospho-Erk (appendix 4). Moreover, levels of phospho-Erk are low in 
WEHl-231 cells that have undergone cell cycle arrest following culture with cell 
cycle inhibitors or BCR-ligation. Taken together, these observations suggest 
that proliferation of WEHl-231 cells requires sustained and cyclic activation of 
Erk and the induction of growth arrest by the BCR involves a suppression of 
these signals whereas the restoration of these signals is important for CD40- 
dependent cell cycle progression.
The induction of Erk-MAPK in WEHl-231 cells therefore can mediate 
diverse functions since early Erk activation induces mitochondrial-dependent 
apoptosis whilst sustained and cyclic Erk signals promote proliferation of the 
cells. The response of WEHl-231 cells to Erk activity is thus dependent on the 
timing and duration of the Erk signals. Indeed, the temporal regulation of Erk 
signals is also important for determining the fate of other cell types. For 
example, ligation of the TOR induces early transient Erk signals and sustained 
Erk activation and these signals regulate distinct components of NF-kB (508). 
Consequently, sustained Erk signals are necessary for T cell activation and IL-2 
production (508). Furthermore, in PC12 cells, transient Erk signals induce 
proliferation whereas sustained Erk signals cause the cells to differentiate (173).
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One factor that is likely to contribute to the divergent effects of temporally 
distinct Erk signals is the intracellular location of the activated Erk. For example, 
treatment of GT1-7 cells with gonadotropin-releasing hormone induces a 
transient Erk signal that cannot translocate to the nucleus. By contrast, 
treatment of HEK293 cells with the same hormone activates a sustained Erk 
signal and such Erk signals accumulate in the nucleus (509). The duration of 
Erk signalling can thus determine the intracellular location of Erk and this will 
regulate the availability of substrates. For example, cPLAg is a cytoplasmic 
substrate whereas transcription factors are generally localised in the nucleus. 
To further examine the mechanism of Erk-dependent regulation of apoptosis 
and proliferation in WEHl-231 cells, the intracellular location of early and 
sustained Erk signals could be determined. Indeed, preliminary results have 
been obtained to suggest that phospho-Erk translocates to the nucleus in 
CD40-stimulated WEHl-231 cells but is largely retained in the cytoplasm of 
BCR-stimulated cells (328).
The specific targets of sustained Erk signals have not been identified but 
given the importance of this signal for the induction of proliferation in WEHl-231 
cells, candidate molecules are likely to be involved in regulating the cell cycle. 
In particular, sustained Erk is likely to enable cells to undergo the G1 to S phase 
transition since BCR-stimulated WEHl-231 cells undergo growth arrest at G1 
phase of the cell cycle (figure 3.6). Indeed, CD40-dependent proliferation 
requires the induction of the Cdk enzymes including cyclin D/Cdk4, cyclin 
D/Cdk6 and cyclin E/Cdk2 since these are required for progression through G1 
phase of the cell cycle and for the G1 to S phase transition (33, 312). In other 
cellular systems, Erk can increase the expression of cyclin D1 suggesting Erk 
may contribute to the induction of cyclin D Cdks in WEHl-231 cells (50). 
However, it has been reported that ligation of the BCR on immature B cells can 
induce cyclin D/Cdk4 and cyclin D/Cdk6 but cannot stimulate cyclin E/Cdk2 
expression or cell cycle progression (33). This suggests that sustained Erk 
signals may target cyclin E/Cdk2 or some other factor that is required for 
proliferation. Rb is a substrate of Cdk enzymes and cell cycle progression of 
immature B cells requires the phosphorylation and inhibition of Rb since Rb is a 
negative regulator of the transcription factor E2F (50, 52). E2F can regulate the 
expression of many genes required for DNA synthesis and cell cycle
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progression including DNA polymerase alpha, thymidine synthetase, cyclin D3, 
cyclin E and cyclin A (33, 50-54). The importance of E2F in mediating cell cycle 
progression of WEHI-231 cells is indicated by studies on Bc 1-xl  WEH1-231 cells 
since these cells are usually susceptible to BCR-driven growth arrest but 
expression of E2F can protect these cells from BCR-driven growth arrest (52). 
Sustained Erk signals therefore are likely to induce proliferation of WEHI-231 
cells via the induction of Cdks, the inhibition of Rb and/or the stimulation of E2F.
7.2 Regulation of Erk-MAPK by the BCR and CD40 in WEHI-231 cells
To further investigate the induction of growth arrest by the BCR, the 
mechanism of BCR-dependent inhibition of sustained Erk signals was 
investigated. The ability of the BCR to suppress upstream activators of Erk was 
determined by comparing the activity of MEK in untreated and anti-lg-treated 
WEHI-231 cells. Despite being able to suppress sustained (12-48 hr) Erk 
signals, ligation of the BCR did not inhibit sustained (12-48 hr) MEK activity 
(figures 3.7-3.8). This suggests that BCR-dependent suppression of Erk is not 
mediated by an inhibition of upstream activators of Erk. Indeed, an alternative 
mechanism of BCR-dependent suppression of sustained Erk signals was 
suggested by the observation that ligation of the BCR increases the cellular 
levels of PAC-1 and enhances its association with Erk (appendix 5). PAC-1 is a 
dual-specificity MAPK phosphatase therefore it inhibits Erk by 
dephosphorylating the threonine and tyrosine residues of the activation loop of 
Erk. Furthermore, it has previously been shown in B and T cells that mitogen- 
induced pac-1 expression is mediated by Erk (384, 385) suggesting BCR-driven 
induction of PAC-1 may also represent an Erk-dependent negative feedback 
loop.
Dual-specificity MAPK phosphatases therefore appear to be key mediators 
of BCR-dependent inhibition of sustained Erk signalling. However, additional 
groups of protein phosphatases are likely to contribute to the regulation of Erk 
since single-phosphorylated forms of Erk (pT-Erk and pY-Erk) were detected in 
WEHI-231 cells (figure 3.9). In particular, pY-Erk was abundant at times of high 
Erk activity whilst pT-Erk was detected even when the levels of dual- 
phosphorylated Erk were low. The use of single-specificity phosphatases to 
regulate Erk1/2 activity in WEHI-231 cells adds an additional level of complexity
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to the control of this kinase. Furthermore, recent studies have suggested that 
single-phosphorylated forms of Erk may have partial activity (379) therefore the 
generation of pT-Erk and pY-Erk in WEHI-231 cells may be functionally 
significant. To begin to explore the functional significance of single- 
phosphorylated Erk, the intracellular location of these forms of Erk should be 
determined since dual-phosphorylated Erk generally translocates to the nucleus 
but many single-specificity protein phosphatases are found in the cytoplasm of 
ceils (381). Furthermore, the identity of the threonine and tyrosine 
phosphatases involved in generating pY-Erk and pT-Erk in WEHI-231 cells has 
not been fully explored. However, preliminary data has suggested that the 
association of PP2A and Erk in WEHI-231 cells is not regulated by the BCR and 
CD40 implying PP2A does not mediate BCR-dependent suppression of Erk 
(428).
Nonetheless, Erk was found in association with SHP-1 and SHP-2 tyrosine 
phosphatases in WEHI-231 cells but the kinetics of association did not 
immediately implicate these phosphatases as being involved in the production 
of pT-Erk downstream of the BCR and CD40 (figure 3.10). However, they did 
suggest that SHP-2 might be a positive regulator of Erk1/2 in WEHI-231 cells 
since the association of SHP-2 and Erk was regulated by ligation of the BCR 
and CD40 and was greatest when dual-phosphorylated Erk was most abundant. 
Moreover, SHP-2 has previously been implicated as a positive regulator of Erk 
in mature B cells (110, 117, 132, 165).
To further investigate the mechanisms controlling the induction of 
sustained Erk signals and proliferation of WEHI-231 cells, the role of Ras and 
its downstream effectors was explored. These studies suggested that Ras is an 
important activator of early and sustained Erk signals in WEHI-231 cells (figure
3.11). Furthermore, either Raf-1 or PI-3-K can mediate Ras-dependent 
induction of Erk. However, constitutive activation of these effectors by Ras did 
not lead to constitutive activation of Erk indicating they were insufficient to 
overcome BCR-dependent inhibition of sustained Erk signals (figure 3.11). This 
is consistent with the observation that the BCR inhibits sustained Erk by 
activating MAPK phosphatases in an Erk-dependent manner rather than 
suppressing upstream activators of Erk (figure 3.8 and appendix 5). However, 
the role of additional activators of Erk has yet to be explored in WEHI-231 cells.
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For example, in DT40 B ceils, B-Raf is a more effective activator of Erk than 
Raf-1 (221) suggesting prolonged activation of Erk in WEHI-231 cells may also 
be enhanced by B-Raf and this might represent a Ras-independent mechanism 
of inducing Erk. Indeed, preliminary data suggests that untreated WEHI-231 
cells display cyclic activation of Rapi, an activator of B-Raf and this appears to 
be regulated by ligation of the BCR and CD40 (428).
To investigate the regulation of Ras by the BCR in WEHI-231 cells, the 
role of the adaptor protein Dok-1 was examined since Dok can differentially 
regulate the activity of RasGAP in various cellular systems (244, 400-402). 
Inhibition of Dok-1, by expressing Dok-PH/PTB in WEHI-231 cells, enhanced 
the activity of Erk in unstimulated and BCR-activated but not in CD40-stimulated 
cells (figure 3.15). This suggests that Dok-1 normally suppresses Erk in WEHI- 
231 cells and this may represent an additional mechanism of BCR-dependent 
suppression of Erk. In T cells, Dok-1 is tyrosine-phosphorylated downstream of 
the CD2 receptor leading to the recruitment and activation of Crk-L (399, 403). 
Crk can function as an adaptor protein that binds to SOS and C3G (171, 172) 
leading to either the activation or inhibition of Erk-MAPK. Similarly, the activity 
of Erk might be regulated in WEHI-231 cells via the Dok-1-mediated induction of 
Crk.
The functional significance of Ras activation in regulating the survival and 
proliferation of WEHI-231 cells was examined using WEHI-231 cells transfected 
with RasV^^, RasV^^S^^ and RasV^ ^C'^ ®. These studies showed that expression 
of constitutively active forms of Ras can partially protect WEHI-231 cells from 
BCR-driven growth arrest and apoptosis. Indeed, after 24 hr, expression of 
RasV^^, RasV^^S^^ or RasV^^C^® prevented BCR-driven growth arrest (figure
3.12). Furthermore, after 48 hr, BCR-driven apoptosis was impaired by 
expression of these constitutively active forms of Ras (figure 3.12). RasV^^C'^® 
was particularly effective at protecting WEHI-231 cells indicating the induction of 
PI-3-K by Ras is important for promoting survival and proliferation of the cells. In 
addition to being able to induce sustained Erk signals to enable proliferation of 
WEHI-231 cells, expression of RasV^ ^C"^ ® was able to induce B c 1-xl  presumably 
to enhance the survival of the cells (figure 3.14) since B c 1-xl  is an important 
survival factor of WEHI-231 cells (292, 293, 305, 427). Expression of RasV^^ 
and RasV^^S^® also increased the levels of Bc I-Xl indicating Ras is likely to
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induce B c I-xl  via Raf-1 and/or PI-3-K. However, expression of RasV^^C" ”^, unlike 
RasV^^ or RasV^^S^®, was able to induce B c !-xl  in BCR-activated WEHI-231 
cells (figure 3.14) suggesting Ras-dependent activation of PI-3-K can impair 
BCR-driven apoptosis via the induction of Bc I-Xl. These observations were 
supported by enriching PI-3-K signalling via the inhibition of the phosphatase 
SHIP since inhibition of SHIP enhanced the activity of Erk and induced B c I-Xl in 
WEHI-231 cells resulting in partial protection from BCR-dependent growth 
arrest and apoptosis (figures 3.17-3.19).
7.3  B c I-x l  is a key mediator of CD40-dependent rescue from BCR-driven 
apoptosis
Previously it has been shown that a key event in the stimulation of BCR- 
driven apoptosis in WEHI-231 cells is the induction of early (^2 hr) Erk signals 
(328) contributing to the activation of cPLAa and leading to the production of 
arachidonic acid and subsequent disruption of the mitochondrial membrane 
potential. The loss of mitochondrial function causes cellular levels of ATP to be 
depleted but cytochrome c does not seem to be released into the cytosol. 
Consistent with this, BCR-driven apoptosis does not appear to be mediated by 
caspases but instead the cathepsin family of proteases is responsible for 
execution of the cell (102). Coupling of the BCR to this apoptotic pathway can 
be abrogated by T cell-derived signals including exposure to IL-4 (218) and 
ligation of CD40 (102, 328). However, it has been widely reported that CD40 
can upregulate the expression of Bcl-2 family members including B c I-x l  
therefore the role of B c I-x l  in CD40-mediated rescue from BCR-driven growth 
arrest and apoptosis was examined in WEHI-231 cells. This investigation 
showed that Bc I-x l  is a key mediator of CD40-dependent rescue from BCR- 
driven apoptosis. Indeed, ligation of CD40 on immature B cells causes B c I-Xl to 
be upregulated and this can be mimicked using WEHI-231 cells that are 
transfected with the pSFFV-Neo plasmid containing the human bcl-Xi gene (Bcl- 
Xl WEHI-231 cells) (figure 4.2). B c I-Xl WEHI-231 cells are protected from BCR- 
driven apoptosis and have impaired apoptosis Induced by exogenous 
arachidonic acid (figures 4.3-4.5 and 4.8). B c I-xl  WEHI-231 cells are also 
protected from BCR- and AA-mediated disruption of mitochondrial membrane 
potential and have impaired BCR-dependent activation of cathepsin B
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(appendix 7). Taken together, these observations suggest that B c I-xl  mediates 
CD40-dependent survival by protecting WEHI-231 cells downstream of 
arachidonic acid, presumably by ensuring the mitochondrial membrane integrity 
is retained.
Nonetheless, expression o f B c 1-x l  can also impair anti-lg-induced 
activation of cPLAa and subsequent arachidonic acid production (appendix 7) 
suggesting B c1-x l  not only protects the mitochondrial membrane integrity but 
also impairs BCR-dependent induction of CPLA2 . The mechanism of B c 1-xl -  
dependent suppression of cPLAg activity is incompletely understood. Indeed, 
evidence is presented in this study showing that exogenous arachidonic acid 
might enhance early pro-apoptotic Erk signals and whilst ligation of CD40 can 
impair AA-mediated induction of transient Erk signals, overexpression of B c 1-xl  
did not prevent arachidonic acid from inducing early Erk activity (figure 4.16). 
However, the activity of cPLAz is dependent on both calcium and Erk (222, 289) 
therefore an alternative potential mechanism of Bcl-xt-dependent suppression 
of CPLA2 is to impair calcium signalling. Indeed, Bc I-Xl has been reported to 
impair calcium signalling in murine T cells by decreasing the expression of IP3 
receptors (510). The ability of B c 1-xl  to regulate Ca^^ flux in WEHI-231 cells has 
yet to be explored.
Bc 1-xl  is thus a very important survival factor of WEHI-231 cells that can 
suppress the BCR-activated mitochondrial death pathway to mediate CD40- 
dependent survival. Nonetheless, additional pro-survival Bcl-2 family members 
may also be induced downstream of the BCR in WEHI-231 cells. For example, 
ligation of CD40 can increase the expression of A1 and ectopic expression of 
A1 can partially protect WEHI-231 cells from BCR-driven apoptosis (302, 304, 
317). However, A1 appears to impair caspase-dependent apoptosis rather than 
target the BCR-activated mitochondrial death pathway and disruption of the 
mitochondrial membrane integrity has been reported to be the major step that 
commits WEHI-231 cells to BCR-driven apoptosis (102) therefore inhibition of 
this stage is critical for CD40-induced survival. Taken together, this suggests 
that CD40-dependent rescue from BCR-driven apoptosis critically requires the 
induction of B c 1-x l  since this can prevent the mitochondrial death pathway. 
However, additional Bcl-2 family proteins may enhance the viability of the cells 
by impairing alternative apoptotic pathways. To further understand the
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mechanism of CD40-dependent survival, it would be interesting to investigate 
the expression and intracellular location of pro-apoptotic bcl-2 family members 
since these are known antagonists of Bci-xu and other pro-survival Bcl-2 family 
proteins (67).
Although Bc I-xl is a key mediator of CD40-dependent rescue from BCR- 
driven apoptosis, the expression Bc I-xl does not protect WEHI-231 cells from 
BCR-driven growth arrest (figures 4.4-4.7 and 4.9) suggesting distinct 
mechanisms regulate survival and proliferation of these cells. Furthermore, 
expression of Bc I-xl was unable to mimic CD40 and restore sustained Erk 
signals to BCR-stimulated WEHI-231 cells (figure 4.10). This is consistent with 
the suggestion that a key event in CD40-mediated rescue from BCR-driven 
growth arrest is the reversal of BCR-dependent abrogation of sustained and 
cyclic activation of Erk1/2. Taken together, these observations suggest that Bcl- 
x l is a key mediator of CD40-dependent rescue from BCR-driven apoptosis but 
additional CD40-dehved signals are required to restore proliferation to BCR- 
stimulated WEHI-231 cells.
To further investigate CD40-dependent rescue of WEHI-231 cells the 
mechanism of CD40-mediated induction of sustained Erk signals and hence 
proliferation was examined. Arachidonic acid is a key mediator of BCR-driven 
apoptosis but arachidonic acid is also a substrate for Cox and Lox enzymes and 
the products of arachidonic metabolism have been implicated in regulating 
survival and proliferation in various cellular systems. Inhibitors of Cox2 and Lox 
were thus used to investigate the importance of arachidonic acid metabolism in 
CD40-dependent rescue of WEHI-231 cells. Inhibition of Cox/Lox induced 
growth arrest and apoptosis of WEHI-231 cells (figures 4.11-4.12 and appendix 
8). The induction of apoptosis is likely to be caused by the accumulation of 
arachidonic acid thus implicating a causal role for BCR-dependent arachidonic 
acid production in mediating the Bcl-xu-sensitive mitochondrial death pathway.
However, the induction of growth arrest by Cox/Lox inhibitors also 
suggested that metabolites of arachidonic acid can promote CD40~dependent 
proliferation of WEHI-231 cells since these inhibitors impaired CD40-dependent 
rescue from BCR-driven growth arrest (figure 4.13). In particular, ligation of the 
BCR appears to reduce the levels of PGE2 in WEHI-231 cells by decreasing the 
expression of Cox2 whilst co-ligation of CD40 can induce Cox2 and restore
305
PGEa levels (appendix 9). Expression of Bc 1-xl  was unable to mimic CD40 and 
restore PGE2 levels suggesting metabolites of arachidonic acid regulate 
proliferation rather than survival of VVEHI-231 cells (figure 4.14A). Furthermore, 
inhibition of Cox/Lox impaired CD40-mediated activation of sustained Erk 
signals (figure 4.146) suggesting metabolites of arachidonic acid can promote 
proliferation of WEHI-231 cells via the induction of Erk. Ligation of CD40 
therefore seems to induce Cox2 and possibly other Cox/Lox enzymes to 
increase the production of PGE2 and other prostaglandins/leukotrienes from 
arachidonic acid. This has two effects: firstly, it reduces the cellular levels of 
arachidonic acid and hence impairs the mitochondrial death pathway; secondly, 
it produces metabolites of arachidonic acid that can enhance sustained Erk 
signals and promote proliferation of the WEHI-231 cells.
Taken together, these results highlight two key mechanisms of CD40- 
dependent rescue of BCR-stimulated WEHI-231 cells. Firstly, ligation of CD40 
induces B c I-X l resulting in a suppression of the BCR-driven mitochondrial death 
pathway. Secondly, CD40 induces Cox2 to increase the metabolism of 
arachidonic acid. This impairs the BCR-driven apoptotic pathway and enhances 
immature B cell proliferation via the production of PGE2 and the induction of 
sustained Erk signals.
7.4 Role of PKC and sphingoliptds in regulating WEHI-231 survival and 
proliferation
The results presented in chapter 3 implicated Ras as an important 
upstream activator of Erk. Expression of RasV^ ^C"^ *^ , which specifically couples 
to PI-3-K, was particularly effective at promoting survival and proliferation of 
WEHI-231 cells. In addition to promoting the activation of Erk1/2 (figure 3.11), 
Ras-dependent activation of P1-3-K also seems to induce Bc 1-xl  (figure 3.14) 
and, as described in chapter 4, Bc I-x l  is an important pro-survival protein of 
WEHI-231 cells, interestingly, the pro-survival protein Akt does not appear to be 
activated downstream of PI-3-K since no Akt activity was detected in WEHI-231 
cells even when they were expressing constitutively active forms of Ras or 
mutant forms of SHIP (figures 3.13 and 3.19). Non-phosphorylated Akt was 
easily detected in WEHI-231 cells suggesting the activation of Akt was 
suppressed in these cells. This may have been due to compartmentalisation
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separating Akt from its upstream activators or perhaps Akt inhibitors such as 
PP2A (185) were abundant
In some respects this observation was surprising since Akt is activated 
downstream of PI-3-K in BCR-stimulated splenic B lymphocytes. However, the 
induction of Akt in mature B ceils promotes survival by stimulating NF-k B and 
NF-AT (188, 193-195) and the BCR of immature B cells cannot sustain these 
signals (261, 296, 297). Nonetheless, ligation of CD40 on immature B cells is 
reported to induce NF-kB (297). The lack of Akt activity in CD40-stimulated 
WEHI-231 cells suggests that immature and mature B cells may use different 
mechanisms to induce NF-k B. A potential mediator of CD40-dependent 
activation of NF-kB in immature B cells is PKC since various PKC isoforms 
have been reported to contribute to the induction of NF-kB in lymphocytes. For 
example, PKCp contributes to the activation of NF-kB in mature B cells (199), 
PKCe in T cells and PKC7. in pre-B cells (212).
Indeed, several PKC isoforms have been associated with promoting 
survival and proliferation of mature B cells via the induction of pro-survival Bcl-2 
family proteins and NF-kB (193, 199, 210, 211, 290). Immature B cells display 
impaired PKC signalling compared to mature B cells but treatment of primary 
splenic immature B cells or WEHI-231 cells with phorbol ester can prevent 
BCR-driven apoptosis suggesting the diminished activation of cPKC and nPKC 
isoforms in immature B cells contributes to their cell death (294, 295). Indeed, 
previous studies have shown that the BCR and CD40 on immature B cells can 
regulate the expression of multiple PKC isoforms and PKCa, PKCô and PKC^ 
were highlighted by antisense studies as potential mediators of CD40- 
dependent rescue from anti-lg-induced growth arrest (unpublished 
observations). The present study now shows that ectopic expression of PKCa, 
PKCô, PKCe or PKCL in WEHI-231 cells can affect the survival and proliferation 
of WEHI-231 cells. In particular, expression of PKCa, PKCô and PKCC slightly 
impaired BCR-driven apoptosis (figures 6,2, 6.5 and 6.12). PKCa and PKCô 
appear to do so by inducing B c 1-Xl (figures 6.4 and 6.7) suggesting the 
expression of B c I-xl  can be regulated downstream of these PKC isoforms in 
WEHI-231 cells. Furthermore, NF-kB might mediate the induction of B c I-Xl by 
PKCa and PKCô since PKC has been observed to induce NF-kB in
lymphocytes and in mature B cells NF-kB induces B c 1-xl  (193, 199, 211).
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However, PKCÇ did not induce Bc 1-x l  (figure 6.14) and is likely to either promote 
survival of WEHI-231 cells independently of Bc I-Xl or by acting downstream of 
this pro-survival protein.
Moreover, expression of PKCa, PKCô, PKCe or PKC^ also promoted 
proliferation of WEHI-231 cells and each of these isoforms of PKC impaired 
BCR-driven growth arrest (figures 6.2, 6.5, 6.8 and 6.12). PKCa, PKCô, PKCe 
and PKC^ appear to promote proliferation, at least in part, by enhancing 
sustained Erk signals in WEHI-231 cells (figures 6.3, 6.6, 6.9 and 6.13). Several 
isoforms of PKC can thus regulate the survival and proliferation of WEHI-231 
cells via the induction of B c I-xl  and Erk, respectively but also via additional, as 
yet unknown, mechanisms. Indeed, analysis of mutant forms of PKC showed 
that the kinase activity of PKCa, PKCô, PKCe and PKC^ was not essential for 
all of these effects suggesting the regulatory regions of PKC enzymes can also 
mediate important signalling functions in WEHI-231 cells.
Sphingolipids are known regulators of specific isoforms of PKC including 
PKCa and PKCt- The role of the sphingosine kinase and hence SPP in 
regulating the survival and proliferation of WEHI-231 cells was thus 
investigated. Previous evidence has suggested that ligation of the BCR reduces 
the levels of spontaneously cycling SPP in WEHI-231 cells whilst co-ligation of 
CD40 restores SPP levels (428). Indeed, inhibition of sphingosine kinase using 
DMS induced growth arrest and apoptosis of WEHI-231 cells and synergistically 
enhanced BCR-driven growth arrest and apoptosis (figures 5.2-5.7). However, 
DMS did not mimic anti-lg in suppressing sustained Erk signals (figure 5.16) 
suggesting SPP acts downstream of Erk to promote proliferation of WEHI-231 
cells. This suggests that SPP is not an upstream activator of PKCa, PKCô or 
PKCe since the activation of each of these kinases impaired BCR-dependent 
suppression of sustained Erk signals. However, these observations do not 
eliminate the possibility of PKCt being activated downstream of SPP to promote 
proliferation of WEHI-231 cells.
Ligation of CD40 partially protected WEHI-231 cells from DMS-induced 
growth arrest and apoptosis (figures 5.6-5.7). Furthermore, overexpression of 
B c I-Xl protected WEHI-231 cells from DMS-driven apoptosis and was actually 
more effective than ligation of CD40 (figures 5.8-5.9). An explanation for this 
was provided by the observation that DMS impaired CD40-dependent induction
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of Bc1-xl  (figure 5 .1 0 )  suggesting one mechanism of CD40-dependent induction 
of Bc I-xl is via the upreguiation of SPP. Nonetheless, ligation of CD40 further 
enhanced the survival of B c I-xl  WEHI-231 cells treated with DMS (figure 5 .1 1 ).  
This suggests that CD40 may also induce B c I-xl  via SPP-independent 
mechanisms. This is consistent with the RasV^^ data that implicated PI-3-K as 
an upstream mediator of Bc I-Xl (figure 3.14). Alternatively, CD40 might promote 
survival of WEHI-231 cells via additional Bcl-XL-independent mechanisms. 
Indeed, CD40 has been found to increase the levels of Bcl-2, A1 and Mcl-1 in 
WEHI-231 cells (427).
7.5 Concluding remarks
This investigation has demonstrated that the differential regulation of Erk- 
MAPK signals and B c I-Xl by the BCR and CD40 is critical for determining the 
survival and proliferation of WEHI-231 immature B cells. Much of this 
investigation has focused on the temporal regulation of Erk 1/2 and Bc I-Xl in 
WEHI-231 cells and the mechanisms used by the BCR and CD40 to control 
these signalling molecules. Indeed, a complex network of signalling pathways 
(figure 7.1) has been shown to regulate the activity of Erk-MAPK and the 
expression of B c 1-x l  and this is likely to ensure the survival and proliferation of 
WEHI-231 cells is carefully regulated. However, future work into these signalling 
networks is expected to reveal additional levels complexity as new mediators of 
these pathways are discovered and as the intracellular compartmentalisation of 
signalling complexes is more closely examined.
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Figure 7.1. The differential regulation of Erk and Bc I-xl by the BCR and CD40 
is mediated by a complex network of signalling pathways enabling the survival 
and proliferation of WEHI-231 cells to be carefully regulated.
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Appendix 1. BCR-mediated induction of an early Erk-MAPK signal is 
associated with commitment to apoptosis of WEHI-231 cells and inhibition of 
early Erk signals abrogates BCR-mediated apoptosis of WEHI-231 cells. BCR- 
mediated induction of an early Erk-MAPK signal is associated with commitment 
to apoptosis of WEHI-231 cells. (A) WEHI-231 cells (1 x 10®/ml) were 
stimulated for 30 min with 0-25 pg/ml anti-lg, as indicated. (B) WEHI-231 cells 
(1 X 10^/ml) were stimulated with medium (lanes 1 and 7) or anti-lg (10 pg/ml, 
lanes 2-6) for 0-60 min, as indicated. (C) WEHI-231 cells (1 x 10®/ml) were 
stimulated with medium (lanes 1 and 7) or anti-CD40 (10 pg/ml, lanes 2-6) for 0- 
60 min, as indicated. (D) WEHI-231 cells (1 x 10®/ml) were stimulated with 
medium (lanes 1 and 7) or a combination of anti-lg plus anti-CD40 (both at 10 
pg/ml, lanes 2-6) for 0-60 min, as indicated. Levels of pErk/Erk expression were 
determined by Western blotting (15 pg/lane). Densitometry indicates relative 
band density of phospho-p42 Erk-MAPK for anti-lg-treated cells as: lane 7,1; 
lane 2, 3; lane 3, 13; lane 4, 22; lane 5, 29; lane 6, 16; lane 7, 0.3. Densitometry 
indicates relative band density of phospho-p42 Erk-MAPK for anti-lg plus anti- 
CD40-treated cells as: lane 7, 1; lane 2, 18; lane 3, 28; lane 4, 10; lane 5, 7; 
lane 6, 8; lane 7, 0.5. (E) Inhibition of early Erk signals abrogates BCR- 
mediated apoptosis of WEHI-231 cells. WEHI-231 cells (5 x 10®) were 
preincubated in the absence (DMSO vehicle) or presence of 1 pM U0126 for 2 
hr. Cells were then treated with medium (untreated) or anti-lg (10 pg/ml) for 48 
hr. Levels of apoptosis were determined by Pl-staining and FACS analysis with 
FL2 fluorescence after 48 hr. This figure was taken from (328) and full details of 
materials and methods can be found in this reference.
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Appendix 2. Apoptotic signalling via the BCR suppresses sustained cyclic 
activation of Erk that can be re-established by CD40-mediated rescue. WEHI- 
231 cells (5 X 10®/ml) were stimulated with medium (untreated) (A), 1 pg/ml anti- 
lg (B), 1 pg/ml anti-lg plus 10 pg/ml anti-GD40 (C) or 10 pg/ml anti-CD40 (D) for 
0-48 hr, as indicated. Levels of phospho-Erk/total Erk were determined by 
Western blotting (30 pg/lane). Densltometric analysis shows fold increase of 
p42 Erk-MAP kinase relative to the 0 hr samples for all treatments. These 
experiments were performed in collaboration with Stephen Gauld and this figure 
was taken from (328). This data is representative of at least eight independent 
experiments.
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Appendix 3. Inhibition of sustained cyclic activation of Erk-MAPK can block 
basal proliferation and CD40-mediated rescue. (A) WEHI-231 cells (1 x 10*^  
cells/well) were preincubated for 3 hr with DMSO vehicle or PD98059 plus 
D0126 (PD + U, both at 1 pM). Cells were then treated as indicated with 10 
pg/ml anti-lg (a-lg), 10 pg/ml anti-CD40 (a-CD40), or a combination of both (a-lg 
+ a-CD40). Cells treated with PD98059 and U0126 were treated with an 
additional dose (1 pM or DMSO vehicle for cells lacking inhibitors) every 4 hr 
during 28 hr post-addition of anti-lg and/or anti-CD40. Proliferation was 
assessed by measuring pH] thymidine uptake at 48 hr. Values are means ± 
standard deviation of quadruplicate wells. (B) WEHI-231 cells (5 x 10® 
cells/well) were preincubated with PD98059 (1 pM) plus U0126 (1 pM) or 
DMSO vehicle for 3 hr. Cells were then stimulated as indicated with 10 pg/ml 
anti-lg, 10 pg/ml anti-CD40 or a combination of both. Cells originally treated 
with PD98059 plus U0126 were treated with additional doses (1 pM or DMSO 
vehicle for cells lacking inhibitors) every 4 hr for a total of 28 hr post-addition of 
anti-lg and/or anti-CD40. Cells were harvested after 48 hr and DNA content was 
analysed by Pl-staining and FACS analysis. (0) WEHI-231 cells (1 x 10*^  
cells/well) were preincubated for 3 hr in PD98059 (1 and 5 pM) or DMSO 
vehicle (none) before stimulation with medium (none), anti-lg (10 pg/ml), anti- 
CD40 (10 pg/ml) or a combination of both. Proliferation was assessed by 
measuring pH] thymidine uptake at 48 hr. Values are means ± standard 
deviation of quadruplicate results. (D) WEHI-231 cells (1 x 10"^  cells/well) were 
preincubated for 3 hr in U0126 (1 or 5 pM) or DMSO vehicle before stimulation 
with medium, anti-lg (10 pg/ml) or anti-lg plus anti-CD40 (both at 10 pg/ml). 
Proliferation was assessed by measuring pH] thymidine uptake at 48 hr. Values 
are means ± standard deviation of quadruplicate wells. This figure was taken 
from (328) and full details of materials and methods can be found in this 
reference.
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Appendix 4. Erk activation is associated with cell cycle progression and cell 
cycle arrest is associated with suppression of Erk signals. (A) WEHI-231 cells 
cultured for 48 hr in medium were analysed for Pl-staining of DNA and 
intracellular staining of phospho-Erk. The distribution of cells in the phases of 
cell cycle and exhibiting phospho-Erk staining were, respectively; G1, 46% 
(70.1% phospho-Erk); S phase, 30.8% (74.8% phospho-Erk); G2/M 11.6% 
(68.7% phospho-Erk); and newly divided cells, 9.2% (30.2% phospho-Erk). (B) 
WEHI-231 cells were cultured in the absence (media) or presence of 
olomoucine (50 pM) for 40 hr. The cells were washed twice in sterile medium 
before being resuspended at 2 x 10® cells/ml and stimulated with anti-lg (10 
pg/ml), anti-lg plus anti-CD40 (both at 10 pg/ml) or medium alone for up to 48 
hr, as indicated. Cytospins were then fixed, permeabilised and stained for PI 
and phospho-Erk before analysis by LSC. This figure was taken from (328) and 
full details of materials and methods can be found in this reference.
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Appendix 6. BCR-mediated downregulation of Erk activity involves the 
induction of PAC-1. (A) WEHI-231 cells (1 x 10^) stimulated with anti-lg (10 
pg/ml) for up to 48 hr were lysed and subjected to Western blot analysis of 
PAC-1 or Erk expression, as indicated. (B) Erk2-containing immune complexes 
derived from WEHI-231 cells stimulated with anti-lg (10 pg/ml) or anti-lg plus 
anti-CD40 (both at 10 pg/ml) for up to 24 hr, as indicated, were analysed for 
PAC-1 or Erk2 expression by Western blotting. This figure was taken from (328) 
and full details of materials and methods can be found in this reference.
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Appendix 6. B c I-x l  is upregulated downstream of CD40. Wild-type WEHI-231 
cells (1 X 10^cells/lane) were cultured with medium, anti-lg (5 pg/ml), anti-CD40 
(10 pg/ml) or a combination of anti-lg (5 pg/ml) plus anti-CD40 (10 pg/ml) for up 
to 48 hr. Cell lysates were prepared and Western blot analysis of B c I -x l  
expression was performed. Experimental conditions were as follows: lane 1, 
medium 0 hr; lane 2, anti-lg 8 hr; lane 3, anti-CD40 8 hr; lane 4, anti-lg plus 
anti-CD40 8 hr; lane 5, anti-lg 24 hr; lane 6, anti-CD40 24 hr; lane 7, anti-lg plus 
anti-CD40 24 hr; lane 8, anti-lg 48 hr; lane 9, anti-CD40 48 hr; lane 10, anti-lg 
plus anti-CD40 48 hr; lane 11, medium 48 hr. This figure was taken from (427) 
and full details of materials and methods can be found in this reference.
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Appendix 7. Overexpression of B c I-Xl suppresses coupling of the BCR to 
mitochondrial PLA2 activation. (A) Increasing concentrations (0-100 pM, as 
indicated) of AA induce PLA2 activation and enhance anti-lg (1 pg/ml)- 
stimulated PLA2 activation as determined by the increased release (intracellular 
+ extracellular) of [®H] arachidonic acid from cellular [®H] arachidonic acid- 
labelled phosphatidylcholine. This was measured by thin layer chromatography 
of cellular lipids in hexane; diethylether: formic acid (80: 20: 2, by volume). (B) 
Due to the loss of [®H] arachidonic acid during the cellular fractionation process, 
anti-lg (1 pg/ml)-stimulated mitochondrial PLA2 activation was determined by 
the measurement of decreased levels of [®H] arachidonic acid-labelled 
phosphatidylcholine in isolated mitochondria derived from wild-type and Bc I-x l  
WEHI-231. Data are representative of at least three independent experiments.
(C) WEHI-231 cells (5 x 10®/ml) were cultured for 48 hr with medium 
(untreated), anti-lg (a-lg, 10 pg/ml), anti-lg (10 pg/ml) plus oligomycin (OM, 8 
ng/ml) or anti-lg (10 pg/ml) plus cyclosporin A (CSA, 1 nM) and the % apoptotic 
cells was measured by Pl-staining of sub-diploid DNA content. (D) WEHI-231 
cells (1 X 10®/ml) were cultured for 3 hr with medium (untreated), anti-lg (a-lg, 
10 pg/ml), anti-lg (10 pg/ml) plus oligomycin (OM, 8 ng/ml) or anti-lg (10 pg/ml) 
plus cyclosporin A (CSA, 1 nM) and isolated mitochondria were prepared. PLA2 
activity was assayed using a PLA2 assay kit (Cayman). Data are presented as 
means ± standard deviation, where n=3 from single experiments that are 
representative of at least three independent experiments. (E) Neo or Bcl-Xu 
WEHI-231 cells (5 X 10®/ml) were treated with anti-lg (10 pg/ml) or AA (100 pM) 
for 24 hr and mitochondrial potential was assessed using DiOCe-staining. The 
data are represented as the change in mean fluorescence intensity (MFI) of 
DiOCe staining following stimulation to demonstrate the extent of depolarisation. 
(F) Neo or B c I-Xl WEHI-231 cells were stimulated for 24 hr with anti-lg (10 
pg/ml) and cell lysates were prepared. Cathepsin B activity as evidenced by the 
cleavage of the cathepsin B substrate, zRR-pNA (z-Arg-Arg-pNA, Calbiochem) 
was then assayed by measuring the absorbance at 405 nm. Data are 
representative of at least three independent experiments. This figure was taken 
from (427) and full details of materials and methods can be found in this 
reference. These experiments were performed by Elad Katz and Caroline Lord.
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Appendix 8. Inhibition of Cox2 enhances BCR-mediated loss of mitochondrial 
membrane potential in WEHI-231 cells. Neo or B c 1-xl  WEHI-231 cells (5  x 
10^/mt) were stimulated with 0-10 pg/ml anti-lg in the absence and presence of 
10 pM NS-398 for 24 hr before determining the % of cells exhibiting low 
mitochondrial membrane potential (Aijj) using DiOCe-staining. This figure was 
taken from (427) and full details of materials and methods can be found in this 
reference.
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Appendix 9. Anti-lg inhibits the production of prostaglandin Ez in WEHI-231 
cells. Wild-type WEHI-231 cells were stimulated with medium (untreated), anti- 
lg (1 pg/ml), anti-CD40 (10 pg/ml) or a combination of anti-lg (1 pg/ml) plus anti- 
CD40 (10 pg/ml) for 24 hr and cell lysates were prepared and PGE2 levels 
estimated by competitive binding immunoassay kit. Data are presented as 
mean pg/ml PGE2 ± standard deviation, n=3. In the insert, such lysates were 
probed for Cox2 expression by Western blot analysis. This figure was taken 
from (427) and full details of materials and methods can be found in this 
reference.
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